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Abstract
This thesis researches and examines how ‘patient experience’ is understood and approached 
through practice in healthcare, social science and design. In the UK, there is a considerable 
effort to access, measure and improve patient experience in the National Health Service 
(NHS). It is considered to be something that can be defined and thus made available for 
intervention alongside and in ways comparable to measures of clinical effectiveness and 
safety. 
As such, current approaches to patient experience from healthcare, social science 
and design will be set out, identifying different assumptions that figure the patient and 
patient experience in radically different ways. The thesis will then go on to use the notion 
of performativity to show how different methods and techniques – and their associated 
rationalities – that aim to capture, measure and improve patient experience actually produce 
and enact different versions of patient experience. 
The empirical and practice-based element of this research is based with the Barts 
Multiple Sclerosis (MS) research team at Queen Mary University of London (QMUL). 
This team researches MS, a degenerative and chronic neurological disease affecting over 
100,000 people in the UK. Through engaging with the empirical contexts of an outpatient 
clinic, a scientific conference and a measurement activity, this research will explore how 
patient experience is enacted in different contexts and consider the ways in which patient 
experience, as human/non-human arrangements, come into being and is made capable 
for action/inaction by way of measurement tools, misbehavior, practices of simulation and 
different experience phenomena. 
 This thesis will demonstrate that design-led research offers the opportunity to 
rethink or redo the patient experience, drawing on scholars in Science and Technology 
Studies (STS) to develop a methodological approach to deal with performativity of method 
and the multiple enactments of patient experience. Viewing interventions as performative 
will disrupt and provoke different forms of knowledge, methods and people, as well as 
revealing processes, practices and procedures (or technologies of experience) that articulate 
patient experience. These then contribute to the design of three research events where I 
set out to develop a new patient-reported outcome measure to produce alternative forms 
of patient experience. As will become evident, this aim proved to be misguided, if not 
impossible; instead, my contribution is a better understanding of the requirements of a new 
approach to working with an expanded notion of patient experience. This thesis concludes 
by reflecting on the implications of design-led interventions to study different versions of 
patient experience alongside expanding on how design researchers can empirically engage 
with this topic.
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Chapter 1: Introduction
14
Most of us have been a patient at one point in our lives. Whether for something minor or 
life changing, we have sought health advice or medical expertise. For most, having to take 
health advice and recover is a temporary state. However, those living with a degenerative 
chronic disease such as multiple sclerosis (MS) are, and will always be, patients. 
 Since the 5th of July 1948, people living in Britain have had access to a publicly 
funded National Health Service (NHS) which has been, and still remains, free at the point 
of delivery. Yet, in recent years, the effects of an increasing and ageing population has put 
pressure on the service to deliver care at the same capacity. While this may be a disaster 
waiting to happen, the NHS seems committed to delivering care to the best of its ability. In 
2003, the National Institute for Clinical Excellence (NICE) produced a national document 
which outlined how MS should be managed in primary and secondary care. This document 
enshrined principles for effective management, including the provision of person-centred 
care with more recent guidance from NICE outlining the components of ‘good patient 
experience’ in adult NHS service (NICE, 2012). 
 Similarly, Lord Darzi, the previous Secretary of State for Health, wrote a report that 
associated healthcare quality standards with patients’ experiences (Department of Health, 
2008). The report asserts patient experience is as important as clinical effectiveness and 
safety in defining high-quality care. The report also aimed to incentivise measuring efforts 
to improve patient experience with further policy outlining payments to hospitals based on 
quality measures. It is thought that by collecting patient experience data, the strengths and 
weaknesses in healthcare delivery could be identified, thus driving quality improvement 
through informing health service commissioning and promoting patient choice (Black and 
Jenkinson, 2009). Following this, gathering patient experience data became mandatory in 
all NHS trusts, along with standards and rights being introduced that patients could expect 
when receiving healthcare from the NHS (Great Britain and Department of Health, 2010). 
 These policy documents have enabled patient experience to be considered a key 
component in improving the quality of healthcare services provided by the NHS. They also 
show how the UK government and healthcare regulatory bodies are driving the patient 
experience agenda forward through introducing pressures to measure service performance 
through health outcomes.1 The health service functions in a system of evidence-based 
practice where medical practice and decisions are based on the best existing evidence rather 
than solely the experience of clinicians, traditions or theoretical reasoning (Guyatt et al., 
1992). Therefore, the health service required an empirical, evidence-based understanding of 
1  Patient experience consistently features in the NHS Outcomes Framework which is a set of indicators created by the Department of 
Health and Social care to monitor how the NHS is performing in relation to health outcomes of adults and children (Department of 
Health, 2018) 
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the experience of patients to improve it. In other words, only by knowing what the patient 
experience is can they then determine how to improve it.
 So, in this healthcare climate, patient experience is reported and accounted for 
during commissioning and service provision. Design is considered capable of changing, 
improving and creating patient and other healthcare experiences as it has already done 
within the commercial contexts of, for example, the entertainment industry. It has been 
used in the entertainment industry to form relationships between products and services 
for sale and for consumer needs based on commercial interests and consumer culture. 
Moreover, design, in relation to health experiences, works to create and alter the experiences 
of people, users and patients when interacting with health services, products, devices and 
information.
In other areas of healthcare, however, designers engage with the practices and 
procedures of medicine and research to explore and expand on the potential for design-led 
research to contribute to the research process. Within this space, they are challenging the 
knowledge practices of medicine and the healthcare service, making room for alternative 
conceptualisations of what it means to be a patient and further questioning who or what is 
capable of having experiences. This links to larger debates across different fields of research 
including design, medicine and social science where the nature of knowledge practices is 
being questioned, for example, in discussions about the positioning of quantitative and 
qualitative data, the accountability of practice-based research, the role of lay knowledge and 
the material turn in recent social–cultural and political theory.
 Patient experience is a multidisciplinary area of study and practice where tensions 
exist between different kinds of expertise from everyday people’s experiences of living with 
a chronic disease to designers’ different ways of knowing and of practicing research, and 
medical researchers’ experience-based knowledge. This topic is the focus of medicine, 
governmental policy, and practices from specialist fields of design while also being 
something that individual people can relate to if they have received healthcare. This is why 
it is my thesis topic. My motivations have also been influenced by my previous experience 
of working within the field of healthcare and design for the past eight years as a designer 
and a researcher. In this time, I have witnessed and been involved in an increasing number 
of initiatives, funding opportunities and research projects focussed on increasing the 
engagement and involvement of patients in healthcare as a direct effect of radical policy 
set out by the Labour government in the early 2000s to involve patients and the public in 
planning and changing services (Health and Social Care Act, 2001). From my experiences, I 
have developed the opinion that design plays a key role in these changes, and this is where I 
hope this thesis can contribute.
 This introductory chapter starts with the background context of the thesis, 
explaining my collaboration with the Barts MS research group based at Queen Mary 
University of London (QMUL) and some of the projects that I have been involved in with 
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them which inspired me to start a PhD. Following this is an account of MS (which is the 
chronic disease that this work is centred around), this thesis’ research question, aims, 
objectives, thesis overview, timeline of the practice-based research, ethics process and 
overview of the thesis’ contribution. 
Background to the Thesis
My interest in working within the field of MS started as a one-day placement project in 2009. 
This placement was part of a design brief set within the Design Interactions Department at 
The Royal College of Art where I was studying for my MA in design. This brief was typical 
of scientist–designer collaborations that came out of the course at that time which aimed 
at exploring the relationship between science and society through design. As part of this 
project, I was introduced to a research nurse from The Royal London Hospital who invited 
me to observe people with MS taking part in a medical research study. Later that week, I 
travelled out of London in a private taxi with her and a neurologist to a district hospital 
where people with MS were having blood samples taken in a port-a-cabin outside of the 
hospital building. I observed about twenty people coming in to have their blood taken. 
At the end of the day, I travelled with the blood samples back to the university research 
institute housed in an impressive, award-winning building (Figure 1). I met a scientist who 
took the blood samples, anonymised them, and then spun them in a centrifuge ready to 
start testing for the study. In one day, I observed a small snapshot of the medical research 
process: patients giving informed consent in the clinic, their blood sample being taken, 
the transport of the blood samples to the lab and the anonymisation of the samples into 
barcodes, as well as the routine work of the researchers in the laboratory with their technical 
instruments and devices. I was immediately struck by the different environments, practices 
and attention that surrounded the patient from those that surrounded their blood. That first 
day of observation led to two design projects within the MA course, followed by an offer of a 
research position within the Barts MS research group. 
 For three years, I worked as a ‘Research Service Designer’ at QMUL with the Barts 
MS research group (Figure 3).2 My main responsibility was to improve the outpatient 
experience for people with MS. In this role, I had unlimited access to neurology clinics both 
in The Royal London Hospital and across London within other specialist neurology centres. 
I would routinely sit in on patient consultations next to the medical students and spend time 
talking to patients in the clinical trials unit as they were receiving their infusions (Figure 2).
 As time went on, the projects I was involved in started producing results, and I 
was invited to meetings with the research team and asked to contribute to discussions 
2  At the time, the group was called the Neuroimmunology Group  ‘Barts MS’ was created in 2014 to give the team and their work a more 
public-facing title  Barts MS was chosen as the team is based in Barts and The London School of Medicine and Dentistry, and the 
hospital is part of Barts Health NHS Trust (previously called Barts and The London NHS Trust) 
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Figure 1 A photograph of the Blizard Institute part of Barts and 
the London school of Medicine and Dentistry at Queen Mary 
University of London where the Barts MS research team are 
based and conduct their lab based research 
Figure 2 A photograph of Ward 11D in the Royal London Hospital 
in Whitechapel, London where people with MS are treated by the 
Barts MS clinical team  
18
Figure 3  A photograph of the Barts MS research team (Photo credit: Dolly Clew) 
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that surrounded research topics and health service delivery. Eventually, I started initiating 
projects with the research team, and my role extended into thinking about how the patient 
experience could be improved through educating people with MS about current biomedical 
and therapeutic research. Over three years, we developed a number of public engagement 
projects which enabled dialogue between the research team and people with MS and 
their families.3 An example of this is Digesting Science, an educational set of activities for 
children aged six to twelve with a parent with MS.4 The main aim of the project is to teach 
children about MS through creative activities, but more importantly, it also works as a 
health intervention where families can be educated about MS prevention (Figure 4-6). 
Another project, PML Risk Calculator is a simple infographic communicating the risk of 
developing a potentially fatal brain infection while on an MS treatment. Through making 
this data clearer for patients, the pharmaceutical companies’ lack of communication around 
informing physicians about these figures was highlighted.5 All of these projects were unlike 
standard healthcare information development as this information was delivered in formats 
and spaces outside of routine clinical practice – mainly as weekend or evening events 
outside of the hospital buildings or as digital platforms. 
 The design perspective and methods of intervention was valued within the research 
group as it could highlight opportunities to design interactions between two groups of 
people, MS researchers and patients, who would not normally interact. The design approach 
also became of interest to others working in the area of patient experience: the MS charities; 
other departments of the university, such as the Centre for Public Engagement; and 
pharmaceutical companies. I was invited to speak about the projects and this approach 
at academic conferences (Thomson et al., 2011, 2013, 2015a) invited to become a features 
editor of the Elsevier journal, Multiple Sclerosis and Related Disorders and peer reviewer 
of a funding stream at the Wellcome Trust. Working as a designer within this research 
group allowed me to experiment with different approaches to how design could tackle the 
perceived disconnect between people with MS and research, with the aim of improving the 
information that is delivered to patients. Through this work, I developed an understanding 
of the limitations of using design interventions to influence the MS services delivered within 
the NHS. I realised the importance and the many challenges of developing designs that 
could fit within and impact upon the complex social, technical and institutional apparatus 
3 The role of designers within the field of public engagement in science is thoroughly described elsewhere (Michael, 2011; Kerridge, 
2015) and is discussed in the methodology chapter 
4 The Digesting Science project exists as a set of educational activities within five activity boxes which addresses topics of how MS 
affects vision, bladder function, walking, treatments and the importance of taking vitamin D  There are five kits which are circulating 
the UK and kits in Australia, South Africa and Israel  The project is multifaceted as events can be led by clinicians, nurses, therapists, 
parents, carer associations, therapy centres or charities  The project website is aimed at encouraging these audiences to access the 
kit and run an event for families in their geographical area (“Digesting Science,” 2015)  Since August 2014, there have been 63 Digesting 
Science events in the UK attended by 269 families and 454 children with a parent with MS 
5 The PML risk communication tool was developed originally in print in 2014, to be used in the neurology and infusion clinics at The Roy-
al London Hospital  Since then, it has been developed into an online resource as part of the Clinic Speak project enabling healthcare 
professionals and patients to access up to date risk information about the Tysabri therapy (Giovannoni, 2016)  
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Figure 4 The Digesting Science kit
Figure 6 A MS specilaist 
physiotherapist and two 
children with a parent with 
MS after completing the 
‘How MS affects your eye 
sight’ activity 
Figure 5 A family affected by MS learning about Vitamin D supplementation 
which has been proven to reduce their risk of developing MS 
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of healthcare delivery. One project that was close to this took the format of a research study 
I developed entitled Multiple Sclerosis Outpatient Future Groups, which engaged patients 
and outpatient staff to use creative tools (Figure 7-8) to imagine improvements to the current 
outpatient department through engaging a future scenario (Thomson et al., 2015b). The 
process of planning the study to fit within the guidelines of the National Research Ethics 
Committee (NRES) introduced me to the many restrictions and guidelines that are in 
place for research within the NHS. This was an interesting process, but I became aware 
of the many assumptions about exactly what the research activity was and how people 
would be engaged and involved in the research process as either a patient or a member of 
staff. As a design practitioner, I felt these assumptions overlooked the located and situated 
interactions that actually occur between researchers, participants and other things within 
research events. For example, one experience from this study involved my request to take 
still photographs of the study participants’ hands using the physical tools I had designed. 
My request to include this in the study was rejected by the local ethics committee as it was 
thought that these photographs of people’s hands could still reveal the identity of the study 
participants. I felt that, apart from being highly unlikely, this gave a larger reflection on 
the issues that the committee were concerned with rather than more realistic or practical 
issues such as considering what the researcher will wear, i.e., something appropriately 
professional, or, unprofessional, or imaginative (in a previous project, I explored the 
potential for patients to design and make garments for their MRI scans. I demonstrated this 
by having an MRI scan wearing a brain lesion costume, which would be my outfit of choice 
if I had MS but would be considered to some as inappropriate. Therefore, I was willing to 
wear imaginative outfits as part of a research project [Figure 9]). This experience, along with 
others, and the inability at that time for me to articulate my frustration with the settings that 
I was working in, motivated me to start this PhD research project.
Multiple Sclerosis
A textbook description of MS describes it as ‘an inflammatory disorder of the central 
nervous system and the most common non-traumatic cause of neurodisability in the 
young’, (Dobson and Giovannoni, 2012, p. 1). According to the MS Society (2015), MS 
affects around 100,000 people in the UK. MS can be characterised by relapses, which are 
the result of an immune attack on the central nervous system which causes the myelin that 
surrounds the nerves in the brain and the spinal chord to be damaged. Historically, MS has 
been categorised into four groups: benign MS, relapsing remitting MS (RRMS), primary 
progressive MS (PPMS) and secondary progressive MS (SPMS) which describe the different 
relapse rates. Benign MS is very mild, and although a person can have lesions (the sign of 
MS myelin damage in the brain and spinal chord) on their MRI scan, they may have no 
symptoms. RRMS is the most common type of MS and is where relapses come and go. It 
can take between one week and six months to recover from a relapse, and the symptoms 
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Figure 7 Photograph of the patient 
journey map created in the MS Outpatient 
Future Group study, where patients and 
outpatient staff came together to imagine 
an alternative outpatient experience using 
the metaphor of travelling on an ideal 
journey 
Figure 8 Props (luggage tags, return 
ticket, passport, translation book, 
postcard) used to engage patients and 
staff to think about interactions within 
an ideal journey within the MS Outpatient 
Future Group study 
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Figure 9 Photograph of me wearing a lesion for an MRI scan, April 2010 
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can vary. The most common symptoms are optic neuritis and a pins-and-needles-like 
sensation in the limbs, but it can also include dizziness, imbalance and fatigue. As a person 
suffers from more relapses, they will recover less from these symptoms, accumulating more 
disability. People with RRMS will eventually develop SPMS where they do not recover from 
relapses and there is a gradual progression of their condition. People with PPMS do not have 
any distinct attacks or remissions but begin with subtle problems that slowly get worse over 
time. 
 Significant advances have been made in the past fifteen years in the development 
of treatments for MS. The aim of these treatments is to reduce the frequency and severity 
of relapses, prevent disability, relieve symptoms, prevent or delay disability arising from 
disease procession and promote myelin repair. Drugs used in MS treatment fall into three 
categories: treatment of relapse (steroids), disease modifying therapies (DMTs) or symptom 
relief. DMTs are used with the aim of modifying the long-term course of MS and have been 
found to be most effective for people with RRMS who are continuing to relapse. As yet, 
there is no DMT for progressive MS due to the neurodegenerative process involved. DMTs 
are either self-administered, meaning the patient can inject the drug or take the tablet 
themselves at home, or hospital administered, where the patient has to attend a hospital 
for infusion. The frequency of these visits depends on the treatment and can range from an 
infusion every four weeks to one every three months for two years. 
Recent MS research, is now describing MS as one disease which operates without 
separate categories as they are deemed to be not supported by science (Giovannoni et al., 
2017; Cerqueira et al., 2018). This argument proposes that the neurodegenerative phase of 
MS is present from the start of disease onset, rather than starting in the progressive stages, 
which would suggest that current treatments could work beyond one disease category. As 
almost all treatments are currently licenced for relapsing MS, the implications of this would 
enable people with progressive MS to access therapies and consider their MS as modifiable 
(Ciotti and Cross, 2018). For this to happen, clinical trials would need to firstly involve more 
disabled patients and outcome measures would need to be sensitive to their likelihood of 
change (Pardini et al., 2017). This makes the case for the need for new clinical tools to be 
able to measure change and improvement in more disabled patients, an important point 
this thesis explores further.
 The Barts MS research group at QMUL is led by Professor Gavin Giovannoni. As a 
biomedical research group, it is at the forefront of clinical trials, re-myelinating studies and 
animal research in pushing the boundaries of MS research. The group consists of clinical 
researchers, PhD students, scientists, lab assistants, research nurses, MS nurse specialists 
and consultant neurologists. The group is part of UCLPartners, an initiative to bring 
together research groups across regional areas in London, which has access to 10,000 people 
with MS, about 10% of the total population of people with MS in the UK. In some respects, 
the group is traditional because its members conduct research, publish papers in academic 
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journals and present at conferences. But in others, it is innovative. Many members of this 
team contribute to the Barts MS Research Blog, which was set up by Giovannoni and the 
professor of immunology, Professor David Baker, in 2013. The blog is hugely successful and 
has a global readership, typically gaining over 7,000 hits per day.6 The team uses the blog to 
have an open dialogue within the MS community (including people with MS, patients of the 
group, family members, other researchers, physicians and pharmaceutical representatives) 
about topical issues of the field. This includes posts on issues such as Political Speak, which 
discusses political issues of funding the NHS; Clinic Speak, which discusses issues from 
the neurology clinic and Neuro Speak, where topics are written about for other healthcare 
professionals. As a treatment centre, it runs a number of clinical trials, and much of the 
research this group produces has gone into developing treatments for people with MS 
currently being used today. The Barts MS research group is also open to collaboration with 
researchers from other fields, such as design. My ongoing collaboration with the Barts MS 
research group is testament to this and has continued through the process of this doctoral 
research.7 
Contribution of the Thesis
This thesis aims to answer the following research question: how can design-led research redo 
‘patient experience’ for people with MS? The inclusion of the word ‘redoing’ is key in reflecting 
how I propose that design-led research methods, conceived and conducted as ‘performative’, 
might enact a different version of patient experience, which I intend to be one of the main 
contributions of this thesis.8 The thesis starts with these initial observations from my 
previous experience of working with the Barts MS research group and further investigates 
and examines how design-led research can rethink how patient experience is approached 
in both healthcare and design. In doing this, this thesis considers and works with different 
forms of knowledge, methods, practices and people. In the literature review, I set out a table 
of experience to think about how different forms of knowledge, methods, practices and 
people consider patient experience differently. This identifies the different assumptions that 
figure the ‘patient’ and ‘patient experience’ in radically different ways and shows how the 
different methods and techniques – and their associated rationalities – that aim to capture 
and measure patient experience actually produce and enact different versions of patient 
experience understood through the notion of performativity. This thesis aims to contribute 
this table of patient experience as an analytic framework to examine the relations between 
experience and design. The methodology used in this thesis proposes a performative 
understanding of patient experience, explored through practice-based, design-led research. 
6 The Barts MS research blog can be accessed from http://multiple-sclerosis-research blogspot com/  On Wednesday the 16th Sep-
tember 2015, the blog received 7,046 page views  The total page views for August 2015 was 185,744 
7 The thesis was conducted part-time while I was working as a researcher as part of the Barts MS research group 
8 The hyphen has been intentionally included in the thesis title, “re-doing”, to emphasis this point  
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Through the remaining chapters of the thesis, I consider how the notion of performativity 
can help examine exactly what goes on in research events that aim to generate patient 
experiences. Finally, the contribution is a better understanding of the requirements of a new 
approach to working with an expanded notion of patient experience.
 The intended audience for the thesis is multiple. Firstly, it aims to contribute 
to practices of involvement and engagement of ‘the patient experience’ in research and 
service development projects, such as Patient and Public Involvement (PPI) activities based 
in universities and NHS trusts and health service design activities within UK hospitals, 
making the case for the unique contribution that design-led research can bring. Secondly, 
it seeks to demonstrate to the design community the opportunities and practical challenges 
of conducting design-led research within a medical research environment with the aim of 
contributing to the development of design research within healthcare. Finally, it considers 
designers’ treatment of experience and how design is deployed within healthcare practice 
and healthcare research. Here, I would like to contribute an expanded understanding of 
how designers can practically engage with healthcare professionals, patients and notions 
of patient experience within healthcare contexts while working without adhering to 
assumptions of either discipline.
Research Question
How can design-led research redo ‘patient experience’ for people with multiple sclerosis?
Aim
The primary aim of this research is to investigate how patient experience is created and 
circulated for people with MS. A secondary aim of this research is to develop a practice-
based way to involve and engage people to contribute to the development of new patient 
experiences. 
Objectives
1. Identify different versions of patient experience and understand how they are influenced 
by social science, healthcare practices and design.
2. Suggest ways in which design can contribute to the performativity of patient experience.
3. Deliver a research study which explores how design-led research can uncover and explore 
the situated enactments of MS.
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Thesis Structure 
This thesis consists of six chapters: introduction, literature review, methodology, pilot study, 
empirical research and conclusion. Below, I provide an outline of the thesis structure with 
descriptions of the content of each chapter. 
Chapter 1: Introduction
This first chapter introduces the thesis with a description of how patient experience has 
become a preoccupation of healthcare commissioning (Department of Health, 2008) and 
introduces the growing involvement of design in this area. I also explain how I came to work 
in the field of MS with examples of previous work in this area, a description of MS and my 
relationship with the Barts MS group at QMUL.
Chapter 2: Opening the Black Box of Experience – Towards a performative 
understanding of patient experience 
The literature review chapter sets out how researchers involved in patient experience 
draw upon different theoretical approaches and how this figures the patient and patient 
experience in radically different ways. Here, I pull out from the literature four different 
theoretical versions of ‘patient experience’. Experience 1 is influenced by phenomenological 
approaches to experience (Heidegger, 1927; Husserl, 1931; Merleau-Ponty, 1962) and can 
be seen in patient-subjective reports in nursing research (Crotty, 1996). Experience 2 is a 
data version which, drawing on Science and Technology Studies (STS) literature, can be 
thought about as immutable mobiles (Latour, 1987) generated through quantitative health 
measurement tools such as patient-reported outcome measures (PROMs) (Walton et al., 
2015) and design approaches to improve service experiences through experience-based 
co-design (EBCD) (Bate and Robert, 2007). Drawing on work of STS scholars, I move from 
understanding the production and enactment of patient experience from the register of 
representation to the idiom of performativity (Pickering, 1995; Law, 2004). Through doing 
this and including further work on performativity (Austin, 1976; Butler, 1990; Callon and 
Law, 1997), I set out how Experience 3 is a performative result of the situated interplays of 
human, practices and objects, among others (Danholt, 2005). Finally, Experience 4 calls for 
a distributed experience around the notion of an event (Fraser, 2009; Wilkie et al., 2014; 
Michael, 2016; Lury, 2018).
Chapter 3: A methodology for studying patient experience
This chapter describes a methodological approach to the study of multiple versions of 
patient experience through design-led research. The chapter starts with the methodological 
rationale I have chosen to use as developed from performative (Law, 2004) and inventive 
methods (Lury and Wakeford, 2012). This is followed by a detailed description and 
explanation of my choice of research methods of pilot studies and three research events 
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(Michael, 2016). This description includes the rationale I developed when I set out to develop 
a new PROM to measure upper-limb function for people with MS as a research study. It 
then provides an overview of the stages of the research study of three patient meetings and 
an online survey including reflections of the process of taking the study through Health 
Research Authority (HRA) approval. This chapter also includes a description of the design 
of these meetings as engaging situations where people, tools, and concepts come together 
to develop a PROM. In doing this, the chapter sets out methodological challenges and 
opportunities of intervening in a performative understanding of patient experience through 
design-led research. This highlights the limitations of current engagement and involvement 
methodologies of involving people in research from within the contexts of healthcare (Ives 
et al., 2013), social science (Lezaun, 2007) and design (Ehn, 2008), as well as outlining the 
ethics of working with a performative method (Danholt, 2008; Wilkie et al., 2014) with 
patient participants. 
Chapter 4: Slowing down technologies of experience through three pilot studies
This empirical chapter reports on the three pilot studies that have been conducted as the 
first practice-based element of this thesis. Consultation Pie, Willow plates and How far can you 
walk? were all conducted between 2013 and 2015 and informed the design of the research 
study Measurement on Our Terms (MOT). It further describes the purpose and role of pilot 
studies as a research method in relation to both healthcare and design research fields. 
This chapter explores what kinds of technologies of experience (Ellwood, 1988) are at play 
in doing patient experience by introducing Stengers’ notion of slowing down (2005). This 
enabled me to analyse experience in the making as chains of translations (Callon, 1986) 
and unpick specific situated practices (Mol, 2002; Suchman, 2007) and knowledges in an 
outpatient clinic, in a scientific conference and in a measurement activity. This chapter 
describes the intended aims of the pilot studies, what happened in their deployment and 
the learnings that each generated in my understanding of patient experience, including 
dealing with mess, misbehaviour, practices of simulation, working with other experience 
phenomena, accountabilities and assumptions of technologies of experience. The chapter 
concludes with an analysis of the performative effects of these studies in the contexts they 
are deployed. 
Chapter 5: Measurement on Our Terms – A study slowing down technologies of 
experience
This chapter presents the Measurement on Our Terms study consisting of three patient 
meetings and an online survey bringing people together to share everyday hand-and-arm 
activities that are affected by their MS. The chapter describes what happened, how the 
participants interacted and responded to the research setting and the accounts they share. 
The activities that are discussed are considered different practices of MS (Moser and Law, 
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2003), or MS ensembles, which involve a combination of human and non-human objects with 
different appreciations (Pols, 2005). The top responses are gathered, discussed and reviewed 
against external factors aided by objects representing each activity. The chapter uses the 
notion of performativity to inform the analysis of how the activities were performative, the 
role objects had in these activities and what specific conditions affected them. Here, I look 
at the results of these interactions as co-productions within material environments (Pols, 
2005). I explore what theoretical questions are brought up about the conditions, procedures 
and instruments for producing knowledge, specifically looking at how the group describes 
and demonstrates the limits of each activity and what it means for their daily lives. I reflect 
on the activities, methods, tools involved and the process of the research study to explore 
patient experience, reporting on the liveness of the research event where bodies, issues and 
research tools come together. I consider the research site and the tools that have contributed 
to the production of new knowledge and associated accountability of this from the expertise 
of people with MS and their situated actions of living with MS (Callon and Rabeharisoa, 
2004). At the end of this chapter, I describe my realization that doing a PROM that could 
simultaneously capture experience ensembles and be scalable is misguided, if not impossible. 
Instead, I discover that a new form of experience technology is required which is beyond the 
scope of this thesis, so I speculate about what this would look like and how it would exist. 
Finally, the chapter points to two directions as future possibilities for a new technology of 
experience, while outlining the practical contingencies of doing this type of work through 
practice-based design research within the NHS.
Chapter 6: Conclusions
This final chapter summarises the research findings and clearly articulates how the 
contributions of this thesis sits within understandings of healthcare, social science and 
design-led research. I reflect on the ways and degrees to which I have addressed my research 
question and how the research has contributed to the development of my design research 
practice and the opportunities it has provided me for further research. I conclude this 
section, and the thesis, with implications for future research in this area, reflecting on 
the contribution this research makes to current practices of patient experience in design, 
healthcare and social science, as well as future developments in areas such as patient 
engagement and involvement practices where the research may be further relevant.  
Accountabilities and Ethics 
One of the challenges of writing this thesis has been framing the work amongst different 
fields of research and practice. As I have already pointed out, there are multiple audiences 
for this work – designers, healthcare professionals, MS researchers and those involved 
in patient engagement and involvement - each with different academic traditions and 
accountabilities linked to them. Therefore, I am accountable to different audiences. For 
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the practice based and theoretical contributions of this thesis to speak to these multiple 
audiences, it must not only meet, but stand on the same ground as them. The substantial 
appendix to this thesis demonstrates the level of transparency required in the health 
research process by presenting the number of regulatory documents involved in this 
work. I include these to clearly show that the research has been conducted according to 
ethical guidance in healthcare but also in part to demonstrate the amount of commitment, 
application and extended work involved to involve patients in research processes with 
design research. For audiences that are not accustomed to this process, the illustration in 
Figure 10 demonstrates the timeline of how I completed and successfully gained QMUL 
ethics, NRES ethics and HRA approval for the Measurement on Our Terms study.
Presentations, Workshops and Lectures Conducted Related to PHD
Throughout the duration of the PhD, I took part in a number of initiatives specific to this 
research, enabling me to present my work to a range of design, social science and medical 
audiences at different points in the research process. These are listed on page 33 and became 
incredibly productive moments as they enabled me to not only organise my thoughts at that 
time into a coherent presentation but also to gather feedback and responses on my research 
direction and thinking. 
Intended Future Outputs
The intention is for this research to be disseminated in many different formats to different 
areas. The practice-based work is ongoing in that it continues to contribute to conceptions 
of a new technology of experience that will enable people with MS to measure their upper-
limb function. At the moment, this involves the Under and Over project, which is briefly 
introduced in chapter 5. This will be shared and distributed across the patient community 
through the Barts MS research blog and the Barts MS and UCLP clinical services. It can also 
take on more participatory approaches of dissemination at patient events, such as MS Life, a 
bi-annual event attended by around 5,000 people with MS organised by the UK MS Society 
and MS Research Days, annual events attended by 350 people with MS organised by the Barts 
MS research team. The sustainment of this project will also contribute to the PPI and public 
engagement academic community at QMUL and wider where different results, insights and 
further research will go on to create more knowledge about the process of patient experience 
exploration.
 The more theoretical aspects of the research, such as the table of experience and 
writing on how performative design-led research can explore patient experience, will be 
disseminated through academic papers aimed at researchers interested in healthcare 
research, design and STS. The hope is this will also be presented at relevant design research 
conferences, such as the Design Research Society, Design 4 Health, Include, and Research 
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Through Design, to communicate effectively the value of this thesis’ contribution to the 
design research community. 
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PRESENTATIONS, WORKSHOPS AND LECTURES CONDUCTED RELATED TO PHD 
RESEARCH
2013 Interviewed by Leah Armstrong, for the Arts and Humanities Research Council project, Mapping  
 Social Design, 4th December 
2014 Lancaster University PhD Summer School presentation: Re-doing patient experience through  
 design-led research: considering the multiplicity and ontological politics of MS  Lancaster   
 University  30th June - 1st July
2015  Panel discussion: Design Culture Salon 15: How does design address immobilities in our society?  
 V&A Design Culture Salon, 13th March
 Research Presentation: Speculation as Design Research, Goldsmiths Design Festival, 2nd   
 September
 Research Presentation: Re-doing the Patient Experience for people with MS  Doctoral Research  
 in Design, part of Goldsmiths Design Festival 3rd September 
 CSISP Salon  Measures of/for health: Practices and instruments  Co-organised with Vera   
 Ehrenstein, 18th November, Goldsmiths 
2016 Take part in Patient Engagement Steering Group, Wellcome Trust, January – September 
2017  Lecture to medical students: How design-research can re-do the patient experience, Complex  
 Healthcare Processes Research Group, University of Southampton, 7th March
 Lecture to MSc students: How design-research can re-do the patient experience    
 Anthropologies of Global Health Lecture to MSc Global Health Modules QMUL, 9th March 
 Research Presentation: Speculation as Design Research  Design Matters  PhD forum, Department  
 of Design Goldsmiths, 13th April
 Research Presentation: Speculation as Design Research  Research Matters, Barts Health NHS  
 Trust, 24th May 
 Research Presentation: Speculation as Design Research  What matters to you?, Patient   
 Experience conference, Barts Health NHS Trust, 12th July
2018 Contribution to Design for Health(care) track at DRS2018, University of Limerick, 25th – 28th  
 June
 Participate in Nordes summer school, Design and Care, Linnaeus university Växjö, Sweden, 14th –  
 17th August  
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Chapter 2: Opening the Black 
Box of Experience – Towards a 
Performative Understanding of 
Patient Experience
35
This literature review will explore how ‘patient experience’ variously operates in healthcare 
and design by drawing on literature from philosophy and the social sciences. Patient 
experience is a phrase frequently used in research involving patients and health interactions 
which can be traced through diverse fields of literature. Therefore, it is important to be clear 
about the trajectory that I take through these different research disciplines to include and 
exclude different ideas and references to notions of ‘patient experience’. There is a large 
body of qualitative research from the sociology and anthropology of health and illness that 
focuses on capturing and theorising different aspects of the patient experience, arguing 
importantly that it extends well beyond the clinical context, the body and its relationship to 
society and the patient themselves. For example, scholars such as Strauss’ work on chronic 
illness expands understandings of illness as work conducted at home (1975). Reviews of 
‘lay’ experiences of health and illness trace the ‘missing voices’ in historical accounts of 
patients life-worlds in medical sociology and point towards more interdisciplinary research 
(Lawton, 2003). More recently, there has been increased sociological attention that is critical 
of the way in which the patient experience is framed and incorporated in health policy, 
research and practice specifically looking at participation in healthcare (Rabeharisoa, 
Moreira and Akrich, 2014) and a more health services research approach to the problematic 
operationalisation of patient experiences (Martin, 2008; Martin, Carter and Dent, 2018).
 The focus of this thesis, however, is on how the patient experience has been 
specifically deployed within clinical and scientific research settings rather than within the 
social sciences more widely. Empirically, my approach is distinct from studies of patient 
experience from sites of patients’ homes or workplaces, to focus on particular situations 
within clinical interactions, scientific dissemination and measurement activities. The broad 
field of potentially relevant literature has been delineated for the purposes of this thesis by 
staying close to how ‘patient experience’ has been predominantly understood in research 
and participatory activities in healthcare, and then goes on to draw on ANT inspired 
research that emphasises performativity to rethink this. This specific trajectory has been 
further influenced and guided from the forms of sociology encouraged from the sociology 
community at Goldsmiths where this research is also closely linked. 
 Patient experience is also considered from embodied perspectives of disability 
studies in relation to equality and social inclusion. Again, this broad field of study 
encompasses a range of medical social scientific and rehabilitative disciplines (Bury, 1991; 
Williams, 1999; Barnes, Oliver and Barton, 2002) as well as the perspectives of disabled 
activists (Oliver, 1990; Shakespeare and Watson, 2001). Thus, though I briefly reference 
work at the intersections of STS and disability studies later in the thesis, the wider area of 
literature is not heavily drawn on. I am conscious that looking to this broader field would 
provide a further source of inspiration for thinking about the generative MS ensembles and 
technologies of experience that I set out later in the thesis.  Although both sets of literature 
provide interesting and promising accounts of patient experience, it is beyond the scope 
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of this thesis to fully incorporate those literatures. These would be interesting directions 
for future research. Therefore, the literature included in this chapter focuses on the use of 
design thinking and practices as a means for rethinking and redoing patient experience in 
the context of primarily clinically orientated MS research and care. 
 This literature review chapter is organised around four versions of ‘experience’ as 
understood and practiced across a range of different fields. The aim here is to identify how 
these are mobilised in and enacted through practice and highlight the different assumptions 
inherent in these approaches. The first understanding of patient experience will start with a 
brief outline of the theoretical tradition of experience, drawing on particular philosophical 
perspectives. The second understanding will go on to review approaches to measure and 
capture patient experience within clinical and design practice. This will establish both 
qualitative and quantitative approaches to measurement as technologies of experience. 
The third understanding will introduce the notion of performativity as an analytic lens 
to further examine the patient experience and unpick exactly what these technologies of 
experience are doing. The fourth, and final, understanding will examine how the notion of 
an ‘event’ can contribute to thinking about how patient experience is brought about and the 
‘felicity conditions’ that are required in its enactment. This chapter will conclude with some 
considerations for a performative understanding of patient experience and consider how 
this will inform the methodology chapter. Figure 18 on page 68, at the end of this chapter, 
presents these different understandings of patient experience alongside one another. 
Throughout this review, I will draw on empirical examples of patient experience from my 
research with the Barts MS research team to illustrate this analysis. 
Experience 1: Subjective Approaches to Experience 
To help follow my indexing of the different understandings of experience, and to help me in 
this discussion, I bookmark each new definition in the format of an indented box and change 
of font as I introduce and refer back to it. This allows me to compare and contrast different 
types of ‘experience’ in Figure 18 later in the thesis.
Experience 1: This first understanding of experience is of a patient’s inner, 
subjective experience of events of which they have a first-hand experience  
This understanding is heavily influenced by phenomenology and is dominant in 
healthcare practices that treat patients as subjective beings  
In this section, I introduce Experience 1 starting with the various philosophical perspectives 
that are drawn upon and frequently referred to when explaining this version of experience. 
The reason for this starting point is that philosophical perspectives underpin and inform 
different approaches to experience within healthcare, and as I go on to point out, are 
similar to how designers approach experience within service improvement projects. This 
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is followed by a discussion on the assumptions that are inherit in the main understandings 
of lived experience – phenomenology. I will then draw on literature in STS to unpack the 
assumptions inherit in both medicine’s and design’s approaches to patient subjectivity.
 The experience of thinking, acting and existing in the world is thought about and 
underwritten by different philosophical perspectives. Much of this can be traced back to 
the eighteenth century, when the approach to philosophy by David Hume, and before him 
John Locke, argued for experience-based thinking where nothing is knowable without 
experiencing it first in the physical world. This is called ‘empiricism’, which states that all 
knowledge comes from sensory experience – what we can see, touch and smell – and this is 
the only knowledge people can have. In other words, we can only know something through 
having had a sensory experience of it. It is through empiricism, and its further development 
into positivism, that the scientific method is logical. Positivism, coined by Auguste 
Comte, goes further than empiricism to argue that for this knowledge to be authentic, it 
has to be created through specific methods with logical principles – the scientific method. 
This scientific and logical treatment of sensory experience enforces principles to ensure 
authentic knowledge is produced. These principles are applied to sensory experiences 
through conducting experiments that produce results that can then be interpreted. 
Shapin and Schaffer (1985, p. 25) argue that experiments, or what was established as 
the experimental and dominant scientific mode of empiricism by Robert Boyle, include 
three key aspects: First, the exact apparatus pieces that are used to conduct experiments. 
Second, experiments and scientific procedures are to be carried out and documented in a 
specific way (e.g., documenting through writing in descriptive language and using intricate 
diagrams). Finally, repeating experiments and exploring if different or unintended results 
are produced. Here, a person witnessing an experiment is not enough to gain consensus of 
a result, it has to be repeated for and by others. The reliability of experiment results and the 
removal of individual bias – objectivity – is key to the scientific method. 
Both empiricism and positivism treat sensory experience in this way, which is a 
very different approach to considering the inner, personal experience of a person. This is 
described as the lived experience, and it is the relationship between how people experience 
things as humans and the meanings things have in their experiences. This would describe 
experiences that people have as a phenomenal experience. This is different from how 
empiricists treat experience; they would try to determine the experience’s meaning through 
third-person reliability and downplay any first-person interpretation. However, the study of 
phenomena argues that people ascribe meaning to every event as a mental construct that is 
unique for each person.
 Since the nineteenth century, positivist thinking about experience dominated social 
and behavioural research where approaches to health research was based on numerical 
measurement and were generally quantitative research methods. But in the 1980s and 
1990s, the use of qualitative methods in healthcare research grew rapidly through a 
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rejection of this positivist paradigm within academic research (Morse, 1991; Smith, 1992; 
Nurse-Patient Relations and Benner, 1994; Greenhalgh and Hurwitz, 1998; Reiners, 2012). 
Influential articles in prominent journals such as the British Medical Journal called for 
more relevant, achievable and appropriate qualitative approaches to produce knowledge 
about patients’ experiences, feelings and emotions than that of the currently dominant 
quantitative methods (Mays and Pope, 1996). This research, and considering people’s 
phenomenal experiences being located in the human mind, went on to produce certain 
views of human subjectivity and patient experience that were taken up in healthcare, which 
I will now go on to explain. 
Phenomenology and Experience
The study of phenomena, phenomenology, is the dominant theory of experience within 
philosophy and is closely associated with the work of German philosopher Edmund 
Husserl and his student Martin Heidegger. It is based on the premise that reality is what is 
perceived or understood in human consciousness. There are essential differences between 
Husserlian and Heideggerian phenomenology, which can be illustrated in how it has been 
taken up in nursing research to try to better understand human behaviour in health and 
illness research. Following Husserl (1931), the nursing approach to understanding patient 
experience considers the patient’s direct awareness of an event. Here, a researcher might 
conduct an interview with a patient to study the patient’s description of their perception of 
an outpatient clinic. This is a descriptive approach to access the phenomena of experience 
concerned with epistemological issues of the basis of human knowledge, where people are 
detached subjects in a world of objects. Husserlian phenomenology retains the Cartesian 
object–subject divide. However, Heidegger (1927) reacted against this and argued that not 
everything is a product of consciousness (e.g., the feeling of anxiety and dread [Walters, 
1995]). Heidegger’s work is interested in more ontological issues and concepts of being in 
the world over knowing the world (Reiners, 2012). This is an interpretive approach based on 
existential perspectives which proposes that an understanding of the person cannot occur in 
isolation from that person’s world. Therefore, a researcher might ask a patient to complete 
a diary about their outpatient clinic experience to better understand the interpretation of 
their experience of being in a clinic. Although both of these approaches to experience have 
been taken up by nursing researchers, much of this work fails to differentiate between the 
different epistemological and ontological focusses which have different implications for 
research methodologies (Walters, 1995, p. 791).1 
 Later developments in phenomenology went on to conceptualise the role of the 
body in how we experience, introducing the idea of embodied knowledge. Maurice Merleau-
1 This is also the criticism of Michael Crotty who in his book, Phenomenology and Nursing Research, argues that the research conduct-
ed by nurses using phenomenology actually developed a North American hybrid of the philosophy  See Crotty (1996) 
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Ponty’s (1962) work considers health and illness as an embodied experience that we have 
a position of, from within a body that we are perceiving the world through. Merleau-Ponty 
calls this the lived body, and this is something separate from the objective body. The 
objective body is that which medicine treats and the lived body is how we experience our 
body. He argues that in first-hand experience of living day-to-day as a healthy person, we 
do not notice the difference between the objective body and the lived body. It is only when 
we are ill or something goes wrong (e.g., we experience symptoms, pull a calf muscle when 
running or get a headache) that the objective body is brought to our attention, and we 
start to notice our body. So this approach to experience would argue that two people can 
be affected by the same thing, but because they have different bodies, it will affect them 
differently. Phenomenology places an important role on humans’ ability to perceive the 
world, stating that perceived experience is the foundation of subjectivity (Merleau-Ponty, 
1962, p. 146). 
 
Assumption 1: Limitation of Perception 
I have started to unpack some of the main philosophical approaches to experience. This 
has highlighted two key assumptions that underpin Experience 1. The first assumption is 
how phenomenology deals with the subjective perspectives of individual people and can 
be described as the limitation of perception. Havi Carel (2012) effectively uses the example 
of a native English speaker and a non-native English speaker hearing the same sentence 
in English. They hear the same sentence but perceive it differently due to their different 
perspectives of the world. Relating this to health, the experience of living with a chronic 
illness is different for everyone. For people living without the illness, the experience may 
look awful, but in fact, the experience of living with illness may be very different from what 
it is perceived to be. This critique on perception is also articulated by scholars of disability 
studies who argue that if we are not experiencing the same events through the same 
body, then we have no way of really grasping or understanding the embodied experience 
(Diedrich, 2005; Moser, 2006; Galis, 2011). 
This assumption impacts how patient experience is thought about and approached 
in healthcare practice, research and policy. Within the NHS, it is widely understood 
that allowing patients to report on their experiences of care is key to understanding 
their experiences, as supported by departments such as The King’s Fund (Goodrich and 
Cornwell, 2008). Within the Barts MS research team, patients talk about their experience 
of living with MS frequently. They run a three-day MS preceptorship teaching course where 
trainee neurologists, clinical nurse specialists and pharmaceutical representatives learn 
about MS treatments and care. The teaching course includes eight, thirty-minute sessions 
where patients share their experiences of issues such as pregnancy and MS, pain in MS, 
diagnosis, sphincter dysfunction, cognitive impairment and treatments. This is widely 
regarded as the most popular component of this course. In this situation, individual patients 
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become representatives or spokespersons (Callon, 1986, p. 13) speaking on behalf of others, 
not just for their own experience but for ‘the patient experience’, representing a wider 
population of patients (Collins and Evans, 2002). 
 This assumption within Experience 1 has further problems for accessing and 
reporting experiences. Phenomenology places experience in the minds of individual people, 
which presumes that an individual’s mind is the centre of and cause for their experience. 
So then, the only way for others (in the case of this thesis, neurologists, researchers or 
designers) to access this experience is through the experiencing person reporting on it. In 
other words, as a person experiences an event, they interpret it, and it goes into that person’s 
memory. As time passes, other memories join it. When that person then reports on that 
event, a description of the memory is reported. This is described as ‘the problem’ (Chalmers, 
1995, p. 200) of subjectivity. As a source of knowledge, subjective experiences are unreliable 
as they are affected by that person’s perspective of the world (their ontological view) when 
going in and out of our memory (Dennett, 1991). So then, when we recall an experience, we 
re-experience it in our minds. This is unlike empiricism and scientific experiments, where 
a third person can verify or falsify a result; it is not possible to separate the event from the 
person’s viewpoint and see another person’s raw data to compare the actual event with the 
report of the event itself.2 
Design and Experience
The phenomenological understanding of experience and the limitations of perception 
highlight interesting aspects of how experience has become a key operator in design. 
Different genres of design have responded to the notion of experience as a hitherto 
untapped and underdeveloped resource. The field of experience design (Shedroff, 2001; 
Benz, 2015; Wendt, 2015) focusses on the design of experiences as an aspect of consumption 
since the rise of the experience economy (Pine and Gilmore, 1999). This distinct historical 
stage of economic development in the 1980s saw an extension of consumer culture where 
global companies and brands such as Starbucks and Disney operated by way of staging or 
‘theming’ (Lury, 2009, p. 75) experiences that provided particular sensations for people as 
customers and, in more recent work, addressing them as audiences (Ben Hayoun, 2017). 
Bill Moggridge (2007), co-founder of IDEO, one of the world’s largest design companies 
at that time, described how experiences emerge in the interaction of objects, interactions, 
spaces and information, transcending different mediums (Svabo and Shanks, 2015, p. 26). 
Lury (2009) goes on to describe these complex relations between consumer and brand as 
assemblages to reflect the diverse practices, technologies and mediums that are involved 
2 The notion of ‘raw data’ is contested (Räsänen and Nyce, 2013) as the term was used by Swedish intelligence practitioners who were 
interested in challenging these common sense understandings of key terms like raw and cooked  They described how ‘data’ is already 
shaped and full of assumptions prior to being analysed – so ‘raw’ data rarely exists, if at all 
41
in the processes of branding. This approach of companies and designers working in this 
way to generate experiences for customers or audiences is described as a first-generation 
understanding of the experience economy in design. In this, people are reduced to passive 
targets who generate experiences as an automatic response to design (Strandvad and 
Pedersen, 2015, p. 108). But, beyond identifying that some form of value is created for people 
as customers, consumers or audiences, there is no more clarity on what an experience is 
according to this generation. 
A second-generation understanding of the development of the experience economy in 
design focusses on customers’ sensory perceptions, the creation of meaning and the process 
of co-creation (Prahalad and Ramaswamy, 2004; Boswijk et al., 2007). This understanding 
along with the growing focus and study of users (Bjerknes et al., 1987; Suchman et al., 2002a; 
Wilkie, 2010) from within fields such as user-centred design (Norman and Drapper, 1986) 
made people who were capable of experiencing, central to design activity.3 Users became 
a central focus of design due to the influence of the Scandinavian design tradition. This 
influence was the result of union-supported projects introducing new workplace technology 
in Norway in the 1970s, which has since become internationally known as Scandinavian 
participatory design (PD). Here, users were invited to co-operate through the entire process 
of design, involving people to contribute their perceptions (and experiences) and taking 
their ‘work practices seriously’ (Greenbaum and Kyng, 1991, p. 15) in the design activity. The 
researcher wanted to empower the workers whose jobs would be otherwise replaced by the 
new technology (Ehn, 1989). This Marxist-inspired approach enacts democratic principles 
by inviting the end users of a design (the people who would be affected by the change, the 
workers) to co-operate in the entire process of design. 
 In the context of healthcare, over the past decade, there has been an emergence of 
PD-inspired approaches of co-design (Sanders and Stappers, 2008), co-creation (Cottam 
and Leadbeater, 2004) and co-production (Boyle and Harris, 2009) to consider the user 
as a central focus and active member of the design activity (Pullin, 2013; Donetto et al., 
2015). Currently, the most successful approach to improve the patient experience of health 
services is experience-based co-design (EBCD) (Bate and Robert, 2006), which is deployed 
by the NHS Institute for Innovation and Improvement to allow staff, patients and carers to 
reflect on their experiences of a service and work together to identify improvement activities 
3 I use the term user-centred design as a generic term to broadly describe approaches to design that consider user involvement and 
use contexts as essential of the design process  This includes Participatory Design (PD) (Greenbaum and Kyng, 1991; Schuler and 
Namioka, 1993; Kensing et al , 1998) and Human Computer Interaction (HCI) (Norman and Drapper, 1986) although I understand that 
these have different methods, practices and have been developed in relation to different theories  For example, early PD work was 
inspired by Marxist and Wittgenstein theoretical models of democraticisation and more recently interested in ANT (Callon, 2015), 
whereas HCI was interested in cognitive psychology concerning human factors, cognition and embodiment to think about human 
interaction with technology 
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(Figure 11). It is then up to this same group of people to devise and implement changes and 
then reflect on their achievements.4 
EBD is a user-focused design process with the goal of making user 
experience accessible to the designers, to allow them to conceive of 
designing experiences rather than designing services. (Bate and Robert, 
2006, p. 309)
The reference to the user in the quote above is typical of the EBCD approach for experience, 
as well as the design literature around experience design more broadly. It highlights the 
assumption of Experience 1, where design deals with experience as a pre-existing subject that 
is stored in someone’s mind. The EBCD approach assumes that patients have access to their 
inner experience, the introspective event, which they can report on (Hollway and Jefferson, 
2000), and in doing this makes assumptions that we can access our own inner experiences 
and know them (Henriques et al., 1998). If a designer wants to understand it then, they ask 
the person to report on it. Ultimately, once a designer can identify and grasp an experience, 
they can change it (Shedroff, 2001; Cain, 2010). 
 Participatory approaches in design, such as EBCD, attempt to remove the limitation 
of perception by involving people who will be part of the end change or service in the 
improvement activity to contribute their individual, subjective experiences to the design 
process (Pullin, 2013). But, this does not account for the reporting of experience being 
problematic, as everyone’s ontological view is different. Further, in approaches such as 
EBCD, it is important to not overlook PD’s original strong political agenda in workplace 
democracy. Due to this agenda, the reason for engaging these potential users within the 
design process is not only to make better products and systems but also to consider the 
social and ethical implications of a new design. In other words, organisations have many 
motivations for initiating these projects other than solely creating new patient experiences. 
For example, in a review of current EBCD projects, patients reported feeling like outsiders 
during the decision-making process, and staff referred to external locus of control (Bowen et 
al., 2013, p. 242) giving rise to particular configurations of power in both co-design activities 
and the implementation of change. 
4 EBCD was originally developed from experience-based design (EBD)  EBD was advocated by Cain (2010) for product development 
then further applied to a healthcare service improvement context by design company IDEO (Freire and Sangiorgi, 2010)  A typical 
EBCD cycle would take between 9 and 12 months with six stages: (1) project set up, (2) gather staff experiences of the service through 
observations and interviews, (3) gather patient and carer experiences through observations and filmed interviews, (4) bring staff and 
patients together to watch a ‘trigger’ film of patient narratives to identify priorities to change, (5) co-design work in groups of 4-6 
around these priorities, (6) have a celebration and review event  See Bate and Robert (2007) 
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Figure 11 Stages in experience-based co-design as described on The Point of Care Foundation 
website where healthcare staff can access the EBCD approach toolkit (Source: The King’s 
Fund (2018)  Stages in experience-based co-design  [image] Available at: https://www 
pointofcarefoundation org uk/resource/experience-based-co-design-ebcd-toolkit/step-by-step-
guide/1-experience-based-co-design/ [Accessed 27 Dec  2014]) 
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Assumption 2: STS and Experience
The second assumption of the phenomenological understanding of experience is that it 
prioritises the human perspective and perceiving subject above all others. John Searle (2008) 
describes how the phenomenological perspective is limited by saying that if something 
is not perceived to be present, then it is not real, meaning it only considers phenomenon 
that can be seen or experienced through human senses. Although Searle is referring to the 
limits of the ontology of phenomenology – what it considers to be real – the limitation of 
solely considering humans and human perception is also a criticism of the construction of 
scientific knowledge from STS. 
 STS is a field that has been preoccupied with the epistemic practices of scientists 
since the sociology of scientific knowledge (SSK) (Bloor, 1976; Barnes, 1983; Collins, 1983).5 
SSK challenged the historical dominance of the philosophy of science by questioning 
the production of scientific knowledge and knowledge claims. Laboratory studies were 
foundational to the development of STS as a response to SSK (Knorr-Cetina, 1981; Latour 
and Woolgar, 1986) where sociologists and anthropologists conducted ethnographic 
fieldwork, observing and following scientists in their natural – laboratory – settings, ‘in 
action’ (Latour, 1987, p. 59), to determine its qualities and attributes. Laboratory studies 
argue that knowledge can be studied through how it is produced and the material practices, 
objects and situations that are involved in creating it. Actor network theory (ANT), an 
approach within STS, grew out of laboratory studies, notably the work of Michel Callon, 
John Law and Bruno Latour, further developing the preoccupation with the empirical 
analysis of material practices.6 
 Somewhat notoriously, ANT includes the view that human and non-human actants 
should be treated symmetrically, or analytically equal (Callon, 1986; Latour, 1987).7 This 
is similar to Callon’s (1986, p. 200) writing about free-association, where both society and 
nature need to be considered without a priori distinctions between them. ANT describes 
human and non-human actants (as the term actor is most likely to talk about the roles of 
humans) with the same language and gives them an equal amount of agency. Actants have 
the power to act and are tied in chains of association which construct networks of humans 
and non-humans. Through these actor networks, human and non-human entities emerge, 
5 Thomas Kuhn’s The Structure of Scientific Revolutions (1969) energised a new discussion about science which opened up a space for 
factors other than scientific method and truth to be considered in the contractions of scientific facts and reality  David Bloor (1976), 
along with Barry Barnes (1983), was influenced by the sociology of science and developed the strong programme in the SSK  The 
strong programme set out to provide sociological accounts of scientific knowledge and went on to have huge influence on STS 
6 The field of STS includes many different approaches - SSK, Laboratory Studies, Social Construction of Technology, feminist approach-
es and ANT history of science 
7 The notion of symmetry was developed by Bloor and Barns is around explaining truth claims of knowledge  This is also described as a 
‘Whig’ history (Law, 2004), where past scientific knowledge contributes to current facts  So, for example, if a scientist is conducting an 
experiment and it comes back positive, they are creating knowledge and can claim that knowledge to be true and scientifically sound 
within their experiment  They can do this without having to go back and re-prove the previous facts their experiments are based on 
because they are also considered true through scientific method  However, if previous knowledge does not fit with current ideas, 
then it needs to be explained  This is described as an asymmetrical explanation, as true and false knowledge are explained in different 
ways 
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interact and produce effects such as the loss of leg function for a person with MS (Moser, 
2000, p. 205). These networks are not pre-determined or absolute, but their identity is 
defined through their interaction with others. For ANT scholars, the relationship between 
all actants is under investigation. This is to say that it is how networks of actors act that 
defines what they are. Callon (1986) demonstrates this in his study of fishermen in Saint 
Brieuc Bay when he describes how, in the process of translation, both non-humans (the 
scallops) and humans (the fishermen and scientists) are being ordered and defined. Latour, 
a key proponent of ANT, directly criticises phenomenology for endorsing the concreteness 
of humans and for being unable to consider other, non-human objects having agency (or 
being capable of having experience).8 Crucially, and in contrast to phenomenology, ANT 
can offer another understanding of patient experience that does not pre-suppose a model of 
the patient as being a subjective figure.9 
 Including STS literature and using an approach that draws on ANT not only 
enables me to unpack the assumptions within the ways that patient experience is currently 
enacted in healthcare and design (e.g., Experience 1), but it is also be an extremely effective 
tool for describing the processes by which patient experiences come into being, or fail to 
materialise. But in doing this, I need to be aware of theoretical and methodological debates 
surrounding the concept of non-human agency, some of which I describe here. Firstly, 
the implications of non-human agency is widely disputed as it is argued that humans and 
non-humans should not be given equal power in the network as humans have intentionality 
(Collins and Yearley, 1992; Winner, 1993; Bloor, 1999).10 Latour (1992) responds to this 
anthropomorphism criticism – that of attributing human characteristics onto non-humans 
and objects – by saying that ANT treats all entities as having agency, but not human 
properties. Secondly, ANT has been criticised as describing accounts of agency as heroic 
(Star and Griesemer, 1989, p. 390) with its privileging of certain heterogeneity over others. 
In a network of heterogeneous actors, Star (1995) argues that the framing of these accounts 
is told from the point of view of the human – the scientist or the researcher – rather than 
the lab technician or the test tube, for example. Finally, there is the ‘god trick’ of viewing 
the world from everywhere and nowhere (Haraway, 1991, p. 189). This is in regards to how 
the researcher traces the networks without accounting for their own participation and 
potential influence. Regardless of these well-known criticisms, including Latour’s (1999), 
which deals with ANT’s central meaning, it is still an effective tool for rethinking ideas 
8 Latour’s account of understanding experience is influenced from Stenger’s reading of Alfred Whitehead and his influence from William 
James, who gives an account of experience that is full of individuals more abstract than that of actors (Latour, 2005) 
9 Varela (1999, p  331) discusses further work being done around the scientific studies of consciousness, which is also suspicious of 
subjective experience  Here, research aims to revise the manner in which accounts of human experience have to be approached in 
empirical research 
10 ANT’s notion of generalised symmetry is a form of radical symmetry which is more extreme than was previously developed by SKK 
scholars Bloor (1976) and Barnes (1983), and does not come without criticism 
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that have been taken for granted, like Experience 1, that are problematised through ANT.11 
STS, and more specifically ANT, provides me with analytical tools through which to take 
apart phenomenologist understandings of patient experience and Experience 1, and can help 
explain how experience is produced and how it travels within healthcare.
Experience 2: Patient Experience Data
Experience 2: This version understands patient experience as a measured and 
objective phenomenon such as a number or a measure produced through data as 
generated from and reported through patients’ subjective accounts  This version 
can travel and have agency in making subjects, and it is an immutable mobile  It is 
reduced into numbers and icons through quantitative tools and diagrams  This is 
not to be confused with the phenomenological perspective of experience which is 
the inner experience of a person, this notion is a generalised data version 
In this section, I will discuss the second understanding of patient experience, Experience 
2, where patient experience is accessed through quantitative measurement tools within 
clinical practice and reduced to diagrams in design activities. I will describe how different 
versions of patient experience are figured through these tools and describe the theoretical 
perspective underpinning their use.
 Over the last decade, there has been a steady increase in efforts to gather data about 
patient experience to improve service quality (Wolf et al., 2014) while being used to get a 
better understanding of a patient’s quality of life. Health-related quality of life (HRQoL) is 
‘the patient subjective perception of the impact of his disease and its treatment(s) on his 
daily life, physical, psychological and social functioning and well-being,’ (Riazi, 2006, p. 
93) and is gathered through a combination of questions which asks patients about different 
aspects of health and about how this affects their lives. Patient-recorded outcome measures 
(PROMs) are the research tools used to record and compile this data, and take the form of 
questionnaires and interviews designed to determine the patient experience. Health-rating 
scales, such as PROMs, are measurement instruments that aim to quantify characteristics 
of people that cannot be directly measured (like height and weight) (Hobart and Cano, 
2009, p. 7). They are said to ‘gain meaningful subjective accounts from those receiving care,’ 
(Jenkinson and Fitzpatrick, 2013, p. 72) as they are completed by patients themselves. For 
example, the MSQOL-54 (Vickrey et al., 1995) includes questions to determine the HRQoL, 
11 I have attempted to be reflexive in my account of patient experience by including an upfront description of my involvement with the 
research context in the Introduction chapter  This is further addressed in the methodology chapter 
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such as ‘In general, would you say your health is,’ with the option for the patient to respond 
with ‘Excellent, Very good, Good, Fair and Poor’.
 The medical community considers these paper-based tools to be new because the 
patient is at the centre of the evaluation activity; however, they are still used in conjunction 
with physician-based measurement tools to supplement more biomedical-defined outcomes. 
In MS care, PROMs are used to record the impact of the disease and treatment from the 
patient’s perspective and are used alongside physician- or clinical-based outcomes, such as 
magnetic-resonance imaging (MRI) scans, relapse rates (Riazi, 2006) or Expanded Disability 
Status Scale (EDSS) scores. In MS, many PROMs have been developed or repurposed to 
create a more complete picture of the patient experience of living with MS.12 Examples 
include: MS Quality of Life 54 (Vickrey et al., 1995), Functional Assessment of MS (Cella et 
al., 1996), MS Quality of Life Inventory (Ritvo et al., 1997), Multiple Sclerosis Impact Scale 
(MSIS-29) (Hobart, 2001), MS Functional Composite (Fischer et al., 1999), UK Neurological 
Disability Scale (Sharrack and Hughes, 1997), MS Quality of Life Index (LaRocca et al., 
1996), the Leeds MS Quality of Life (Ford et al., 2001) and the Health Related QoL for MS 
(Pfennings et al., 2009). 
 Within MS, PROMs are used as clinical outcome assessments to measure the 
efficacy of treatments in clinical trials (Walton et al., 2015). The importance of choosing the 
correct clinical outcome assessment for trials was recently discussed in the results of the 
ASCEND trial, where for the overall population of patients made up of people with RRMS 
and SPMS; the results of the trial were reported as negative (Giovannoni, 2014, 2015; Kapoor 
et al., 2018).13 Yet, for people with SPMS involved in the trial, participants reported and 
showed signs of improved upper-body ability, but this was not reflected in the trial results 
because the PROM that measured the clinical outcome assessment was not sensitive to 
measure this improvement. The choice of PROM to report this then came under scrutiny, as 
it did not reflect this result.14
To have a better understanding of how these tools produce patient experience data 
and what assumptions of experience they draw on, it is necessary to have a closer look at 
how the tools are developed. One of the most widely used PROMs in MS is the MSIS-29 
12 Some outcome measures have been developed in one condition, such as stroke, and then used in another  This is a point of debate 
within the measurement field (Hobart et al , 2005) as although the original tool provided considerable evidence for validity in a variety 
of populations including MS, (Vickrey et al , 1995), later publications have disproven this with the inclusion of psychometric measures  
‘Psychometric limitations of the SF-36 in multiple sclerosis include significant floor and ceiling effects (Freeman et al , 2000), limited 
responsiveness (Freeman et al , 2000), underestimation of mental health problems (Nortvedt et al , 2000) and a failure to satisfy 
assumptions about scaling summary scores (Freeman et al , 2000)’, (Hobart, 2001, p  963) 
13 The ASCEND trial was a clinical study on the Efficacy of Natalizumab on Reducing Disability Progression in Participants with Secondary 
Progressive Multiple Sclerosis 
14 The clinical outcome assessment for the ASCEND trial was the 25-foot times walk and 9-hole peg test  People with SPMS are likely 
to suffer severely from mobility problems, which would not likely be improved through the use of the drug on this trial  Whereas, 
for people with RRMS who have less severe mobility problems, their walking would improve  As neither the RRMS or SPMS patients 
improved in the 25-foot test, the trials results were negative  Although, for people with SPMS, their upper-limb function did improve, 
which was recorded by the 9-hole peg test, but was not given enough importance in the reporting of the results of the trial  So, 
although the trial of the drug reported as negative, the drug had a positive impact for those patients with SPMS, as picked up by the 
upper-limb PROM and through their accounts 
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shown in Figure 12, which was developed in 2001 by a team of physicians (Hobart, 2001). 
This was an important tool because it was one of the first to incorporate psychometric 
methods in its development.15 PROMs (and other rating scales) map out people’s responses 
as variables on a line where they can all be located. Psychometric methods evaluate the 
rating scales to determine their success at making the variable operational and locating 
people on this line. Psychometric methods are described as the theory of measurement and 
enable tools to become a measure by situating one person’s response within a population 
of others. These methods combine ‘the patient perspective with rigorous psychometric 
methods of data quality, scaling assumptions, acceptability, reliability and validity,’ (Hobart, 
2001, p. 962) to ensure that the final questionnaire would detect change in a person on the 
physical and psychological impact of MS.16 In this tool, the patient answers 29 questions 
about how their MS affects their daily activities. Figure 14 on page 50 describes the 
standardised steps in the MSIS-29 PROM development process as endorsed by the Federal 
Drug Association (FDA). This shows the steps for using patient-derived data to generate 
PROM items. 
 In Figure 13 (Barrett et al., 2013, p. 810), the responses from the paper questionnaires 
have been turned into data in a spreadsheet. This acts like an inscription device where 
entities are translated into numbers, symbols and visualisations that are then considered 
‘facts’ (Latour, 1987, p. 64). Star (1983, p. 270) describes this translation process as an 
essential part of scientific work where the presentation of cleaned-up results (from the messy 
labs, clinics and spreadsheets) are screened out through the production of graphs where 
facts are made. The graph displays the distribution of disability as concrete facts. This 
diagram is a typical visualisation of the responses to the PROM and acts as a demonstration 
of psychometric properties. These facts can then be transported, overlaid and calculated, 
becoming immutable mobiles (Latour and Woolgar, 1986) that can be acted upon. Immutable 
mobiles describes how representations of data such as this is made flat, which ‘enables 
mastery’ (Latour, 1990, p. 45) from the researchers showing this data. These immutable 
mobiles can go on to be transported without changing the inherent characteristics of those 
things as they are suspended in space and time through the diagram. They have agency as 
they are inscribed and circulate in the practices of healthcare, trial results, medical records 
15 It is interesting to note that the incorporation of psychometric methods in measurement tools is relatively new in neurology, having 
only been introduced in the 1980s (Cano et al , 2011)  None of the PROMs and health measures mentioned above have developed 
using the psychometric approach, including the most widespread physician-based measure, the EDSS (Kurtzke, 1983)  The EDSS is 
now said to have limited measurement properties (Sharrack et al , 1999; Hobart, 2001) when analysed with psychometric methods as 
it is heavily weighted towards measuring mobility and does not account for other aspects of MS that impact people’s lives  This has 
led to an inter-disciplinary dilemma within the health measurement field where measurement researchers argue for psychometric 
properties and standards to be created for all measures (Cano et al , 2011; Giovannoni, 2015)  Yet, clinicians argue that the time and 
resources to create new tools is too high 
16 Data quality is concerned with the percentage of how many responses are missing and how much the target sample can be predicted 
from this  Scaling assumptions outlines a series of criteria for the set of items to legitimately form a single total score when values are 
given to them individually  Acceptability of the score is achieved when scores are well distributed across the scale  Reliability ensures 
that the scores are free from random error, and validity is whether the scale measures what it sets out to measure 
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Figure 12 A photograph of the MSIS-29 paper based PROM 
Figure 13 The diagram above shows the distribution of the manual ability of the people who have completed the 
PROM with people less disabled on the left and people more disabled on the right 
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Figure 14 Table describing of the three stages of PROM development for the MS-IS 29 
Step 1
Step 2
Step 3
Thirty people with MS were interviewed, expert opinion was 
consulted and a literature review was carried out to create 129 
questionnaire items (questions) to start the development of the 
PROM  
1530 people with MS were sent a questionnaire with the 129 
questions on it 
The 129 items were reviewed and reduced depending on statistical 
testing of data quality, scaling assumption, acceptability, reliability, 
targeting and validity  Data from 766 responses was analysed to 
determine which questions would make up the final questionnaire  
The instrument now consists of 29 questions where people are 
asked about the impact of MS on their day-to-day life in the past 
two weeks  22 questions relate to the physical impact of the 
disease and 11 items on the psychological aspects  
Example questions in the tool asks, “In the past two weeks, how 
much has your MS limited your ability to…”
• Do physically demanding tasks?
• Grip things tightly (e g  turning on taps)?
• Carry things?
Patients have the choice to select from a Likert Scale of 1 - 5 with 1 
being “not at all” and 5 being “extremely ”
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(Berg, 1996), diabetes technologies (Danholt, 2008) and screening procedures (Singleton, 
1998) that circulate healthcare and design, far beyond the original patient and paper PROM. 
They are reproducible in that they can be printed and copied with little effort. Latour’s 
printing press example (1990) demonstrates how ideas can be shared across the world 
without distortion and how their activity occurs through further process of publication. 
 This second model of experience is different and arguably incompatible with 
Experience 1. Where Experience 1 takes patient-reported accounts of the subjective experience, 
Experience 2 starts with this then produces numerical data creating immutable mobiles. 
Although, we can see how both versions typically and unproblematically operate in 
combination during clinical work of PROMs, they are not the same. As demonstrated 
through the ASCEND trial results (Giovannoni, 2015), the subjective experience of SPMS 
patients did not hang together (Mol, 2002, p. 55) with the PROM data of Experience 2. 
Following Anne Marie Mol, this is not a case of choosing one version of experience 
over another, but rather it concerns witnessing how different and divergent versions of 
experience, theories and practice hang together. This is raised by Callon and Rabarisoa 
(2004, p. 196) who point out in the French Muscular Dystrophy Association community, it 
is not about changing experiential knowledge to become accountable to the scientific and 
medical community, but about seeing the difference in the two forms of knowledge and 
giving them the same validity. The practical question for this thesis is how to work with 
different versions of experience symmetrically, without valuing one version as more valid or 
important than another. 
Assumption 1: Failing to have Experiences
It becomes clear that there is more going on in PROMs than just measurement and 
representational activities. But, there are two practical assumptions about this approach 
to experience that should be explained. This technique of measuring presumes that 
people are not only physically capable of completing the questionnaire and recording 
information about their disease but are also reflexive, rationale actors. MS is a disease of 
the central nervous system and commonly affects peoples’ cognitive functions; therefore 
these symptoms, practically speaking, could disturb the patient as a capable actor with the 
ability to read questions and write down answers. Firstly, this assumption is problematised 
in Jeanette Pols’ work with people with mental illness where the consequences of 
understanding patient experience in this way says that if you do not have a voice or cannot 
complete a questionnaire, then you fail to have a patient experience (Pols, 2005; Carel, 2012). 
Literature from the ethnographic turn in the (STS) field of public understanding of science 
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(PUS) further examines how questionnaires are answered.17 Alan Irwin and Mike Michael 
(2003) highlight that this assumption is reflected in the provenance of questionnaire 
methods in psychology where the person is viewed as a repository of knowledge that 
can be ‘quizzed’ (p. 24) over aspects of their knowledge or experience. The standardised 
questions (developed through psychometric validation) that are quizzing the patients create 
a generalised patient experience in which that respondents need to fit. Secondly, this raises 
questions of whether individual differences might be left out and what type of knowledge the 
patients might have. Pols distinguishes this difference between the knowledge of medical 
professionals and patient knowledge as it involves many different ‘techniques, values and 
materials,’ (Pols, 2005, p. 74). This is practical knowledge that has been developed through 
action – living with the disease. It is contextual and is based on the day-to-day experience 
of living with a chronic disease involving activities such as dressing, washing yourself and 
cutting the grass rather than through an evidence-based process. The reductionist PROM 
approach of science to experience potentially overlooks the fact that people possess relevant 
and useful knowledge that do not meet standards of scientific inquiry (Star, 1983, p. 206).
 The reductionist generation of diagrams and immutable mobiles in the creation 
of experiences is also identified within design approaches to patient experience. Within 
EBCD approaches, diagrams are created and used to represent the patient journey through 
a healthcare service. Marked on these diagrams, shown in Figure 15, are people, objects, 
spaces, things, websites and locations referred to as touchpoints (Clatworthy, 2011) where 
the user and the service interact and it is claimed the service experience is created (Robert, 
2013).18 Through the process of visualising these interactions on temporary paper diagrams 
and making changes to points represented on the map, it is thought that different service 
experiences are created (Shostack, 1984). Arguably, this immutable mobile acts to reduce 
the complexity of both humans and the act of design into simple shapes and lines that can 
address a reduced form of ‘patient’. As Latour describes in reference to Dagognet (1969, p. 
213), the power of the visual vocabulary in chemistry, through the periodic table, enables 
the compounds to become actionable and manipulated. Through visualising the different 
human and non-human entities in the service, they can be assigned agency and be made 
17 The field of public understanding of science, public engagement in science or public engagement of science and technology (these 
terms are used interchangeably) has been described as ‘a wide and ill-defined area’ (Wynne, 1995)  This change in the naming of the 
field demonstrates a shift from a deficit model of engagement (Irwin and Michael, 2003) where the notion of an ignorant public that 
needs to be informed has changed to a more upstream engagement model (Wilsdon et al , 2004) of engaging empowered citizens 
(Irwin, 2006, p  301)  Within the field, established and traditional formats and methods for engagements between scientist and the 
public were originally outlined in the Bodmer report (Royal Society, 1985) from consultations at both a national and local level, delib-
erative polling, focus groups, citizen juries, consensus conferences, dialogues with stakeholders etc  Contemporary practices of public 
engagement of science based within and supported by UK institutions take the form of awareness events, conferences, science cafes 
to arts and design projects 
18 This terminology has emerged in the language of service design (Evenson and Dubberly, 2009)  The journey map has been developed 
from blueprinting where services are made an actual and visible object of design (Mager, 2008) which is similar to graphical represen-
tations of experience models, profiles, scenarios and opportunity maps to visually communicate service interactions (Blomberg et al , 
2003)  These are the moments where the service experience will arise and are specific points of interaction between a user and a 
product or brand 
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Figure 15 A photograph of a patient journal map constructed in a EBCD project 
representing the stages in the health service that the patient can interact with 
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workable. Star (1983) makes this point about science, but is applicable to design, describing 
how to conduct scientific research, things must be drawn, tasks must be made simple and 
goals must be made easy enough to achieve (p. 207).
 The agency of this type of design is through both the visualisation and manipulation 
activity. Discussion topics could include how patients are approached by staff, the day-to-
day working practices of the staff, information that is provided and procedures that take 
place. Literature about users from design and STS (Akrich, 1992; Suchman et al., 2002b; 
Danholt, 2005a), specifically Wilkie’s definition of user assemblage (2010, p. 58), highlights 
the multiplicity of users that get both resourced and defined through the design process. 
Within the stages of the service design process, post-it notes are used as objects to determine 
current experiences and are also used to talk about future possibilities, identities and 
capabilities of existing, emergent and future users. Taking this further, Wilkie explores the 
performative potential that these temporary objects have when used in the prototyping 
activity (2010) and explores how each note could bring one potential future into being 
over another. The diagram acts as a distributing and collecting device (Berg, 1996) where 
the experience begins and ends. Although the diagram aims to simplify and make this a 
transparent process, involving people and eliciting patient experiences is complex and 
messy. 
 This raises questions as to what counts as experience. For designers, do they think 
that making changes to a simplified diagram, visualising a service counts as an experience? 
This is one of the criticisms of the EBCD approach (Bowen et al., 2013, p. 242). ANT puts 
forward the argument to re-consider what is thought of as facts. For example, Experience 1 is 
typically viewed as a pre-existing property of humans that need only be correctly recorded. 
Or, Experience 2, which is produced and circulated through PROMs and documented in 
material objects, become representations of people’s diseases (Berg and Bowker, 1997). 
When actually, all the recording apparatus, medical expertise, measurement techniques and 
so on recede into the background or get erased (‘bracketed out’, in Mol’s language) to meet 
the factish demands of medical epistemology where it ultimately is presented as knowledge 
produced through scientifically rigorous methods. Arguably, however, what actually counts 
as experience is the upshot or effect of all these human/non-human relations.
 In this thesis, I draw on ANT-inspired approaches, where experience is not a priori 
property of humans as cognitively endowed persons (Experience 1). Here, experience emerges 
out of the situated interplays between MS patients, medical technology, measurement tools, 
design practices and clinical expertise and draws attention to the relationships that all take 
part in patient experience. The following discussion is going to elaborate on and explain 
Experience 3.
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Experience 3: Opening the Black Box 
Experience 3: This third understanding emerges out of the situated interplays 
between people, measuring instruments, diagrams etc, which are socio-
materially mediated  It argues that ‘experience’ is the result of these practices, 
devices etc  and cannot exist without them  It is performative in that it has 
agency, can cause other actants to act and produces subjects  Experience 3 is 
constituted in relation to various elements with there being no single central 
core  There is an indexicality of this experience where it is dependent of where it 
is embedded  
In the case of MS, the MSIS-29 in the PROM produces a measure of the patient’s HQoL, 
making it seem as though the HQoL is a fact that exists before the process of creating 
it. Following ANT, I would argue that the HQoL does not exist before or without the 
questionnaire, the spreadsheet and the process of calculating it. These recording devices 
can be described as technologies of elicitation (Lezaun and Soneryd, 2007) where the PROM 
acts an instrumental tool to elicit (and in doing so shape) patient experience, which raises 
questions about the conditions, procedures and instruments for producing knowledge. 
This patient experience data is co-produced (Pols, 2005, p. 211) in the liveness of the 
measurement activity which includes bodies, researchers, recording equipment, and many 
different entities coming together. If thought about as pervasive technologies (Lezaun and 
Soneryd, 2007) the conditions in which Experience 2 is produced is available for analysis. 
This, then, raises questions around the efficacy of these methods to uncover and ‘represent’ 
an authentic patient experience, and if patient experience is produced at all through these 
techniques (Pols, 2005). In science for example, Boyle set out the conditions needed to 
create authentic knowledge through an experiment. But I ask the question, when there are 
different types of knowledge hanging together, what types of conditions create them? 
 Latour’s notion of immutable mobile shows how the PROM makes experience a 
concrete entity that can be acted upon, for example, to participate in clinical practices. 
In this thesis, I claim, measurement tools also produce new versions of experience. There 
is currently a preoccupation in sociological and cultural literature about questions of 
method and the realities they are purposively reporting on where research techniques (or 
measurement practices) contribute to the shaping of new phenomena (Osborne and Rose, 
1999; Mol, 2002; Law, 2004). For example, members of the public’s opinions are elicited 
through opinion polls, and through this, the seemingly objective fact ‘public opinion’ 
was created (Osborne and Rose, 1999, p. 1). Similarly, Lezaun describes how knowledge 
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about people is generated from their opinions shared in focus groups, which then produce 
statements that help form particular marketplaces (2007).
 The presumption that has been set out at the start of this thesis is, within 
healthcare, patient experiences need to be made reportable and accountable for 
commissioning and service provision reasons (e.g., to measure the financial effectiveness 
of service improvement activities), and it is the role of the researcher to research, measure 
and produce representational material about this.19 Similarly, when designers are said 
to design and change patient experiences, they visualise it. But scholars interested in 
performativity would argue that, through the process of measurement and representation, 
patient experience is performed. In other words, specific versions of patient experience are 
an upshot of the measurement and representational devices, which is a key argument of 
this thesis. This claim requires a close consideration of how knowledge is produced and a 
sensitivity to the techniques, situations and objects that are involved in this process. Here, 
Andrew Pickering puts forward what he calls the performative idiom (1995, p. 13), where 
the empirical context is considered as having the ability to produce something new. This 
is a performative understanding of science and knowledge practices, where tools, such 
as PROMs, measure entities and phenomena while producing and verifying facts. It is 
important to note that the performative understanding of (patient) experience has a key 
implication for an important assumption in this area of research. Performativity provides 
an alternative way to understand how experience is produced: it is not predicated on the 
assumptions of a subjective individual with cognitive capabilities, which phenomenology 
and areas of nursing research have encouraged. Nor does it limit understandings of patient 
experience to the objective body of any person that a disease might inhabit (Mol and Law, 
2001).
 Performativity has important implications for how to think about patient experience 
as a topic of research and for how to understand how design operates and might be 
practiced. The notion of performativity has been increasingly used within the humanities 
and social sciences to problematise the representational idiom of science, economics and 
the arts where language is understood as that which reflects states of affairs. The notion of 
performativity is frequently traced back to John L. Austin’s (1976) series of lectures from 
Harvard University in 1955. Here, Austin states that there are two types of speech acts: 
constative and performative utterances. Constatives are descriptive statements which can 
be either true or false. When, for example, someone says, ‘I went to the hospital’, they are 
reporting on a matter of fact, and this statement can be true or false. They either did or did 
not go to the hospital. However, as Austin describes, performative utterances bring a state 
of affairs into being and, thus, perform reality. The term performative derives from the word 
19 I discuss the reflexive role of the design researcher in producing accounts of the research and new knowledge (Woolgar, 1988) in the 
methodology chapter 
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‘perform’ relating to the noun ‘action’, indicating that language has agency and the capacity 
to create action. The example that Austin puts forward to describe this is uttering the words, 
‘I do’, in a marriage ceremony. Here, the speech act is actively doing something in that 
moment (confirming the union of two people in matrimony). In other words, a performative 
speech act operates to bring new realities into being, rather than simply reporting on 
existing states of affair. Similarly, when we say, ‘I promise to...’ these words engage in the act 
of making a promise to another person that will (or should) affect the consequences of our 
actions.
 According to Austin, for a statement to be performative, it needs to happen within 
‘appropriate circumstances’, (1976, p. 6) or felicity conditions. These circumstances can 
include the words being uttered by an appropriate person (e.g., someone who is able 
to conduct marriage ceremonies), the act happening in a suitable context, the correct 
words being spoken and the interests of the utterer being considered. This can be further 
illustrated by way of diagnosis in clinical settings. Here, for example, if I were to sit across 
the table from someone in a hospital consultation room and tell them they had MS, the 
statement would not act as a diagnosis of the condition, as it would have no performative 
force for that purpose. I am not a trained neurologist, and the person does not identify me 
as such. Similarly, if a neurologist was to tell his pet dog that it had MS, then this statement 
would have no force. More accurately, it would not have an appropriate force because, for 
example, the dog might respond, but it would not be in relation to the semiotic valence of 
the statement, making the context inappropriate. Dogs do not develop MS, and it is in not 
the neurologist’s interests to diagnose his dog. Following Austin’s understanding of the 
performative utterance, it is the combination of the specific language used and the ability 
of the circumstances to set in motion a chain of events (further tests, scans, examinations 
etc.) that gives the speech act of diagnosis its performative force. The reliance on these 
circumstances suggests there is an indexicality of performativity in how statements can be 
considered reliant on the context in which they are embedded to make sense (Garfinkel, 
1967). In other words, the meaning of the words ‘You have MS’ changes depending on the 
context in which they are spoken. Taking them out of this context not only changes the 
meaning of the words but also changes their agency. Felicity conditions is the precise point 
that current debates around performativity hang and I will come back to later. 
 The notion of performativity was first taken up and developed by feminist scholar 
Judith Butler, who has played a leading role in exploring the performative power of speech 
acts when applied to gender in feminist and queer theory. Following Austin and Jacques 
Derrida, Butler removes the focus from the utterer and puts more emphasis on what is 
being said in performative acts. Butler’s (1990) approach to performativity shows there is a 
disconnect of linguistic agency from the human speaker. She argues that the power of the 
speech act is not entirely dependent on the person uttering the words, but it is the actual 
words they say. This puts forward an understanding of gender and sex formations not as 
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expressions of an inward nature but as performative acts. In other words, gender does not 
happen at birth, but it is a repeated sequence of acts that construct, and create, an identity. 
The implications of this for patient experience is that patient statements recorded and 
distributed through PROMs do not just report on events that a patient has experienced, 
they actually perform (deliver the action of creating) the patient experience. The statements 
‘speak’ by way of being material-semiotic entities. This is the upshot of the translation 
process that begins with the conversion of patients’ responses into data. Patients are 
performed through all kinds of linguistic activities (such as diagnosis, examinations and 
descriptions of symptoms) and, so by extension, patient experience. This goes further than 
the indexical nature of Austin’s performative utterances, and for Butler, these statements, 
once produced, have the capacity to act beyond the original location. They create versions of 
patient experience which then are used to refer to the patient in other contexts (dependent 
on specific felicity conditions). This is where Butler, drawing on Derrida’s (1988) reading 
of Austin, situates the effects of performativity. For people with MS, once versions of 
patient experience are measured and brought into being, they cause different effects such 
as affecting the disability benefits for that patient, limiting their access to treatments 
and affecting the results of a drug trial. The statements contribute to the performance of 
instruments of experience. These are consequences of the performative act and can have 
important impacts on people’s lives. This is why performativity has been the focus for many 
humanities and social science scholars as semiotic and material processes can produce 
and transform reality. Butler locates it in the ‘performative act’ (1988, p. 521), meaning 
that performative agency is not in a pre-existing subject that exists before language, but 
is an effect of the process of citation. This suggests that patients, and experiences, do not 
pre-exist particular clinical and healthcare mobilisations, they are performed through and 
because of them. They are constructed in these encounters. This hints to an indexicality 
of experience which points to what else needs to be in place – the felicity conditions that 
Austin previously mentioned. Butler explains that this is how subjectivity is performative, 
as it is something that is done in an ongoing practical process. Gender, or for that matter 
being a patient with MS, is not a fixed and stable attribute of a person. There is not a pre-
existing subject that people enact, or not, each day. Butler argues that people are always in 
a process of reiterating, producing and maintaining their subjectivity through their actions. 
Patient experience is something that is done and needs to be re-done every day in different 
situations. Another way of thinking about this would be as an achievement or situated 
accomplishment (Lynch, 2001, p. 140) – an ongoing, collective, and practical process. These 
accomplishments are generated on every occasion by different actors, and this process does 
not just involve language but also action and things. This is an extension of Experience 3, 
which opens up the analytic possibility of other non-humans acting.
 Karen Barad provides another prominent approach to performativity, suggesting a 
more post-humanist understanding of the wider practices that enable patient experience 
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to be produced. This is focussed on the idea that non-humans can contribute to the 
performance of both human and non-human arrangements. Like Butler and Austin, she 
questions the representationalist assumption of science by disagreeing, arguing that entities 
do not have prior attributes and there is nothing out there waiting to be represented as 
knowledge (Barad, 2003). Along with Pickering (1995), Barad argues that the world is full of 
agency and that we, the observer or researcher, are part of this ongoing ‘intra-action’ (2003, 
p. 815). Barad describes how if things do not have prior attributes, then they become or are 
made in the moment when intra-action occurs. It is through this intra-activity, an iterative 
and reciprocal two-way process, that specific entities and phenomena come into being, and 
they are all part of this doing, or process of becoming. It is thought that through a process 
of becoming, both knowledge and a new existence is produced. This process of becoming 
involves different things described by Peter Danholt (2005b) drawing on Isabelle Stengers 
(2000, p. 148) as vectors of becoming which are brought together. Alfred N. Whitehead 
(1978, p. 23) describes ‘How an actual entity becomes constitutes what that actual entity is…
It’s “being” is constituted by its “becoming”’. Considering this, and work by Wilkie (2013) on 
design prototypes, enables me to view patient experience not as objects and subjects, but 
rather as a process (of experiencing) that undergoes continual change. The measurement 
tools, patient body, subjectivities and clinics co-become and are mutually defined in the 
measurement process. Key here is that this change is dependent on the felicity conditions 
that are contained within the moment of becoming. Danholt, who says this becoming is a 
located practice where the outcomes are always indexical, echoes this.
 This understanding has profound implications for conceptualising patient 
experience, suggesting that it is not attributed to the physical body, like Butler argues, as 
a predefined property, but it is a ‘doing’ through performative actions and gestures. If the 
subjectivity of a patient is not pre-existing, nor determined by the body, then the cause of 
it is the effect of a practice making it happen – or as Butler describes, recitations of cultural 
norms which regulate it (1990). For patient experience, this then includes the material and 
physical PROMs, interviews, consultations and the human, material, object and nonhuman 
elements that surround the patient. Callon accounts for a combination of the performativity 
of language and action as happening within the performative utterances. He draws on 
the work of Deleuze and Guattari and the notion of assemblage which is neither linguistic 
nor outside of discourse to describe how heterogeneous agency and (non-human) action 
is achieved (1986, p. 4). He describes that it is within the heterogeneous socio-technical 
assemblage of actor-networks that material-discursive entities exist.
 For Butler, gender can be removed from the object, the physical body, and 
performed, and similarly, the patient experience can be performed away from the body of 
the patient through things such as data visualisations, diagrams and service maps which 
all do this work. Although this also means, following Barad’s rethinking of entities, not 
having a priori attributes calls into question the ‘givenness’ of the categories of human and 
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non-human. If nothing has qualities before it is interacted with (and if the subject/object 
divide is removed, or the man/machine distinction removed [Suchman 2007]), then there is 
no distinction between human and nonhuman and everything has the ability to act, then 
everything has agency, raising the question of who and what has agency to perform. 
 Performativity has become a widespread conceptual resource across many 
substantive areas of gender studies (Butler, 1990), economic sociology (MacKenzie and 
Millo, 2003; Callon, 2006), social and cultural research, and design (Danholt, 2005b; Ehn, 
2008; Yaneva, 2009; Wilkie et al., 2015); however, it is not without its critics. In the field of 
economic sociology, Uskali Mäki (2013) establishes some interesting arguments as to why 
the notion of performativity has become confused when developed beyond its Austin’s 
original purposes. Mäki describes how modern finance theory performs the financial 
market (MacKenzie, 2004). He also describes how MacKenzie, in his three definitions of 
performativity, ‘generic’, ‘effective’ and ‘Barnesian’, (Mackenzie, 2006, p. 17; MacKenzie, 
2008, pp. 55–56) misinterprets the ‘direct constitution’ that is required for something to 
be performative. Mäki argues that Mackenzie’s use of the concept misinterprets this for 
causal influence, i.e., there is no constitutive, or direct, relationship between the economic 
theoretical model and the empirical practices or the effects that MacKenzie claims are 
performative. In other words, the effects on the economy are not actually directly caused 
by the performative claim, but by other things. In light of this, Mäki calls for a returned 
to Austin’s original understanding of the term and for the emphasis to be placed back on 
the felicity conditions. Before I going further, I will outline three other key critiques of 
performativity that are relevant to this thesis and my understanding of the term.
Assumption 1: Backstage Performances
Erving Goffman’s dramaturgical model of sociality (1990) views human interactions as 
theatrical performances. This model uses the analogy of the stage and its associated actors, 
where people perform for an audience on a stage with curtains frontstage, and there is 
also the existence of a backstage for preparation to conceptualise performativity. This 
analogy can be problematic as it can lend itself to misunderstandings of the term where 
humans have the ability to choose the staging of the interaction in their daily lives, the 
objects involved in it and the audience they would perform to (Mol, 2002). But, this would 
presuppose a cognitive decision, referring back to Experience 1, where patients would be 
cognitively aware of their inner subjectivity and could choose what they wanted to perform, 
insinuating that there is a ‘doer’ behind the deed (Salih, 2007). This is quite different 
from other scholars’ understanding of performativity who argue that performativity is 
an action brought about through the happening of a situation. To move away from these 
misconceptions, in The Body Multiple, Mol suggested renaming performativity as enactment 
to move away from theatrical connotations. Since then, the term enactment has been 
taken up in a number of health studies (Berg and Bowker, 1997; Law and Singleton, 2003; 
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Lin, 2013), but arguably, this renaming is not really doing much more because scholars 
(Mol, 1998, 1999; Law and Urry, 2004) tend to use the two terms interchangeably, but 
more importantly, they are not engaging in the critical debate around the theoretical and 
empirical use of the notion of performativity (Mäki, 2013).
Assumption 2: Performativity of Language
In Austin’s original description of performativity, agency is clearly displaced from the 
utterer to language. Callon’s (2006) work on performativity of financial markets draws 
attention to the socio-technical networks of agency, providing a basis to criticise the 
emphasis on discourse. From an ANT-informed perspective, as well as discourse analysis, 
language and semiotic entities can thus be seen to have agency. A good example of this 
can be found in Monica Greco’s (2012) work around medically unexplained symptoms. 
Here, medical research literature has performative effects when naming and categorising 
the range of symptoms that people are experiencing that cannot be explained. This work 
acknowledges the performative power of words through analysing the effects of the rejection 
of psychological dimensions of these unexplained symptoms by classifications by the 
medical community. Further, Mark Learmonths (2005) analyses the performative and 
non-performative effects of language practices used within and around administration and 
management in the NHS, and Lars Nordgren (2008) traces the performativity of service 
management discourse in the linguistic usage of the customer concept in healthcare as 
going from a passive recipient of care to a co-producer of care. Evident in all these examples 
is that the performative dimension stays with language. They draw on Butler (1993) who, 
although going on to talk about the body, is unable to move away from the construction of 
language as the performative force. Mol (2002) also highlights that Butler’s performative 
construction of female identities fails to consider the materiality of medical instruments and 
female organs. 
Assumption 3: Performativity of Non-action
Up until this point, I have developed an understanding of performativity where some 
form of action or agency is happening that can involve some combination of humans and 
non-humans. This view depends on there being a resulting effect of the performative act. 
This would then mean that if there is no end result, then something is not performative. 
However, I would argue there is the possibility that sometimes interventions produce 
effects and sometimes they do not. Note that this is different from saying that something 
has failed to be performative.20 Nevertheless, what does this mean empirically if some 
20 Christian Licoppe (2010) describes how every social performance is open to failings, as well as creative invention  Moreover, per-
formative action is continually being repeated, however, following Butler, there is no guarantee of the same subject being produced  
Licoppe provides an interesting example of video communication technology being used in a French courtroom where the video fails 
to deliver the performative instruction from the judge in one room to a security guard in another 
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things fail to produce effects? Hennion and Gomart illustrate this through their work with 
drug users and music amateurs where their ‘active passion’ is the effect of an experience 
with something (1999, p. 220).21 Their description of a sociology of attachments describes 
the active passion and performative relations that humans can make to objects and 
situations. They apply action beyond ANT concerns around who is acting in the network, to 
questioning the limitations of action suggesting that within events there can be active and 
passive modalities (p. 222). For example, with drug users, even though sometimes there is 
no physical effect of their addiction visible on their body, the addiction is still performative 
and does not make it any less real. Hennion and Gomart justify this move away from ANT 
in critically saying that ANT does not allow access to events that are not actions. Their 
argument is that ANT is preoccupied by asking ‘Who’ acts within a network, which implies 
both human action to objects and a perspective on the network itself.22 Instead, they propose 
that we start to consider ‘what happens?’. This also aligns itself with Butler’s description of 
performativity not being a single act, but a series of repetitions. If everything is constantly 
performing all the time, then what enables some actions to create effects and consequences 
and others not?
 Performativity has been taken up as a way to inform design practice in regards to 
how designers perform future users in the things they make (Niedderer, 2007) as well as 
inform theoretical accounts of design practice (Danholt, 2005b; Wilkie and Michael, 2009). 
Work on the performativity of prototypes (Suchman et al., 2002b; Danholt, 2005b; Wilkie et 
al., 2015) describes how prototypes can be performed in how they shift between the present 
and the future. Danholt (2005) makes the case for considering the fruitfulness of thinking in 
terms of performativity in design in his study where he develops a diet diary for users with 
diabetes. Moreover, he considers how including users and artefacts in a design process affect 
each other. Described as socio-material prototypes, the interaction of socio-material forms 
are concrete and present as well as imaginary and futuristic (Danholt, 2005a, p. 5). This is 
a materiality of performativity where the material contributes. Through the prototyping 
process, the interaction of objects and bodies, subjectivities and bodies are also produced. 
Designers play a part in this production through the objects they introduce to this situation.
 This is where I anticipate there being space for this thesis to contribute, as it works 
with a performative understanding of experience that is currently used in both medicine 
and design. For example, a popular tool used in design are experience prototypes. Developed 
by IDEO, designers use proxy objects (camera, diaries) to attempt to access ‘first hand 
appreciations’ of (p. 424) particular situations, such as living with a pacemaker, travelling 
on a train or living with a physical disability (Buchenau and Suri, 2000). This approach 
21 This understanding of experience is similar to John Dewey who describes the experience of art as a mix of doing and undergoing 
where the subject does not bring it about, rather it is something that overwhelms us  See (Dewey, 1934) 
22 This echoes some of the criticisms around ANT and how agency is described as ‘managerial’ (Star and Griesemer, 1989; Fujimura, 
1992) as well as Haraway’s criticism of a world where everything is performative, where there is no innocence  See Haraway (1991) 
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aims to enable designers, clients and users to experience something themselves through 
staging Experience 1 for others around specific situations. This is a different understanding 
of prototypes from that of experience prototypes where designers attempt to stage a 
performative effect for others but are unaware of the potential multiplicity of performative 
effects. I would argue that such tools, experience prototypes, also operate to engender 
commercial practices around the design of experiences that are similar to a first-generation 
understanding of the experience economy.
Experience 4: Experience and the Event
Experience 4: Distributed and de-centred experience where agency is dispersed  
It is not pre-existing and can have no visible effects  It is dependent on felicity 
conditions  This understanding of experience is influenced by the notion of event 
to consider the situated action of this model of experience 
This brings me to the final understanding of experience that I have identified in the 
literature, Experience 4. Mariam Fraser’s notion of event (2009) can contribute to the critique 
of performativity to understand how performativity reduces or centres agency to particular 
acting entities – neurologists, drug users, patients and measurement tools. Drawing on 
Deleuze’s version of event, Fraser describes it as more than just something that happens. 
It is described as the coming together of entities that are social and material, human and 
non-human. The ‘giving up action for events’ (Gomart and Hennion, 1999, p.2) seeks to 
describe the relations between things, bodies and happening, and the independent reality 
of these events in themselves. I will use an example of an event in MS to illustrate and 
examine this critique of action from the literature. The recent controversial case of the 
unproven Chronic Cerebrospinal Venous Insufficiency (CCSVI) therapy as a cure for MS 
was escalated through the use of YouTube (Mazanderani et al., 2013).23 The scientific and 
medical community disassociated with this therapy because it was scientifically unproven 
(Gafson and Giovannoni, 2014), whereas the patient community endorsed it because it 
claimed to provide miraculous improvements in walking ability and cure people (Benjaminy 
et al., 2018). 
 Between 2011 and 2013, a range of videos started to appear on the internet of 
people with MS sharing their experience of the CCSVI therapy before and after they had 
the procedure. In these videos (Figure 16 and Figure 17), the patients carried out medical 
23 CCSVI is a reported abnormality in blood drainage from the brain and spinal cord  In 2009, Dr  Paolo Zamboni from the University of 
Ferrara in Italy published a hypothesis that this may contribute to nervous system damage in MS  This hypothesis was both socio-po-
litically and scientifically controversial and went viral via social media informing many people with MS about the therapy  Since then, 
Dr  Zamboni’s results have not been validated, yet many people with MS have undergone the therapy  This situation is particularly 
interesting due to the role that social media played in the development of the controversy around the treatment for MS  See Gafson 
and Giovannoni (2014) 
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Figure 16 Image still of a YouTube video where a person with MS is filming herself walk as far as she can after receiving 
the CCSVI treatment (Source: 23SheaCera (2011)  CCSVI Before and After Video  [video] Available at: https://www 
youtube com/watch?v=NoAdoNSvUbI [Accessed  19 March 2015]) 
Figure 17 Image still of YouTube video where a person with MS films herself walking with a cane before receiving the 
CCSVI treatment, and then without the cane after the treatment (Source: kumquat509 (2010)  Barbara Before and 
After CCSVI Video  [video] Available at: https://www youtube com/watch?v=Hn6p9R6fQaY [Accessed 10 March 2016]) 
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outcome measures to demonstrate their improved physical ability and fitness, particularly 
people walking further than a previous video after the treatment. These videos consisting of 
personal stories (Experience 1) and the completion of medical outcome measures (Experience 
2) created action and enough evidence for other patients to go out and get the dangerous 
therapy. There was a widespread increase in the number of patients going to get the 
treatment who then reported back in the same format. This example shows new and novel 
ways that experience circulates outside of the expert setting. 
 Using Fraser’s notion of event, it is much more difficult to identify where the agency 
is in this situation, but it does give importance to consider the materials that are actively 
involved in the production of experience. Is it the person filming themselves, the technical 
capacity of the camera, the home environment, the use of examples of things they can 
and cannot do or the aesthetics of the video, or is it a combination of all the above coming 
together? It is these specific felicity conditions that are part of the process of becoming, 
creating these versions of patient experiences. Gomart and Hennion (1999, p. 416) describe 
these as ‘mediators’ that ‘are not passive…but active producers’. Also, all of the entities 
existed before they came together, but changed in this process. The medical information 
existed in the clinic, in journals, at scientific conferences and the patients interacted 
with this knowledge through healthcare professionals. Within these videos, patients were 
adopting, adapting and appropriating the practices of medicine to demonstrate differences 
in their disease. Viewers of these videos were interacting with medical knowledge along 
with experiential knowledge through the videos, and this became very problematic for 
the medical community as it created something else, while also changing that which was 
involved. Everything changes in this coming together – the drug user (Gomart and Hennion, 
1999), the researcher (Michael, 2011) or the user with diabetes (Wilkie, 2013). So regardless 
of the scientific community rejecting the therapy, scientific knowledge and the medical 
community were part of the becoming of these experiences. Some of these are analytically 
available and others exist where access is not possible. Stengers describes how events occur 
outside the control of any single actor and the effects of an event remain unknown and 
unknowable (2000, p. 66).
 The concept of the event highlights a process where patients, experiences, 
practices, tools and researchers co-become, which is currently being discussed in design 
literature (Wilkie and Michael, 2009; Wilkie et al., 2014; Jönsson, 2014). The focus of this 
discussion is on how design can work with the potential of events while acknowledging 
the performativity of method. In other words, moving away from the idea that experiences 
can be designed or scripted as, ultimately, entities may do something quite different from 
what the designers intended. This is an opportunity to use the research event to ask more 
inventive questions about what could become in moments of interaction between patient, 
bodies, clinics and measurement tools (Wilkie et al., 2014). In relation to my thesis, what 
potential combinations of things (humans and non-humans) can be brought together in 
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designing research events to consider forms of patient experience? Answering this will then 
push to imagine, and create, new forms of patient experience. Also, what changes through 
these events and how? What conditions need and should be in place to direct this? What are 
productive felicity conditions?
 This focus on event over actions when thinking about patient experience allows me 
to consider the limited access to events that are not actions and the limited ways of relating 
to patient experience when it is not being measured. In developing a working definition of 
performativity to take forward through this thesis, I understand it as a development from 
the performativity literature which opens up the view that entities can do things, which is 
precisely the point that ANT makes, but along with becoming and event, it says that things 
can change in this process of action. By taking up my previously developed definition 
of performativity around the notion of event, I can think about the design process, and 
moments of design, as where multiple and diverse elements come together and, in coming 
together, change one another (Wilkie, 2013, p. 4).
Conclusion
In this first chapter, I have examined literature around four different versions of patient 
experience. Experience 1 describes the phenomenological approaches dominant within 
healthcare and design methods, such as EBCD. ANT points out how this understanding 
prioritises the subjective mind within humans, rendering them capable of having 
experiences. Drawing further on STS, Experience 2 is the immutable mobiles version 
generated through quantitative tools and design inscriptions circulated as data and 
visualisations in health measurement activities and EBCD processes. After this, I explore 
how Experience 3 is a performative result of the situated interplays of patients, objects and 
measurement practices and yet is limited by assumptions related to performativity around 
backstage analogies, terminology and limitations of recognising performativity as capable of 
only producing visible effects. Finally, Experience 4 calls for a distributed experience around 
the notion of event. By pulling out assumptions within these versions and considering how 
they either successfully or unsuccessfully hang together, patient experience as a knowable, 
concrete entity starts to unravel. 
The table of experience, shown in Figure 18, has now been populated with few 
exceptions with the different versions of experience identified throughout this chapter. As 
can be seen, there are two blank boxes marked with question marks at the bottom right of 
the table. These identify, at this stage in the thesis, unknowns. It is here that I am focussing 
my research and hope to contribute. I very much see this table as marking out the practo-
theoretical boundaries of this thesis and will return to address these empty boxes at the end 
of Chapter 5. 
 Moving on to the methodology chapter, STS provides sensibilities on how to look at 
the empirical situations where accounts of patient experience are co-produced and highlight 
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the attention that must be paid to the particular conditions in which such expressive 
arrangements take place. I will also take forward an understanding of patient experience 
as a situated accomplishment that is indexical to its site of production and to its locale of 
circulation. In light of the strengths, weaknesses and challenges set out in the performativity 
literature, I argue that performativity is an important conceptual tool for understanding how 
patient experience is constructed and mediated in practice, and that this performativity is 
situated, indexical and dependent upon particular felicity conditions. 
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Description Assumptions Design approach
Experience 1 This first understanding 
of experience is of a 
patient’s inner, subjective 
experience of events 
that has happened to 
them  This understanding 
is heavily influenced by 
phenomenology and is 
dominant in healthcare 
practices that treat patients 
as subjective beings 
The limitation of perception 
where individual people 
view the world differently 
depending on their 
embodied perspective and 
ontological view  This also 
presumes that humans 
know their own minds and 
access their thoughts, i e  
their memories  STS would 
argue that this point of 
view prioritises humans as 
perceiving subjects above 
all others  
A first generation of 
experience design 
understands customers as 
being passive recipients of 
experiences that designers 
can create  A second-
generation understanding 
likens experience design 
with co-creation and 
participatory design tradition 
where users are involved 
to talk for themselves and 
contribute to the change 
process  This understanding 
has underlying motivations of 
democratic principles of work 
management dynamics 
Experience 2 This version takes patient 
experience as a measured 
and objective phenomenon 
such as a number or a 
measure produced through 
data as generated from and 
reported through patients’ 
subjective accounts  This 
version can travel and have 
agency in making subjects  
This is not to be confused 
with the phenomenological 
perspective of experience, 
which is the ‘inner 
experience’ of a person, 
this notion is a generalised 
data version 
Presumes people are 
reflexive, rationale actors  
If you fail to produce 
data, you do not have an 
experience  People are a 
repository of knowledge 
that need to be quizzed  
Raises questions about 
the different forms of 
knowledge left out by 
methods to capture or 
represent this information 
Typical design inscription 
(immutable mobiles) that 
visually reduces knowledge 
production to simple and 
interrelated shapes  Action is 
ascribed to these shapes that 
are at the center of design 
activities 
Experience 3 This third understanding 
emerges out of the situated 
interplays between people, 
measuring instruments, etc  
which are socio-materially 
mediated  It argues that 
‘experience’ is the result 
of these practices and so 
cannot exist without them 
and has agency that can 
cause other actants to act 
and produce subjects  It is 
constituted in relation to 
various elements, and there 
is no single central core  
There is an indexicality of 
this experience where it is 
dependent on where it is 
embedded 
This version rejects the 
object/subject divide, 
but as a performative 
understanding, it has 
been used to focus on 
language, presupposes a 
backstage where there 
is a consciousness and 
is limited to recognising 
performativity as producing 
visible effects  
An understanding of the 
design process as entirely 
performative where both 
subjectivities and bodies 
are performed  Socio-
material assemblies of 
patients, measurement 
tools, health professionals, 
spreadsheets, etc  are 
performed that achieve 
different experiences  Can be 
simulated through experience 
prototypes and design tools  
Experience 4 This is a distributed 
experience that has 
distributed agency  It 
is not pre-existing and 
can have no visible 
effects  It is dependent 
on felicity conditions  
This understanding of 
experience is influenced 
by the notion of event to 
consider the situated action 
of this model of experience 
? ?
Figure 18 Table of experience (unfinished)
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Chapter 3: A Methodology for 
Studying Patient Experience
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In this chapter, I describe my approach to studying a performative understanding of patient 
experience through design-led research. The chapter will start with the methodological 
rationale I have chosen to use in this thesis, describing a combination of conceptual 
underpinnings from sociology and design-led methods. I then provide a detailed description 
and explanation of my research method choice. Finally, I discuss the methodological issues 
and challenges I anticipate encountering when conducting a study of patient experience 
through design-led research.  
Methodological Rationale
The methodological rationale of this thesis builds on the assumptions within approaches 
to patient experience discussed in the literature review from the fields of social science, 
medicine and design. These assumptions raise methodological challenges such as how 
to develop knowledge about patient experience that is not influenced by the method of 
knowledge generation and how different understandings of experience that are seemingly 
incompatible (e.g., quantitative and qualitative, ANT and subjectivity) can and are, in 
practice, made workable and hang together. Finally, it challenges what the implications 
of a performative understanding of patient experience are, taking into consideration the 
weaknesses that have been pointed out by critics of performativity.
 The methodological rationale for this thesis is inspired by ANT approaches and 
the performativity literature which considers knowledge to not be pre-existing, fixed or 
stable. Rather, according to the literature, knowledge is produced through practices and 
interactions of different actors. For example, in Enacting the Social, John Law and John Urry 
argue that social inquiry and its methods are not only means of uncovering but also means 
of enacting because they can make social realities and social worlds. As already outlined 
in the literature review, the performativity of method views them as constitutive, meaning 
they do not only describe worlds but they also participate in, reflect upon and enact these 
worlds. Law and Urry ask the question to researchers and, in my case, to designers, ‘Which 
realities? Which do we want to help to make more real, and which less real? How do we 
want to interfere (because interfere we will, one way or another)?’ (2004, p. 11). Here, I take 
‘interfering’ as intervening through design, contributing to making new worlds by adding 
new relationships, elements and capabilities. Therefore, I too am enacting a reality and 
version of patient experience through attempting to study it. Danholt (2008, p. 74) argues 
that ‘When not subscribing to a sharp distinction between description and intervention, the 
repertoire of what constitutes intervention and thus potential contributions is considerably 
broadened’. So, in relation to this thesis, how can design construct ‘good’, better or different 
patient experiences? Within this, it is interesting to think about what the potential 
connections that could be made between different human and non-human actors through 
my research are, what might be brought into being, or more importantly, ‘what should be 
brought into being’, (Law and Urry, 2004, p. 6). This decision, or ontological politics (Mol, 
71
1999, 2002; Law and Urry, 2004), describes how, or through which methods, we enact ethical 
worlds (and what kinds of ethics), shape new realities or design new tools for understanding 
and describes how these decisions are made and dealt with through design. Marc Berg 
(1998) argues that design is ontological politics and in doing so charges design with the 
responsibility of enabling certain outcomes whilst downplaying others. Law and Urry 
recognise the challenge of this methodological rationale (2004, p. 5); additionally, Haraway 
articulates there is no neutral position to research and describe the patient experience in a 
world where everything is performative (1988, 1991, 1994). So, my challenge is to think about 
how design research can move forward in this precarious position.
 To start, I suggest that, by following Callon’s notion of generalised symmetry, 
I can trace the networks that claim to make an Experience. Callon states that we must 
not constantly separate humans from non-humans when making these new entities 
and understandings of patient experience. This has been Callon’s (2004) criticism of 
participatory design processes which solely consider the participation of humans actors and 
the resources available to them. Hence, when developing and researching alternative forms 
of patient experience, or designing new methods, it is not just a question of satisfying the 
needs of human beings involved in the process (people with MS, clinicians, MS researchers). 
Rather, it is also about enabling the non-human agencies in enacting future possibilities. 
This argument, along with Pols’ (2005, p. 207) work describing how studying the patient 
perspective through talk only silences those without those capabilities, establishes why 
I am not directly asking people to report on their experiences. They would only produce 
Experience 1 and support these human-centric assumptions.
 In the previous chapter, I argued that experience is indexical to the site of its 
production and is dependent on felicity conditions. Therefore, in this research, I am 
aware of how the felicity conditions contribute to making different patient experiences 
and also take seriously the empirical settings (including things in them) that contribute 
to current versions of experience. In this research, I focus on the outpatient clinic, 
scientific conference and measurement activities that have been the subject of previous 
studies which observe the clinical practice (Singleton, 1998; Mol, 2002) and the scientific 
conference as a location where scientific resources are mobilised (Irwin and Michael, 
2003). In her study on the patient perspective of people in mental healthcare, Pols (2005) 
describes that observations of ‘situations’ with specific characteristics will allow humans 
(and non-humans) to enact appreciations. As I go on to describe later in this chapter, for 
the practice-based element of this research, I develop three pilot studies to scope out these 
situations. A more in-depth rationale for the pilot study approach is described later in this 
chapter, with the next empirical chapter providing a full description of each study and 
an empirical account of what happened. Through practice-based design interventions 
in these spaces, I attempt to enact new patient experiences and test their ‘success’ or 
efficacy and, like ANT, open the black boxes (Callon, 1986; Latour, 1987) of experience to 
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shed light on the complex relationships that exist amongst all actants, from MS patients, 
clinical practices, knowledge and non-medical objects to measurement technologies. 
In doing this, I use a similar descriptive framework when faced with either a human, 
questionnaire, trundle wheel or tuning fork. This helps me see how actor communities 
rally, network and position themselves to become knowable, hang together and also fail 
(Callon, 1986; Latour, 1987). This proposes the empirical task of following and tracing the 
actors and complex assemblages of practices, materials and discourses in and through 
which patient experiences are made. So, similarly to Latour (1988, p. 255), I study the 
practices and processes of making patient experience, paying attention to the places where 
patient experience is produced, circulated, made stable and inscribed in the practices of 
healthcare. Mol and Law (2004) demonstrate it is the routine and in-situ enactment of these 
bodies, diseases and medical practices where different versions of patient experience are 
enacted alongside each other. By following the procedural process of PROM development 
(the measurement tool used to measure patient experiences of their MS), I follow the 
process of knowledge production. This highlights opportunities for exploration and also 
identifies assumptions within these practices. This includes, for example, the clinic site as 
a specific location where Experience 1 is generated through consultations and measurement 
procedures, the scientific conference where Experience 2 is circulated through poster 
presentations with the patient body absent, and Experience 3, which is generated through 
design processes. This research explores the potential for Experience 4 to be brought into 
being through considering the notion of a research event.
This calls for a methodological engagement with the open-endedness of the social 
world where the object of study is multiple, and any intervention is performative. In 
Inventive Methods (2012), Celia Lury and Nina Wakeford build on Law and Urry’s (2004) 
understanding of the performativity of method to propose an inventory of research methods 
that enable the happening of the social, rather than just capturing or recording the here 
and now. Lury and Wakeford give examples of research tools such as tape recorders, 
patterns and design probes that actually come closer to being devices or instruments that 
go onto expand the present as ‘on going maximisation of the agencies involved in social life’ 
(2012, p. 5). This description enables the happening of the social through these research 
tools, acknowledges a socio-material perspective and gives attention to the properties of 
the medium, which is a core interest of design practice. Designers are already aware that 
materials have different capacities within the situations they are deployed. For example, 
using a focus group, a post-it note, mapping tools or prototypes in the situation makes a 
huge difference in what is achieved. The articulation of inventive methods encourages 
working with the potential agencies that design can provoke where designed interventions 
can prompt emergent enactments of potential situations while highlighting problematic 
existing practices. Yet, Inventive Methods further articulates the implications of using design 
within this methodological approach. For example, the inventiveness of the design can 
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never be known in advance of its deployment within a situation. Although the design can 
have an intended aim, I do not know what the social world will do until the research event, 
and thereby the heterogeneous network of actors, goes live, bringing together participants, 
knowledge, resources, recording devices, spaces and speculative forms of design.1 In relation 
to this, what emerges from the design is completely dependent and reliant on its relation 
to the situation in which it is used. This involves the agency and performativity of both 
human and non-human actors. This is a broader definition of method than used in more 
traditional social science. However, for design practice, I am engaged in working with 
the unpredictability of method inventiveness and in designing interactions that take the 
research context and specific problems into consideration. Moreover, I engage others in this 
process. Here, I think it comes down to a continuum of how things play out in practice with 
what is planned, what can be hoped for, what is brought forward in these moments and the 
capacity of what emerges in the use of design to address the problem.
Research Methods
This next section will give an account of the research methods I use to involve and engage 
people in this design research. I start with a brief background to the setting of the thesis, 
describing the current situation in design research as practiced in healthcare. I then 
describe the two main methods, the pilot studies and a research study involving three 
research events, followed by how these methods draw on engagement and involvement 
techniques currently being used in the health service, design and social science. In doing 
this, I highlight some issues, critiques and challenges of involving people in design research 
within healthcare context. 
 The practice-based element of this PhD thesis started in October 2012 and was a 
continuation of the work I was conducting as a visiting research assistant within the Barts 
MS research team at QMUL. Throughout the thesis I have held a research role at QMUL. 
As such, I have access to resources such as hospital and university spaces, conferences 
and lab meetings, as well as medical and scientific expertise that are relevant to the PhD 
research. It is important to acknowledge that this research is also positioned in the field of 
design research, along with engaging with the very specific field of MS. There are different 
definitions and understandings of design research which are generally described as research 
for design, research into design and research through design (Frayling, 1993), where the 
use of design within research is represented within these three different approaches. For 
this practice-based PhD, I understand design-led research to be when design practice has 
informed subsequent research, reflection and analysis, and where knowledge production 
involves the design and development of designed interactions. In other words, I practice 
1 Michael (2014) provides an interesting account of a research incident with a cat and a tape recorder which demonstrates how non-hu-
man agency can intervene in a research event 
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design through deploying interventions and use these events, and the interactions of 
different actors within them, as performative and empirical knowledge generating moments 
to explore new knowledge about patient experience (Sevaldson, 2010; Löwgren and Reimer, 
2013). In this thesis, I am using design as a method to research my object of study, which 
is the different, future possible versions of patient experience (Jonas, 2007). So, I would 
describe this work as research through design where the ‘process of iteratively designing 
artefacts as a creative way of investigating what a potential future might be’ (Zimmerman 
et al., 2010, p. 312). This is a design epistemology where the designerly way of knowing 
(Cross, 1982, p. 6) is valued as an important part of the research process and is separate to 
the practice of design, which is an approach to knowledge creation (Wilkie, 2013). In other 
words, thinking about design and doing design can be separated. This is why this thesis is 
practice-based. Doing design involves the practical engagement with the messy practices 
of measuring, visualising, acting on and designing patient experiences which goes on to 
inform further thinking.
 It is also important to keep in mind that the design practice presented in this thesis 
is not intended to solve perceived problems in the patient experience, nor is it to develop 
potential products or new services.2 The intention of each design intervention is to redesign 
the relations that are enacted in the specific sites to change patient, clinician and medical 
interactions, as well as roles within the sites, to generate new knowledge by provoking the 
existing system structures. Therefore, the designs presented in this thesis should not be 
judged as standalone design outcomes or solutions, but as reference points in a research 
process of exploring new knowledge about how patient experience can be generated, altered 
and affected by introducing design. As such, the research in this thesis did not begin with a 
research approach or perspective. Instead, it has been guided and informed by my current 
and previous design practice. 
 Similarly, this methodology was not in place prior to the start of the PhD. Rather, it 
has developed as I engaged further with the literature and the practical projects. Both the 
establishment of the literature review and the results of the pilot projects contributed to the 
methodology and suggest further directions for the practice-based research. Figure 19 shows 
a reflective image of how the pilot studies feed into the design of the research study.
Pilot Studies: Engaging with patients, healthcare professionals and MS researchers 
The three pilot studies are designed to further explore the assumptions within patient 
experience that are identified in the literature review. These are around different versions 
of experience hanging together, non-human agency and the performativity of design. The 
aim of the pilot studies is to empirically explore the conditions, procedures and instruments 
2 I would argue that this PhD started from my observation of designers attempting to design for the perceived problem of ‘patient 
experience’ in healthcare through approaches such as EBCD 
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Figure 19 How the pilot studies informed the study design 
76
that produce knowledge about the different versions of patient experience  The pilot studies 
are designed from my previous experience of the clinic and scientific conferences as I 
am already familiar with the conditions of these sites (different groups of people, my role 
within these spaces, the technical apparatus, environment, procedures etc.). I explore the 
performative effects of deploying specific activities and objects to see what happens in these 
sites as the studies are designed to engage with the social world rather than just investigate 
it.
I have been working with the Barts MS group for around eight years and within this 
time have delivered and been involved in many different projects as a design researcher. 
Although I am known in the field and at the study sites, in a way I am still an outsider, as 
I do not have medical training. This enables me the position to ask questions about ‘what 
everybody knows’, (Shapin and Schaffer, 1985, p. 6) asking questions about simple or obvious 
aspects of medical and scientific culture without being thought of as a trouble maker. The 
pilot studies probe at and investigate some of the taken-for-granted aspects of medical and 
scientific culture and practice to highlight aspects of patient experience that I am researching. 
The participant groups involved in each study are different. I approach each group of 
participants myself and invite them to take part in the project, explaining what the purpose 
of the study is, what their role is and how their involvement would be used. Each study has 
an activity for the participant to complete, which strikes a balance of being novel, enjoyable 
and inviting while being able to prompt participant engagement. 
The aim of the pilot studies is not to produce information to be analysed. Rather, 
the aim is to use and deploy them, providing information and insights on the connections 
of present actors. The activities and associated tools enable playful, explorative responses 
from the participants that generate new thinking about how patient experience is performed 
in the clinical encounter, at scientific conferences and through measurement activities. In 
this way, the pilot studies can be likened to cultural probes (Gaver et al., 2004) which are 
deployed in the design process to develop unique and often unexpected understandings of a 
situation rather than produce coherent, generalisable accounts. 
Speculative design is a body of work that grounds the practice-based element of this 
thesis. As a field of design, speculative and critical design marks itself as different from 
that of affirmative and commercial design in that it is a design practice which does not 
respond to the practical needs of users and are developed outside the rules and constraints 
that inform and direct the development of normative commercial products.3 This design 
approach creates combinations of obliquely functional objects, manipulated photography, 
imagery and film to present fictional scenarios to create space for dreaming, challenging 
3 Critical design is often connected to the works of Anthony Dunne and Fiona Raby from the Royal College of Art, London (2001) where 
it was introduced almost fifteen years ago and has continued to resonate by practicing designers and within the design research 
world   As a previous student of the MA Design Interactions department at the Royal College of Art, these approaches have had a large 
influence on my design practice and my perspectives on design research 
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and debating. The purpose of this is to engage people to explore how the world could 
be, which in turn aims to highlight problems, complexities and opportunities to move 
forward. These scenarios are intended to appeal to a broad and diverse audience, and 
though a variety of contexts such as the general public in museums and galleries or experts 
working in related fields. Dunne and Raby (2001) suggest that designers can initiate a 
critical discussion about the long-term implications of emerging technologies, such as 
nanotechnology and synthetic biology through workshops, exhibitions and publications, 
which provide opportunities for audiences to engage with this form of design and its ideas. 
Unfortunately, it is precisely these dissemination formats that have been the focus of much 
of the criticisms of critical design.4 However, situated in an emerging scientific discourse 
and material culture, speculative design (which tends to have a more ethnographic approach 
through techniques such as cultural probes) seems to have become more absorbed into 
design research practices. For example, in the Energy Communities project led by the 
Interaction Research Studio at Goldsmiths, speculative prototypes were implemented and 
installed in users’ homes to encourage novel relations amongst participants and prototypes 
to potentially reconfigure what the very ‘fact’ or ‘problem’ might be around issues such as 
what counts as energy and what actors, communities and issues are involved (Gaver et al., 
2015). Michael (2012a, p. 174) describes how these probes and speculative design artefacts 
seek ‘the idiotic’. Michael does this using Stengers’ (2005) reflective figure of the idiot, 
which she adapted from Deleuze. It is also characterized by a ‘proactive idiocy’ in what he 
calls ‘engagement events’ (2012b). The idiot is a designed object, responding to events in 
non-sensical ways, challenging their meanings. So, for example, the idiotic prototypes that 
were deployed in domestic settings were described as creating inventive problems through 
participants’ responses. Thereby, they were framed not as satisfying human needs but, 
rather, as designerly ways to frame public engagements around energy-demand reduction. 
This work reflects the recent growing interest from STS scholars and design researchers 
to work together to explore the potential of a messier, more material and more speculative 
process of research, where researchers from both sides show an interest in each other’s 
practices, skills and philosophical offerings.
 The main point here is to show how the design of activities, tools, objects and 
interactions between people, other objects, issues and so on act as creative explorations 
into emerging issues and situations bringing things about, rather than returning data. The 
designs in this thesis follow the ethos and practice of speculative design for two reasons. 
Firstly, speculation can be used as a tool for questioning how patient experience, as a 
generally accepted fact within healthcare and design, is done to open up conversations 
4 Matt Malpass describes how critical design has suffered from oversimplification through its chosen formats of communication  For 
example, a typical output of a critical design projects is in galleries or magazines, which present the work alongside short captions 
which in cases have misrepresented the work (2013, p  335) 
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about what might be left out through inventive problem making and question how current 
practices enforce specific kinds of patient experience. And the second reason is to allow 
the potential of the objects of design to speculatively intervene in clinics, conferences and 
measurement activities, enabling the possibility of these events to become apparent. This 
then allows a less human-centred approach to be used for one that is more performative. 
This thesis aims to contribute how to understand the coming together of entities, people, 
bodies, knowledge and tools, and understand the potential of the contribution of design 
to enter into these new relationships. The pilot studies are explained further in the next 
chapter of the thesis.
Research Study: A Design-led Approach to Explore the Performativity of Measuring 
Upper-limb Function in MS
The final and substantive method of this thesis is the design of a research study that 
sets out to develop a new PROM to measure upper-limb function for people with MS.5 
The study brings together people with MS to take part in three research events that are 
based on the FDA PROM development process.6 I have already pointed out how the FDA 
PROM process uses different versions of patient experience (Experience 1, 2 and 3 and their 
associated assumptions) to create a reduced list of general measurement activities which 
further work to distribute versions of Experience 2  The research study in this thesis focuses 
on the situated enactments of MS and goes through the development process, exploring 
the potential for design methods to create a new PROM and generate alternate versions of 
patient experience. Going through these stages allows me to study the simplification process 
that medicine operates in to generate facts of patient experience and seeks to creatively 
explore what new types could be created through the introduction of design.
 This research study, focuses on meaningful, situated and interesting activities where 
people’s upper-limb function is affected by their MS. These can be anything, including 
hobbies, daily routines, interests, desires or wishful activities. The aim is to investigate what 
happens to the arm and hand function when attempting to complete these activities – what 
is the combination of bodies, tools, environments and objects that come together in these 
moments. I use an empirical, situated approach to see what versions of experience and 
issues come up (Star, 1983, p. 206). This takes the situated action of MS seriously, which 
has been discussed in the STS analysis of disability studies (Galis, 2011), where disability 
is an effect of a process of associations in a network. For example, pavements, outpatient 
departments, medical practices and measurement tools, can all enact action – agency. 
5 At the start of this research, I set out to develop a new PROM in the final research study  As we shall see in Chapter 5, this effort 
proves to be misguided  However in this methodology chapter, I explain the reasoning I used in setting up the study with this original 
aim  
6 I am describing these as research events, rather than workshops or focus groups to open up the event to consider the performativity 
of method (Michael, 2012a)  The aim is to raise questions about the conditions, procedures and instruments for producing knowledge 
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As ANT extends intentionality to non-human entities, I can consider a range of objects 
and how they perform action. This is a closer consideration of the material politics of 
design. If fastening shirt buttons and peeling an onion can become enactments of health 
progression as developed through a system by medical experts, then what would a system of 
measurement look like if developed by people with MS? What if other instruments are used 
for producing knowledge?
 These activities are recorded and collected through a combination of participant 
insights and comments, along with observations of physical demonstrations of the activities. 
With the participants, we investigate what measurement means in the context of each 
everyday activity to develop some form of understanding of how it is completed for different 
people in different contexts. Introducing objects into this discussion enables people to take a 
new perspective on the measurement activity, triggering reactions, affects and responses to 
the activities. This is a re-imagining of the measurement activity where there is an openness 
and playfulness to prompt participants to share unexpected rationalities. This builds on 
insights from the pilot studies where the reactions and actions of both the participants and 
the researcher contribute to the performative effects of a design. The research events are 
settings for a generative collaboration between myself, the participants and the interaction 
of objects (tools, setting, environment) present to create a space for new versions to emerge. 
The three events are held in a non-medicalised setting as I am particularly interested to 
find out what versions of experience can be made without the inclusion of medical spaces, 
equipment and assumptions. This is an opportunity for the patients, bodies, tools, objects 
and activities to come together and co-become, changing in this process.
 At the simplest level, this process gathers a range of activities that affect the upper-
limb function of people with MS that are meaningful to them in their daily life, rather than 
activities that are statistically meaningful to medicine. I imagine this to be a contribution to 
the existing ABILHAND tool which requires its current activities to be updated for people 
with MS (Penta et al., 1998; Barrett et al., 2013). However, I aim for something more radical 
in both its format and its function.
 In the responses and reactions from participants, I am not looking for patterns or 
solutions, but specificities that can be developing into what I originally intend to produce, 
a new PROM to generate new and different versions of patient experience. I am looking to 
explore the potential of creating an alternative PROM tool that is not limited to producing 
numbers (Experience 2 like current PROMs). But, rather, generate, or script, more inventive 
and playful activities to measure upper-limb function and other versions of patient 
experience. The format this takes – digital, video or instruction manual – is unknown. 
However, it is a more engaging material object than the existing paper-based questionnaire. 
This acts to reframe the measurement activity not only as something that is done to people 
with MS but rather as something that also is more participatory and engages other actors. 
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Involving patients in research activities
This research is part of a part-time PhD registered at Goldsmiths, University of London, so 
it must comply with the University of London ethics procedures. As it also involves people 
who are patients of the NHS trust that this research is linked to, it must have successful 
Health Regulatory Authority (HRA) approval. This is the process for research conducted 
in England with the NHS trust that assess the governance and legal compliance of the 
research. I will discuss the ethical issues around this work shortly. The implication of going 
through this process is that specific research procedures that apply to medical research must 
be followed. This involves producing a protocol document (see Appendix C) which sets out 
the procedure for conducing the research, including information on the sampling decisions, 
consent process, dissemination plan, confidentiality and data storage.7 There is an 
increasing number of design research projects that engage with HRA approval procedures 
which also aim to explore aspects of design research (Bowen et al. 2010; Macdonald 2013; 
Neves 2014).8 This engagement with the practical procedures increases the accountability in 
the positioning of the project as design research does not have authority in medical research 
since it is from a different field. This is an important point for practitioners working with 
patients in a healthcare context, or those that would like to establish themselves as a 
researcher in this field and have impact within it. It involves strict and rigorous regulations 
and is a time-consuming and complex process to complete as part of a PhD. I have previous 
experience putting together and delivered previous research involving the deployment of 
design tools within a healthcare study (Thomson et al., 2015). This experience highlighted 
strengths, limitations and opportunities within the medical research process for design-
led research to further explore, interrogate and make proposals around the assumptions of 
involving people in research. This also allows me to further explore some of the assumptions 
that are inherent in the process, for example, the way patients are produced within the 
7 Operational documents, like the study protocol are more frequently encountered in medical research than design (Berg, 1997; Tim-
mermans and Berg, 1997; Berg and Mol, 1998) where its aim is to outline the procedures of the research study, or bring order where 
there is disorder (Berg and Mol, 1998, p  228)  The protocol can also be thought about analytically as a technique, or a tool that em-
bodies of script of how the research event is supposed to be implemented with delegated roles and tasks for researchers, patients, 
healthcare professionals and ethical committee members (Akrich, 1992)  The protocol is a sequenced description of how to act in 
each situation of the research study  Although it is a written text, it affects peoples work and as I attempt to argue, contributes to the 
definition of versions of patient experience 
8 This point is in comparison to design projects that engage with healthcare but under a consultancy model such as those ran by the 
Design Council, Think Public, Helen Hamlyn Centre at the RCA and also projects produced from the hybrid design and healthcare 
space, the Helix Centre  Problematically, all too few design projects are asking questions of what types of research we are enacting 
and how we intervene through the design projects and proposals 
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medical research process and the limited role ascribed to patients in the process of being 
either research subjects or participants.
There are two reasons for choosing to conduct this research.9 Firstly, practically, 
contribute to the field of practice-based design research within healthcare. Secondly, it 
enables me to highlight assumptions about patient experience in the medical research 
process. Patients are currently involved in the research process through patient public 
involvement (PPI) activities.10 These have traditionally been considered activities that 
increase trial recruitment. However, now PPI activities are working towards being more 
participatory, empowered roles for patients in the research process. Levels of participation 
in PPI projects are commonly categorised using Arnstein’s (1969) ladder of participation, 
ranging from no participation and tokenistic involvement to full participation. More 
participatory activities would be patients contributing to research studies steering 
committees, analysing data and contributing to writing up the research. Unfortunately, 
these are difficult to achieve with most PPI activities that are actually carried out being 
criticised as being tokenistic formats of involvement (Buck et al., 2014). However, 
considering the assumptions of Experience 1 and an ANT-informed understanding of 
participation (Andersen et al., 2015), these levels are ascribed through subjective intensions 
both from participants and those leading PPI activities. Whereas, ANT is concerned 
with things in the making and so enables me to look beyond the participation of specific 
and solely human actors, and see participation as an achievement of a network with 
performative effects. 
 Further criticism of existing PPI activities is said to be about the lack of theoretical 
consideration about the ways that patients are included in research activities and the lack of 
analysis of the epistemological implications of these modes of engagement (McKevitt, 2013; 
Boaz et al., 2016). For example, focus groups are a popular method to gain patient opinions 
on topics of potential research in the grant-writing stage and frequently used to evidence 
PPI activities. Lezaun (2007) describes how the group dynamic is used to bring relevant 
opinions into existence. Focus groups which originated in business and were used to obtain 
a range of opinions on products with the goal of enhancing marketing strategies (Krueger 
and Casey, 2009). Where a selected group is brought together with the goal of getting the 
individuals to share ideas and perspectives by asking them questions to start the discussion. 
Yet, further literature describes focus groups as technologies of elicitation, a term I will explore 
9 Research activities within medicine and healthcare that involve human participants can be described in different ways  Clinical 
studies, sometimes called clinical trials for example, are where participants are assigned specific interventions according to a research 
protocol  Observational studies are where participants are not assigned to specific interventions and the group is observed  But there 
are many other types  Common to all these studies is their aim to answer specific questions on how to prevent, diagnose and treat 
the participants that are involved in the study  There is no clear definition of a research study, but I would describe it as the recog-
nised procedural process, involving established research methods, of developing new knowledge within healthcare 
10 INVOLVE are a national advisory group set up by the Department of Health who promote and support public involvement at every 
stage of the research process  They have published widely in this area, including guidance on planning, managing, designing research 
instruments, undertaking, analysing, writing, disseminating and implementing research  
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further in Chapter 4, as they empower the agenda of the researcher. These assumptions of 
participation have not been problematised in the field of PPI. Design that engages with the 
politics of knowledge production, as influenced from fields such as public engagement in 
science, has an opportunity to engage patients in research in novel ways. Therefore, there 
is an opportunity for design research that has a performative understanding of method and 
an awareness of the assumptions of patients’ experience to contribute to the field of PPI 
empirically and theoretically. 
Research Participants 
Participants that are invited to take part in the research study are people with MS and 
healthcare professionals (neurologists, occupational therapists, MS nurses). These groups 
of people are involved in this study due to the type of knowledge they can potentially 
contribute in an attempt to provide a symmetrical approach to engagement. The 
involvement of people with MS in the research process is due to their embodied, practical 
knowledge of MS. I describe it as knowledge rather than experience of MS to try and 
avoid picking up some of the assumptions surrounding the use of experience that have 
already been highlighted in the literature review. Unlike scholars associated with public 
engagement in science, I do not describe it as ‘lay opinion’, which stands in contrast to an 
expert opinion.11 Ives et al. (2013) point out that as people with lay knowledge become more 
involved in the research process, they ultimately lose their ‘layness’ and become ‘tamed’ 
(p. 3), therefore becoming unable to remain objective of the process they are involved in. 
Instead, involving people in contributing their embodied knowledge attempts to keep an 
empirical focus on the study while also following the participatory design tradition and 
identities, and recognises people as competent practitioners (Suchman, 2007). Within this 
project, they are competent practitioners, as they contribute their knowledge of day-to-day 
situations where MS affects them in the home. 
 This study invites people with MS who suffer from problems with their upper-limb 
function and generally have the progressive form of MS either PPMS or SPMS. This type 
of MS is characterised by having a persistent increase in disability, where other forms of 
MS will have plateaus with periods of not getting worse. People with SPMS and PPMS will 
usually have walking difficulties and rely on either a walking aid such as a stick, a walker or 
be in a wheelchair. Until recently, the treatments that have been developed for people with 
MS have focussed on people with the relapsing form of the disease, as it was considered 
that once a person had gone onto the SPMS and PPMS stages, they could not be helped 
by treatments. Now there is an argument to save as much function in people with MS, 
regardless of the fact that they are already in a wheelchair (Giovannoni et al., 2017). But the 
11 Ives et al  (2013) describe the importance of the lay opinion within research processes as it brings the opinions and experiences of 
illness and service use of ‘outsiders’ into the research process 
83
problem, that has been outlined in the literature review, was illustrated in the ASCEND trial, 
where treatments are not considered to help improve (or save!) function in SPMS and PPMS 
as the outcome measures to measure and prove the improvement of taking the treatment 
all focus on walking distances. The ASCEND trials showed an improvement in upper-limb 
function through using the 9-hole peg test.12 This calls for a more sensitive and realistic 
measure of people with MS’s upper-limb function.  
 Clinicians are involved to contribute their practical knowledge of MS from medicine 
and their understanding of the body. This group involves one MS specialist occupational 
therapist and one MS specialist neurologist, Gavin Giovannoni (Professor of Neurology), 
to ensure that the study is designed and carried out with interest and relevance to the field 
of MS while also ensuring the ethical conduct of research. My role in the research study is 
as the principle investigator, which has responsibilities for designing the research study, 
completing the procedural ethical requirements, recruiting for the study, managing the 
research team and managing logistics (patient travel, funding, room booking, catering). The 
research events are facilitated by Harriet Smith, a collaborator from my previous work, who 
is also a professional facilitator and a person with MS; therefore, she has a skillset that can 
facilitate the session and contribute to the suitable set up of the sessions. 
Measuring upper-limb function in MS
The procedure follows the standard stages of the PROM development process as set 
out by the FDA, focussing specifically on item generation and selection, developing a 
scale and testing (U.S. Department of Health and Human Services and Food and Drug 
Administration, 2009). The aim of the research study is to develop a new PROM to measure 
upper-limb function for people with MS. The current PROM that is used to measure upper-
limb function is the ABILHAND questionnaire shown in Figure 20 (Penta et al., 1998). It 
lists 56 questions which measure manual ability (defined as the capacity to manage daily 
activities using the upper limbs, regardless of the strategies involved) and asks patients 
to record on paper by making an ‘X’ on a Likert scale of difficulty, ranging from ‘Not at 
all’ to ‘Extremely’. The results of all of the questions are given scores so, when summed 
up, a total score is produced which is used to measure the variable upper-limb function. 
The questions that are asked are considered measurements of the variable, upper-limb 
function. The appropriateness of this measure has gone under scrutiny recently as it was 
originally developed to measure people recovering from stroke and was not developed 
with psychometric measures. This work highlights the need for extending the scale in two 
ways (Barrett et al., 2013). Firstly, by adding tasks that are more difficult than question 16 
(threading a needle) and easier than question 14 (washing your hands). Secondly, it was 
12 For a full comparison of upper-limb function measures, see Lamers and Feys (2014) 
84
Figure 20 The Abilhand Questionnaire listing the upper limb activites 
that are currently measured in people with MS by the clinical team 
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described that there is a need to make the activities more relevant to people with MS, as the 
activities listed on the questionnaire are not specific to the condition.13 Through the three 
events of the research study, participants propose new items to include in this new scale and 
measure that are both more relevant to them, and better measure their capabilities. 
Activities 
The three research events take place two weeks apart and each last three hours in total, with 
comfort breaks throughout. The three-hour session is structured around a number of group 
activities that are encouraged and supported by objects displayed in the room. Each event 
begins with a welcome from the facilitator and a description of what is about to happen. 
 The new items are represented through objects which invite participants to take an 
active role in contributing their knowledge to the study while also being designed in a way 
that allows non-humans opportunities for agency. The use of objects, tools, props or probes 
in design activities has been widely used in design research.14 Ehn and Kyng (1991) describe 
how the use of prototypes of rough materials such as foam, cardboard and clay can create 
a language where everyone in a workshop can share. Other tools such as probes (Gaver et 
al., 1999; Mattelmäki, 2006) or design games (Brandt, 2006) can engage participants to 
experiment and explore new possibilities. Figure 21 illustrates and explains the three stages 
of the research study.15  
 Involving objects to represent activities recognises the performativity of design and 
moves on from Butler’s performative understanding of language to involve thinking about 
the material agency of the tools and activities that are involved in the research events. These 
have been described as co-agents in performative acts (Anderson, 2006) where, in a way, we 
can create what we study through the design of activities, taking into account our knowledge 
practices and their capacity and involvement in making knowledge. I aim to work with 
this productively, in choosing to study patient experience through upper-limb activities 
positioned around activities of measurements which celebrate situated interactions to bring 
about interesting future experiences. 
13 In an article on the Barts MS research blog, people with MS suggested activities of popping a pill packet, picking their nose, playing 
dominoes and bum wiping as example activities that are affected by difficulties in upper-limb function (Giovannoni, 2016)  These were 
in response to a blog article about the limitations of the ABILHAND questionnaire to capture activities that affect people with MS 
14 Cultural probes are starting to be adapted and used by health researchers and applied within healthcare contexts (Wherton et al , 
2012)  This has sought criticism from designers as a misappropriation of the core principles and values of the technique and described 
as a discount ethnography (Boehner et al , 2012)  Therefore, it is important that I am clear of the purpose of these explorative tools 
and what they contribute to the research activity 
15 Figure 21 is itself an immutable mobile in how it renders the research event as flat and contrivable (which I know it is not)  This 
illustration has been produced to describe the procedural process of the study here in this thesis and also for the ethical planning 
process 
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Figure 21 The MOT study process
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Removing assumptions 
The research study is held in a private meeting room in a venue at the Olympic park, 
Stratford, East London. The main reason for this is that it is a neutral environment which 
does not prioritise any of the participant groups (i.e., it is not a clinic space). This physically 
removes the participants from the hospital space with medical devices and sterile flooring 
and reduces the chance of interruptions by clinical colleagues. Similarly, all participants 
have to travel to the study venue, which is a journey to a new space rather than their regular 
journey to work, or journey to a hospital appointment. The material environment can have 
an enabling or disabling role and play an important part of interactions, as Pols (2005, p. 
212) describes how hospital spaces can influence how and if appreciations are enacted. 
It is hoped that this material engagement moves participants beyond categorised roles of 
‘patient’, ‘researcher’ and ‘clinician’ that are ascribed to people in professional, hospital and 
research contexts to enable them to explore different or alternative roles.
Recording
Within the research study, I take on an analytical role to observe the research events. 
This is a form of participant observation, a data collection method most commonly used 
in ethnographic studies that has been adapted by designers.16 Design-led approaches to 
participant observation differ from the more social science or anthropological approaches 
where descriptive accounts are produced and analysed via formally recognised means. 
When designers directly observe social situations, they do this with the aim to not produce 
‘good’ descriptive accounts, but to produce insights for the design activity. 
 Within the research events, I focus on the empirical interactions between human 
and non-human actors, their orderings, disorderings and effects. Also, by tracing how things 
go wrong in social processes, we can trace how non-humans play their part (Michael, 2004, 
p. 6). I document the reactions and actions of the participants through sound recording and 
hand transcription (Appendix A), note-taking (Appendix B) and still photography. I focus 
on the ‘liveness’ of the research event, reporting on the heterogeneous network of actants 
that are brought together and their agency. I also include non-humans into the analysis in a 
16 Ethnography is a methodology that originally developed within anthropology where a researcher aims to produce descriptions of 
people’s practices and interpretations of their meaning by becoming involved in their everyday activities (Blomberg et al , 2003)  
‘Traditional’ ethnography is often seen as difficult to integrate with design processes (which are deadline-driven, or play a smaller part 
of a larger design activity) as ethnography is intended to be a ‘prolonged activity’ over several years, and produces findings that are 
often long and discursive (Hughes et al , 1995)  As a result of this, several forms of more flexible approaches to participant observa-
tion have developed that provide designers with valuable insights into the perspectives and experiences of those they are designing 
for  ‘Design ethnography’ (Salvador et al , 2010, p  36) or ‘quick and dirty’ ethnography (Hughes et al , 1995) is where short, focused 
studies are conducted to quickly gain a general picture of the research setting  These approaches are used within academia as well as 
industry, with IDEO developing ‘corporate ethnography’ (Suri and Howard, 2006) for manufacturers to aid product development and 
evaluation  Here, the approaches focus on portions of contexts and patterns of everyday life that are deemed important to inform 
design, instead of attempting a comprehensive understanding of a context  Yet, it is for this reason that designers have been criticised 
as not being suitably qualified to produce an understanding of a context as they develop bias understandings with superficial over-
views and lack analytical sensibilities 
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way that does not imply dichotomy of human/non-human, subject/object (for this Michael 
proposes the term co-agent [2004, p.19]).
 Following the critique of performativity through the lens of event, it becomes much 
more difficult to identify where agency is happening. I expect that some of the performative 
effects are analytically unavailable, and for others access is not be possible (for example 
the effect of drug users as described by Gomart and Hennion [1999]). The point here is that 
events occur outside of the control of any single actor and the effects of this is unknown and 
unknowable. Therefore, in an attempt to record non-action, I sound-record, note-take and 
capture still photography where necessary to capture how the activities unfold. 
Consent
Conducting any form of research involves ethical procedures that need to be followed to 
ensure that the research is carried out in a procedural and ethical way, but delivering a study 
within a healthcare context involves an extra level of contractual and procedural processes. 
This thesis is based within the design department at Goldsmiths, and the practice-based 
element, the pilot studies and the research study situated within the Barts MS research team 
at QMUL. The people involved in this research are clinicians (neurologists, occupational 
therapists, clinical researchers and neuroimmunologists) and patients (people with MS) who 
are invited to take part in the research activity from the Barts health NHS trust. Therefore, 
I gain informed consent from all of the participants involved.17 A participant information 
sheet explains how their involvement and information shared in the session is used, what to 
do if they would like to withdraw from the study and confirm, for the patient participants, 
that their clinical care is not affected by their involvement. There is no formal ethical 
approval in place for the pilot studies as they are linked to service-improvement activities 
related with my professional role within QMUL. All participation in these studies, and the 
research study, is voluntary and confidential where no data collected will make it possible to 
identify any individuals. 
 In regard to anonymisation throughout the thesis, I have changed the names of 
individual patients, but unlike other studies of healthcare groups in sociology (Berg, 1996; 
Singleton, 1998; Mol, 2002; Pols, 2005) or in design (Danholt, 2008; Wilkie, 2010), I do not 
anonymise the locations or institutions. The reason for this is that the work is practice based 
and will be in the public sphere associated with my name, and so would be easy to find.
17 Medical research ethics were put in place after the horrific treatment and experimentation of the sick and other groups of people 
carried out in the medical institutions of the Third Reich’s Universities, hostels and concentration camps  After World War Two, this 
led to the development of principles intended to regulate the relationship between patient and doctor, science and subject  The key 
to this relationship was the recognition of the right of the patient, or the subject, through the principle of ‘informed consent’, which 
is a contractual agreement and understanding of what their participation will involve 
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Ethical considerations of methodology
This design research engages in the practice of medical measurement of individual’s 
physical disability and chronic illness progression, investigates practical activities that are 
conducted between healthcare professionals and patients, and attempts to have a closer 
look at how MS is enacted in people’s lives. I use explorative design research methods that 
are inventive, and where I am even unsure of the effects of their deployment, in that they 
can bring some things into being over others. There is no standard design-led research 
procedure for navigating this complex situation, so I must take on, re-design and adapt 
current health service research procedures to make this work, and conduct responsible and 
accountable design research. In light of this, the study does not necessarily encourage the 
involvement of newly diagnosed patients. I also acknowledge and am aware that people with 
MS are coming together to share their thoughts and feelings about their care and life living 
with MS, including potential private and upsetting stories. I treat all of these contributions 
with the greatest respect and can provide details of further sources of support if this is 
necessary. There are more details on this process in the MOT study protocol in Appendix C.
Reflexivity
In most research methodologies, interfering with the object of study constitutes bias. Hence, 
researchers are encouraged to account reflexively for their biases in order for others to 
evaluate the knowledge claim. The idea of bias is significantly reconfigured when drawing 
on STS and understandings of performativity where the possibility of obtaining unmediated 
access to an ‘objective world’ is disregarded.18 Further, this idea needs to be extended with 
practice-based design research that aims to intervene in the world it aims to study, in one 
way or another. Therefore, the concern of bias changes and becomes somewhat irrelevant 
as it presumes that research should be conducted out with limitations of interventions and 
perspectives.19 
 This is of particular interest to practice-based design research that focusses 
on physical interactions within the world which, in my case, are embroiled with the 
researcher’s involvement in the research setting. Through my research, I am not aiming 
to produce pristine objective descriptions of the world and the research context.20 Instead, 
using a performative understanding of research, I consider the instruments, techniques 
and representations, considering how they enable knowledge to be produced. Following 
18 For critiques and further unfolding of the problem and implicit assumptions of reflexivity, see Latour (1987) and Barad (2007) 
19 As previously mentioned in the literature review, Haraway (1991) points out how some accounts of STS researchers tracing tech-
noscientific networks do not include accounts of their own participation and influence in the construction of knowledge and can be 
likened to a ‘god trick’ with their view of the research as from above looking down 
20 This is related to the criticisms of design approaches to ethnography which suggest that designers do not observe in such a way as 
to minimise their influence, and that any understanding they develop is biased, subjective and not formulated according to any formal 
analytic techniques  In order to clarify the role and influence of my subjectivity in this research, I include evidence of my research 
development process in the accounts of the pilot studies, the study development and as documents in the Appendix of this thesis 
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STS, a central contention is an appreciation of those instruments, apparatuses, theories 
and representations, since they are practices through which the world is cultivated and 
performed. 
 When writing up my account of the research events, I include descriptions of my 
involvement to attempt to provide a reflexive account. For this, I draw on Latour’s ‘infra-
reflexivity’ (1988, p. 169) and Donald Shön’s (1983) reflexive practitioner to make clear how 
my accounts of the research texts are produced. The notion of the reflexive practitioner, 
and extension to the reflexive designer, produces accounts of design that are situated and 
emergent through the thesis and made valid for design research. Michael (2004) describes 
this as being a co-agent where the researcher is situated, embodied, emergent and embroiled 
within the range of actors present.
 In this research, and for this thesis, I am telling the stories of the research, so I am 
aware there is a certain impossibility of symmetry as I provide an account of the research 
from my perspective as a human actor and a feminist design researcher. In relation to 
providing reflexive written accounts of the research activity, there are three main formats 
that are produced: the analytical and theoretical descriptions in reference to the different 
perspectives set out in the literature review and methodology chapter; practical and 
operational descriptions of the research study in the study protocol informed by medical 
research to comply with the HRA process; and another account for participants in plain 
English describing their involvement in the study, what information is gathered and how it 
is used.
Conclusion
In this chapter, I have outlined the methodological rationale I have developed to study a 
performative understanding of patient experience. I have also discussed the key issues 
and challenges involved in working with patients in this research. I described how patient 
experience can be studied as a performative, emergent phenomenon in a design-led research 
process involving pilot studies and research events. To do this, I argue that these forms of 
inventive methods are necessary to explore the potential for studying something that, I 
argue, can have no visible effects. This equips me with an empirical approach for exploring 
and understanding the PROM development process, and how different versions of patient 
experience are brought about, can co-exist and can also be made through the introduction of 
design.
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Chapter 4: Opening up 
technologies of experience 
through three pilot studies
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This chapter starts with a question: what kinds of technologies are at play in the doing of 
patient experience? I ask this question to open up the locked-in world of patient experience 
as a given, or an existing, authentic truth that is considered available to be acted upon, 
measured, designed and improved. Therefore, experience-in-the-making affords an 
opportunity to investigate the performative activities through which different versions of 
patient experience are currently accessed, captured, measured, defined, reproduced and 
circulated. In studying how new versions of experience emerge, I will draw on the table of 
experience developed in the literature review that put forward many different versions of 
experience from different writings in recent science studies, medical sociology and design 
practices. These different versions pose problems and challenges for the potential for 
working with new and different versions.
This chapter presents and reflects on three pilot studies where practice-based 
design interventions are deployed to investigate situated circumstances in which 
approaches to patient experience might be re-thought within three distinct contexts of 
an international academic medical conference, of a neurology outpatient clinic and in a 
clinical measurement activity between a clinician and a person with MS. The pilot studies 
aim to rethink how patient experience is done in these settings through considering how 
slowing down the processes by which experience is grasped can thereby open up ways of 
understanding other kinds of experience that are being ignored and screened out, as well as 
the possibility of determining new kinds of experience. I am interested in how techniques 
of experience measurement can be rethought as the situated enactments of experience 
rather than the generation of cleaned-up versions. Finally, if I slow down experience-in-the-
making, I can also appreciate how the exchange of other objects, or experience phenomena, 
might be understood as another example of situated experience that gets screened out of 
measurement practices. Once sensitised to new versions, it becomes clear how new versions 
of experience can be located, how they operate and how they circulate in contrast and 
amongst other versions. But before this, I include a brief survey of the literature that I will 
draw on throughout the rest of the chapter and a description of the use of pilot studies in 
design-led research. 
This chapter is organised backward, flipping the traditional order of conventional 
research processes. It starts with dissemination, then considers processing, and ends with 
capturing patient experience. The intention is to discover how new versions might operate 
away from existing assumptions and unlike other forms of knowing. The chapter concludes 
with some reflections on how the pilot studies sensitised me to different contexts where new 
versions of experience might be identified, traced and potentially better understood. 
Technologies of experience and slowing down
Technologies of (patient) experience work to capture, record, process, format and circulate 
patient experience as different versions – in other words, instruments and technologies 
93
of experience produce experience. The term can be traced back to Paul Ellwood’s 1988 
article in the New England Journal for Medicine which outlines the introduction of outcome 
management after the US health reforms in the 1970s. These are ‘designed to help patients, 
payers, and providers make rational medical care-related choices based on better insight 
into the effect of these choices on the patient’s life’ (1988, p. 1556) bringing together multiple 
concerns from the US health system linking health outcomes with financial interests. In the 
context of patient care for people with MS and upper-limb function, the impact of this view 
can be evidenced today within the NHS with a wide range of subjective measurement tools 
such as PROMs (described in Chapter 2), as well as objective measures such as the nine-hole 
peg test (Feys et al., 2017) and the Box and Blox test (Platz, 2005).1 
I want to draw similarities between Ellwood’s call for the development of outcome 
measurement as critical for physicians to remain in control of their profession (Sullivan, 
2003) and Lezaun and Soneryd’s (2007) framing of technologies of elicitation in the study 
of public consultations in PUS. Public consultations, research interviews (Jerak-Zuiderent, 
2015; Mazanderani and Paparini, 2015), opinion polls (Osborne and Rose, 1999), home 
interviews (Callon and Rabeharisoa, 2004) and focus groups (Lezaun, 2007) are framed 
as techniques to capture events where experts are brought together with devices and 
instruments to make communities real for the productivity of interested parties as they 
‘generate lay views on the issues at hand’ (2007, p. 279). Further ethnographic work by Vinh-
Kim Nguyen (2010; 2013) draws on Foucault’s notion of ‘technologies of the self ’ (1988). In 
it, Nguyen looks at peer support, counselling, participatory research and public testimonies 
as ‘confessional technologies’ (2013, p. 440) in a performative approach to knowledge 
practices of HIV in Africa. These all raise epistemological and ethical questions about the 
use of different technologies as a means of accessing and producing knowledge of people’s 
experiences. 
In this chapter, I argue that technologies of experience are important theoretical 
sites for feminist technoscience studies because of how the materiality of bodies, roles and 
knowledge are positioned as matters of fact and ‘do-able’ (Fujimura, 1987), by scientific 
practice and medical work.2 This thesis takes a material-semiotic perspective developed by 
ANT (Haraway, 1991; Law and Hassard, 1999; Latour, 2005), which views material objects, 
tools and bodies, as active participants that shape human bodies as part of heterogeneous 
networks creating new practices and knowledge (Ruppert, Law and Savage, 2013). Here, 
I use a broader definition of technology. Therefore these technologies, even if they are as 
simple as chairs around a table, measurement tools, or conventions in interactions, are 
used across health services, national trials and research studies in the form of PROMs 
1 A concise overview of outcomes measures related to upper-limb function in MS can be found in Laymers and Feys (2014) 
2 Casper and Berg (1995) make similar points in their analysis of developments of sociology of medical and scientific work  Interestingly, 
they call for more communication between the sociologies of science and medicine when considering this field of study  
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(Giovannoni, 2017), patient experience surveys (Barts Health, 2018), self-monitoring apps 
(Roche, 2018), PPI initiatives (Thomson, 2014) and patient registers (Osborne et al., 2013) 
contributing to the creation of large-scale data collection, aggregation and quantification 
of different forms of experiential data. This shows socio-technical progress towards 
measurement-based medicine where medical data is assembled online on websites such as 
Patients Like Me (Scanlon, 2013).
Patient experience metrics, such as the distance a person with MS can walk (which 
is considered an important indicator of the health of a person’s neurological system), can 
be sorted, combined with other people’s data and compared and re-assembled through 
different categories of type of MS, EDSS score, month and country of birth, creating 
‘population objects’ (Ruppert, 2011, p. 219). This, along with other data, is used to generate a 
variety of predictions about that person’s current health, including their disability prognosis, 
their response to treatment (along with assumptions about their personal relationships) 
and their occupational future. Used in this way, these technologies have direct impact on 
the lives of those with MS, as shown with the recent personal independent payment (PIP) 
walking criteria change from 50 to 20 meters. This is crucial because the dependence on 
walking criteria effects how MS benefits are calculated, with a miscalculation reducing or 
even stopping weekly payments to people who greatly need it.3 Described by MS charities as 
‘senseless criteria’ (Wetherly and Erez, 2018, p. 28), it raises many questions about the nature 
of the knowledge generated by these technologies of experience, as well as the influence of 
market forces and healthcare-provider incentives in the production of metrics.
Isabelle Stengers’ notion of slowing down (2005) is a helpful tool to question the role 
of technoscience and expert knowledge in shaping contemporary worlds. She introduces 
the idea of slowing down thinking and decision making in the context of experimental 
scientific research, but it also has important implications for researching patient experience 
through design research. The implications for patient experience would stop experience 
from being seen as a resource that can be exploited for the sole benefit of research or 
service development and would create opportunities to engage with the uncertainties of 
human (patients, researchers, designers) and non-human (measurement tools, research 
objects, scientific processes) entanglements. Specifically, this enables me to think about 
whose interests are being fulfilled or suited in the way that patient experience is currently 
researched and produced, allowing me to question the influences of healthcare policy 
(WHO, NICE, NHS trusts), research funding and agendas (set by MS charities, research 
councils, national clinical guidelines) or the pharmaceutical industry in the production of, 
what Stengers describes as, fast science. This is an opportunity to develop an awareness 
3 The PIP is the new disability living allowance which calculates how much weekly financial support a person with MS should receive  The 
new PIP guidelines introduced in 2013 use the 20-meter walk test to determine how disabled a person is and has received negative 
feedback from charities, healthcare professionals, patient groups and their families  
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of the particular and selective thought style of researchers and clinicians in the field of 
neurology and MS. 
In this chapter, I embrace this call for slowing down and apply it through design 
research in a practical way. In the presentation and analysis of the pilot studies, I consider 
what happens when working with patient experience is slowed down. It then becomes 
possible to pay attention to the things that are not counted or included in the scientific and 
medical methods of doing patient experience. Slowing down through design research will 
enable me to look and learn from things left out and consider if what they fail to capture is 
interesting, useful or important. So, an important question at this point in the thesis is, what 
can design research aimed at slowing down tell us about technologies of experience and 
experience in the making?
This engagement with patient experience could be a way to perform different versions 
of patient experience as an opening that slows down thought and potentially generates new 
possibilities, rather than researching what does, or does not, already exist as found objects 
of Experience 1. This call to slow down is not about offering another solution. Instead, it 
enables an opportunity to rethink how patient experience is done and opens up new ways 
to explore differences. It creates opportunity to arouse a slightly different awareness of the 
problems and solutions around us. This important point effects the analysis of all three pilot 
studies, as firstly it slows down the creation of the material things (Bingham, 2008) such as 
scientific posters, research abstracts and emails between colleagues, which have important 
performative effects in the circulation of new versions of experience. Secondly, bodily 
practices become settings where things get slowed down, such as how walking can embody 
what Stengers (2005) calls a politics of slowness. Existing scholars looking at walking 
methodologies consider the human walker as the animate agency on a walk (Springgay 
and Truman, 2017) creating space for hesitation and resistance, producing new modes of 
relating. This enables me to think about what else is happening in walking activities. 
The pilot studies slow down and open up the chains of translations, or how different 
actors form different networks (Callon, 1986) involved in the construction, or enactment, 
of new patient experiences. The translation and inscription process, or simplification 
work (Star, 1983), of scientific and medical research transforms one version of experience, 
Experience 1, to another, Experience 2, and then inscribes it in a specific format of the 
poster as a result. In other words, this is experience as immutable mobiles (Lynch, 1985; 
Latour, 1987). Meaning data versions that are mobile, in that they can be shared while also 
remaining unchanged, can be used as evidence in scholarly papers, reports and posters 
adhering to demanding standards about their reliability. As interventions, the pilot studies 
propose different forms of interaction amongst different actors and material forms – or 
inscriptions (Callon, 1991, p. 143) – and the researcher. By slowing down this process, 
the possibility of translating and inscribing in unexpected ways becomes possible. This 
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supports the argument that patient experience is precisely what emerges out of the chain of 
translations, or technologies of experience, that produce it. 
Slowing down can also help understand not only planned interventions but also 
responses from participants. Stengers’ figure of the idiot (2005), taken from Deleuze, is a 
helpful analytical tool to interrogate the implicit assumptions about patient experience and 
the way it shapes existing arrangements, relationships and interactions in specific settings. 
This makes it possible to be more sensitive to the ways in which particular identities and 
participant reactions emerge, as well as understanding the role of design research in the 
context of MS. Michael (2011) uses the conceptual figure to describe how speculative 
design experiments in public engagement activities can idiotically affect the sense of what 
constitutes a piece of research material. The idiot, as well as the practice of pausing and 
reflecting, helps think through what is known, what is not known and what cannot be 
known. Here, I am looking to see how the pilot studies work within and also overspill the 
framing of existing measurement procedures, dissemination events and clinical encounters 
to question whether I can know what is going on and, in this case, whether experience is 
really being captured. 
In this chapter, I bring the notion of slowing down to experience technologies 
to analyse the knowledge production process and practices around it. Technologies of 
experience process, format and produce taken-for-granted versions of experience, arguably 
speeding up the process of patient experience generation and circulation for the purpose of 
external actors, such as commissioners, health trusts, funders and regulators. Through this 
research, I am intentionally intervening and disrupting this process, slowing it down both in 
thought and in practice. This will have implications on how it results in everyday contexts.
Pilot studies as part of design research
The short practice-based pilot studies described in this chapter are experiments where I 
use design to investigate patient experience in three distinct contexts: an international 
academic medical conference, a measurement activity and a clinical consultation. Within 
these specific settings, there are many different opportunities for design to intervene 
and a number of different roles that design could take. Design is frequently positioned or 
implicated within healthcare as contributing to increasing efficiency and productivity, 
reducing error (West et al., 2014), improving care (Donetto, Tsianakas and Robert, 2014) 
and ultimately improving experiences. However, this thesis problematises this positioning 
of design in relation to generating and altering pre-existing experiences. So, it becomes a 
balance between problem solving and more playful explorations to open up valuable new 
directions (Pullin, 2009) when working as a designer within healthcare. I suspect that by 
slowing down design’s involvement in healthcare will enable design researchers to think 
beyond ‘doing good’ and spend more time thinking through how else design can contribute 
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to new notions of patient experience.4 To do this, design work needs to be relieved from the 
reductionist constraints and limitations of solving problems so that design exploration can 
disrupt, react and provoke reactions which otherwise would not come forward (Danholt, 
2008).
Pilot studies are frequently used when designing clinical research to evaluate 
feasibility, efficiency, accuracy of measurements, recruitment and outcome rates, and effect 
sizes to improve study design prior to performing a full-scale research project (Hulley et 
al., 2007; Thabane et al., 2010). For example, in a pilot study looking at how feedback from 
patients can improve nursing care, the study provided evidence that conducting surveys 
on hospital wards via staff was a feasible approach to gather patient experience data 
(Reeves, West and Barron, 2013). The study could then deliver a phase-three, randomised 
and controlled trial using this approach. Considered as preliminary tests, pilot studies are 
particularly helpful to the overall research process for new interventions when the risk of 
failure is high but the value that they bring in exploring the unknown is worth this risk. 
In design practice and research, activities of testing and iteration are described as 
workshops, probe activities (Gaver, Dunne and Pacenti, 1999), prototypes (Wilkie, 2013) 
and storyboarding where early ideas are tested with participants and design expertise is 
enacted in specific ways. There are a few studies where these early test activities have been 
referred to as pilot studies. Interestingly, they all relate to health and wellbeing research 
(Hielscher, Fisher and Cooper, 2007; Dong and Vivat, 2008; Bossavit and Parsons, 2018; 
Knutz, Markussen and Thomsen, 2018). This suggests that design researchers are borrowing 
language from clinical research in an attempt to increase the validity of processes and 
methods that are unfamiliar to the medical field. This is one example of how the practice-
based work of this thesis must acknowledge its precarious positioning between design and 
health research. 
The pilot studies used in this thesis have been developed from a design perspective, 
rather than the medical perspective that would value qualities of reproduction, validity and 
efficacy. The purpose of these pilot studies is to make a foray through new and unfamiliar 
activities to enable behaviours, practices and interactions within moments where patient 
experience is generated, measured and circulated. The aim of approaching patient 
experience through these unfamiliar directions is to look at these contexts in new ways and 
hopefully uncover potentially exciting and unexpected results. This addresses one of the 
main aims of this thesis: the ways design research creates new ways to think about current 
problems, what design brings forward, and who or what else design speaks to.
From the perspective of design research, and for the purpose of the research presented 
in this thesis, the studies are being used as the crucial first practice-based explorations 
4 Jerak-Zuiderent (2015) takes a similar approach in social science investigation by slowing down the problem-solution-found plot of 
accounts in qualitative healthcare interview research 
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into working with patient experience to direct further research activities. It is key that the 
design of the studies are not considered finished design ideas, or even possible or plausible 
directions for further development or iteration. Instead, they should solely act as props that 
play a role in enabling interactions to happen (Moggridge, 2007). 
In the remainder of this chapter, the three studies are presented in sequence. This 
is so each study can be described and analysed separately, allowing me to discuss the 
particularities of each pilot study in the discussion. I explain the background to each of the 
three pilot studies. Then, I describe the rationale for the study, the results, my reflections 
and responses. This is followed by an analysis. I am not going to explain everything that 
happened nor go through each response in detail, but I will highlight key points that 
developed my thinking on how design can work with patient experience. At the end of 
the chapter, I weave the pertinent data from each pilot study and my discussion into one 
paragraph, considering their relation. 
Pilot Study 1: Willow Plate
Academic conferences are key sites in which medical and scientific versions of patient 
experience are enacted, shared and disseminated. For MS research, the ECTRIMS 
conference is the largest, attended by over 10,000 MS specialists, including neurologists, 
nurses, health and scientific researchers, and pharmaceutical companies. Often, 
researchers stand next to their A0 poster (which displays research objectives, methods, 
techniques, findings and implications), and they respond to questions from fellow 
conference participants (Figure 22). These academic posters are important tools for research 
dissemination. As such, I designed the Willow Plate pilot study to intervene in the poster 
session at the 2013 conference and explore the process by which patient experience is 
translated and produced in this setting.5 
I approached researchers standing in front of their posters and invited them to 
participate in the Willow Plate pilot study using an information sheet (Figure 23), to which 
they all agreed. Participants were asked to draw a description of their research on paper, 
copy this onto a ceramic plate, and then use the plate to describe their research in place 
of the poster. Traditionally, the existing research visualisation methods found on research 
posters follow institutional guidelines, have bulleted text, and have computer-generated 
graphs to represent complex statistical results. However, drawing on a ceramic plate 
removed these physical and visual constraints, allowing for other representations and forms 
to come forward. Creating hand-drawn patterns of complex science on ceramic plates was 
inspired by the elaborate blue and white Willow pattern painted on eighteenth-century 
5 To give a sense of scale, there are 4,000 posters on display at ECTRIMS 2013  Recent regulation has stopped pharmaceutical compa-
nies taking clinicians to conferences (e g , paying for their registration, travel, accommodation and meals) if they are not themselves 
contributing research, hence the large number of poster acceptances (Anand, 2011) 
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Figure 22 Photographs of the poster exhibition at the ECTRIMS conference, October 2014 
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Figure 23 Instructions given to participants to explain the Willow Plate exercise 
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tableware conveying Chinese narratives and fables. I drew similarities between how an 
observer must learn to understand these distinctive patterns for the story to unfold as being 
similar to the technical presentation of research on a scientific poster and the technical 
knowledge needed to be able to understand the poster content. 
Engaging researchers to hand draw a description of their research created an 
opportunity for them to be spontaneous and expressive, much like Surrealist Games 
(Brotchie and Gooding, 1995).6 The aim of this was to help bring about surprising or non-
ordered responses from participants, breaking their traditional thought patterns to create 
unpredictable outcomes.
Eight participants (with roles as biomedical researchers, PhD students, 
pharmaceutical representatives and clinical academic researchers) engaged in the activity 
with even more conference delegates interacting with these participants throughout the 
process shown in Figure 24-27 (Gurkan et al., 2013; Kearney et al., 2013; Sethi et al., 2013; 
White et al., 2013).7 Below, I report on three examples of unexpected encounters from the 
activity:
1. In the poster hall, there was a steward’s station that provides support for poster 
authors to hang their posters. I stored the plates here during the activity, and as 
I returned with each completed plate, one of the stewards became increasingly 
interested in the activity. On the creation of the final plate, the steward left the station 
to approach the researcher, listened to the description of the plate, and then asked 
questions about his sister (who was a participant of a cancer research study).
2. While one of the PhD student participants was drawing their plate, a conference 
delegate asked what they were doing. They responded with ‘We’re making our work 
easy for patients to understand’.
3. One week after the conference, I received an email from the participant who worked 
for a pharmaceutical company and created Plate 2 asking for images of the plate so 
they could request legal approval for it. All material produced by pharmaceutical 
6 I filmed the participants explaining the research on their poster, drawing their pattern on paper and then on the plate, and using their 
plate to explain their research again  At the end of the activity, I took a portrait photograph of each participant with their completed 
plate 
7 I had originally aimed to work with 20 researchers, but the participants took longer than expected to draw and re-draw their plates, so 
I reduced my expectations of this number and was able to produce eight completed plates 
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Figure 24 Photographs documenting the creation of Plate 1, entitled: Does the lobar distribution of cortical grey matter lesions correlate 
with cognitive impairment seen in multiple sclerosis patients? The first author, Varun Sethi, is pictured above  
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Figure 25 Photographs documenting the creation of Plate 2, entitled: Immunogenicity with 
peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis: data from the 
pivotal phase 3 ADVANCE study  The first author, Joleen White, is pictured above 
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Figure 26 Photographs documenting the creation of Plate 3, entitled: Paced auditory serial 
addition test: normative data in a Turkish population  The first author, Muharrem Gurkan, is 
pictured above  
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Figure 27 Photographs documenting the creation of Plate 4, entitled: Neurite orientation 
dispersion and density imaging in multiple sclerosis spinal cord  The first author, Hugh Kearney, 
is pictured above 
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companies need to comply with the Association of the British Pharmaceutical 
Industry guidelines (PMCPA, 2016). 
The activity was met with positive responses from the participants who engaged with the 
study and from passing conference delegates commenting ‘what are you doing?’, ‘Wow - 
interesting’ and ‘this is better than your poster’.8 This could be due, in part, to many things 
– such as the novelty of the activity, its similarities to public engagement projects that are 
common at UK research institutions, or my association with patient-involvement sessions 
that I run at ECTRIMS. 
I was surprised that none of the participants re-drew any of the scientific 
visualisations, line graphs or illustrations from their original posters. Instead, they drew 
a variety of objects and icons, such as a patient lying in an MRI machine, brains being 
cut, MRI scans of spinal cords, an ear, music notes, a house, a bonfire, a bicycle, a money 
symbol, male and female bodies, walking sticks, and happy and sad faces. These objects 
provided insight into some of the other bodies, medical apparatuses and techniques 
necessary to conduct their work that are not included or represented on the original poster. 
This suggests the pilot studies can intervene in the chain of translations that produce 
patient experience, involving other experience phenomena, i.e., stewards, conversations, 
graphs, and approvals.9
Dealing with the mess
Academic posters as technologies of experience produce cleaned-up versions of Experience 
2, which are precisely framed as workable, generalizable, knowable, analysable and 
measurable as immutable mobiles, like other forms of objective data (Lynch, 1985, p. 43).10 
When immutable mobiles that have to travel around and get worked upon are made in this 
clinical research setting, things get left out. The creation of the plates slowed down this 
translation and inscription process. It also enabled me to pay attention to the removal of 
objects or cleaning up of the mess of unworthy objects. This included the brains of deceased 
patients, dissected spinal cords, medical apparatuses, and emotion, in addition to tensions 
and complexities that were screened out and erased (Star, 1983), ultimately resulting in new 
versions of cleaned-up research. Moving away from cleaned-up versions exposes different 
realities of this work, including failed studies, patients’ feelings, emotions and gender, which 
8 The plates were not intended to be used beyond the poster session because I was specifically interested in the process of their 
creation, rather than them as a final product or resource, thus in part reflecting the short lifespan of the posters themselves  Many 
posters are not claimed at the end of the session and are disposed of after the poster sessions by the stewards 
9 By this term, I refer to objects, responses, and events caused or performed by doing patient experience 
10 Latour and Woolgar (1986) refer to this as the work that goes into the social construction of scientific realities through the making of 
‘facts’ 
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play an important part in influencing research, and which are left out by medical science.11 
By looking closely, I analyse the negotiations between included and excluded visualisations, 
bodies and tools and create opportunities to arouse ‘a different awareness of the problems 
and situations that mobilises us’, and the scientific community (Stengers, 2005, p. 994). 
Slowing down brings this new awareness to the problems and situations that are not 
predetermined or vetted through the translation process. This pilot study shows that having 
a different activity represent research brings into play research elements that would have 
otherwise been stripped away. 
This brings me to an important question: how do technologies of experience generate 
versions of experience with issues implicit within them? There is a possibility for a less 
predictable or prescribed version of experience to come forward if you do not adhere to the 
rules and traditions of medical science. This version is less scientific, as it is not beholden to 
characteristics of heterogeneity, comparability and transferability. Instead, it is more about 
context and specifics, which result in a different form of knowledge claim. This begs the 
question, should experience be solely based on clean accounts? Or, instead, what happens 
when we follow Stengers and reclaim the mess, learning how to deal with what escapes 
objective categories (2002, p. 27)? Then, technologies of experience must be designed to 
allow for problems and issues to come forward.
Misbehaviour
Stengers argues that an understanding of slow science must include the ways that other 
kinds of experience come to matter for other collectives, suggesting a diversity of actors 
involved in patient experience (2002, p. 84). Translating a paper poster into a ceramic, 
hand-drawn plate mobilised experience in a new and unusual format and enabled new 
connections amongst different implicated actors to come forward (Stengers, 2002, p. 252). 
This included the unexpected actions and responses from the steward sharing a healthcare 
experience of a sibling, the pharmaceutical industry seeking regulatory permissions, and the 
PhD student’s assumptions becoming explicit. In the form of a plate, experience comes to 
matter (or not) for the implicated actors.
In the conference setting, researchers, scientists and clinicians are seen as more 
powerful than non-experts. Additionally, in this setting, the technologies of experience 
ascribe, or script, the roles of researchers, stewards and representatives, making them 
experts participating in a research dissemination activity with other experts. This is 
evidenced with the PhD student’s response exposing a knowledge hierarchy between the 
authoritative position of researchers and others. Here, design explores this directionality of 
11 MS is predominantly a disease that affects women, yet most people recruited onto studies are men, and there is very little research 
into issues that affect women (pregnancy, menopause, etc )  This, coupled with the uneven gender distribution in the clinical and ac-
ademic workforce (most MS specialist clinicians are male, and almost all MS nurses are female) is gaining more attention (International 
Women in MS, 2018) 
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knowledge and expertise and shows how the involvement of different formats exposes this. 
The plate becomes an accountable version of experience for the steward, encouraging him 
to misbehave as a steward (Michael, 2012), which allows him to become a resource in his 
interaction with the expert. This re-configures his identity as a brother an associated patient 
experience. The steward takes the plate seriously, has the powerful right to do so, and in 
doing this, serves to trouble the very exercise of the poster when he does not value or feel 
entitled to participate in the workable, generalisable and knowable Experience 2. But, to treat 
audiences symmetrically, I cannot say the poster is more important, serious or sensible than 
the plate or steward’s stories about his sister. The methods of the pilot studies deliberately 
leave the definition of the actors underdetermined and the direction of travel open. Here, I 
have learned that patient experience can travel in different directions and also be reclaimed. 
In the process of exploring other ways of eliciting experience through design research, 
it is important to be aware that the techniques are still beholden to certain requirements, 
such as regulatory guidelines of the pharmaceutical industry and organisational rules and 
regulations. If thought about as a technology, they predetermine the identity and role of 
the actors in the script, formatting the conduct of researchers and of where and how they 
can circulate. Although, in the example of requiring company approval for the plate, the 
experience phenomena is able to undermine these pre-existing identities, roles and scripts 
by becoming subject to the demands of medical science and highlighting them as unnatural. 
It seems ridiculous that the same requirements for scientific posters are applied to the plate, 
a very different technology of experience that exposes different things and acts radically 
different, which the company’s rules evidently consider equivalent. This builds on previous 
questions around whose interests are these versions of experience produced and what 
counts as experience, and for whom. 
Pilot Study 2: How far can you walk?
The second pilot study explores how medical versions of patient experience and patients 
walking distance are defined and generated through outcome measures. Interestingly, 
there is lack of consensus within the neurology literature and clinical field around exactly 
how to measure and record the optimum walking distance of a person with MS safely and 
rigorously within clinical research and practice. The following approaches and associated 
critiques are put forward: a clinician pushing a trundle wheel while walking with a patient 
is criticised to be time consuming (Bethoux and Bennett, 2011)(Figure 28); patients walking 
on a treadmill is said to be unrealistic (Bethoux and Bennett, 2011); and patients verbally 
describing their walking ability over specific distances, or between two landmarks such 
as the hospital and the tube station, is flawed because people are unable to judge exact 
distances (Sharrack and Hughes, 1997; Giantomaso et al., 2003; Commins et al., 2013). 
Arguably, this debate is preoccupied with determining the optimum environmental 
conditions and practices to generate clinical data through simulating walking in real life, 
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Figure 28 Stills from a video recorded on my phone of a patient with MS using a walking stick and having their walking 
ability measured by a neurologist outside the Blizard Institute in Whitechapel  I have observed my clinical colleagues 
‘walking’ a patient with MS on many occasions  In doing this, they adhere to the requirements to generate walking 
distance for a clinical trial 
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i.e., re-creating a patient walking that is not for measurement purposes. This argument is 
based on this field’s understanding and associated assumptions of thinking about patient 
experience 1. I am interested in how this procedural uncertainty from within the neurology 
field reflects their conceptual assumptions about how patient experience is generated and 
performed and how this materializes in the practices in conducting measurement activities 
with patients. 
In the How far can you walk? pilot study, the participant, who is a consultant 
neurologist (not a person with MS), was instructed to walk 360 meters before pausing for a 
two-minute rest. After the pause, we continued to walk for 360 meters, then paused again, 
and so on until we reached the final destination. The distance of 360 meters was selected 
because this was the distance that the person with MS filmed in Figure 28 could complete 
before needing to rest. I measured the distance by pushing a trundle wheel and documented 
the activity with a sound recorder, video camera and the Moves application running on my 
phone (Figure 29-31). 
The pilot study aimed to explore the assumptions of simulating patient experience 
as a measurement activity. For this design intervention, I drew on approaches from user 
studies in design, where the subjective experience of users are simulated as part of the 
design process to create a ‘connection with the users’ and get close to ‘contexts, actions, 
feelings, attitudes and expectations’ (Mattlemäki, 2002, p. 267) through empathy probes and 
experience prototypes (Buchenau and Suri, 2000) by simulating the measurement activities, 
tools and behaviours.
This was conducted in the neurologist’s everyday life setting of commuting to 
work. This was done to see if it could provide active participation in another’s subjective 
experience, as these tools claim it can (Buchenau and Suri, 2000; Mattlemäki, 2002). Also, 
it aimed to explore the apparent need to provide ways to help physicians gain empathy for 
their patients, which is well known in medicine (Halpern, 2003; Jeffrey, 2016).
On the morning of the study, the neurologist and I walk from their home in South 
West London at 7 am to the tube station, stopping every 360 meters. While we walk and 
pause, conversations cover multiple topics (e.g., our immediate surroundings, topics the 
participant brings up of their next house move, people who live in the area we are walking 
through). By the time we arrived at the station it was later than usual. As such, rush hour 
made it impossible for us to board the train. The participant suggested we travel south 
one station to board the train when it is quieter, before it gets to this station. We do this 
and complete the journey to their work. The consequences of conducting this activity and 
deploying this data on the participant’s commute to work was immediately apparent for that 
participant. 
Not surprisingly, while walking our conversations started around the task at hand and 
the limitations of only being able to walk 360 meters. It then moved on to topics of interest 
to both of us, such as living in London, house prices in the area, marathon training, and 
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Figure 29 An illustration of the set-up of the walking device and different technologies involved 
in recording the pilot study 
112
Figure 30 A compiled illustration of the tracking data gathered from the Moves App running on 
my phone showing the distance covered and time duration  By visualising this data, I am able to 
show our journey and the misdirection of the train, shown in red  This shows the route that we 
travelled from SW7 to E1 plotted on a map, marking each time we completed 360m in distance 
with a time stamp from the sound recording  We travelled to the underground station, then 
passed through it  The total journey took 1 hour 14 minutes  
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Figure 31 Video stills taken from the camera attached to the trundle wheel show clips from 
the journey on the way from the underground station to the participants work  
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a recent public scandal of someone who lives in the area. What we did not consider were 
the implications of only being able to walk 360 meters at a time for a person with MS or the 
associated activities related to this, such as having to leave at a different time to incorporate 
the rest times, pre-planning areas to rest, and asking for a seat on a busy tube. These are 
all important considerations that people with MS who have limited walking ability must 
consider, and will be crucial to ensure they can complete the journey.
When conducting this activity and simulating the walking limitations as an embodied 
feminist researcher, I realised the limited access I had to any actual pre-existing walking 
distance limit and also any pre-existing patient experience. The participant actually became 
frustrated by the activity and continually having to pause. After the activity, I attempted to 
visualise, illustrate and capture some of the other things that came forward on the walk and 
created a visual account of the study. This made me reflect on the constraints I had designed 
into the activity, and I compared them to the constraints in place within the medical 
simulations with patients – tools, routes, clinical observation, time of appointments, etc. – 
which impact its creation.
Practices of simulation
Measurement activities, such as walking a person with MS, attempt to uncover, measure 
and record the true experience of another person through practices of simulation. In 
temporarily signing up to this claim, this pilot study aimed to remove the true walking 
distance from the patient body and sought to apply it in a different event to explore how 
it would travel. The pilot study shows how the artificially imposed walking limitation of 
360 meters (of a person with MS on a person that does not have MS) is only one part of a 
person with MS’s experience, as it was also only one part of the stuff that happened on our 
walk. This demonstrated the entangled relation of both humans (patients, clinicians and 
researchers) and non-humans (measurement tools, recording devices and trains) in the 
ongoing practice of making experience, and shows how the simulations themselves actually 
create new Experience 3, which are dependent on the measurement tools, bodies and subjects 
that produce it. Therefore, if a true distance existed, it could never be separated from the 
other potential things going on (e.g., the weather, possibly having a relapse, possibly having 
a bladder infection, and their shoes).
Measurement outcomes as technologies of experience, attempt to capture a snapshot 
of a person’s life in the production of stable, valid and generisable measurement. But as 
a practice of simulation, they are perspective-less assessments, much like disembodied 
scientific objective knowledge (Haraway, 1988), which removes standpoints of patients 
and researchers from nowhere (Mol, 1999). Feminist scholars point out that walking is an 
embodied practice (e.g., [Haraway, 1988]). Disembodying data may make them transportable 
to certain places within medical practice and scientific research (audit reports, medical 
notes, cost calculations), but it does not transport it to other bodies. Scientific reliability and 
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robustness is situated, bound to the constraints of its production. So when these leave, they 
leave behind specific reliability and robustness (Stengers, 2005, p. 118). So walking with a 
person with MS works in a very constrained, narrow way that is utterly unlike ‘walking’ in an 
everyday context. For it to be successful, it depends on the conditions of its creation. 
This pilot study shows the tension of how measurement outcomes value impairments, 
such as walking, and shows the tension of how standards are set up and fail to shift 
during the course of an illness. This raises important questions about how experience 
is represented in knowledge practices and how crucial things such as endpoints of 
improvement or deterioration are determined. The consequences of this is seen in how 
population metrics are applied in the PIP as ‘senseless criteria’. These technologies produce 
or exclude subjectivities with immediate material affects that detrimentally impact people’s 
lives. By slowing down this technology, I reject the properties of fast science and what it 
represents – efficiency, replicability, reliability – and discover these relations have been 
replaced by oppositions between contradictory interests (Stengers, 2005, p. 103). Examples 
of contradictory interests that came forward in this intervention were that of deciding the 
best tube stop to get on at, consider the time of day to complete an activity, and figuring out 
how to cope in extreme weather.
The pilot study shows how these representations of reality through technologies 
of experience as different words, images and practices are contestable when taken out 
of the clinical field. Although I attempted to use design visualisations to explore other 
representations, it seems clear now that the way to move forward would be to ask how 
patients might represent themselves. This contributes to my understanding of experience, 
as it highlights that Experience 2’s quality of transferability is actually an assumption. In 
other words, as an immutable mobile, the version of experience in this pilot study does not 
move or transport anywhere else as it is presumed to.
In summary, the contribution of this pilot study was to show that you cannot actually 
recreate other people’s experiences, as these are embedded in specific contexts involving 
specific objects such as environments and patient bodies. This study also showed that as 
the participants of the study discussed other things while walking, so will a patient when 
being measured. Patients have other concerns, and walking can only be part of it. This 
study also contributed that simulation can only teach you about part of what is going on 
in the experience of a measurement activity. There are larger things happening that you 
do not have access to through this method. This is particularly important for designers to 
understand when working with patient participants so they understand that disability, for 
example, is thoroughly intertwined with other aspects of a person’s experience that they will 
not get access to.
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Pilot Study 3: Consultation pie
At the Royal London Hospital, people with MS have appointments with their clinical 
team in either MS-specific or neurology clinics held in the outpatient department (Figure 
32).12 The clinic always has a busy waiting room with patients waiting to be seen, family 
members accompanying patients, healthcare assistants moving notes, and medical students 
approaching patients to take part in research, audits and database projects.13 Data generated 
from patients through these tools go on to create data versions of patient experience 
(Experience 2) circulating as academic papers, audit reports, research posters and databases. 
The Consultation Pie pilot study is designed to explore how patients and healthcare 
staff report on actual events once probed by a recording tool in order to question what these 
tools gather, what they presume to be valid data (Experience 2), and what is left out. The 
pilot study activity consisted of me giving both a healthcare professional and a patient a 
recording tool (much like an over-photocopied A4 paper questionnaire) before and after the 
consultation, shown in Figure 33 and Figure 34. Both groups were asked to describe how they 
thought the time would be spent in the consultation on the first sheet. It then asked how it 
was actually spent on the second sheet, completing a section of the pie for each activity.14 
So, for example, 100% of the pie would represent the entire clinic time, and they could draw 
different percentages of time for each activity or topic.
The tool was designed to prompt participants to respond and capture these responses 
in an open way. Arguably, measurement tools with pre-determined responses work to 
maintain the assumptions that the tool itself is a rational actor and that there is a logical 
relationship between the question being asked, its intentions and the format for recording 
the response. Further, that data generated from the tool can then be used elsewhere, 
unbeknown to original context, and keep its (human) logic. This tool puts this assumption 
under pressure by blurring the boundaries of what it is intended to do. I am interested in 
opening up the assumptions within measurement tools to consider how to question their 
intention.
I attended the MS clinic on two occasions and I approached five patients who all 
agreed to take part. Once the patient had verbally agreed to participate, I informed their 
healthcare professional (two patients saw the neurologist, two saw the MS nurse and one saw 
12 Regular appointments are allocated fifteen minutes, but patients who are newly diagnosed will be given an appointment slot lasting 
thirty minutes  However, most run over that time  Depending on their health and which treatment they are on, patients could attend 
this clinic three times a year or once a year 
13 The Royal London Hospital is a teaching hospital and is linked to the medical school at QMUL – Barts and The London School of Med-
icine and Dentistry  Trainee doctors of different levels (medical students, foundation year doctors, registrars) are frequently involved 
in this clinic when they are on placement with the Barts MS team  Depending on their role, they can sit in and observe clinics, conduct 
research in the waiting room or run consultations for the clinicians 
14 The concept of patient experience is problematic because researching ‘patient experience’ would ignore the assumptions of the 
performativity of speech acts and the views of patients reporting; therefore, this pilot study is described as recording humans’ 
expectations rather than their experiences  Further, I had doubts when I found out others had written about how patients learn to 
enact the types of experiences that are legitimate (Renedo and Marston, 2011)  In other words, I wanted to avoid asking people about 
their experiences and them providing a predictable response as this would play into the assumptions that I have previously criticised 
earlier in the thesis 
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Figure 32 Photographs of the Royal London Hospital Outpatient 
Department consultation and waiting room in Whitechapel, where the 
MS clinic takes place 
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Figure 33 Copy of the blank pie given to each 
participant before the consultation 
Figure 34 Copy of the blank pie given to each 
participant after the consultation 
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the registrar) and asked them to complete the pie for that patient noting their expectations 
of how the consultation would go. Figure 35-39 show scans of the completed consultation 
pies.
There are a number of typical topics that are covered in a neurology consultation, 
‘small talk/catch up’, ‘recent events/new symptoms’, ‘old symptoms’, ‘social issues’, 
‘future therapies’, ‘medication review’, and ‘blood tests’, which were described to me in 
a preliminary activity with the neurology professor. Yet, for patient 2, the neurologist 
includes ‘olive oil’ as a before and after entry. This is because this patient always brings the 
neurologist a bottle of olive oil from her home in Spain. This is clearly an important object 
involved in their time spent together, yet it would certainly not be something that would be 
valid in a database, nor in medical notes. 
Involving different healthcare professionals in the study allowed me to observe how 
they responded to the tool differently, and the scans show visible differences in the amount 
of information from the neurologist (Patient 1 and 2), the MS nurse (Patient 3 and 4) and the 
registrar (Patient 5).
The physical paper object worked well as a tool to facilitate interactions between 
myself and the participants without having to verbalise their response (Experience 1). Not 
affording, or scripting (Akrich, 1992), specific actions such as ticking boxes or selecting from 
pre-determined responses enabled other responses to come forward . The activity generated 
a variety of responses in participant reactions to the activity and content in what it gathered 
because it was an unusual task for people to be invited to complete.
Working together with other experience phenomena
The ambiguity and openness of the tool leaves space for other phenomena, with different 
types of agency, to come forward in this activity. The olive oil bottle is a non-medical object 
that the neurologist and the patient have made an accountable object of patient experience 
and validated it by including it in the tool ‘before’ the consultation, the patient bringing 
the bottle, and then repeating this entry in the ‘after’ pie. This situated interaction suggests 
that they have established a way of working together, with a different type of experience 
phenomena involved in patient experience allowing one concept of what is important 
(discussions on symptoms and treatments) to move aside for another (receiving a bottle of 
olive oil as a gesture). It mobilises another kind of knowledge, through a situated activity of 
knowing, drawing attention to which objects are counted as valid in medicine and which 
are not. Stengers (2005) points out that what matters is rather the possibility of creating 
relevant modes of togetherness between practices, both scientific and non-scientific, finding 
relevant ways of thinking together. This is especially the case for the neurologist who has 
developed professional autonomy (Winthereik, van der Ploeg and Berg, 2007). This version 
of patient experience is based on their mutual dependencies and ambiguities, as well 
as the ambivalences of the doctor–patient relationship. However, this is screened out of 
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Figure 35 Four scans of the pies completed by Patient 1 and the neurologist for the consultation pie activity 
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Figure 36 Four scans of the pies completed by Patient 2 and the neurologist for the consultation pie activity 
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Figure 37 Four scans of the completed pies by Patient 3 and the MS nurse for the consultation pie activity 
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Figure 38 Four scans of the pies completed by Patient 4 and the MS nurse for the consultation 
pie activity 
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Figure 39 Four scans of the pies completed by Patient 5 and the registrar for the consultation pie activity 
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medical work and medical discourse. Yet, both the patient and the neurologist make this an 
accountable practice (Latour, 1990; Winthereik, van der Ploeg and Berg, 2007).
I see it as a task for design to create technologies of experience to explore ways of 
thinking together beyond reductionist categories of subjective, objective, quantitative, and 
qualitative to find ways of working together and explore the techniques people develop and 
use to validate experience. It also shows how there are other ways to validate experience and 
create versions which can be accountable to multiple actors.
Accountabilities and assumptions of technologies of experience
Slowing down the data producing site of the clinic exposes a number of competing 
assumptions and expectations within that clinic within the hospital materials, routine 
clinical activities and work requirements of healthcare staff to maintain it (Star, 1999; 
Wiener, 2000). These are infrastructures to keep the clinic working as a technology of 
experience. This highlights the institutional pressure for patient experience data, the work 
involved in this process of healthcare staff to collect data, the work dedicated to prove 
the quality of the service they deliver (Wiener, 2000), and the distributed responsibility to 
actors (staff, recording tools, medical notes, clinic schedules) in the field. These factors 
affected how the healthcare professionals completed the pilot study through wanting to 
do it correctly,15 its effect on increasing time pressure on the clinic,16 competing requests 
from other data-generating tasks and patient expectations to complete correctly under the 
demand of making healthcare practices accountable takes work (Star and Strauss, 1999). 
More generally, the material practices observed in the clinic within and around patient 
consultations are mundane and draw attention to them (through slowing down in the 
pilot study). They also help disrupt the commonplace production and reproduction of 
the ‘neglected things’ of patient experience (Puig de la Bellacasa, 2011, p.100), such as the 
olive oil. Slowing down shows how design interventions can explore the agendas around 
patient experience that are enrolled and translated in everyday clinical and healthcare 
environments (Latimer, 1998). It tells me that producing and generating patient experience 
makes demands on spaces and material practices in which it is embedded.
This pilot study shows that MS is a situated disease, and medicine is leaving 
information out through their existing recording and measurement tools. Importantly, 
things that are left out by medicine can get revealed by other activities.
15 In contrast to the neurologist, the registrar completed the activity with a huge amount of detail including information on every topic 
that was covered in their discussion  The registrar actually completed the activity twice for this patient, as she was unhappy with how 
the pie looked once she completed it, she then remade it a second time with different proportions  You cannot tell this from the final 
image as it is the second version 
16 The neurologist had a long waiting list of patients and was running over time and as such completed the tasks very quickly, stating, ‘I 
need to be quick’ 
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A new technology of experience
From the analysis of the pilot studies, it has become clear that patient experience is not 
just a thing that is found, waiting to be measured.  It is something that is made. The work 
involved in performing experience involves not only patients, healthcare professionals, and 
researchers but also medical measurement tools, representational devices and non-medical 
objects (including olive oil bottles, plates and emails). Experience technologies can make 
things transportable, fast and fluid, but in doing this, things get left out. These practices 
and technologies that make things transportable are taken for granted and are designed 
to be as frictionless as possible, thereby speeding this process up. I argue that currently, 
healthcare professionals, researchers and designers working with patient experience do not 
stop to question what they are doing. The pilot studies have shown how design research 
can intervene in the making of experience to slow things down to let different experience 
phenomena come to the surface.
Further, these techniques show how other experience phenomena which have 
different representations, renderings and expressions can be made valid, even though they 
come with different assumptions attached to them. Experience is situated in practices that 
create it and are not transferable in the sense you can give somebody the same experience 
that somebody else has. If it travels, it creates other things.
The deployment and subsequent analysis of the pilot studies has brought me to the 
point where I can set up my approach to a different technology of experience. This is a 
proposal for an alternative treatment of experience through technologies that value different 
things (e.g., situatedness), ignore transportability and include other things (e.g., does not 
clean up), and can contribute to different understandings of the treatment, research and 
care of individual people living with MS. 
The interesting thing about my experience technology is that it performs experience 
which is purposefully not transportable. What that means is that it insists on a specific 
context and specific experience that they are exposing. It can then focus on the properties of 
staying with the issues and practices that are currently screened out in MS care. Therefore, 
if design research slows down technologies of experience and the versions of experience 
they produce, I can then pay attention to other experience phenomena which are valid and 
do not scale. The question then becomes about how to work with these and what happens 
if you do not scale experience. Can I make a virtue of them not being transportable? Patient 
experience has always been approached from a statistical and population-metric perspective 
with technologies inbuilt and with the assumptions of that type of relationship between the 
individual case and the data set, as well as the larger population. Arguably, these are bio-
political technologies because existing technologies of experience, both from medicine and 
design, operate to match the individual to the group and work to configure the individual 
as a population. In other words, how an individual experience matches up with a larger 
population of people. This scaling happens in design. For example, in medicine, how does 
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the design of your individual experience match up with a larger population, which is the 
same approach as in design and can be predicated on mass production and taking the 
individual user (Wilkie, 2010) as a proxy for populations of people. However, I am saying 
something different. Instead, I am proposing that, instead of matching people to a group, 
there are opportunities to pay attention to experiences that do not fit and do not scale. These 
experiences will tell you something else. At this point in the thesis, I can now start to explore 
the implications for designers working within healthcare settings (maybe they need to think 
about designing slower experience technologies).
Conclusion
The pilot studies presented in this chapter have investigated specific points of investigation 
and pulled out a number of new learnings about working and researching patient 
experience. It has uncovered that in trying to make experience transportable, crucial 
information is left out. This provides an opportunity for people that work in and research 
this field to pay attention to experiences that might not scale and make more out of what is 
getting left out.  
The chapter has described and analysed bespoke design interventions deployed 
as practice-based designs. In doing this, it has attempted to make the case that it is in 
designers’ interest to intervene in the creation of experience. It can suggest alternative ways 
to think about and approach experience while also contributing to medical and scientific 
understandings. In saying this, these were initial design experiments where some worked 
better than others in accessing the object of study. In this deployment process, I learned that 
design leaves information out too. This is an important point. 
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Chapter 5: MOT – A study slowing 
down technology of experience
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This final empirical chapter describes practice-led design studies of patient experience-in-
the-making through the stages of developing a new technology of experience. This work 
continues with the approach introduced in the previous chapter of slowing down to think 
through how new associations and arrangements of patients, researchers, healthcare 
professionals, designers, technologies of experience and experience phenomena can 
produce and bring into being different versions of patient experience. By continuing to 
do this, I can reconsider how patient experience is made and what it is made up of. I can 
also start to consider the potential implications of these new ontological compositions. By 
continuing this commitment to work with those affected by this research issue, specifically 
the experience phenomena that emerge by way of my research practices, it becomes a 
speculative obligation. This is speculative as this process does not define in advance what 
the end result of this process is or what it could be. This research process has brought me 
to the point where I am tasked with exploring the potential of working with experience 
phenomena through performative research events.  
This chapter starts with a brief description of the setting of the Measurement on Our 
Terms (MOT) study,1 describing how I brought people with MS together to discuss how 
their upper-limb function is affected by their MS. This is the final piece of research practice 
in this thesis. I use the analysis of the material produced through these research activities 
to develop my model for a new technology of experience that started in the previous pilot 
study chapter. In this chapter, descriptions of what happened in these research activities 
will be framed through the lens of the following theoretical instances: MS ensembles (a term 
introduced later in this chapter), homegrown technologies, artefacts as entry points, non-
transferable experiences and frictions. Each section will include analytic discussions which 
draw on accounts, findings and reflections from the activities. This will allow me to develop 
the model to see how it does or does not work with this new material. The chapter will 
end with a discussion on directions for the future of the research and implications for my 
understanding of working with patient experience through design-led research.
Working towards a new technology of experience
As previously described in this thesis, PROMs are technologies of experience in that they 
produce and circulate specific versions of experience that hold certain assumptions about 
the nature of experience, subjectivity and what it means to be human. Slowing down the 
process by which medical technologies of experiences are developed will allow me to pay 
close attention to the practices and assumptions within each procedural stage of PROM 
development. This includes specific objects, tools, phenomenon, processes, spaces and 
1 The study name, Measurement on our Terms, was developed by the Barts MS advisory group who were consulted on the development 
of this study in August 2017  The title is intended to reflect the perspective of people with MS having previously been not involved in 
PROM development activities  It is to show that I am interested in working with people’s experiences on their terms, instead of those 
set by medicine or science  The phrase ‘on our terms’ has been used in mental health participatory research (Gillard et al , 2012) 
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bodies involved in their creation. This is a speculative exploration in that I am now not 
aiming to produce a new PROM tool or questionnaire to measure or capture patient 
experience but instead aim to explore the techniques of developing a new technology to see 
what the potential for an alternative type of technology of experience could be. Therefore, 
this research is interested in addressing the characteristics and assumptions inherent in 
existing medical and healthcare technologies: for example, the assumption that the unit 
of measurement is pre-existent, that some entities are excluded, and that versions remain 
unchanged by tools to gather and create it. 
To research these different practices, assumptions and versions within the PROM 
development process I developed and ran the MOT study. The medical PROM development 
process involves patients in limited roles of producing Experience 1 and commenting on the 
dissemination format. However, involving patients directly in my study enables me to work 
with an expanded notion of experience relatively free from assumptions while being able 
to consider how the participant’s direct involvement can contribute to new understandings 
of working with different versions of experience. This is aligned with current PPI practices 
in healthcare research of involving patients throughout the research process to contribute 
in more inclusive, collaborative and democratic ways as well as co-design and participatory 
design practices. Further, involving people with MS is an exciting opportunity to explore 
both the administrative and regulatory research practices of involving people who are not 
researchers or clinicians in a research activity based in healthcare and involving design, as 
well as the theoretical possibilities and practical issues of working with patients.
MOT study overview 
The MOT study consists of three meetings and one online survey shown in Figure 40. These 
were roughly modelled on the medical PROM development process of item generation 
(collecting new activities to measure), item reduction (reducing activities to a manageable 
number) and psychometric measures (calculations on internal validity amongst other 
things) (Hobart and Cano, 2009). The medical PROM development process values 
characteristics of replicability, scalability, and anonymisation to ensure that the measure is 
coherent and can measure patient populations (Dowrick et al., 2015). 
The MOT study ran from November 2017 to January 2018 and was held in The Unity 
Kitchen community café, a location not associated with the hospital or the university in 
East London (Figure 41 and Figure 42). The three meetings involved ten participants whose 
hand and arm function are affected by their MS.2 These people can be considered patients in 
this context since they are seen as patients of the MS service at the Royal London Hospital. 
2 I intended to include between ten and twelve people in the meetings  The selection criteria is outlined in the study protocol (Appen-
dix C) which describes the requirements for people to take part, along with the resources, research techniques and equipment that 
you need to run the project  The purpose of this was to ensure that they could in fact discuss an experience of their upper limb being 
affected by their MS  Marc Berg compares the protocol document to a form of scripting of the research process (Berg, 1997) 
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Figure 40 Diagram showing how the two groups of patients interact in the face-to-face meetings involving 10 people and the online 
survey which received 89 responses  
Measurement on Our Terms study
Meeting 1 Meeting 2 Meeting 3
Design 
questions
Run 
survey
Discuss 
responses
Online survey
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Figure 41 Photograph of the Unity Kitchen Café where the meetings took place  The photographs are taken before the 
meeting when the participants were not present  I did not have ethical approval to take photographs of participants in 
the space 
Figure 42 Photograph of the view from the Unity Kitchen Café in the Olympic park, London 
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Therefore, the study sought and successfully received National Research Ethics Service (17/
LO/1684, Appendix D) and QMUL (QMERC2017/52, Appendix E) ethical approval, QMUL 
sponsorship (Appendix F)3 and Health Research Authority approval (IRAS project ID: 
228062, Appendix G).4
In the first meeting, patients verbally shared activities where MS affected their hand 
and arm function in response to some opening questions (Appendix J). The participants 
shared accounts of situations, challenges and techniques of everyday life living with MS. 
They were curious about other people doing similar things, so we designed questions to ask 
a larger group of people through an online survey. The questions were:
1. What hand and arm (upper limb) activities do you find difficult, due to your MS?
2. What external factors affect how you complete these activities?
3. Are there any tips, hacks, devices or tools you use to help you complete any of these 
activities?
4. Are there any upper limb activities that you avoid doing?
The survey was posted on the Barts MS research blog (Figure 43) and received 89 survey 
responses over three weeks from readers whose hand and arm function is affected by their 
MS.5 This took place in between the first and second face-to-face meetings.
From the responses of the 89 survey participants, I brought the most frequent 24 
activities in response to question 1 to the patients in the second meeting (Figure 44), and 
they reviewed them with the most frequent external factors shown in Figure 45, which were 
responses to question 2. A full listing of the data gathered and categorised into activity 
groups and external factors is presented in Appendix K and Appendix L. 
At the second meeting, the participants discussed these activities in two groups aided 
by an object to represent each activity (Figure 46). They selected and categorised the top 
three external factors that would have the biggest impact on them completing each activity. 
The purpose of this was to replicate how traditional PROMs reduce Experience 1 through 
psychometric calculations. Instead of this reduction happening through calculations, I let 
3 There were many conversations about which institution would sponsor the study (i e , take legal responsibility for the project)  My 
professional role, and where I conduct my practice-based work, is based in QMUL, but the study would be included in this thesis, 
which is registered at Goldsmiths  It was concluded that QMUL would sponsor the study as they had existing links with Barts Health 
NHS Trust where the patients are treated  I think this situation is important to include here because it highlights the procedural issues 
that need to be navigated and addressed to carry out this work  
4 Recruitment for the study was conducted through the Barts MS service at the Royal London Hospital in Whitechapel  Clinicians of 
this service suggested patients who met the inclusion criteria and would likely be interested in taking part  Once I had their phone 
numbers and email addresses, I contacted them individually to share the participant information booklet (Appendix H) and consent 
form (Appendix I) which was signed at the beginning of the first meeting  Potential participants then confirmed their interest and their 
availability to attend the meeting dates  The recruitment process took eight days 
5 The Barts MS Research Blog itself is an interesting technology of experience in how it mediates patient experience amongst health-
care professionals, MS researchers, pharmaceutical companies, charities and people with MS and their families  The role of digital 
technologies in medical interactions related to patient knowledge, expertise and experience is discussed elsewhere (Vennik et al  
2014; Speed, Davison, and Gunnell 2016; Dudhwala et al  2017)  
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Figure 43 Screenshot of the MOT survey on the Barts MS Blog 13th December 2017 (Source: Thomson, A  (2017)  We need a new way to 
measure upper limb function in MS: can you help us?  [Blog] Barts MS Research Blog  Available at: http://multiple-sclerosis-research 
blogspot com/2017/12/we-need-new-way-to-measure-upper-limb html [Accessed 13 Dec  2017]) 
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Activity
What hand and arm (upper limb) activities do you 
find difficult, due to your MS?
1 Opening crisps 
2 Knife and fork
3 Carrying liquids
4 Dealing with coins
5 Pills out a blister pack
6 Changing sheets
7 Tying shoe laces
8 Sewing
9 Using keys
10 Playing piano / guitar / instrument
11 Lifting heavy pots while cooking
12 Hair; washing, drying, brushing, straightning
13 Typing
14 Touchscreen tech 
15 Handwritting
16 Putting on Jewellery
17 Make up
18 Putting on a bra
19 Opening a jar
20 Chopping vegetables
21 Getting dressed
22 Carry heavy plates
23 Buttons
24 Heavy kettle
Figure 44 The 24 top activities gathered from the MOT online survey  
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Figure 45 The top 8 external factors gathered from the MOT online survey 
What external factors affect how you complete 
upper limb activities?
External Factor 1 Time of day
External Factor 2 Duration of activity
External Factor 3 Temperature
External Factor 4 Visibility
External Factor 5 Emotion
External Factor 6 Being watched
External Factor 7 The activity before
External Factor 8 Other
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Figure 46 Activity objects displayed on the table in the meeting 
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patients decide which activities to ‘other’. In the third meeting, we collated the discussions 
by counting the frequency of each external factor featured in the top three of an activity. 
This activity was recorded visually on a series of display signs that displayed one external 
factor per sign (Figure 47 and Figure 48). The study concluded with a discussion of potential 
new ways to measure upper-limb function at home. 
This next section pulls together the responses from what happened when patients 
were brought together around the proposal of developing a new technology of experience. 
Each section describes an overview of what happened, a demonstration from the data and 
analysis.
MS experience ensembles
The assumption that healthcare staff, researchers and designers can process the experiences 
of people with MS has now been positioned as problematic by this thesis. One of the primary 
motivations to work with patients directly in this final piece of research is to uncover exactly 
how patients can contribute to a technology of experience or provide material to participate 
through it. 
In the discussions, patient participants shared accounts of having temporarily or 
permanently lost lower- and upper-limb function. In great detail, they explain the effort and 
organisation involved for them to complete everyday activities of getting dressed, eating, 
interacting with others, moving about their homes, caring for their children, and so on. 
They shared examples of the struggles to complete very specific tasks of fastening buttons 
on a shirt, fastening earrings, writing with a pen, cutting food, handling spaghetti with a 
fork, tying shoe laces, and more. 
I find eating food and handling cutlery increasingly difficult. Handling 
a knife just ends up slipping and turning in your hand when trying to 
cut things. It’s very strange actually, just trying to get to get food to your 
mouth. That sort of action [brings hand to mouth] is still very hit and 
miss. Participant 1, meeting 1 
Although you see me now making notes, writing should be avoided at all 
costs. I’ll use the PC. Writing for literally a few minutes and I can’t read 
my own writing. Participant 6, meeting 1 
Give up the idea of swirling spaghetti. Participant 7, meeting 1 
Some of these activities were shared by more than one participant, whereas others were 
unique to individuals. Patients who responded through the online survey shared similar 
accounts of these everyday activities.
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Figure 47 Close up photograph of the external factor signs  The top three most influential external factors were 
selected per activity and ordered in first (blue dot), second (orange dot) and third (black dot) level of importance 
Figure 48 Photograph of the external factor signs  
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While I can type and knit I cannot do it for any length of time. My hand 
can be quite painful if I do too much. It is quite restricting. Holding a 
needle to sew is very difficult as I cannot feel the needle with my fingers. 
Survey respondent 22 
Difficulty using hair dryer and brushing/combing hair, some days I 
cannot lift my arms high enough and find the hair dryer too heavy to 
hold steady. Survey respondent 65 
Writing, small buttons, putting on earrings and necklace, hand tires 
quickly so struggle to eat pudding and main, putting on makeup, picking 
up coins/small objects, measuring pulse (can’t feel it), sewing. Doing 
hair (arm tires easily), hanging out washing (arm tires after a few items). 
Survey respondent 4 
Both groups of patients described the objects, or experience phenomena, involved 
in supporting them to complete these tasks – using wheelchairs, using cutlery, using 
technology software, using gadgets, using the floor or chairs to help them put on trousers 
and also using other people such as partners, other family members or professional carers. 
Three participants attended the meetings with a family member and one with a professional 
carer to support them in their involvement.6 The important role of the carers is exposed 
in the meeting where a partner as a carer describes that ‘Yes, we see an MS Nurse’ in their 
routine care, including herself as part of the patient ensemble that is affected by MS. 
A significant part of the discussion was around other things that affect their ability 
to take part in the rigours of daily life, which they termed ‘external factors’. These included 
the temperature of the room they were in or a hot summer, visibility in a space or at night, 
being watched and the fear of dropping something, or time of day that they were completing 
the activity (as they have more energy in the morning). Below are some examples from the 
meeting discussions and the survey responses around the external factor ‘time of day’.
I find it hard doing up buttons. Doing up my eldest daughter’s dresses. 
She always comes to me “can you do up the button on the back.” 
Typically, she’s going to ask me at 7, 7.30 at night or whenever and it’s 
just impossible. If she asked me at 7 in the morning I’m normally able 
6 Most notably, one participant did not have any hand or arm ability and had full-time professional carers  Interestingly, this participant 
should not have been involved in the study since her MS was too severe, according to the inclusion criteria of the study  However, 
her clinician highly recommended I invite her because she is still able to work as a jeweller supported by technicians  This participant 
could attend the meeting because she was supported by a professional carer throughout the project 
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to but when we get to 7 at night it’s a bit more of a chore. Participant 2, 
meeting 1 
The evening is worse, when I am tired. Survey respondent 41 
Worse as day goes on. Much better first thing in the am. Survey 
respondent 43 
Left side does not function when tired so need help afternoons and 
evenings. Survey respondent 54 
These external factors are situated and contextual. Although hard to quantify, each person 
had to take them seriously. The discussion below demonstrates how the risk of fatigue 
makes managing the external factors priority in everyday life. 
Participant 1: I found there is ways you can save energy for something  
  else you’re going to have to do. Save energy. You know I  
  have a limited amount of energy available and have to use  
  it sparingly, or choose how you use it. 
Participant 5: If you can do it, do it. 
Participant 1: You need to try and preserve the energy you have. 
Another example was that ‘being watched matters’. Because people must simultaneously 
assess the uncertainty of the activity, their bodies and the situation, the addition of being 
watched only adds to the pressure of the situation. One participant felt fine drinking a pint 
of water at home, but felt very self conscious drinking a pint in the pub in the fear that they 
would drop it in front of people. It is important to remember that the MS ensemble produces 
the careful person in the pub. In these examples, bodies and specific external factors all play 
a part in how these ensembles are performed (Mol, 2002).
It was surprising that these external factors had been experienced by all the 
participants but affected each one of them slightly differently within each activity. For 
example, none of the participants could function after taking a hot bath or shower or in hot 
weather because they were affected by the heat.7 
7 People with MS are unable to control their core, or inner body, temperature as temperature control is part of the autonomic nervous 
system, which is affected by MS  This has a major impact on the functioning of their nerves which become sensitive to temperature 
and block or stop conducting at even modest rises in core body temperature (Romberg et al , 2012) 
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I find the hot weather really difficult, you just get wiped out. Participant 8, 
meeting 2 
I’m more tired after being in a hot bath. Participant 7, meeting 2 
If I get out a hot shower I can’t do anything. Participant 5, meeting 2 
The temperature also affected many of the survey respondents.
Heat. Survey respondent 43 
If it’s hot weather I feel very fatigued. Survey respondent 5 
When it’s very hot I find everything more difficult. Survey respondent 77 
Patients are aware of the capacities of their bodies, which are enhanced or not by machines 
or people, and where they can and cannot circulate. What became clear early on in the 
discussions with patients is that people with MS were aware of the work involved just 
existing as a person. In these accounts, it becomes clear that these people depend on the 
network of different entities – the floor, chairs, carers – to take part in the rigours of daily 
life. If thought about as hybrid collectives (Callon and Rabeharisoa, 2004) or MS ensembles, 
it shows how action is distributed across human and non-human networks that are adapted 
for their survival with all the articulation and connections required. Everything must 
work meticulously together in the ensemble between people with MS, their bodies, others 
bodies, technologies, objects and tools around them just to perform everyday tasks. These 
are ceaseless practices, hidden labours and situated actions (Suchman, 2007) to maintain 
everyday life, where things work as a network of care to enable them to complete tasks.8 I 
initially did not comprehend the demand it took on their bodies and energy to do this nor 
their commitment to complete the simplest of activities. The limit of the MS ensembles 
became apparent when one of the partners had a cold and decided not to take part in the 
meeting so as not to spread germs amongst the participants with MS. This would have been 
high risk to those with weakened immune systems as this could cause a relapse of their MS. 
Here, she has to account for her body as part of the MS ensemble she is part of, and the 
other ones in the session. 
8 Moser (2006) points out that disability is ordered and performed in situated and particular ways and importantly for this thesis, 
material objects have a role in enabling or limiting interactions  Further, focussing on taken-for-granted stories is a common strategy 
for scholars of feminist science and technology studies (Latour, 1987; Star, 1990; Suchman, 1995; Star, 1999; Bowker and Star, 2000)  By 
doing this, I am enabled to unpack the invisible work requirements that make up this taken-for-granted work, of living as a person with 
MS  
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These accounts make me aware of the maintenance that is required everyday to live 
and how they constantly have to deal with and take into account many factors and make 
a number of decisions before they do things many people would take for granted. This 
is different work to that of doing patient experience, as these accounts describe the work 
involved in just being a person with MS before they can even be captured by a technology 
of experience (such as in a questionnaire, or an interview). But what this highlights for my 
understanding of patient experience is that the examples of patient experience discussed in 
this thesis so far have the assumption that experience is being performed for other people 
– healthcare professionals, researchers and designers – to access and utilise. What these 
accounts of experience do not consider or account for is any of the upfront work patients 
are already engaged in. This work not only enables these people to exist and function, but 
it also enables them to participate in this study as participants. I experienced a glimpse of 
this demand when the cups the meeting venue provided had no handles. A partner of a 
person with MS pointed out that we needed to change them because the patients could not 
use them without a handle. This work enabled them to attend this meeting and tell me their 
accounts to make patient experience – Experience 1 
This pre-capture information then becomes interesting to turn into patient 
experience, as it has not yet been cleaned up by any technology of experience and probably 
is the stuff that normal measures of patient experience do not actually get at. This material 
may not pertain to innovative outcome development or scientific expertise, but as Haraway 
(2008) points out, it is the mundane and the ordinary that helps understand what kinds 
of worlds are being made (and unmade). In healthcare research, this requires attention 
to the role of the mundane, everyday materials and practices of these people’s lives to 
make their worlds (Latimer, 2018, p. 379). It also shows an awareness of the problems that 
concern patients, and does not take this for granted. The exclusion of what does not count 
according to medical research is seen in how the carer’s role is not considered as a valid part 
of patient experience by the research ethics team, as they were not considered to be part of 
the meeting. So, the question of whether they should grant informed consent did not arise. 
However, without them, many of the MS ensembles would not have been able to participate. 
Another point here is that patients brought forward external factors which affect both 
them and their MS ensembles. Here, it is not just that time of day is important, but that the 
patient’s involvement in this process has demonstrated how these factors need to be part 
of working towards a new technology of experience. It is clear that the participants value 
them and take them seriously, so should not the research community also? I suggest here 
that perhaps a technology of experience needs to look at people’s skill in recognising and 
working with these external factors. Thinking back to how work practices of healthcare staff 
is erased from Experience 2 in the clinic, it is important that patient work and skill are not 
erased.
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Homegrown technologies of experience 
An important assumption for existing technologies of experience is that experience is 
transportable, fluid, friction-free and fast. This study works with the mess and what is 
left out of medical versions of patient experience. In slowing down the process of PROM 
development in these encounters with patients, I take a closer look at how exactly things 
are included, considered as valid or excluded. The pilot studies showed how non-medical 
objects, such as olive oil bottles, can be validated as an object of experience by a clinician 
and patient in the clinical setting; and the scientific validation process has been written 
about elsewhere (Shapin and Schaffer, 1985), but what about in different settings of the 
everyday lives of people with MS. 
Participants shared their stories in the discussions and the survey of how their MS 
affects their hand and arm activities. A number of examples came forward, demonstrating 
a practical knowledge of managing activities.9 These included using dictation software to 
write emails, opening a packet of crisps with scissors, buttoning up a shirt before putting it 
on, and buying pre-cut frozen butternut squash rather than having to cut it yourself.
Participant 6: I work in an office, I’m still working and I wear shirts all  
  day. I have a few remedies I found is one when I take this  
  shirt off…
Participant 2: Leave it done up?
Participant 6: This button (top) gets undone, the rest stay done. It goes  
  in the wash and it stays that way. I have been known to  
  spend 5 minutes, especially the top one, not the very top,  
  the next one down, because you can’t see it. So frustrating.  
  So a little gadget and it’s got a little loop, like a paperclip  
  sort of metal which you put through the button hole.   
  It hooks the button up and you pull it back out and I can  
  do that in seconds. Very very useful. 
Participant 7: Didn’t know they worked.
At the next meeting the same participant reported the below:
Participant 7: [Participant 6] said about the button tool, so I bought one. I  
  was saying earlier that I can do buttons up now!
9 See Appendix M for practical examples collected through the online survey 
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They also, interestingly, shared examples of activities they conduct regularly to measure 
experience for themselves. One participant shared an activity he completes everyday and 
uses to tell how his hand function is changing:
I eat a yoghurt most days and things like using a small teaspoon to clean 
out the bottom of the yoghurt pot is impossible to turn it and do that 
action [gesturing a wrist turn movement]. It’s just one of those things it’s 
not so difficult that I can’t eat them. Just sometimes you notice and you 
think, that’s getting more difficult. It’s just an observation when your 
scraping out the last bits. Participant 1, meeting 3 
Similarly, another participant shared their experience of seeing the change in their painting:
I’m right handed, I feel things with my left arm and generally I’m quite 
a broad painter, I’m not going to … but I used to be a mathematician, 
partly because in art I can be messy, you don’t have to be so tidy. So, 
I’m not worried because if I lose fine movements, I’ll start painting in 
different ways. I already see changes in my brush strokes. Participant 3, 
meeting 3 
Here they discover what their bodies are capable of in the process of adopting mitigating 
tactics. These examples show patients’ ways of working with their bodies and within their 
MS ensembles is through practical interactions involving experiments and tests with 
everyday objects found in their homes. Pols (2014) frames patient knowledge, developed 
out of routine practices in their everyday lives, as practical knowledge which considers 
how patients use medical forms of knowledge to work with what they know and do. As 
practical knowledge, it aims to improve daily life of people living with disease (Mol, 2006). 
Patients have developed knowledge and techniques to interpret and shape their daily lives 
with a disease to ‘cope’. Coping here is a matter of adjusting, coordinating, gaining advice, 
and testing. This is a messy type of knowledge involving a variety of different things. This 
is in contrast to the medical way of working with patient experience through knowledge 
and knowledge practices. In the button example, one technique for one person is shared 
practically and becomes valid for someone else. This has also been seen in examples of 
Chronic Obstructive Pulmonary Disease (COPD) patients (Pols, 2005) and patients with 
muscular dystrophies (Callon and Rabeharisoa, 2004) transferring practical knowledge. The 
point is not to privilege patient accounts over medical versions but to analyse the utility of 
these accounts for understanding patient experience and how it is done. What is interesting 
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for this thesis is that a practical way of knowing is more akin to design with similar 
approaches to generating knowledge that are also practice based.
The yoghurt pot tests and the painting examples can be thought of as a home-grown 
technology of experience or practices of everyday monitoring. They have developed a 
situated personal measure of how their MS is doing out of everyday activities. Pols describes 
this type of knowledge as a form of ‘know-now’ (Pols, 2014, p. 80) as they are situated 
activities of knowing. These practices are developed between interactions of their bodies, 
their environment and other objects framed in this way to produce knowledge of their MS 
and bodily functions. The practices simultaneously mitigate and produce knowledge about 
MS. Unlike medical and scientific measures, it is not separated from the everyday flows of 
life. Importantly, this information is for themselves. If we go back to Ellwood’s description of 
the purpose of technologies of experience in that they were originally intended for patients 
to make decisions about what to do or change, then this example demonstrates how patients 
are currently using their everyday activities to capture, process and format their experience. 
Facilitating this discussion in the study enabled the patient to circulate it to another patient 
who was then able to validate it for themselves in their home and returned to report on it. 
Techniques invented locally may not travel beyond the places of their creation and so 
become problematic for medicine since they cannot be used for care. One design proposal 
would be to make them transportable as a resource, which leads me to think about proposals 
to collect these techniques and make them available to others. This would need to be done 
not through methods of medicine, but through design methods of practice.
However, if I take a different direction and do not see what is generated as a resource, 
then what can it be used for? Well, the patients have put forward their accounts of purpose 
– a useful tool to help patients articulate change in their daily lives. So, if everyday practices 
are supported to exist and circulate, and not put under pressure to be cleaned up or scaled, 
then they could supplement clinical data. Mol (2006) suggests the notion of tinkering to 
show how healthcare professionals and patients together can come to specific standards for 
medical practices which are valid and accountable for patients’ specific situations. These 
articulations could contribute to this area. In other words, these specific, situated patient 
practices – involving external factors and mitigating strategies – give a view of patient 
experience that is different from (and perhaps a more accurate reflection than) those given 
by traditional clinical experience technologies. Following Mol, I argue that these should 
be allowed to exist without trying to convert it into a (traditional) experience technology. 
This would be a more practical, everyday consideration of experience brought forward in 
everyday interactions and be closer to thinking through a lens of care (Puig de la Bellacasa, 
2017; Latimer, 2018). Thinking about experience through care exposes the need for changing 
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how science and technology, medicine and healthcare are produced. I explore this further 
later in this chapter.
MS is a disease that fluctuates daily, changing either through relapses or in 
progression over time, making living with a changing body and everyday negotiations 
crucially important. It needs to be re-done daily in changing situations. Being able to know 
what you are capable of one day, and not the next, is something that people with MS and 
other degenerative diseases will be used to. However, it poses specific challenges for ways of 
measuring and reporting in sporadic annual medical visits. The proposal of a technology of 
experience that patients can use at home to report on where they are suggests a hopeful way 
of reporting on their experience. What this means is that technologies of experience need to 
work and adapt to situations far more varied than the clinic or the scientific conference and 
to places such as kitchens in people’s homes, the pub, workplace offices and artist studios. 
These situations are where people with MS need approaches to diagnose a situation and 
find out how to react to it. 
Artefacts as entry points to experience
By opening up the PROM development process, I can compare the knowledge practices 
of medicine and healthcare research to the practice-based approach of design research. 
Accounts of everyday practices of living with MS feature heavily in patient discussions 
and also in the role of objects and artefacts. This study foregrounded practice as a way 
to further articulate the focus of research (patient experience), taking a closer look at the 
socio-material conditions (tools, practices, methods) for bringing new versions of experience 
into being through the discussions and accounts of patients. This picks up on the findings 
from the previous chapter to further explore how exactly non-medical objects can become 
included as valid versions of patient experience.
I took the accounts from the group and the survey and presented this back to the 
group through physical displays (Figure 49). They were specific in their description of the 
activity and specified a material constraint of the specific object presented in the meeting 
space (i.e., not the home). The purpose of displaying the objects that are involved in these 
activities was to further explore the role of the object in these accounts and to be a technique 
to help participants express their ideas about measurement.
The objects presented on the table, although proxies, have been brought into 
discussions about patient experience through their accounts. They represent activities and 
interactions which have come into being through the discussions to uncover and represent 
different realities of MS (Mol, 2002, p. 5). 
There were two purposes of introducing the objects in the second meeting. Firstly, 
as people reported problems with specific activities that involved different MS ensembles, 
they commonly included specific objects such as laces, needles, coins, and keys in their 
descriptions. However, with this, there is ambiguity around what type of shoe or size of 
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Figure 49 Photographs of the objects displayed in the second meeting  
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needle, or type of keys for which lock. Secondly, patients suggested involving physical 
artefact representations of the activities in the meeting in a preliminary activity for people 
to use, manipulate or touch, if they wanted, to help articulate their descriptions. In the 
designing the study activities, I have to be mindful of the capacities of the people involved 
and their potentially limited ability to interact with any physical activities or tasks presented 
to them. Therefore, it was important not to limit them to contribute ideas only physically, 
but to allow verbal responses and the possibility of interacting with these objects.10 I was 
aware of other studies in design which have found that people with physical and cognitive 
impairments struggle with probe-drawing activities provided by design teams (Smeenk, 
Sturm and Eggen, 2018). Therefore, I limited responses to verbal contributions. 
What happened was unexpected. Through these activities, I found that the simulation 
of activities with these objects did not work in the meeting. Patients did not touch or 
manipulate the objects nor comment on their specific design. They described activities 
of opening a packet of crisps, using a knife and fork, carrying liquids, dealing with coins, 
changing bed sheets, typing on a computer, sewing, using keys, and so on. However, it was 
not this specific set of keys or this hairbrush on the table that they would struggle to use. 
Them using keys in their homes gives rise to a practice with accountabilities that are linked 
to their MS ensembles. By placing the keys or an example keyboard on the table, it then 
becomes isolated from any ensemble or ‘bracketed out’ (Mol, 2002, p. 36). This is because 
it is different from the object at home and also not in the usual context of use. Objects in 
practice are not the same from one site to another. The situation at home triggers other ways 
of behaving than the situation in this meeting or in clinics for example. Clinics are about 
organisation and cleanliness, this meeting was about groups of people coming together to 
discuss and give feedback, the home is about comfort and probably involves family members 
and friends. 
This goes back to the discussion in the earlier chapter around practices of simulation 
and the utility of recreating bodily practices for the purpose of measurement. In the pilot 
study, clinicians were walking patients to measure their optimum distance in front of them 
and with validated medical tools. Here, I am similarly asking patients to do the same. The 
lack of response to this activity supports the findings of the pilot studies in showing that 
patients do not engage in simulation. I know now that MS ensembles do not engage in 
simulations because the objects presented were not situated and were stripped out of their 
ensembles (i.e., it was not their keys nor was it their usual setting).
The variety of objects show how almost anything can be part of an MS ensemble since 
everything has the capacity to be painful and problematic, everything has capacity to be a 
struggle (Moser, 2006), and therefore tell you something about your MS. In addition, it can 
10 This is unlike many participatory activities in design research which commonly ask people to write responses down on some form of 
paper tool (Knutz, Markussen and Thomsen, 2018) 
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be part of the practice of experience. Unexpectedly, the objects on the table became an entry 
point in thinking and talking about a situated activity with certain types of conditions and 
factors, where the object acts as proxies for generalised activities. What this tells me is that 
patient experience can be brought forward through specific artefacts and not just human 
reporting. This is an important finding as it adds to the limits of Experience 1 which is limited 
to cognitive reporting. This work shows that patient experience does not sit in people’s 
heads, in protocol documents or in textbooks. It is part of practices, devices and situations. 
I think it might be helpful here just to clarify that working with a situated experience 
is different from working with a subjective experience – which would be a human-centred 
cognitive entity. I am making the point that experience can be brought forward through 
artefacts, not just human reporting, which I think contributes to the discussions in co-
design where ANT has been celebrated for its ability to explain how materials and artefacts 
always play a role as non-humans determining how people and materials participate in 
collaborative activities (Eriksen, 2012). 
So, what does this mean for healthcare design? What was interesting was the 
participant’s reflections on objects that had been adapted in their design to try to 
compensate for their lack of upper-limb function to, for example help with reduced grip 
strength or dexterity. Products such as the OXO range and thicker cutlery were described as 
‘useless’ because they made a presumption that if the physical impairment was subsidised 
by a product, then the task could become achievable. This leads me to question the success 
of these designs for this group of people. What was discussed to be a more productive 
suggestion was that their hacks around activities be shared. Here, design has made 
assumptions about MS bodies and ensembles and what they are and are not capable of. 
Therefore, this is a different role for design; rather, in trying to compensate, design should 
work to support existing MS ensembles to produce experiences they want to produce and 
find interesting and useful. 
Non-transferable experience
A key stage in the translation of experience within a technology is the generalisation and 
reduction of data to become visualised. The purpose of this attempts to formalise and 
scale this version of experience. In the meeting, participants discussed how they complete 
activities and then compared them to accounts from other patients from the survey data. 
It became clear through these discussions when comparing others’ activities and personal 
choices to their own experiences that there are a number of different ways to do things. This 
is for a number of reasons – external factors affected people differently, there are different 
153
ways of completing each activity, some activities are irrelevant to some people, and different 
people had different priorities.
Participant 1: Yeah I mean there are some things you want to do yourself.
Participant 4: Do you have to wear a shirt?
Participant 6: I work full-time, I literally just came from work.
Participant 4: Do you have to wear a shirt?
Participant 6: I can get away with not wearing a tie, but not a shirt.
Participant 4: Smart casual?
Participant 6: Fridays I would say.
Participant 4: Do the people in the office know your situation?
Participant 6: Yes.
Participant 4: I’m sure they wouldn’t mind, if you didn’t wear a shirt.
Participant 6: I just choose to try and stay the same as much as I can.  
  People say, “Why are you working?” and I intend to stay  
  working as long as I can. There’s no other reason for it.  
  Personal choice.
Combining the responses of the survey with those of the patients enabled a deeper 
discussion to take place where patients expressed anger, humour and disagreement. This 
actually became the source of tension and disagreement where some of the suggested 
activities brought forward from the survey were rejected by the patients in the meeting and 
asked to be removed from any future way of measuring your function, such as when taking 
pills from the packet was considered not valid as it was ‘too difficult to measure’.
Translation caused friction
What is interesting about involving patients in this PROM activity is their reactions and 
responses. It was if they were validating the survey responses to their own Experience 1 and it 
caused friction. For example, when discussing how MS affected their ability to tie shoelaces 
Participant 5 stated, ‘Laces, laces. In the morning I can do them up but after lunch I need 
my mum’. Participant 4 shared that he opted to wear Velcro shoes: ‘Aren’t you better buying 
the shoes with the Velcro? I’ve had the same shoes, the same type of shoe for 10 years. Don’t 
walk anymore, don’t wear them out and so much more convenient’. Participant 5 explains 
that he liked his trainers and did not want Velcro, which Participant 4 could not understand. 
Their experiences did not match, and this caused friction between the coherent stories and 
messy practices of everyday life. 
When the information was being collated on the visual displays with categories and 
dots, the participants began to show reactions of surprise and almost disbelief at some 
of the results. Even though they had been part of the generation and collection of them, 
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visualised in this way, they did not match their own Experience 1. Here, the discussion data 
is combined through the collation of their categorised external factors. This is a key step in 
PROM development where messy contextual information is formatted to produce Experience 
2 data. This activity positioned the participants as spectators (or an audience) to the 
reduction process. When they were not participating any more and their experience become 
redundant, part of the information was left out of the new version being created in front 
of them. This is shown in a comment from a participant: ‘It’s like your Carol Vordamin on 
countdown’.
This comment was followed by laughter from the group of participants. There 
was laughter at different points through the discussions, highlighting feelings of 
nerves, jokes or tensions. However, this specific moment of laughter is interesting and 
I think worth analysis, due to the activity we were engaged in. It is important to pay 
attention to the interruption and response in the visualisation activity as an opportunity 
to generate sensitivities and questions about the activity rather than ignore it. As a 
design researcher, this was a disconcerting moment where I feared I was excluding the 
participants and became part of the translation process. Likening me to a TV host within 
a joke is an interesting response to the activity. Laughter is a situated activity that is 
part of the communication between the people involved and has been discussed in the 
ethnomethodology literature (Jefferson, 1979). This is interesting for a number of reasons. 
The moment of laughter could indicate how ridiculous and strange the participants find 
the idea that you reduce accounts of life into dots on paper. Alternatively, it could be a sign 
that they are nervous in that they are now not in control of their contributions. If thought 
about through the role of the idiot here, laughter ‘slows us down to resist the consensual 
way in which the situation is presented’ (Stengers, 2005, p. 994–995). Only by slowing down 
can I challenge the taken-for-granted-ness of what should be taken seriously. This use of 
humour stops to check if we really know what is going on here. Is experience really being 
captured? This is an important moment as it shows that focussing not on coherent moments 
where subjective accounts are shared but on messy practices can activate their potential for 
generative critique.
This activity demonstrates how making Experience 2 visible and tangible is a 
disembodying process. The purpose of creating the visualisations is to remove the mess 
of the working, the individual bodies and the outliers, and objectifying the information. 
This is exactly what scientific knowledge and processes do when they objectify the body in 
making it visible in these formats (Callon and Rabeharisoa, 2004, p. 28) and making data 
comparable for populations of people. At this point, the information becomes unhelpful for 
patients to use in their everyday situations, for the here, and now to complete the necessary 
tasks to exist. It also alienates them so that they do not recognise their own practices in 
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the data. This suggests that data visualisations are useful for medicine, but not often for 
patients. 
This also raises questions about the relations between Experience 3, Experience 4 and 
recording tools. Patient experience is done in different ways and in different contexts, and 
depends on everything and everyone necessary to it to be active. The previous section 
has shown how you cannot consider an object independently of the ensemble; so again I 
follow scholars of ANT who pay attention to the richness of settings, which is a common 
trait of ANT research (Star, 1990; Singleton and Michael, 1993; Mol and Law, 2004). These 
visualisations exclude the patients and their bodies, and this is why patients cannot relate 
to them as versions of their experience and result in this reaction from the group. As a 
technology of experience, the production of visual representations is key to its ability to 
circulate. The removal of bodies enables these visualisations to happen. In contrast to this, 
these visualisations could not travel to patients homes, whereas the button technique could. 
This becomes a crucial turning point in working with patient experience as I’m now 
treating it as Experience 4 rather than Experience 2 – deciding not to reduce it, clean it up or 
marginalise the tinkering going on (Mol, 2006). Ultimately, this limits the possibility for it 
to travel to create a population metric scale, but in doing this, ensures that specific versions 
of people are included. As demonstrated in the previous chapter with the olive oil bottle 
being included in a consultation, healthcare professionals and patients are already working 
together to calibrate alternative versions of experience, and Mol argues that we should be 
strengthening these practices (Mol, 2006). 
What I have learned in developing a new technology of experience?
• MS ensembles are critical to people living with their MS and includes 
much of the stuff that is left out of the medical PROM development 
process. 
• At the moment, understandings of working with patient experience are 
too general and formal, and they don’t account for plural settings with 
a range of diversity within them. These meetings have shown how what 
happens in a hospital is different to what happens in the home. 
• By foregrounding practicalities and materialities of patient experience, I 
can take account of the heterogeneous actors involved, and their non-
coherent accounts, in contributing to what is done in practices through 
specific conditions. This is a new approach to working with patient 
experience that values practice, the everyday and the mundane. It does 
not value scale over specifics. 
• Material objects and tactics are part of these ensembles performing 
experience.
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• The problem with using objects to somehow capture or measure experiences 
(considered as Experience 2) is that they are deeply embedded in their situations / 
ensembles.
A turning point – what does a new technology of experience look like?
When I designed the MOT study, I set out to make, or at least be able to initiate the 
creation of, a new PROM for people with MS through design-led research. But through the 
investigation and development of the different theoretical versions of patient experience 
and observations of practice from the pilot studies, I have come to the point where I have 
realised that this is, in fact, impossible. I am unable to make a PROM from what I have 
found because these things do not travel and they cannot scale. What is needed is an 
experience technology that could simultaneously capture experience ensembles, respecting 
their situated nature and also be scalable. That really calls for a new kind of technology of 
experience. And so, the question then becomes, what does a technology of experience look 
like that does not reduce, clean or marginalise particularities?
From the trajectory that I have taken in this thesis, I do not think it is enough to leave 
it at this point as the discussions in this chapter have fundamentally challenged the idea of 
capturing patient experience (Experience 1 and Experience 2) when framed from healthcare 
and medical perspectives. I have alluded to inviting another perspective or purpose. In 
the context of delivering quality care, Mol (2006) has shown that it is a problem to assume 
one gold standard for all if health is at stake. If I apply the purpose of PROMs to my new 
thinking about patient experience, then it seems silly to only have one format to produce 
technologies of experience. We need multiple, and I now want to know what this might 
look like. Therefore, it is clear to me that the next thing to do would be to briefly present two 
possibilities to take this proposal of a new technology of experience forward. 
Proposal 1 – Individualised experience technologies built around a patient’s own 
ensembles 
The first proposal is around the existing practices of people’s daily life, such as the yoghurt 
pot test mentioned in the MOT meeting, which are not scalable. This proposal suggests 
working with MS experience ensembles before they have been cleaned up. It aims to take the 
mundane, everyday activities that people with MS find important, seriously. Developing this 
as a proposal would involve going to people’s homes to uncover practices of measurement 
embedded within the situated actions and activities that are personal and meaningful 
to them. If this activity then became the technology of experience for that individual 
person, then it could be used in conversations with their neurologist or nurse to talk about 
change, subtleties and progress of their condition within the context of their life. This is 
an individualised PROM for situated, individual people. As it is for this one person, it does 
not need to travel. Therefore, it could become even more specific within their lives based on 
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how they are affected by external factors. To develop these patient-embodied measures, I 
propose an ethnography or participatory form of research within the homes of people with 
MS willing to participate to discover the situated actions that are used as ways of measuring 
their experience. 
The challenges of this proposal for medicine are that it would require individualised 
care, letting go of scale and comparability. Nevertheless, it would allow the patient to 
measure and articulate their experiences in ways that are relevant to them, and the only way 
of doing this is through the actions the patients have, not through statistics or psychometric 
calculations. I can imagine this could be of value to patients with progressive MS who are 
likely to have co-morbidities (i.e., multiple health concerns and illnesses) and are patients 
with complex medical needs (MacLurg et al., 2005). This proposal would address the 
limitation that current PROMs perform patient experience at a population level at the 
expense of those patients being able to recognise themselves in the results (as demonstrated 
in the MOT study). Patients would be able to identify themselves in the data generated. This 
would lead to further questions such as, what could a homegrown technology of experience 
tell us about accountability practices for people with MS, and for generating knowledge 
outside of clinics and labs?
As an Experience 4 based proposal, it recognises ensembles including people, objects 
and activities rather than the phenomenological version of Experience 1. Therefore, it does 
not do what existing technologies of experience do. By staying situated in everyday actions 
involving the specificities and complexities of individual people’s lives, it can not be part 
of population data as it stays completely individual. Experience 4 is not applicable to others 
and not transportable. This proposal intentionally sacrifices scalability by creating a really 
situated personal measurement of home based ensembles. This is a trade-off between 
engaging with the very situated worlds, actions and meaningful activities of patients’ lives 
and the need to be transportable, which is currently not explored in outcome measurement 
research and development.
I argue that this proposal has agency in other ways. In relation to how this proposal 
works with different versions of Experience, this approach could actually compliment 
transportable versions or forms of Experience 2 e.g., the clinical data, the visualisations and 
graphs, produced in routine clinical care. The proposal reveals and works with things left 
out by medicine and follows Stenger’s reclaiming of mess to deal with what escapes objective 
categories. It operates differently to clinical technologies of experience as the patient, rather 
than the clinician, researcher or designer, works with the demands on material practices to 
produce experience. In other words, it stays with a person’s subjective experience, embodied 
perspective and ontological view as they validate experience for themselves, through 
their interactions within specific activities. As a technology of experience, it includes and 
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celebrates the materiality of subjectivities that are central to impacting on people’s everyday 
lives through how they work, care for themselves and their families. 
This would enable Experience 4 to become a clinical tool that could be useful to further 
illustrate specific and complex aspects of people’s lives, that current tools struggle to access. 
This proposal provides a way to contribute knowledge to crucial clinical conversations such 
as what is improvement or deterioration in everyday situations providing information that 
might not be picked up by clinical tools. For example, the pilot studies highlighted a tension 
in how measurement outcomes, such as walking distance measures and the PiP criteria, 
are set up to include and consider only certain things as valid and fail to shift during the 
course of an illness. This proposal would be sensitive to subtle changes for individual 
people, such as being able to eat a yoghurt better than the day before, having better control 
of the paintbrush, or being able to do up more buttons in the evening. Ultimately, it centres 
on activities that people actually care about e.g., controlling a paintbrush won’t matter to 
everybody, but it will matter a great deal to some.
If these two versions (Experience 4 and Experience 2) could hang together, co-become, 
or collaborate in this way it would be quite radical as it would recognise the everyday 
practices of (non-clinical) people could supplement and work with the cleaned up practices 
of medicine. This has the potential to contribute to wider discussions about trial or 
treatment endpoints of improvement and how these are determined for different people 
living with MS. What this also does is work towards creating versions of experience that 
count for patients in their everyday lives, not just the original intensions of PROMs for 
medical accountabilities and resource management – which has been a key question raised 
throughout this thesis. 
Proposal 2 – Under and Over
The second proposal is to design a task that could become part of everyday life for more 
than one person. This is actually an approach that I am starting to work on outside of this 
thesis in my work with the Barts MS research team and collaborators The Agency of Design. 
In September 2018, we launched Under and Over, a hand-and-arm activity pack that comes 
with a plastic grid, two shoe laces and a pattern book (shown in Figure 50 and Figure 51). 
The grid has been designed for people with MS whose hand and arm function is affected 
by their MS. They can thread the grid with the laces, creating an endless variety of different 
patterns and designs. The book that comes with the grid proposes a range of designs, from 
simple patterns to complex imagery. Initial design development with five people with MS 
has been conducted and it has been exhibited at the ECTRIMS conference in October 
2018 (Figure 52 and Figure 53), where the response has been very positive. One participant 
we tested it with had significant hand-function impairment and physically struggled to 
complete the simplest pattern. However, the participant found this challenge motivating, 
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Figure 50 Under and Over grid 
Figure 51 Under and Over pattern book 
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Figure 52 Developing the activity with a person with MS with upper-limb disability in their homes as part of patient design activity  
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Figure 53 Under and Over was exhibited at the ECTRIMS conference in October 2018 in Berlin (Photo credit: The Agency of Design)  
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allowing them to compete against their own ability. As such, ultimately it was rewarding and 
enjoyable. 
So this proposal provides a group of people with a standardised activity but at the 
same time, also allows a large amount of individualisation, as they can make it part of their 
everyday lives in different ways. The tool is flexible enough that people can create their own 
patterns or complete pre-designed patterns in any way they like, and conduct the activity 
where and when they like. Once this has been further developed, I anticipate that what 
people do with the tool will be indicative of their hand and arm function; they will be able 
to complete more complex patterns over a longer period of time if they have more cognitive 
and physical function. This then opens the door to explore if this activity contributes to the 
rehabilitative functions for a person who completes it regularly. This is a work in progress 
and requires a major study involving a large group of patients to use this tool in their homes 
over a long period of time. Given the institutional complexities of arranging such a study, 
this is beyond the scope of this thesis. 
This proposal seeks to explore and take seriously external factors, paying close 
attention to how people with MS manage to complete a standard activity in different 
conditions. This is done in an open way involving design without being overly scripted 
or dominated by being externally visualised into Experience 2. This avoids some of the 
assumptions of designs current involvement in designing patient experiences as mentioned 
in the literature review as a first and second generation understanding of experience 
design. In Under and Over specifically, the visualisations that patients can make work with 
the assumptions of materiality (where people are solely depositories of knowledge to be 
visualised) to establish it as an Experience 4 tool where the artefact is the entry point into 
experience. Through making the patterns, they are performing their patient experience. 
These patterns are not pre-existing but are dependent on felicity conditions, or external 
factors, so are created in response to the changing MS ensemble which fluctuates and 
changes daily. In the pattern’s creation, it brings forward MS ensembles to produce 
knowledge, instead of reducing it.
It is interesting to think through the implications of this proposal for how MS is 
practiced in clinical care and in research. As mentioned in Chapter 1 when introducing the 
field of MS research, the categorisations of MS are changing where the historical disease 
categories are being rethought and challenged to create new opportunities for the treatment, 
care and monitoring of people with MS. The Under and Over proposal supports this future 
outlook as it is sensitive to the changing nature of MS as a degenerative disease over time 
and recognises and works with the variety of external factors affecting people each day. This 
activity is open ended enabling people to adapt it to their lives by standardising conditions 
around them depending on a number of factors such as how they feel, their upper limb 
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ability, if they’re being watched, the weather etc. In a very subtle way, it can be used as an 
indicator or test of upper limb function for people that use it. 
I imagine three different ways this standardised design tool could be used in practice 
which would have productive implications for my different understandings of experience. 
Firstly, giving this standardised object to a variety of people in a variety of ensembles, 
could go onto create controlled Experience 2 visualisations by removing the openness of the 
tool and administering it with specific tasks. So this would be a controlled use of the tool 
where some of the specificities (such as pattern choice, or activity duration) are controlled 
or standardised across a group of people. The completed pattern can be considered as an 
immutable mobile, visually representing and recording the specificities of experience for 
different people based in different ensembles. In doing this, the tool speaks to Experience 2 
and becomes a tool to enable patients to represent their ability at that time. Interestingly, the 
validity of this technology sits in the material object as it is standardised across all patients, 
bodies and ensembles.
Secondly, if you give it to people with MS to use at home with the pattern book they 
can use the tool freely and there is an openness to it. People can do whatever they like - 
they are in different situations, they have different interests, aesthetic preferences as well 
as abilities. What they will produce is totally unknown before they start the activity, and is 
completely dependent on the external factors of that time and space. This would produce 
Experience 4 however, any appearance of Experience 2 might be misleading. In this example, 
Experience 4 becomes positioned arguably closer to experience, or can be thought of as 
a fuller way of talking about experience by incorporating different versions, as the MS 
ensemble has more freedom over what is produced making it an entry point to think about 
experience. 
Thirdly, there is an option where the tool could work between these two previous 
examples. So even when someone might produce the same pattern as someone else, they 
could be produced in different ways. For example, one person would complete the pattern 
over three days and another person in one hour. Here, they could be producing data for 
Experience 2 in ways that don’t imply the constraints of a cleaned up Experience 2 process. 
These three scenarios illustrate how the tool spans a range from Experience 2 to 
Experience 4 depending on how it is used. This means that the same tool can service multiple 
forms of experience as it moves fluidly between recognising Experience 4 and being allowed 
to be used for Experience 2. This shows how the different versions of experience are not 
competing, but provide lenses on the same experience. 
Discussing the two proposals in this section of the thesis has brought me to the point 
where I am starting to develop a narrative about how these tools might work based on my 
understandings of a new technology of experience. The implications of this impacts on my 
understanding of the different versions of experience and this productively starts to suggest 
how the separation of these versions in the experience table might not be as clean cut as it 
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might originally suggest. For example, this initial discussion has demonstrated how they 
can be used as different lenses to view what is going on in different practices of patient 
experience. 
Limitations of proposals
These two proposals outline practical and theoretical directions to which the research of this 
PhD has led me. It is important that I describe the limitations as to why I am unable at this 
point to take either of these directions further within this PhD. The practical contingencies 
of working in a practice led way with patients within the NHS demands a significant 
amount of time and preparation. I have illustrated the ethics process with timelines involved 
for the MOT study (see Figure 10 on page 32) and have included documents generated 
in the appendix of this thesis to demonstrate the demands involved in this work. For me 
to conduct either approach with people with MS would involve another research study, 
involving protocol design and development and seek ethical and HRA approval.11 These 
activities are beyond the scope of this PhD. I understand that it is a shortcoming that 
I cannot present the results of this work here. Nevertheless, I describe these promising 
research directions as they are the direct results of, and evidence for the success of, the 
research reported in this thesis. 
Completing the table of experience
I now refer to the table of experience developed in the literature review to complete, albeit 
tentatively, the final two boxes at the bottom right of the table shown in Figure 54. The 
reframing of Experience 4 aims to contribute to a better understanding of the requirements 
of a new approach to working with experience in light of the assumptions raised in 
previous versions. This describes the positioning and properties of Experience 4 as being 
distributed and embedded within experience ensembles. These ensembles show how 
action is distributed across human and non-human networks where everything must work 
meticulously together just to perform everyday tasks. These are not pre-existing and are 
totally dependent on external factors including specific differences in environments, bodies, 
objects etc. Assumptions in this version include how everything can be performative and be 
able to change in moments of coming together. This accounts for how Experience 4 includes 
much of the stuff, or mess, that is left out of the medical PROM development process and 
includes it as experience phenomena. By involving design to work with Experience 4 it can 
foreground practicalities and materialities so objects can capture and measure experiences 
if they are deeply embedded in their situation or ensembles. But the limit to this is that they 
can not also be scalable nor generate simulations of experience. In order to work in this way 
11 I am currently developing a protocol for Under and Over to allow me to test it in people with MS’s homes  It is planned to submit for 
ethical review later in 2019 
165
Figure 54 Completed table of experience 
Description Assumptions Design approach
Experience 1 This first understanding 
of experience is of a 
patient’s inner, subjective 
experience of events 
that has happened to 
them  This understanding 
is heavily influenced by 
phenomenology and is 
dominant in healthcare 
practices that threat 
patients as subjective 
beings 
The limitation of perception 
where individual people 
view the world differently 
depending on their 
embodied perspective and 
ontological view  This also 
presumes that humans 
know their own minds and 
access their thoughts, i e  
their memories  STS would 
argue that this point of 
view prioritises humans as 
perceiving subjects above 
all others  
A first generation of 
experience design 
understands customers as 
being passive recipients of 
experiences that designers 
can create  A second-
generation understanding 
likens experience design 
with co-creation and 
participatory design tradition 
where users are involved 
to talk for themselves and 
contribute to the change 
process  This understanding 
has underlying motivations of 
democratic principles of work 
management dynamics 
Experience 2 This version takes patient 
experience as a measured 
and objective phenomenon 
such as a number or a 
measure produced through 
data as generated from and 
reported through patients’ 
subjective accounts  This 
version can travel and have 
agency in making subjects  
This is not to be confused 
with the phenomenological 
perspective of experience, 
which is the ‘inner 
experience’ of a person, 
this notion is a generalised 
data version 
Presumes people are 
reflexive, rationale actors  
If you fail to produce 
data, you do not have an 
experience  People are a 
repository of knowledge 
that need to be quizzed  
Raises questions about 
the different forms of 
knowledge left out by 
methods to capture or 
represent this information 
Typical design inscription 
(immutable mobiles) that 
visually reduces knowledge 
production to simple and 
interrelated shapes  Action is 
ascribed to these shapes that 
are at the center of design 
activities 
Experience 3 This third understanding 
emerges out of the situated 
interplays between people, 
measuring instruments, etc  
which are socio-materially 
mediated  It argues that 
‘experience’ is the result 
of these practices and so 
cannot exist without them 
and has agency that can 
cause other actants to act 
and produce subjects  It is 
constituted in relation to 
various elements, and there 
is no single central core  
There is an indexicality of 
this experience where it is 
dependent on where it is 
embedded 
This version rejects the 
object/subject divide, 
but as a performative 
understanding, it has 
been used to focus on 
language, presupposes a 
backstage where there 
is a consciousness and 
is limited to recognising 
performativity as producing 
visible effects  
An understanding of the 
design process as entirely 
performative where both 
subjectivities and bodies 
are performed  Socio-
material assemblies of 
patients, measurement 
tools, health professionals, 
spreadsheets, etc  are 
performed that achieve 
different experiences  Can be 
simulated through experience 
prototypes and design tools  
Experience 4 This is a distributed 
experience that has 
distributed agency  It is 
not pre-existing and can 
have no visible effects  It 
is dependent on external 
factors  This understanding 
of experience is influenced 
by the notion of event to 
consider the situated action 
of this model of experience 
brought forward through MS 
ensembles 
Everything is performative 
and changed in the 
moments of coming 
together  Everything has 
the capacity and potential 
to become an experience 
phenomena – not limited 
to medical or scientific 
objects  It is not scalable 
and cannot be simulated 
Can work with experience 
through artefacts as entry 
points  Works with mess 
through practice  Can be 
inventive and speculative in 
that it is unknown before 
the event  By slowing down 
can let other things come 
forward that would have 
been othered   
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through design, it is necessary to slow down to let other things come forward, that would 
have otherwise been othered. 
In a way, the proposals presented in this chapter problematise the presentation of 
these categories of experience that I set out in the experience table in that they appear 
separate from one another and appear to sit in contrast. Thinking through these proposals 
actually suggests that the different categories might influence, or serve each other, 
working as different lenses to view and understand the same experience. These versions of 
experience are not different experiences, they are different lenses on the same experience. In 
the conclusion I reflect on the table of experience as a contribution of the thesis along with 
further implications and limitations of this work.
Conclusion
This chapter has described the MOT study, which emulated the tactics of producing a 
PROM. It did this by bringing together people with MS whose upper limb function is 
affected by their MS to discuss activities they do every day. Through comparing these with 
others’ experiences and interrogating the specificities of these situations, things came up 
like aspects they have difficulty with, personal preferences and external factors. This was 
interesting, as I found that introducing substitute objects to the discussions were unusually 
unlike the situated experiences of their homes. It further highlighted points about the 
limited performative effects of visualisations of experience data and the potential for MS 
ensembles to travel and scale.
This study has challenged the ability of a PROM development process to represent 
the world out there to involve actual patients and actual practices. Slowing down patient 
experience has enabled me to unpack the motivations and requirements of generating 
experience for research and medical purposes. This then suggests that there is a world of 
experiences and other technologies that is jeopardised by the practices and existence of 
current PROM tools and approaches. 
This chapter, in the description of the MOT study, has opened the door for the need 
for a radically new way to do patient experience – one that privileges the ensemble over 
scalability. I have concluded this chapter by pointing to two different directions as future 
possibilities to continue to build on the work presented in this thesis and to propose the next 
steps of how they might operate.
From the discussions in this chapter, I have completed the table of experience 
developed throughout this thesis while also starting to explore how these different 
understandings might be brought together, or could work together in different ways in 
clinical practice and care. This is an incredibly interesting proposition and point for further 
research. 
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Chapter 6: Conclusion
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In this final concluding chapter, I revisit the main arguments of the thesis to draw out the 
contributions of knowledge to the fields of healthcare, social science and design research. 
I will also use this chapter to address and answer some of the practical and theoretical 
questions that I have raised throughout the thesis. 
This thesis has identified different ways that patient experience is enacted in the NHS 
for people with MS in an environment with multiple pressures from government policy, 
quality standards, commissioning and measurement outcomes. This leads to a number 
of specific versions and practices of working with patient experience from different fields 
that carry with them a variety of assumptions, procedures and tensions. I referred to these 
as different versions of experience and present them as a table of experience in the table in 
Figure 54. I use this table to firstly identify areas to contribute conceptual understandings 
of the notion of patient experience, then again at the end of the thesis to position my new 
discoveries. Methodologically, this thesis has investigated the conditions, procedures and 
instruments for producing these versions by opening up existing technologies of experience. 
The methodological rationale for this thesis is built on ANT approaches and 
performativity literature, which considers knowledge not to be pre-existing, fixed or stable, 
so that any object of study is brought into being through specific situations, interactions, 
objects and humans involved in them. Therefore, this practice-based design research 
approach has shown how practical interventions can be deployed in specific situations to 
enable alternative versions of experience to come forward. In doing this, design research 
slows down existing technologies of experience to see how certain things are left out, are 
made transferable and can be made valid. The discussion and analysis from the practice 
and theoretical discussion, in light of the resulting interactions from the pilot studies, 
affected the trajectory of the final piece of research and my original intensions to make a 
new PROM. As it became clear in the analysis and discussion in Chapter 5, I cannot make a 
PROM based on individual ensembles because respecting them means sacrificing scalability 
and transferability. These, however, can be worked with if considered appropriately. 
Therefore, at the end of Chapter 5, I point to two directions as future possibilities for a new 
technology of experience around Experience 4, involving the development of individual 
embodied experience measures based on individuals’ activities and the design turn of 
introducing a physical artefact that could become part of people’s lives. These directions 
as future research work will take years to unfold, given the practicalities of working with 
design-led research in the context of the NHS.
This thesis contributes to knowledge in three main areas. Firstly, it contributes to 
understandings of the notion of patient experience as it has identified and articulated a 
range of versions of experience in theory and practice. Secondly, this thesis reports on and 
provides analysis of design-led research within a complex and challenging health care 
environment involving patients, healthcare professionals and medical researchers to explore 
different versions of experience. Thirdly, it has uncovered situated actions of people whose 
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MS is affected by their upper limb function and the work involved in everyday practices of 
maintenance, measurement and care. I will now go into each contribution in more detail. 
A contribution to understandings of the notion of patient experience 
This research was initiated from pressing concerns that emerged from my previous practice 
when I was asked to “improve the patient experience for people with MS through design.” 
This first engagement with patient experience as a concept, was as something to improve 
through my involvement as a designer working in an interdisciplinary landscape. By 
unpacking the assumptions and claims in this statement, mainly that patient experience 
can be known, that it can be improved, and importantly, that design can be involved in this, 
my understanding of this concept has radically changed. I trace this exploration through the 
construction of the table of experience which is a key infrastructure of the thesis that I now 
return to and reflect on as an important contribution. 
The work in this thesis has demonstrated that patient experience is not a topic of 
research restricted to healthcare, medicine nor design, but involves interconnected fields 
and practices. The table articulates nuances between these contrasting fields, where 
patients are positioned differently and are beyond being predictable generators of data, or 
resources to be accessed. It has become a resource that situates and juxtaposes a number of 
contrasting understandings next to each other in an accessible way. As patient experience 
is a timely, complex and multifaceted object of study, the table initiates a vocabulary 
to tease out different characteristics useful to multidisciplinary work. This will support 
interdisciplinary conversations between teams of designers interested in healthcare projects 
or healthcare researchers interested in design methods to understand the principles within 
different methods and approaches of engagement and involvement when working with 
patient experience.
Having summarized the strengths of the table, it is also important to consider the 
limitations, weaknesses or unresolved aspects of this model of patient experience. Reflecting 
on these also help to point me towards ways in which this research can be further developed. 
In the presentation of these different versions of experience, I am mindful of the cleaning 
up process that scientific facts go through and do not forget that design leaves stuff out 
too. This table has been constructed from my empirical work based in one specific chronic 
condition, within a clinical academic research groups in east London through my practice 
of relatively unconventional interaction design. A point of interest, or future work, would be 
the investigation of this table either across another chronic condition or through other forms 
of practice. The nature of the table and the different understandings of experience being 
transportable to other conditions or areas of health research is an interesting and important 
consideration. It would be interesting to consider how the approaches and assumptions 
behind Experience 1 and Experience 2 would seem to travel between different situations e.g., 
for a cancer or diabetes patient opposed to someone living with a degenerative neurological 
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disease, or whether Experience 2 would operate in the same way in a rural hospital in the 
Outer Hebrides as our centre in East London. 
In response to the practice-based elements of the work, I am frequently asked if my 
existing practice-based work would ‘work’ with other conditions so for example if Digesting 
Science could be used with children suffering from asthma, or cancer and not just children 
affected by MS. I am reluctant to speculate as to the efficacy of transporting the pilot 
studies or either proposal to another condition or context, but transporting the tasks, tools 
and design process used to produce them could provide further interesting work. The 
methodology of inventive methods and pilot studies can be explored elsewhere but applying 
the finished practice feels like a discounted form of research, and design. Although this 
non-transferability could be considered a limitation of the work, pulling out and articulating 
different definitions and assumptions has demonstrated the richness of paying attention 
to sensitivities to specific settings of research that we are always already involved in. For 
example, the situatedness of scientists communicating at the ECTRIMS conference, or 
people with MS having their walking measured uncovered particular insights to this setting. 
This follows what Puig de la Bellacasa (2017) frames in Matters of Care as the possibilities 
and obligations of being involved in more than human worlds. This puts forward ways 
to start to care again for patient experience through situated practices of research. This 
involves taking into account others who have cared for it, for example through different 
research disciplines understanding of experience. So instead, what I hope that this thesis 
has demonstrated through the building of this table is the importance that the question of 
how to do patient experience needs to be posed and reposed for different bodies, illnesses 
and spaces by different researchers and practitioners. 
The task of this research is not only to identify how patient experience is currently 
done, but also how it can be undone, and re-done through the creation of different versions 
and technologies of experience.  This is relevant to designers, design researchers, health 
researchers and clinicians working with patient experience as a subject, topic, or as 
material to highlight that patient experience is something that is made, and continually 
re-made in the everyday practices between patient bodies, tools, environments, objects, 
and people. By consciously addressing this topic through research and practice, there is a 
danger of enacting our own assumptions and those from our field when engaging patients 
in research. Therefore, the purpose of the work in this thesis is to illustrate that we are also 
in position to do it differently, as this research is concerned with producing knowledge that 
can inform others to work differently when working with patient experience. The reframing 
of Experience 4 at the end of Chapter 5 supports this and aims to contribute to a better 
understanding of the requirements of a new approach to working with experience. 
As is frequently the case in healthcare research and service improvement projects, 
there is a requirement to involve patients directly in the process. This thesis has shown how 
to work with an expanded notion of patient experience to contribute to these practices by 
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acknowledging the variety of differences in people and not reducing or constructing them 
as vulnerable subjects, nor responding to a need to empower them through solutions.1 By 
paying attention to people and their capacity to participate through different methods 
enables different possibilities to come forward. This is a move away from working with 
patients in forms that are already constructed, to different understandings where they 
can be actors in ensembles - a network of different entities working together - that have 
the ability to say, think and act in the way they want. This is relevant to those concerned 
with involving people in either a research, design, or service development process, such 
as PPI practices, EBCD work (Donetto et al., 2015) or experience prototyping (Buchenau 
and Suri, 2000), where practitioners are responsible for enabling the articulation of patient 
contributions and relevant sensitivities to conduct this work. Hopefully, the contributions 
of this thesis can suggest how to address some of the barriers and challenges in the complex 
institutional processes ingrained in the settings of this work, where, for example, ethical 
approval or guidelines does not guarantee that you are prepared for the ethical dilemmas 
that you may be confronted with in practice. Thus, researchers and research participants 
cannot be dealt with in a single guideline. If we are to start to uncover the messiness of 
patient experience work, and relations within the richness of settings, then a more nuanced 
understanding of ethical principles needs to be developed. The table of experience, for 
example, could be a starting point in practice-based work involving patients to articulate 
their roles and unique contributions to collaborative projects. 
A contribution to design 
This thesis suggests a new way to work with patients as MS ensembles through design. 
As a whole, the design interventions allowed for a better understanding of the values and 
processes underlining and within different understandings of patient experience. It revealed 
some of the requirements and considerations of working specifically with the ensembles of a 
degenerative, chronic illness, opposed to the experiences of users or consumers. In contrast 
to medical or scientific research approaches, this design led process of inquiry engaged MS 
ensembles involving people with MS, their carers, technology, objects and tools to bring 
forward new insights and issues relevant to this specific group. From the results of this work, 
I now suggest that design needs to consider slowing down (Stengers, 2018) in order to be 
sensitive to external factors and account for specific versions that are an upshot of existing 
measurement and representational devices. This is a key argument of this thesis and 
1 Arguably, Callon (1986) argues that this is working against empowerment, as to speak for others is to silence them 
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suggests opportunities for further intervention within this context to better understand the 
different values and processes underlining different practices of MS. 
One of the questions discussed in this thesis has been, what counts as experience, 
and for whom? This is still an important question to take forward by designers interested 
in this area. I imagine this will contribute to a discussion about how designers working in 
healthcare specifically consider patient experience, both practically and theoretically, with 
influence on their own reflective positions. Here, this would be a consideration beyond 
what designers can see and anticipate, including the representations and reduction of 
patients in visualisation and workshopping activities or the potential assumptions that 
design tools may carry within them. This particularly sets a challenge for designers to 
encourage participation without limiting activities to physical interactions, but to engage 
ensembles in design activities. In doing so, this recognises the limitations to participation 
and acknowledges the capabilities of humans to take part, along with the potential for non-
humans. Thus, this calls for creating spaces and approaches where things can come forward 
and invites a new consideration of what designers think they are making or doing (Michael, 
2011). It could also further support designers to be critical of how design is possibly being 
enrolled or involved in service improvement projects and the assumptions that others have 
of designs’ role.
For this research process, the idiosyncrasies of the pilot studies and being able to 
respond to what I was experiencing was crucial to developing both the MOT study and 
constructing insights on ways of working with experience that had an important influence 
on shaping the thesis. This thesis sets out to research patient experience and then create 
a PROM. Through the course and trajectory of the combination of the theoretical and 
empirical research process, it turns out that in actual fact, creating a new PROM is not the 
correct thing to do. Re-positioning the research to respond to these insights enables this 
work to become a form of brief or requirements, or a starting point for other’s research to 
create a new form of experience. Or to continue my own. This decision steers me clear 
of being pressured into creating an intervention that runs the risk of assuming pre-made 
experiences. By not presenting a concrete solution to patient experience but demonstrating 
how to re-configure the problem, or the starting point and technologies for those practices, 
I turn patient experience from matters of fact to matters of concern (Latour, 2004).2 If 
thought about as a matter of concern, this then offers new possibilities for conceptualising 
patient experience in alternative ways compared to how it has currently been positioned i.e. 
as a pre-existing resource to be measured, acted upon and improved. This then contributes 
towards building a critical approach to patient experience work with a sensitivity for 
the implications of individuals involved in this work. For example, my proposal for a 
2 As matters of concern, patient experience can be thought about as open to critique where the different ways it is gathered and 
assembled can be interrogated 
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performative understanding of experience emphasises the practices of patients as well 
as researchers and clinicians as concrete material actions that produce knowledge. By 
researching the performativity of patient experience in the making of research events, new 
compositions of the topic of study have been produced. This is a benefit of slowing down the 
design involvement in patient experience, as it opens up new ways of thinking about current 
problems and how they are presented, to thinking about what design can bring forward, as 
well as who else design can speak to. 
On reflection, I possibly could have anticipated that by not choosing traditional 
methods of research – interviews, observations, and questionnaires, but to critique them 
for enacting coherent accounts and employing inventive methods, would not enable me to 
create a PROM on their terms. My argument is that by using scientific or medical research 
methods to investigate patient experience would cause the subtleties, frictions, and mess 
of practices of patient experience to be overlooked. This has productively been described 
as ‘undoing methodological hierarchies through care’ (Jerak-Zuiderent, 2015, p. 903), where 
the hierarchal order of different empirics – ways of producing knowledge - is removed 
to value practice-based knowledge. By having a sensibility or attending to the research 
topics as ‘matters of care,’ has enabled me to stay with the process of new understandings 
of experience in the process of becoming. By keeping close to the frictions, mess and 
complexities of what happened in practice enabled me to uncover where and how to study 
these new versions. This helps to avoid the ‘god trick’ (Haraway, 1988) of researching from 
nowhere and instead, enabled me to stay situated. For me, this is an incredibly valuable 
lesson that the PhD has taught me.
Another important point to reflect on in concluding the arguments of this thesis is 
my position in relation to feminist technoscience and how the work of this thesis engages 
with this field. Feminist technoscience is a field of work that I did not intentionally address 
in the outset of this research, hence the lack of direct reference to it in the early chapters 
of the thesis, but one that I naturally stumbled across both in theory and practice. Looking 
back now, as I was trying to find my way through notions of patient experience within 
the literature, authors such as Annemarie Mol, Susan Leigh Star, Vicky Singleton, Donna 
Haraway and particularly Jeannette Pols have guided me through both the empirical and 
theoretical work. From examples of practice, my colleague from PhD By Design, Bianca 
Elzenbaumer and other feminist design researchers including, Sarah Pennington, Ramia 
Mazé, Kristina Lindström and Åsa Stahl demonstrated how to account for and think 
through my embodied position as a researcher embedded in an empirical context, with an 
emergent topic of study. 
I can now trace how these influences have guided the investigation and discussion in 
the thesis, in particular in the ways I have taken up the notions of slowing down and paying 
attention as interesting ways to think through exactly what happens in moments when 
patient experience is brought into being and circulated. These concepts build on established 
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feminist modes of observing and doing technoscience in a situated manner which enabled 
me to think through my practice and deny any form of reliance on unmovable assumptions. 
This gave me the confidence to involve my own subjectivity and remove the distance which 
might have created safe and disembodied analysis or design proposals. Within the practice, 
it encouraged me to have confidence to slow down and stay with the specific of what I was 
uncovering with the patients I was working with. It encouraged me to pay attention, and 
take the yoghurt pot or paint brush example seriously. I see this call for slowing down design 
research as an empirical approach to dealing with the mess uncovered and brought forward 
through design encounters within design-led research.  These concepts have come to show 
me the importance of my voice, my design insights, and my approach to engaging in new 
and different contexts as a design researcher. These sensibilities provide me with skills for 
not just my future research endeavours, but for how I navigate academia and the institution 
in the next stages of my career as I continue on my academic journey. 
I come back to this balance of working as a designer within healthcare, where the 
demand (onus) is to constantly do good and improve people’s lives, productivity, reduce 
error, etc. Thus, almost resisting this, in the name of research, is to seek out what is arguably 
equally as important and takes time to slow down and study properly. This contributes 
towards design research being understood through its own terms rather than through the 
lens of the dominant positivist approaches of science and medicine, which is the historic 
effort of the field of design research (Rodgers and Yee, 2016), or being pressured into 
commercial interests to produce solutions. This contributes to design being acknowledged 
as a distinct research discipline, which can contribute to better understandings of research 
problems from other fields, such as science and medicine. In turn this will strengthen other 
fields’ understanding of design as more than visualisations or problem-solving practices, 
but as a research discipline. In light of this, I plan to disseminate the findings of this 
thesis directly to the design research community but also in the medical and healthcare 
research communities highlighting the unique contribution of practice-led design research 
to the topic of patient experience. These publications will contribute to the growing body 
of healthcare design research collaborations and contribute knowledge on the unique 
interdisciplinary nature of this work.
This thesis was initiated from my reflections from my long-term collaboration 
working as a designer within an MS research team based in at QMUL. My reflections and 
learnings were brought about through investigating patient experience and have enabled 
new directions in my design practice that I doubt would have otherwise happened. It has 
also enabled me to position this design practice within the context of academia in a number 
of fields, such as STS and healthcare research. This contributes to existing evidence around 
the fruitfulness of design-science collaborations and contributes to the practice of design 
researchers working within NHS services and healthcare research requirements. The benefit 
of a long-term collaboration has enabled me time to demonstrate to the MS team, the 
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medical school and the university (which does not have a design department) the potential 
of design-led research. This is another important lesson at this early stage of my academic 
career, as I’m aware of the national academic climate where researchers need to be able to 
clearly articulate and demonstrate the contributions and impact of their work. It is hoped 
that the completion of this thesis and future work relating to it can encourage and support 
more design research collaborations with academic healthcare research groups.
This prior experience with the Barts MS team along with the experience of the PhD 
has equipped me to work with the NHS, which I have already described as challenging. 
Ethical processes and obtaining permissions to conduct practice-based research takes a 
heavy demand on time, which is limited over the course of a PhD and is demonstrated in the 
number of procedural documents included in the appendix. By including these documents 
I hope to demonstrate how this process is far more complex (practically and conceptually) 
than any guidelines currently describe for designers wishing to work with patients as part 
of a research process (Suri and IDEO, 2015). So, I hope that this thesis can productively 
contribute to the growing body of literature and practice which demonstrates how practice-
based design can work within the NHS research processes and procedures and not only this, 
but also use this as a site to be conceptually productive. For there to continue to be design 
research conducted in collaboration with medical researchers, in my opinion, there needs to 
be more work to support the HRA and NHS ethics panels to understand different research 
approaches and forms of knowledge, beyond the restrictive categories of qualitative or 
quantitative divisions.
As I conclude the work of this thesis, I am now in a position to reflect on my own 
personal position within the research and also the Barts MS research team that I have 
been embedded for so long. I am very privileged to be able to conduct research within a 
medical research environment and in such close proximity to biomedical researchers and 
clinicians who are world leading in MS. This is not to say that at times, it hasn’t been a 
lonely pursuit, being the only designer in a medical school, but more often it has provided 
me with inspiration and endless insights into the fascinating world of MS. The trajectory of 
this PhD has opened up many possibilities to study and work with this team of health care 
clinicians and medical researchers beyond what I could have ever expected. As I deployed 
the pilot studies in the clinic, or asked researchers to take time out of their poster session 
to draw a plate, I was always conscious that I was asking them to do something that wasn’t 
possibly what they would consider as research as it was not following anything like their 
methodologies or techniques. After much analysis over the pilot studies, I can now see that 
it was because of the constraints of medical research and specifically the field of Neurology, 
that I was inspired to respond through practice in these unconventional ways. 
As I have become more accustomed to the Barts’ teams’ research processes, their 
language and formats of work over the past 8 years, it has been challenging to remain an 
outsider. I am now very much part of the Barts MS team. A consequence of this is that 
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now, perhaps, I have gone too far into the wild, I have become ‘native’ as I am now more 
comfortable with a group of neurologists than I am with designers. For this I attribute the 
specific qualities that I brought to the research in being able to connect with a wide range 
of people including consultant neurologists, nurses, people with MS and their families and 
engage them into different forms of design exploration. This makes the act of writing this 
thesis and my experience with PhD By Design even more important as it has ensured that 
I know how to speak back to design researchers, and those interested in leading design-led 
research in health contexts. This in itself is a process that has taken time to craft, but in 
doing so also enables me to value and reflect on the skills and assumptions inherit to design. 
In saying this, I am conscious that my research process and results appear to be 
presented in this document as a somewhat linear narrative. This process was in fact messy, 
full of uncertainty and analytical iteration and the presentation of this work within this 
finished thesis is at risk of tidying up the mess and producing a sanitised version. I mention 
elsewhere in this chapter my concern that the table of experience may now come across as 
an essentialist reading of experience. But as a researcher, I will never forget the false starts, 
the uncertainties, the sketches of research ideas, the disagreements with my supervisors, 
the looks of puzzlement on the face of my clinical colleagues, and importantly, the sense 
of reward when working with different people. So I see it as a challenge for the future, to 
somehow stay closer to the mess, and in a way, celebrate this for what it is. One step towards 
this, I feel, will come from the validation and confidence that completing this thesis will 
provide, which builds on the support of the research communities and scholars that I have 
engaged with and been supported by throughout this process. I am encouraged and excited 
to think about how I can not only present, but also produce different versions of my research 
without sacrificing the mess for accountability.
A contribution to MS research and healthcare professionals 
The MOT study I conducted was the first to involve patients whose upper limb function 
was affected by their MS in the development of a new measurement activity. The findings 
from this research activity suggest opportunities for intervention within the context of 
upper limb studies, rehabilitation and outcome measure development in order to elicit, 
uncover and better understand what is at stake, as well as the different priorities and 
concerns of the different actors involved. The study found that the current experience of 
trying to complete upper limb activities are dependent on a variety of external factors that 
are important considerations for the everyday practices of being a person with MS. Here, 
design-led research has provided a valuable approach to directly involve patients and their 
MS ensembles in the generation of this valuable information. 
Specifically, for people with MS, these findings have uncovered and articulated 
the work that goes into completing everyday activities, and possibly, ones that would 
have been overlooked by medical methods of investigation. This design-led approach of 
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inventive methods was unpredictable and investigated patient experience in the making 
to demonstrate how to think with mess and deal with unusual or non-typical responses 
from participants. In these encounters, the design activities, tools, objects, and interactions 
between people and issues acted as creative explorations into emerging situations, 
bringing new things about, rather than returning data. In doing this, the use of design has 
highlighted the pre-occupations with functional aspects, validation, measurement and 
revealed an absence of patient input or human factors. The research has revealed new 
knowledge that could be valuable for considering contexts of use for outcome measures, 
occupational therapy and rehabilitation strategies as patients share their concerns about 
what is changing in their lives due to their MS. This approach has demonstrated how 
involving design can elicit further, deeper conversations about measurement and the role 
of this in people’s lives and about healthcare practices in general.  I hope this work can 
contribute to enriching the way that clinical outcomes are studied to consider what is left 
out. This is not suggesting that design-led approaches replace medical ways of developing 
outcome measures or recording experience, but hopefully, I have made the case that design 
approaches can strengthen and enrich these practices. This thesis has argued to not dispute 
the present, nor confirm it, but to add to it. 
Future work
As I conclude this thesis, it is important to reflect on plans for this work beyond this thesis. 
I anticipate there being three kinds of future work, one conceptual, one methodological and 
the third practical. Conceptually, there is potential to further consider how different versions 
of experience work together, which has already been suggested in the proposals along with 
how patient experience is enacted in other spaces of MS treatment and care not considered 
in this thesis. Specifically, these could be MS research areas around prevention where 
there is an interesting role of speculation in research events. In relation to design, there are 
aspects around the notion of slowing down healthcare practices to investigate how patient 
ensembles are brought forward. This could lead to productive explorations for how design 
could play a role in thinking through new engagement and involvement practices. 
At the beginning of this thesis I set up the notion of performativity and used this 
as an analytical lens throughout the research. It is a notion that has already been used 
in economics (MacKenzie, 2008), linguistics (Austin, 1976), gender (Butler, 1990) and 
healthcare (Danholt, 2005) and I now consider how my exploration of the performativity of 
patient experience contributes to existing understandings. The material I present articulates 
how performativity can be considered to enact patient experience in particular and specific 
ways and explores designs role in what changes, making proposals towards what can be 
changed. The main question around performativity is around the ongoing make up of 
things, such as gender. If that’s the case of gender, then there are parallels in healthcare, and 
patient experience of a chronic disease, such as MS, is performed in everyday activities on 
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an ongoing basis which is not a self-contained process. In the final chapter I introduce the 
term ensemble, which suggests that patient experience ensembles brought forward would 
include gendering processes as well as lots of other processes. What I have learned through 
this research is that I cannot treat healthcare discreetly, I have to take these other things, 
such as gender, into account in experience ensembles. This thesis is limited in scope and the 
activities around gender in these experience ensembles could be something that I go onto 
look at in the future.
Finally, this practice-based research will continue through the development of the 
two proposals introduced in Chapter 5. Although they look like they are leading in separate 
directions, they are actually speaking to each other as suggested in the final discussion in 
the chapter. The ethnographic, participatory home based proposal seeks to work through 
the tensions within how specific practices in people’s everyday lives produce different 
experiences and understanding exactly how these might work with clinical versions. The 
second proposal, the Experience 4 based tool, accounts for the changing nature of MS and 
how it can impact on people’s everyday lives from day to day. It is easy to understand how 
Under and Over could be the basis for a new form of Experience 2 measurement, while 
nonetheless respecting Experience 4. How this artefact is capable of producing different 
experiences is conceptually and practically an interesting question for the future. Both 
proposals start to imagine how new technologies of experience could work amongst clinical 
tools, home environments and different MS ensembles. I am currently developing a research 
protocol to study Under and Over in people’s homes which will follow on from the research 
of this thesis.
On a wider scale so to speak, this work sits within the changing context of MS research 
where clinical categories and understandings of the disease are being challenged. The 
practical work presented in this thesis and the table of experience proposes to contribute 
to this changing field through endorsing practice-based knowledge to contribute to some 
of the complex problems of the field. For example, in this changing treatment and research 
landscape of MS in the UK, the proposal suggests moving on from PROMs being static, 
population measures driven by economic pressures to open up the potential for them to be 
a tool to have real impact in people’s daily lives. Ultimately, enabling a way for people to 
account for change in their condition. The proposals, as performative re-figuring’s, suggest 
another way of thinking about patient measurement and engagement, arguing for and 
working with the expanded notions of experience I have identified. They do not transgress 
the present, nor confirm it, but add to it. The implications of this is that these different 
versions of experience, which are not intended by medicine and design practices thus 
become usable by other areas and other reasons which are more than functional, positivist 
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tools. They become ideas to re-imagine what patients, and their activities that generate 
experiences, could become.
Central to all of this future work is the continuation of my research position with 
the Barts MS research team at QMUL where I now occupy the role of a Lecturer. This will 
ensure that I can continue to build on our collaboration as a design researcher based within 
a clinical team and hope to build a hub for this kind of work in the future. This would 
involve the continuation of publications, presentations and teaching around the topic of 
study. 
In conclusion, this thesis set out to answer the following research question: how can 
design-led research redo ‘patient experience’ for people with MS? I can now answer this 
question through the reflecting on the work of this thesis which has identified different 
versions of patient experience and understood how they are influenced by social science, 
healthcare practices and design. Through the practice-based work in the pilot studies and 
research study it has suggested ways in which design can contribute to the performativity 
of patient experience building on the key argument of this thesis that specific versions 
of patient experience are an upshot of the measurement and representational devices. 
Finally, by delivering a research study which explores how design-led research can uncover 
and explore the situated enactments of MS I concluded by creating two proposals which 
explore how changing material practice and representational devices enables alternative 
experiences to be produced. By outlining the different versions, or lenses with which to 
view experience practices, this thesis has pointed out how this can be potentially useful 
to clinicians and researchers. Equally this work acknowledges a broader range of patient 
experience which is potentially rewarding, and less alienating for patients, as they can 
recognize their experience in ways that they haven’t been able to do before. 
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SUMMARY 
  
Short Title Measurement on Our Terms: exploring the role of patients 
when developing an upper limb Patient Reported Outcome 
Measurement (PROM) for Multiple Sclerosis (MS) 
  
Research Sites 
  
1. Participant Identification CentreRoyal London Hospital 
Outpatient Department part of Barts Health NHS Trust  
2. Site: Utility Kitchen Cafe in the Queen Elizabeth Olympic 
Park  
3. Technical Department: The Blizard Institute, Queen 
Mary University of London  
Objectives 
  
Primary objective: 
1. To develop a PROM to evaluate upper limb function in 
people with MS 
 
Secondary Objective: 
2. To explore how patients experiential knowledge can 
contribute to the development of a PROM  
Methodology This is a mixed method study using three focus groups to 
identify patient important upper limb activities to develop a 
PROM specific for people with MS.  It has a nested 
component exploring the impact of experiential knowledge 
on PROM development and will use descriptive analysis to 
describe the study participants. 
Number of 
Participants 
Three focus groups conducted by a patient facilitator and 
the researcher consisting of between eight and ten 
participants. Each participant will attend all three focus 
groups. 
  
Main Inclusion 
Criteria 
 
 
 
! Be able to give informed consent without assistance 
! Male and female patients aged 18+ and willing to 
participate in the study. 
! All participants will have been diagnosed with multiple 
sclerosis according to the revised “MacDonald” criteria 
(Polman et al., 2011) at least 6 months beforehand. 
! Participants will have an EDSS of 3.5 to 8.0 inclusive as 
measured through the WebEDSS with identified upper 
limb function problems 
! Be able to attend the three focus group sessions in East 
London and must have the ability to understand and 
communicate in English. 
! Have a documented assessment attempt for the 
cardboard 9-Hole Peg test (c9HPT) prior to focus group 
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Data analysis 
 
 
  
Quantitative data collected in this study will be used for 
descriptive analysis of the study participants. 
Immersion/Crystallization will be used to for qualitative 
data analysis to develop activities for the PROM as well as 
exploring experiential knowledge of patients during PROM 
development.  
 
Proposed Start Date 01/10/2017  
  
Proposed End Date 31/05/2018 
Study Duration 
  
8 months 
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GLOSSARY OF TERMS AND ABBREVIATIONS 
  
 
 
DMT   Disease Modifying Therapy 
EDSS                       Expanded Disability Status Scale 
FDA   Food and Drug Administration 
c9HPT          Cardboard Nine Hole Peg Test 
MS                           Multiple Sclerosis 
Participant                An individual who takes part in a study 
PF        A person with MS who is also a professional facilitator 
PPI                           Patient Public Involvement 
PI   Principle Investigator 
PROM                      Patient Reported Outcome Measure 
PwMS                      Person with MS 
QMUL  Queen Mary University London 
QR   Qualitative Researcher 
9HPT                       Nine Hole Peg Test 
WebEDSS  Web-based Expanded Disability Status Scale 
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SIGNATURE PAGE 
  
  
Chief Investigator Agreement 
  
  
The clinical study as detailed within this research protocol (Version 0.5, dated 12th September 
2017), or any subsequent amendments will be conducted in accordance with the Research 
Governance Framework for Health & Social Care (2005), the World Medical Association 
Declaration of Helsinki (1996) and the current applicable regulatory requirements and any 
subsequent amendments of the appropriate regulations. 
  
Chief Investigator Name: Alison Thomson 
Chief Investigator Site: Blizard Institute, Queen Mary, University of London 
Signature and Date:    
  
  
  
  
  
  
Principal Investigator Agreement (if different from Chief investigator) 
  
  
The clinical study as detailed within this research protocol (Version 0.5, dated 12th September 
2017), or any subsequent amendments will be conducted in accordance with the Research 
Governance Framework for Health & Social Care (2005), the World Medical Association 
Declaration of Helsinki (1996) and the current applicable regulatory requirements and any 
subsequent amendments of the appropriate regulations. 
  
Principal Investigator Name: Alison Thomson 
Principal Investigator Site:  Blizard Institute, Queen Mary, University of London 
Signature and Date:     
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1  INTRODUCTION  
1.1 BACKGROUND  
This study is being led by Alison Thomson, Lecturer in Patient Public Involvement (PPI) and 
Public Engagement in Science from Queen Mary University of London (QMUL), who has 
extensive experience involving patients in research activities (Thomson et al., 2011, 2015b, 
2015a). Alison established and chairs the Barts MS Patient Advisory Group (a PPI group) and 
has involved them in the design, conduct and dissemination of this study. The outcome measure 
being developed through this study is a requirement Alison’s professional role at QMUL, while 
the exploration of patient involvement in this process will form part Alison’s PhD thesis 
registered at Goldsmiths, University of London.  
1.1 PATIENT REPORTED OUTCOME MEASURE (PROM)  
PROMs are an umbrella term referring to questionnaires, interviews, and other methods of 
assessing health, illness and benefits of health care from the patient's perspective. From a 
clinical perspective, PROMs are essentially an evaluation of the meaningfulness of therapeutic 
effectiveness and management strategies as rated by patients (Smith and Weldring, 2013). 
PROMs are sometimes referred to as quality of life measures for this reason. For a person with 
MS (PwMS), PROMS are claimed to measure and capture the direct impact of the chronic 
illness on the day-to-day lives (Riazi, 2006) as they are completed by patients, as opposed to 
tests conducted on patients, like MRI scans or examinations. 
1.2 UPPER LIMB FUNCTION AND PEOPLE WITH MULTIPLE SCLEROSIS 
Multiple Sclerosis (MS) is a chronic progressive disease of the central nervous system 
(Compston and Coles, 2008) and is the leading cause of non-traumatic disability in young and 
middle aged adults (Compston, 2005; Pugliatti et al., 2006). It commonly leads to cumulative, 
heterogeneous mixed disabilities over time, ranging from motor and sensory impairments to 
fatigue, impaired vision, cognitive deficits, speech and swallowing problems, bladder, bowel and 
sexual dysfunction. The combination of different symptoms and disabilities often limits a 
person's ability to perform activities of daily life and social activities which then affect people's 
quality of life. 
Historically, MS treatments have focused on preserving lower limb function – the ability to walk - 
and this is reflected in three main areas of clinical practice and research. Firstly, within the 
current climate of disease modifying therapies (DMTs) available to PwMS, none are licensed for 
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people with advanced forms of MS. Secondly, wheelchair users are excluded from the majority 
of clinical trials as (i) it is thought to be difficult to measure clinical change in PwMS whose motor 
functions are already severely affected leading to concern the impact of DMTs is too subtle to 
detect and (ii) pathophysiological dogma suggests that once a certain level of EDSS is reached, 
MS becomes a neurodegenerative disease that is not amenable to DMT (Leray et al., 2010). 
Finally, and related to the second point, the gold standard of disease measurement, the 
expanded disability status scale (EDSS) (Kurtzke, 1983; Schwid et al., 1997) is weighted 
towards mobility i.e. a person's ability to walk. Results of a recent study (ASCEND, 
NCT01416181) highlighted these problems as the primary outcomes of the trial were negative; 
the EDSS and 25-foot timed foot walk, measures of lower limb function dominated the 
composite measure. However, the nine hole peg test (9HPT), a measure of upper limb function, 
was positive; trial participants who received natalizumab showed no loss of upper limb function, 
confirmed at 12 weeks, compared to participants with secondary progressive MS who received 
placebo.  
The Barts MS Research team based at Queen Mary University of London (QMUL) and Barts 
Health NHS Trust feel that there now needs to be a shift in focus to re-position the importance of 
upper limb functions for PwMS. In August 2016 we launched the #ThinkHand campaign to raise 
awareness and also initiate discussions amongst PwMS, clinicians, charities, pharmaceutical 
companies, regulators and the general public to realise the importance and work towards 
generating evidence to license DMTs for advanced MS. As part of this campaign, our team has 
conducted a number of PPI activities at academic conferences, online and at patient events 
around this topic. Part of this included an online survey where 88% of PwMS (314 of 360 
respondents) described their upper limb function to be more important to them than their lower 
limb function (Dubuisson et al., submitted for publication). This highlights the importance of 
upper limb function from the patient perspective and the unique experiential knowledge of living 
with the condition that PwMS have (Beresford, 2005). This is supported by clinical studies; 
Bertoni et al. (2015) provide evidence that 75% of PwMS have bilateral impaired manual 
dexterity even in the early stages of the disease. Arm and hand function, are very important to 
perform activities of daily living like eating, dressing and grooming (Yozbatiran et al., 2006), and 
even more so for people who have already lost lower limb function as further loss of functioning 
contributes to low mood, reduced independence and quality of life. Therefore, it is imperative 
that treatments are aimed at preserving upper limb function.  
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1.3 PROMS TO MEASURE UPPER LIMB FUNCTION FOR PEOPLE WITH MULTIPLE 
SCLEROSIS 
As healthcare providers place increasing emphasis on evidence based practice, outcome 
measures such as the EDSS and quantitative descriptions of patients’ disease experience have 
become more important. Particular emphasis is now placed on including PROMs in trials and 
clinical practice driven by governing bodies such as the US Food and Drug Administration 
(FDA)(U.S. Department of Health and Human Services and Food and Drug Administration, 
2009), the European Medicine Agency (European Medicines Agency, 2005), and the 
Department of Health (Department of Health, 2001). 
Current PROMs focus on measures of body functions and structures looking at the capacity to 
assess the maximal ability to execute a task or an action (e.g. the 9HPT is gold standard 
objective measure for manual dexterity (Fischer et al., 1999)) or an activity performance 
measure measuring the person's habitual performance of tasks in their normal environment (the 
ABILHAND). 
There are a range of upper limb PROMS in use, but few have been used in MS research and we 
are aware of only one developed specifically for PwMS (Lamers et al., 2016). For example the 
ABILHAND was originally developed for rheumatoid arthritis with subsequent versions 
developed for people with stroke (Penta et al., 1998). Although these have been validated for 
use with PwMS (Barrett et al., 2013) their transference from another condition poses problems in 
that the activities that are included lack relevance to the activities specific to living with MS. They 
also lack relevance to modern living. For example, they are influenced by the ability to walk and 
there is no mention of urinary catheters, and no mention of new technologies such as the use of 
touchscreen phones or tablets.  
1.4 DEVELOPING A NEW PROM FOR UPPER LIMB FUNCTION IN MS 
This study will develop a new PROM to specifically measure upper limb function in people with 
MS using a more participatory approach to PROM development. This is inspired by participatory 
research as the study has been designed by PwMS and will involve PwMS with upper limb 
problems, who are the people whose activities and life worlds are under study (Bergad and 
Thomas 2012) throughout.  
PROMs are typically derived by clinicians and University researchers who only involve patients 
at specific stages. They therefore embed what these medical and academic professionals 
believe to be a “good” outcome (Rose et al., 2011), i.e. one that is clinically meaningful from the 
perspective of the clinicians and the researcher but these outcomes may not be meaningful to 
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the patients themselves. Jenkins and Morley (2016) describe how the potential for PROMS to be 
useful for individual patients still remains unresolved. Further, Lamers and Feys (2014) state that 
a key characteristic of PROMS that has been overlooked in MS is how they can be used to 
facilitate the evolution of rehabilitation content and strategies. This highlights the need to 
develop PROMS that include activities that are meaningful to individual patients and can enable 
them to develop strategies and continue to do these activities. 
1.5 PATIENT INVOLVEMENT IN PROM DEVELOPMENT 
It is increasingly recognised that PROM development needs to involve patients at more stages. 
For example, the increasing importance of PPI highlights the key role of patient involvement in 
healthcare policy (Savory, 2010), service improvement (House of Commons Health Committee, 
2007) the democratisation of research (Fals-Borda and Rahman, 1991) and is increasingly 
recognised as crucial to the development of PROMS (Wicks, 2015). The process of PROM 
development and the role of both the patient and their experiential knowledge has already been 
explored in mental health (Rose et al., 2011; Trujols et al., 2013) and there have been a number 
of patient-generated or patient-led outcome measures developed in the field of Rheumatoid 
arthritis but not in MS. Classified as “patient-generated” they are developed from the perspective 
of users, with the involvement of people who have experienced the context of use first hand 
(Rose et al., 2011). This is done through participatory approaches where these people are 
involved at all stages of development from item selection, to scale development and testing. 
This suggests that effort should be put into developing PROMS that are entirely patient 
generated so the development process continually captures, incorporates and values the 
experiential knowledge and perspectives of patients, not just that of the researcher and 
clinicians (Beresford, 2005; Trujols et al., 2013). Including the people who will be using the end 
measure in the PROM development process in a participatory way will produce a measure that 
reflects the needs and experiences of patients and is more likely to improve clinical practice 
(Kjeken et al., 2010) and produce outcomes of meaning to the patient experience. Further, 
including these people in this process through face-to-face meetings can reduce power relations 
between patient and academic researchers, which is the axiom of participatory research 
(Cornwall and Jewkes, 1995).  
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EDSS score of 4.0 will have very different upper limb experiences to those with an EDSS score 
of 8.0. The MS Consultant and MS Nurse will be aware of this sampling method and so will be 
selective in considering potential participants to speak to the researcher when recruiting in 
outpatients. 
3.3 STUDY RECRUITMENT  
The MS consultant and MS Nurse will identify potential patients of theirs who would be suitable 
to take part in the focus groups within their outpatient clinic over a duration of one month. If a 
patient meets the inclusion criteria and is happy to speak to the researcher, only then they will 
be approached. This will happen after their appointment while they are still in the outpatient 
department. The researcher will not approach patients without direction from the MS consultant 
or MS Nurse notifying them.  This way we avoid approaching patients who would like to take 
part but are ineligible. Recruitment will approximately take one month and it is anticipated that 
three months later the focus groups will be completed with the study completed a further four 
months later. 
3.4 INFORMED CONSENT 
Patients will be given a verbal and written description of the study by the PI who has received 
GCP training and will answer any immediate questions or queries individuals may have.   
The study patient information describes the purpose of the focus groups and describe that they 
will be asked to participate in discussions as well as contributing their experiences of living with 
MS. This information will also include details of how confidentiality will be maintained throughout 
the research process, how data will be recorded and their right to withdraw from the study or 
withdraw their consent at any point without having to supply a reason.  Practical information 
such as details about the location of the facilities, car parking and transport arrangements will 
also be included. Study participants will either have travel expenses reimbursed or will have 
travel arranged for them by the PI. The patient information has been designed and reviewed in a 
previous PPI activity in June 2017 with the Barts MS Patient Advisory Group who stipulated that 
information about the study was to be presented in an engaging and easy to read format that 
communicates the patient-centred approach to the study.  
Once the PI has spoken to patients, provided them with the printed study patient information and 
confirmed they would like to be involved, she will make a note of the patient’s contact details 
(name, email, telephone number, address), the date the patient information is given to the 
patient and a convenient time to contact them within 24-48 hours to enable them to remember 
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2 STUDY OBJECTIVES 
2.1 PRIMARY OBJECTIVE 
• To develop a PROM to evaluate upper limb function in people with MS 
2.2 SECONDARY OBJECTIVE 
• To explore how patients experiential knowledge can contribute to the development of a 
PROM. 
2.3 PRIMARY ENDPOINT:       
 
• Produce a draft upper limb outcome measure 
 
2.4 SECONDARY ENDPOINT:       
 
• Develop a list of daily upper limb activities that are affected by people with MS 
 
3 METHODOLOGY 
This is a mixed method study consisting of three qualitative focus groups and an online survey. 
Within the study, there is a nested analysis of the impact of experiential knowledge on the 
development of a PROM.  
3.1 FOCUS GROUPS 
This study uses a focus group method to involve patient participants in the PROM development 
process, similar to the FDA process of item generation, item reduction, measure development 
and design. The focus group sessions will enable interactions between participants to help with 
the generation of new ideas and personal reflections based on their experiences of living with 
MS. The three focus groups will take place over three months with an on-line survey posted after 
the first focus group to identify topics for the subsequent focus groups. Participants will then 
discuss the results of the survey and develop categories for a new PROM to measure upper 
limb function for PwMS.  
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The focus groups will be led by a professional facilitator (PF) who is also a PwMS supported by 
the PI. Working together, the PI and PF have extensive experience developing and leading 
patient sessions. There will also be a qualitative researcher (QR) in each focus group, who is a 
leader in the field of patient experience and participatory analysis.  All researchers will have up 
to date research governance training. 
STUDY SCHEME DIAGRAM 
 
 
 
Diagram 1: Demonstrating an overview of the study and how the focus groups and online survey 
interact 
3.1.1 STUDY – RLH AND QUEEN ELIZABETH OLYMPIC PARK, EAST LONDON 
The recruitment for the focus groups will be held in the outpatient department of the Royal 
London Hospital when patients are attending their routine appointments with their MS consultant 
and MS Nurse. 
The focus groups will be held in a community cafe meeting room in the Queen Elizabeth 
Olympic Park, East London, lasting an average of three hours, led by the PF in conjunction with 
the PI. They will be held between two and three weeks apart to ensure some memory of the 
previous discussion and to allow the study to keep up some momentum. This space has been 
chosen by the Barts MS Patient Advisory group as it is not only has the capacity to hold a 
meeting with a number of wheelchair users with a taxi drop off space at the entrance but it will 
provide a safe and respectful environment which is important for focus groups to be held in a 
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non-medical venue in the belief that this will encourage participants to speak more freely (Kjeken 
et al., 2010). 
3.2 STUDY PARTICIPANT CRITERIA 
3.2.1 INCLUSION CRITERIA 
Participants will be invited to take part in the focus group sessions if they meet the inclusion 
criteria of: 
! Be able to give informed consent without assistance 
! Male and female patients aged 18+ and willing to participate in the study. 
! All participants will have been diagnosed with multiple sclerosis according to the revised 
“MacDonald” criteria (Polman et al., 2011) at least 6 months beforehand. 
! Participants will have an EDSS of 3.5 to 8.0 inclusive as measured through the WebEDSS 
with identified upper limb function problems 
! Be able to attend the three focus group sessions in East London and must have the ability to 
understand and communicate in English. 
! Have a documented assessment attempt for the cardboard 9-Hole Peg test (c9HPT) prior to 
focus group 
3.2.2 EXCLUSION CRITERIA 
• Participants will be ineligible to participate if any inclusion criteria are not met. 
• Due to the nature of study we will be unable to recruit non English speaking participants. 
This is due to not having the resources to translate patient information or consent into 
different languages. 
3.2.3 SAMPLE SIZE 
There will be three focus group sessions and each will comprise of, between eight and ten 
participants (Krueger and Casey, 2009). Each participant will attend all three focus group. This 
number was decided upon recommendation from the literature (Kitzinger, 1994, 1995), previous 
research experience with focus groups (Thomson et al., 2015b), and the Barts MS Advisory 
Group, involving ten. As this is a qualitative study, the number of participants is small due to the 
role of their involvement in producing data.  
3.2.4 SAMPLING TECHNIQUE 
PwMS will be purposively sampled to ensure that a range of experiences of upper limb function, 
as described by their EDSS score, are captured and to ensure they are representative of the 
wider population of people living with MS. For example, people living with MS and have an 
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the conversation, or at another convenient time agreed with them. Each participant will be 
telephoned or emailed as they prefer, to arrange dates, times and potentially transport for the 
three focus group sessions. Once verbal consent has been gained, written informed consent will 
be gained from each participant on attendance to the first focus group. To reduce patient burden 
and upper limb fatigue, written consent will be gained once per participant. 
Each participant will be asked to initial and sign the consent form if they agree to their 
involvement in the study and sound recording of each session. The PI will later scan and post a 
copy of this consent form to the participants and store the original.  A member of the patients 
care team, will the add the consent form to the patients notes.  The PI will explain that all 
participants can withdraw, either before, or during the sessions, if they wish. The PI will also 
explain that there is no need to take part in any discussion they feel uncomfortable with.  
3.4.1 WITHDRAWAL OF PARTICIPANTS 
Participants may end their involvement at any time.  We will advise them that we plan to keep all 
data collected from them before they end their involvement, unless they specify otherwise.  
However, if they require it, we will destroy all their data, which will be done securely. If data have 
been used in disseminations before withdrawal, we will advise participants that this information 
cannot be withdrawn. 
Participants must tell us by the end of the study if they wish to avoid their data being included in 
reports, presentations and research materials. After this time, we can still remove data from our 
archives.   If a participant withdraws from the study, they will not be replaced.  
3.5 DATA COLLECTION PROCEDURES 
If participants agree to take part in the research, they will be asked to complete a WebEDSS and 
c9HPT at home before the first focus group. When they arrive at the first focus group, they will 
be asked to share with the researcher, their WebEDSS and c9HPT score. This data will be used 
for descriptive purposes to describe the level of impairment that the focus group participants 
experience, which may contribute to the decisions that they make when developing the outcome 
measure.  
Each of the focus groups will be sound recorded to capture the discussions around how patients 
contribute to the development of a PROM.  
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3.6 SCHEDULE OF ASSESSMENT 
 
Task/ Weeks 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Focus group:   
  
Recruitment in Outpatients                                         
Arrange participant travel                                         
Written Informed Consent                     
Complete WedEDSS                     
Complete c9HPT                     
Focus group 1                                         
Focus group 2                                         
Focus group 3                                         
If opt-in, review draft 
publications, measures and 
protocol publication 
                                        
Online survey:   
  
Seek final QMUL ethical 
approval 
                              
Post survey online                                         
Survey open                                         
If opt-in, receive protocol 
publication 
                                        
  
Chart 1: Chart showing time lines of MOT study involving both the three focus groups and online 
survey ethical application 
 
3.7 STUDY PROCEDURES 
3.7.1 FOCUS GROUP 1 
The aim of the first focus group is to start the research process to identify upper limb activities 
important to people with MS. The PF will introduce the participants to the study topic, the focus 
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group process and to each other. The objective of the focus group is to engage the participants 
to develop questions for an online survey, to gather activities of upper limb function from another 
group of PwMS.  The focus group will be approx. 3 hours long. The PF will lead the group 
through the three focus group sessions following the focus group topic guide (Appendix A). This 
topic guide was developed through meetings with the research team and Barts MS Advisory 
Group. Each of the focus groups will be sound recorded. 
3.7.2 ONLINE SURVEY 
By the end of the first focus group, the group will have developed questions that could be used 
to develop an online survey.  This will be used to gather information on the different upper limb 
activities that are affected by living with MS with an EDSS of between 3.5 and 8.0. The survey 
will be created by the PI in survey monkey and posted on the Barts MS Research blog. Social 
media (specifically blogs) have been used to collect evidence of content validity and concept 
identification in new PROM development in the area of ALS  (McCarrier et al., 2014; Rothman et 
al., 2015). The benefit of using social media, over face-to-face interaction is that the tool can be 
used to access a wide range of patients for the PROM development stage that would have not 
originally been accessed as it reaches people who can not travel, and is also a cost effective 
way of including more patients.  
The survey aims to gather a minimum of 50 responses but we anticipate the survey gathering 
around 200 responses through the Barts MS Research Blog. The survey will be closed after two 
weeks giving time for the data to be prepared to be included in the second focus group. The 
response data will be anonymised of any identifiable information. If less than 50 responses are 
gathered, the survey will be left open for three weeks, but the second focus group will not be 
moved.  
The respondents for the survey are not patients and so the survey is seeking local University 
ethical approval.  
3.7.3 FOCUS GROUP 2 
The aim of the second focus group is to review and discuss the results from the online survey. 
Working in groups of 5, each group has to work round tables reviewing the responses to 
identifying similarities, repetition and relevance. They will then identify all the environmental 
factors which contribute to the different ways to complete each activity.  
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3.7.4 FOCUS GROUP 3 
The aim of the third focus group is to develop the format for the new PROM. The participants will 
discuss practical aspects such as the name of the tool, the format of administration (digital, 
paper or group based), how it should be distributed and discussing the need for instructions.  
3.8 DATA ANALYSIS  
Descriptive statistics will be used to analyse quantitative information to describe the sample 
explaining the range of EDSS and 9HPT scores of participants involved in both the focus groups 
and the online survey. 
Qualitative data analysis will be used to determine how participants contributed to the PROM 
development and interacted as a group in this process.  The process of 
Immersion/Crystallization described by Miller and Crabtree in 1992 will be used to analyse the 
data gathered from the focus group sessions. This method has been successfully used before 
by the researcher (Thomson et al., 2015b) and in similar research around analysing experiential 
knowledge (Dewar and Kennedy, 2016) and will enable the researcher to consider the unique 
role that patients experiential knowledge plays in PROM development. The 
Immersion/Crystallization method is unlike more formal schematic methods of data analysis and 
allows the researchers to become more engaged with the data to go beyond ‘obvious 
interpretations to hear, see and feel the data,’ (Borkan, 1999).   
Data analysis will occur before (recording the initial engagement with the topic and any prior 
biases), during and after the data is collected to ensure it is high-quality (Miles and Huberman, 
1994). This will allow the researcher to consider the influence of their own background on the 
final results and interpretation.   
The research team will then meet and establish key themes as a framework for initial analysis 
from the teams previous knowledge and experience of PROM development activities and 
professional experience. Involving the research team in the analysis process can ensure pitfalls 
such as drawing premature conclusions or inability to reach closure, are avoided. 
Discussion of the three focus groups will be transcribed verbatim by the researcher and 
subsequently coded along with the researcher’s handwritten field notes recording group 
interactions and taking into consideration any ‘crystallizations’, insights or reflections noted 
during data collection in the field notes. This is key as a secondary aim of the study, is to 
analyse the interactions amongst the participants within the focus group sessions. 
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The PI will immerse themselves in the data to create sub-themes can then be associated to key 
themes. The PI will then aim to validate the established sub-themes by rereading the text, 
searching for alternative hypothesis and interpretations.  The analysis will be presented back to 
the research team.   
After the three stages of focus groups have finished, the PI will feedback the conclusions 
reported to the participants.  This will give the participants an opportunity to express any further 
reflections or points for discussion. After the researcher has completed the analysis, a final 
account of the data will be created for dissemination. 
3.9 END OF STUDY DEFINITION 
The study will end four months after the third focus group has been completed. Within this time, 
the data will have been analysed, written up in a publication format and disseminated to both 
staff and patient groups. The study will last eight months in total. 
3.10 POST STUDY ACTIVITIES 
Once the study has finished, the newly developed PROM will be reviewed by the Barts MS 
Advisory Group to ensure it is easy to use (patients can complete it without assistance), brief 
(not too long in length), straightforward to answer (meaning of the rating system clear), to 
approve the content (familiar and easy to understand tasks) and ensure the scales are relevant. 
It will then be shared online for people to try. This activity is beyond the scope of this research 
study, but will continue.  
4 STUDY TEAM AND ROLES 
 
Role title Role and activity in this research study 
Principal 
Investigator and 
main researcher 
(PI): Alison 
Thomson 
PPI lead for QMUL and organiser of Barts MS Advisory Group. 
Will administer and manage the study (protocol writing, research 
activity administration, travel organisation, payments, analysis, 
dissemination). 
Patient 
Facilitator (PF): 
Harriet Smith 
PwMS for 10 years; professional experience facilitating 
educational and service development projects within QMUL; 
contributed to developing focus group topic guide 
Barts MS Ten PwMS; contribute to departmental research projects over the 
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Advisory Group past five years; contributed to developing the study design, focus 
group topic guide and visited the venue to evaluate it’s 
appropriateness. 
Qualitative 
Researcher 
(QR): Carol 
Rivas 
Expert in patient experience, qualitative research and patient 
analysis who will be present in each focus group to both observe 
and contribute to data analysis. 
Research Team Team consisting of the Professor of Neurology (Gavin 
Giovannoni), Occupational Therapist (Karen Hoffman) (with 
experience of PROM development), QR (Carol Rivas) and PI 
(Alison Thomson). 
Focus group of 
participants 
PwMS adhering to study inclusion and exclusion criteria, recruited 
for this study to attend three focus groups in London. 
Survey 
participants 
PwMS; readers of the Barts MS Research Blog and involved in 
the survey over the blog.  
Table 1: Description of roles and research activity 
5 ETHICS 
  
The PI will ensure that the study will be carried out in accordance with the ethical principles in 
the Research Governance Framework for Health and Social Care (Department of Health, 2005) 
and its subsequent amendments as applicable legal and regulatory requirements. 
5.1 ETHICAL CONSIDERATIONS OF THE FOCUS GROUPS: 
The PI and the QR have extensive experience conducting qualitative research projects involving 
patients and so are experienced at engaging and supporting patients through these projects. 
The PF also has experience facilitating patient focus groups with the PI who will be on hand at 
all times to provide reassurance, if necessary. The focus group topics have been developed with 
the Barts MS Advisory Group to ensure that they are appropriate for this group of participants.  
Although the PF is a professional she is being involved in the study for both her professional 
facilitation skills and also her experience of living with MS. Therefore, there is a responsibly of 
the study team to ensure that she is fully supported and comfortable with her role. Care will be 
given to not overburden the PF and participants by expecting them to read large amounts of 
technical text, meet for extended periods of time or engage in energy draining tasks. Time 
schedules can be adjusted if needed. The PF will be verbally briefed about how to deal with any 
distressed participants and will carry details and contact numbers for suitable support. Both the 
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PI and PF are aware of Queen Mary Universities lone working policy which can be accessed 
here: http://hsd.qmul.ac.uk/A-Z/Lone%20Working/index.html. The PI will also keep a reflective 
diary throughout the research process to record her feelings throughout the process. 
The PI will act in a respectful and professional manner when recruiting participants as it is 
important to spend time at the recruitment stage and at the start of each focus group ensuring 
the participants understand their role within the focus group and what is expected of them. The 
PI will strive to provide a supportive, safe environment to ensure individuals can talk freely and 
informally, allowing them to share on their own experiences which the researchers will have 
utmost respect for. The groups will have the opportunity to introduce themselves at the start of 
the sessions to help them feel at ease and to maintain privacy, a “Focus group in progress – Do 
not disturb,” sign will be on the door. The focus group sessions will be held in a comfortable 
location, with soft furnishings, wheelchair access and accessible toilet facilities nearby and there 
will be a break in each session where refreshments will be provided. 
Within the focus groups, discussion will be facilitated in a purposeful and open way, making sure 
everyone has the opportunity to take part.  The well-being of the participants in the group will 
take precedence over the session itself.  Participants talking about their experiences of living 
with MS may arouse feelings that need to be acknowledged and responded to sensitively.  
There is the potential that patients will share experiences of increasing disability and describe 
activities that they no longer can take part in or complete due to their disability and their MS. If 
any participant looks uncomfortable, the PF will call a short break and the session can be 
resumed if the participant(s) are happy to continue.  If not, it may be necessary to end the 
session.  The researchers can provide appropriate contact names and telephone numbers so 
that the patient participants can seek further support if they wish. 
5.2 ETHICAL CONSIDERATIONS OF SURVEY  
In the event that a participant from the online survey shares information through the service or 
directly with the PI that conveys information about the immediate safety or wellbeing of that 
participant, the PI will discuss this with the Research Team. If appropriate, the PI may respond 
with appropriate information. In this situation, the PI  will act in compliance with GMC social 
media conduct guidelines (General Medical Council, 2013). The PI has extensive experience 
interacting with patients online via the Barts MS blog, has developed and delivered social media 
training for clinicians and has published articles on this topic (Thomson et al. 2017). This 
information, and the identity of any of the survey respondents will not be shared with the focus 
group participants.  
Version 0.5 
12th September 2017 
MOT Protocol 
26 
6 PATIENT PUBLIC INVOLVEMENT 
The involvement of PwMS in the design of this research study and development of this protocol 
has been key to ensure that the research process and activities are appropriate for PwMS to be 
included in as participants in focus groups with other PwMS. For example, considering factors 
such as the impact of fatigue for PwMS which has been carefully considered. Further, there is 
the possibility that the participants will share experiences of increasing disability and describe 
activities that they no longer can take part in or complete due to their disability and their MS. The 
study protocol has considered how to deal with this. 
Following INVOLVE principles, services user have been involved in all stages of the research so 
far, including development of this protocol, reviewing the patient information, consent form and 
focus group topic guide. Further, this study has been designed based on learnings from the 
previous six years of delivering an active PPI programme of events within Barts MS at QMUL. 
The PI has extensive experience developing and delivering PPI initiatives. 
The Barts MS Advisory Group (led by the PI and consisting of 10 PwMS who advise on all 
clinical and research projects from Barts MS) was involved in the study design and planning. 
They were instrumental in the development of the study protocol, activities, naming and study 
documentation. They were consulted at the inception of the study idea, throughout protocol 
development, have commented on and proof read the patient information and consent form, and 
will be again consulted at the end of the study with the study findings. 
The focus group topic guide was developed by the PF and PI from the literature (Hobart, 2001; 
U.S. Department of Health and Human Services and Food and Drug Administration, 2009) and 
in consultation with the Barts MS Advisory Group and research team.  
7 DATA HANDLING AND RECORD KEEPING 
All research and personal data will be stored and managed in accordance with the Data 
Protection Act 1998 and the Research Governance Framework for Health and Social Care. 
Participants details (Names, addresses, email addresses and phone numbers) will not be 
shared.  When they sign the consent form they will be given a “Participant Identification Number” 
which will be a randomly generated number, generated from a simple Excel random function.  
This randomised number will ensure anonymity of the patients throughout the research and 
analysis process. 
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We will give the participants the option to have their names or pseudonym included in the study 
publications. 
The sound recorded data will remain on the recording device until back at the Blizard Institute 
building where it will be transferred to the storage device where it will be stored in a password 
protected folder on an encrypted hard drive. The sound recorders memory will be wiped. 
The original sound recordings will then be stored by the PI, Alison Thomson, on a QMUL 
encrypted hard drive and stored in a locked cabinet in the Blizard Institute, a QMUL building.  
Only the PI will listen to the sound recordings.  All documents related to the study will be 
archived at QMUL, including the listing of the identities of the participants involved in the study 
which will be kept separate from other documents.  All documents relating to the study will be 
retained for at least 20 years after the end of the study before being destroyed in line with the 
then existing secure QMUL practice. Patient identifying data will be securely destroyed 
according to current QMUL practice at the end of the study.   
8 DEVICES AND TOOLS 
8.1 DEVICE: C9HPT 
The cardboard 9HPT medical device will be used within this study to create a description of the 
participants MS that have taken part. The device is called the “Cardboard 9 Hole Peg Test” 
manufactured by “Barts-MS” and holds a CE mark. Participants for the focus group will be asked 
to complete the test at home before attending the first focus group. For participants of the online 
survey, they will be asked to supply their postal address and will be sent a c9HPT and asked to 
upload their results into the survey. The patient information will describe where they can view 
online instructions for how to self administer the test. 
The c9HPT was developed by the Barts MS Research team and has been validated against the 
existing plastic version (Dubbisson et al., submitted). Its inclusion in this study is innovative as it 
will enable the research team to gather descriptive information from a large number of 
participants.  They are made from cardboard and therefore are cost effective for the study to 
supply. Participants are welcome to keep the device after the study has completed. It can be 
viewed here: http://www.clinicspeak.com/9-hole-peg-test/ 
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8.2 TOOL: WEBEDSS 
The WebEDSS is an online questionnaire that both focus groups participants and survey 
participants will be asked to complete at home. It can be accessed from here: 
https://edss.clinicspeak.com/#/welcome 
9 SAFETY REPORTING 
  
There will be two researchers (PI and QR) and one PF in the focus group sessions that will take 
responsibility for the safety of the participants while taking part in the focus groups.  This team 
will be aware of the building’s safety procedures and emergency telephone number for the 
location.  If any medical emergencies occur during a focus group session, a member of the team 
will contact 999 emergency services. 
It is also likely that many of the focus group participants will be wheelchair users. The focus 
group venue has been informed of this and has both the bathroom and emergency facilities to 
host this number of wheelchair users as well as appropriate evacuation procedures in the event 
of an emergency. 
If any safety measures occur then the PI will inform the sponsor and Research Ethics 
Committee via email of any events immediately. 
 
MONITORING AND AUDITING 
The Principal Investigator will retain the right to audit any study, study site or central facility. In 
addition, any part of the study may be inspected by the regulatory bodies and funders where 
applicable. Quality control checks of procedures and documents will be undertaken should a need 
be identified. The sponsor delegates this responsibility to the Principal Investigator. An internal audit 
may be conducted by the sponsor representative. For monitoring and audit purposes, the Sponsor 
and individuals from regulatory authorities may need to view data generated by the study. 
10 FINANCE AND FUNDING 
This study has been funded by the Horne Family Foundation. The research team applied to the 
foundation for funding in December 2016 for this specific study and other #ThinkHand initiatives. 
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The funding will cover the focus group venue hire, refreshments, resources and participants 
transport for the three focus group sessions. It will also cover the cost of a c9HPT for each focus 
group participants and survey responded (including postage and packaging). Following the 
INVOLVE guidelines, members of the PPI Barts MS Advisory Group are paid for their time and 
so is the patient facilitator. 
11 INDEMNITY 
Queen Mary University of London is the sponsor and has arranged suitable indemnity 
concerning negligent harm to be in place for this study.  
12 DISSEMINATION OF RESEARCH FINDINGS 
The results of the study will be reported first and foremost to the study participants along with a 
letter of thanks.  They will be sent a one-page hand-outs summarizing the key findings from 
each focus group session and copies of any publications. 
12.1 STUDY REPORT 
The data will be analysed and produced in a Final Study report that can be accessed directly 
from the PI and will be sent around the study mailing list.   
12.2 MAILING LIST 
The research participants will have the option to be added to the study mailing list where they 
will be updated on the progress of the draft measure, development of the papers, and any poster 
or conference presentations. Once in use, biannual updates on use – how many people using, 
edits, etc. This newsletter will be co-authored by the PI and the PF. The aim of this method of 
dissemination is to continue the sense of involvement in the development of the tool. 
12.3 ACADEMIC PEER-REVIEWED PUBLICATION 
If participants would like, they can opt in if they would like their name included, their initials or a 
pseudonym in the academic publications. The participants will have an opportunity to review the 
publication before it is submitted to the journal. This will be posted to them on paper and via 
email. Unless the participants opt to have their name on the paper, their name will not be 
publically available. 
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12.4 PROTOCOL PAPER 
The research team aim to publish this protocol, along with another research article describing 
the draft measure in one of the MS Journals. We believe that these journals have never 
published any research in this format before, but due to the topic of PROM development in MS, 
it will be of great interest. In this article, the funder, Horne Family Foundation will be 
acknowledged. They do not have any review or publication rights to the paper. The results will 
advance knowledge, improve the concrete situation and improve PROM design methodology.  
The researcher will publish articles in technical journals to reach colleagues; applied articles in 
periodicals read by practitioners and the public; and methodological and reflective articles in 
associational and professional journals designed to improve the practice of PPI research. The 
researcher will attend the European Committee for Treatment and Research in Multiple 
Sclerosis in September 2018 and RIMS conference in 2018 to present the data to contribute to 
the respective fields.  
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18 APPENDICES 
A Focus Group Topic Guide 
 
Focus Group 1 
 
1. Welcome and introduction 
The facilitator will start by introducing themselves and the other researchers in the room. She will 
give a brief overview of the research study and check that all participants are happy to continue, 
and to be audio recorded.  It will be made clear that if there are any questions, to either ask at 
any time, or mention to a researcher.  
 
Run through the timings of the focus group, mentioning breaks and refreshments.  
 
Safety information will be shared about the facilities and also ensuring confidentiality of any 
information that is shared within the focus group. 
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As an ice-breaking activity, participants are to turn to person next to them and share an 
interesting fact. Then we share this with group.  
 
2. Background to the study 
a. Introduction to the study topic area of PROMS and their role in upper limb function for 
people with MS.   
b. Introduce the aim of this research  
i. Run three focus groups to find out: 
1. What are the relevant UL activities for PwMS? 
2. How do you complete these at home? 
3. If we created a PPROM, what would this be? 
c. Process for developing PROM (FDA) 
i. Focus group 1 – Design online survey  
ii. Run survey 
iii. Focus group 2 – Discuss survey results 
iv. Focus group 3 – Develop format for new PROM 
 
3. Group Discussion 
The facilitator will hold an open discussion with the participants around how their upper limb 
function, and the ability to complete everyday tasks has been affected by their MS.  
 
This will then lead onto a discussion about their experience of completing PROMS and the role 
and meaning of measurement in their lives. Is this something that they find important or useful? 
 
4. Break 
 
5. Design an online survey to collect a range of UL activities: 
This section will  
a. Design survey questions 
b. How should we collect the survey responses? E.g. text, written, video, image (non-identifiable) 
c. How will we discuss this information? 
d. Appropriate information for survey respondents - within the survey: consent, results. 
 
6. Close and next steps 
Thank them for taking part in the focus group and describe what the next steps are.  
 
 
Focus group 2 
 
1. Welcome: 
Outline session timing reiterating important information about logistics and confidentiality.  
 
 
2. Discuss survey results 
Discuss the general response from survey including numbers of responses and any comments 
left relating to format of survey 
 
All of the participants will be given printed copies of the survey results and be asked to read 
through them all.  
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• What are the common themes or categories of activities that come up? 
• Are there similar locations, formats or purpose of activities?  
 
3. Break 
 
4. Create terms of measurement 
What is a meaningful way to measure these activities? Is it success if completing it or doing it 
quickly? Are headings “impossible, difficult, easy” meaningful or useful? 
 
5. Close and next steps 
 
 
 
Focus Group 3: 
 
1. Welcome: 
Outline session timing reiterating important information about logistics and confidentiality.  
 
a. Re-write new instruction 
b. How and where does this PROM exist 
c. What does it do, and enable people to do? 
 
2. Designing the PROM: 
a. Decide method of administration: self-administration, interview, group activity 
b. Format of administration: paper based/ digital 
c. Group to decide naming of the tool 
d. Develop instructions of use. 
e. What to do with results 
 
3. Break 
 
4. Close and next steps for dissemination 
 
Thank them for taking part in the study and describe what the next steps are. Discuss logistics of 
compensation for travel expenses.  
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Miss Alison Thomson 
Lecturer in Public Engagement and Patient Public 
Involvement 
Queen Mary, University of London 
Centre for Neuroscience & Trauma Blizard 
4 Newark Street, Blizard Institute, QMUL 
London 
E1 2AT 
 
Email: hra.approval@nhs.net 
 
07 November 2017 
 
Dear Miss Thomson 
 
 
Study title: Measurement on Our Terms: exploring the role of patients 
when developing an upper limb Patient Reported Outcome 
Measurement for Multiple Sclerosis  
IRAS project ID: 228062  
Protocol number: 0.5 
REC reference: 17/LO/1684   
Sponsor Queen Mary, University of London 
 
I am pleased to confirm that HRA Approval has been given for the above referenced study, on the 
basis described in the application form, protocol, supporting documentation and any clarifications 
noted in this letter.  
 
Participation of NHS Organisations in England  
The sponsor should now provide a copy of this letter to all participating NHS organisations in England.  
 
Appendix B provides important information for sponsors and participating NHS organisations in 
England for arranging and confirming capacity and capability. Please read Appendix B carefully, in 
particular the following sections: 
 Participating NHS organisations in England – this clarifies the types of participating 
organisations in the study and whether or not all organisations will be undertaking the same 
activities 
 Confirmation of capacity and capability - this confirms whether or not each type of participating 
NHS organisation in England is expected to give formal confirmation of capacity and capability. 
Where formal confirmation is not expected, the section also provides details on the time limit 
given to participating organisations to opt out of the study, or request additional time, before 
their participation is assumed. 
 Allocation of responsibilities and rights are agreed and documented (4.1 of HRA assessment 
criteria) - this provides detail on the form of agreement to be used in the study to confirm 
capacity and capability, where applicable. 
Letter of HRA Approval 
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Further information on funding, HR processes, and compliance with HRA criteria and standards is also 
provided. 
 
It is critical that you involve both the research management function (e.g. R&D office) supporting each 
organisation and the local research team (where there is one) in setting up your study. Contact details 
and further information about working with the research management function for each organisation 
can be accessed from www.hra.nhs.uk/hra-approval.  
 
Appendices 
The HRA Approval letter contains the following appendices: 
 A – List of documents reviewed during HRA assessment 
 B – Summary of HRA assessment 
 
After HRA Approval 
The document “After Ethical Review – guidance for sponsors and investigators”, issued with your REC 
favourable opinion, gives detailed guidance on reporting expectations for studies, including:  
 Registration of research 
 Notifying amendments 
 Notifying the end of the study 
The HRA website also provides guidance on these topics, and is updated in the light of changes in 
reporting expectations or procedures. 
 
In addition to the guidance in the above, please note the following: 
 HRA Approval applies for the duration of your REC favourable opinion, unless otherwise 
notified in writing by the HRA. 
 Substantial amendments should be submitted directly to the Research Ethics Committee, as 
detailed in the After Ethical Review document. Non-substantial amendments should be 
submitted for review by the HRA using the form provided on the HRA website, and emailed to 
hra.amendments@nhs.net.  
 The HRA will categorise amendments (substantial and non-substantial) and issue confirmation 
of continued HRA Approval. Further details can be found on the HRA website. 
 
Scope  
HRA Approval provides an approval for research involving patients or staff in NHS organisations in 
England.  
 
If your study involves NHS organisations in other countries in the UK, please contact the relevant 
national coordinating functions for support and advice. Further information can be found at 
http://www.hra.nhs.uk/resources/applying-for-reviews/nhs-hsc-rd-review/. 
  
If there are participating non-NHS organisations, local agreement should be obtained in accordance 
with the procedures of the local participating non-NHS organisation. 
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User Feedback 
The Health Research Authority is continually striving to provide a high quality service to all applicants 
and sponsors. You are invited to give your view of the service you have received and the application 
procedure. If you wish to make your views known please use the feedback form available on the HRA 
website: http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/. 
 
HRA Training 
We are pleased to welcome researchers and research management staff at our training days – see 
details at http://www.hra.nhs.uk/hra-training/  
 
Your IRAS project ID is 228062. Please quote this on all correspondence. 
 
Yours sincerely 
 
Maeve Ip Groot Bluemink 
Assessor 
 
Email: hra.approval@nhs.net  
 
Copy to: Dr Sally Burtles, Queen Mary, University of London – Sponsor Contact 
Pushpen Joshi, Queen Mary, University of London – Lead R&D Contact 
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Appendix A - List of Documents 
 
The final document set assessed and approved by HRA Approval is listed below.   
 
 Document   Version   Date   
Covering letter on headed paper [Cover Letter]    13 September 2017  
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only) [Insurance]  
  24 July 2017  
Interview schedules or topic guides for participants [Topic Guide]  0.1  15 August 2017  
IRAS Application Form [IRAS_Form_14092017]    14 September 2017  
Letter from funder [Funding Letter from Horne Family Charitable 
Foundation]  
  22 December 2016  
Letter from sponsor [Provisional Sponsorship letter from QMUL]    12 September 2017  
Participant consent form [Patient Consent Form]  0.4  19 October 2017  
Participant information sheet (PIS) [Patient information]  0.5  19 October 2017  
Referee's report or other scientific critique report [Peer Review 
confirmation]  
  18 August 2017  
Research protocol or project proposal [MOT Research Protocol]  0.5  12 September 2017  
Summary CV for Chief Investigator (CI) [CI Alison Thomson CV]    15 August 2017  
Summary CV for supervisor (student research) [Supervisor 1 CV]    25 July 2017  
Summary CV for supervisor (student research) [Supervisor 2 CV]    01 June 2017  
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Appendix B - Summary of HRA Assessment 
 
This appendix provides assurance to you, the sponsor and the NHS in England that the study, as 
reviewed for HRA Approval, is compliant with relevant standards. It also provides information and 
clarification, where appropriate, to participating NHS organisations in England to assist in assessing 
and arranging capacity and capability. 
For information on how the sponsor should be working with participating NHS organisations in 
England, please refer to the, participating NHS organisations, capacity and capability and 
Allocation of responsibilities and rights are agreed and documented (4.1 of HRA assessment 
criteria) sections in this appendix.  
The following person is the sponsor contact for the purpose of addressing participating organisation 
questions relating to the study: 
 
Name: Dr Sally Burtles 
Tel: 020 7882 7265 
Email: sponsorsrep@bartshealth.nhs.uk  
 
HRA assessment criteria  
Section HRA Assessment Criteria Compliant with 
Standards? 
Comments 
1.1 IRAS application completed 
correctly 
Yes The applicant confirmed that NHS 
activity is limited to patient identification 
and initial approach.  
    
2.1 Participant information/consent 
documents and consent 
process 
Yes No comments 
 
    
3.1 Protocol assessment Yes No comments 
    
4.1 Allocation of responsibilities 
and rights are agreed and 
documented  
Yes This is a non-commercial single site 
study taking place in the NHS where 
that single NHS organisation’s partner 
University is the study sponsor. 
Therefore no study agreements are 
expected. 
4.2 Insurance/indemnity 
arrangements assessed 
Yes Sponsor's insurance policy will cover 
the design, management and conduct 
of the study. 
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Section HRA Assessment Criteria Compliant with 
Standards? 
Comments 
Where applicable, independent 
contractors (e.g. General Practitioners) 
should ensure that the professional 
indemnity provided by their medical 
defence organisation covers the 
activities expected of them for this 
research study 
4.3 Financial arrangements 
assessed  
Yes External funding has been secured from 
the Horne Family Foundation. 
    
5.1 Compliance with the Data 
Protection Act and data 
security issues assessed 
Yes Clarification has been requested around 
access to medical records. 
5.2 CTIMPS – Arrangements for 
compliance with the Clinical 
Trials Regulations assessed 
Not Applicable No comments 
 
5.3 Compliance with any 
applicable laws or regulations 
Yes No comments 
 
    
6.1 NHS Research Ethics 
Committee favourable opinion 
received for applicable studies 
Yes REC Favourable Opinion was issued by 
the London – Stanmore REC 
6.2 CTIMPS – Clinical Trials 
Authorisation (CTA) letter 
received 
Not Applicable No comments 
6.3 Devices – MHRA notice of no 
objection received 
Not Applicable No comments 
 
6.4 Other regulatory approvals 
and authorisations received 
Not Applicable No comments 
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Participating NHS Organisations in England 
This provides detail on the types of participating NHS organisations in the study and a statement as to whether 
the activities at all organisations are the same or different.  
The applicant confirmed that only The Royal London Hospital (Barts Health NHS Trust) will be used 
for patient identification and initial approach but no consent or research activities will be conducted at 
the NHS site.  
 
This is a non-commercial single site study taking place in the NHS where that single NHS 
organisation’s partner University is the study sponsor. There is only one site type involved in the 
research. 
 
The Chief Investigator or sponsor should share relevant study documents with participating NHS 
organisations in England in order to put arrangements in place to deliver the study. The documents 
should be sent to both the local study team, where applicable, and the office providing the research 
management function at the participating organisation. For NIHR CRN Portfolio studies, the Local 
LCRN contact should also be copied into this correspondence.  For further guidance on working with 
participating NHS organisations please see the HRA website. 
 
If Chief Investigators, sponsors or Principal Investigators are asked to complete site level forms for 
participating NHS organisations in England which are not provided in IRAS or on the HRA website, 
the Chief Investigator, sponsor or Principal Investigator should notify the HRA immediately at 
hra.approval@nhs.net. The HRA will work with these organisations to achieve a consistent approach 
to information provision. 
 
Confirmation of Capacity and Capability 
This describes whether formal confirmation of capacity and capability is expected from participating NHS 
organisations in England. 
This is a non-commercial single site study taking place in the NHS where that single NHS 
organisation’s partner University is the study sponsor. The participating NHS organisation will 
therefore be expected to formally confirm their capacity and capability to host this research 
according to local requirements.  
 Following issue of this letter, participating NHS organisations in England may now confirm to 
the sponsor their capacity and capability to host this research, when ready to do so. How 
capacity and capacity will be confirmed is detailed in the Allocation of responsibilities and 
rights are agreed and documented (4.1 of HRA assessment criteria) section of this appendix.  
The Assessing, Arranging, and Confirming document on the HRA website provides further 
information for sponsors and NHS organisations on assessing, arranging and confirming capacity 
and capability. 
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Principal Investigator Suitability 
This confirms whether the sponsor’s position on whether a PI, LC or neither should be in place is correct for 
each type of participating NHS organisation in England, and the minimum expectations for education, training 
and experience that PIs should meet (where applicable). 
A Principal Investigator (PI) is expected for this type of study. 
 
GCP training is not a generic training expectation, in line with the HRA statement on training 
expectations. 
 
HR Good Practice Resource Pack Expectations 
This confirms the HR Good Practice Resource Pack expectations for the study and the pre-engagement checks 
that should and should not be undertaken. 
The activities at the participating NHS organisation will be undertaken by local staff therefore it is 
expected that adequate contractual relationship with the host organisation are already in place. 
 
Where contractual arrangements are not already in place, external staff (or similar) undertaking 
research activities would be expected to obtain Honorary Research Contracts on the basis of a 
Research Passport (if university employed) or a Letter of Access on the basis of an NHS to NHS 
confirmation of pre-engagement checks letter (if NHS employed). 
 
Other Information to Aid Study Set-up  
This details any other information that may be helpful to sponsors and participating NHS organisations in 
England in study set-up. 
 The applicant has indicated that they do not intend to apply for inclusion on the NIHR CRN 
Portfolio. 
 Some participants may also be recruited outside the NHS and some activity may take place 
outside the NHS. HRA approval does not cover activity outside the NHS. Before recruiting or 
undertaking activity outside the NHS the research team must follow the procedures and 
governance arrangements of responsible organisations. 
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          Queen Mary, University of London 
                  Room W117 
      Queen’s Building 
      Queen Mary University of London 
      Mile End Road 
      London E1 4NS 
      
                  Queen Mary Ethics of Research Committee 
                  Hazel Covill 
                  Research Ethics Administrator 
                                                                                                                                 Tel: +44 (0) 20 7882 7915 
                 Email: h.covill@qmul.ac.uk 
c/o Dr Alison Thomson 
Centre for Neuroscience and Trauma 
Blizard Institute  
Queen Mary University of London  
Mile End Road  
London        18th October 2017 
    
To Whom It May Concern: 
 
Re: QMERC2017/52 – Measurement on our Terms: Survey (MOT: Survey)  
 
The above study was deferred for later review by The Queen Mary Ethics of 
Research Committee (Panel A) on the 6th September 2017; full approval was 
ratified by Panel’s Email Action on the 10th October 2017.    
 
This approval is valid for a period of two years, (if the study is not started before 
this date then the applicant will have to reapply to the Committee). 
 
Yours faithfully 
 
Dr Helen Jenner – QMERC Chair.    Patron: Her Majesty the Queen 
Incorporated by Royal Charter as Queen Mary 
and Westfield College, University of London 
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SOP 13a AD 9d QMUL Non-CTIMPs Provisional Sponsorship Letter V2.0 18/8/16  Page 1 of 1 
 
 
 
 
 
 
 
Non-CTIMPs Provisional Sponsorship  
 
 
12th September 2017 
 
Alison Thomson  
Lecturer in Public Engagement and Patient  
Public Involvement 
Centre for Neuroscience and Trauma 
The Blizard Institute 
Barts and The London School of Medicine and Dentistry 
64 Turner Street 
London 
E1 2AB 
 
Dear Miss Thomson,  
 
Declaration of QMUL Provisional Sponsorship  
 
PROJECT TITLE:  Measurement on Our Terms: exploring the role of patients when 
developing an upper limb Patient Reported Outcome 
Measurement for Multiple Sclerosis 
Protocol version #: 0.5 
Protocol date: 12th September 2017 
ReDA Reference:  12062 
Host site:    QMUL 
  
The above referenced study and supporting documentation have been reviewed and Sponsorship, 
as defined in the Research Governance Framework for Health and Social Care 2005 and/or the 
Medicines for Human Use (Clinical Trials) Regulations 2004, will be provided on the condition that 
the relevant regulatory body approvals are obtained and the “Conditions of Sponsorship” are 
adhered to.   
 
A further declaration of formal Sponsorship will be made by the Joint Research Office on proof of 
relevant regulatory body approval/s being in place.   
 
Please contact the Joint Research Office if you require any further guidance or information on any 
matter mentioned above.  
 
Yours sincerely 
 
 
 
 
 
Sally Burtles  
Director of Research Services & Business Development 
 
Cc: Alison Thomson 
Joint Research Management Office 
Queen Mary Innovation Centre 
5 Walden Street 
London  
E1 2EF 
 
Tel: 020 7882 7260 
Fax: 020 7882 7276 
Email: Sponsorsrep@bartshealth.nhs.uk 
 
233
Appendix G: IRAS form
234
 Welcome to the Integrated Research Application System
 IRAS Project Filter
The integrated dataset required for your project will be created from the answers you give to the following questions. The
system will generate only those questions and sections which (a) apply to your study type and (b) are required by the
bodies reviewing your study. Please ensure you answer all the questions before proceeding with your applications. 
Please complete the questions in order. If you change the response to a question, please select ‘Save’ and review all the
questions as your change may have affected subsequent questions. 
Please enter a short title for this project (maximum 70 characters) 
Measurement on Our Terms (MOT)
1. Is your project research?
 Yes  No
2. Select one category from the list below:
 Clinical trial of an investigational medicinal product
 Clinical investigation or other study of a medical device
 Combined trial of an investigational medicinal product and an investigational medical device
 Other clinical trial to study a novel intervention or randomised clinical trial to compare interventions in clinical practice
 Basic science study involving procedures with human participants
 Study administering questionnaires/interviews for quantitative analysis, or using mixed quantitative/qualitative
methodology
 Study involving qualitative methods only
 Study limited to working with human tissue samples (or other human biological samples) and data (specific project
only)
 Study limited to working with data (specific project only)
 Research tissue bank
 Research database
If your work does not fit any of these categories, select the option below:
 Other study
2a. Please answer the following question(s):
a) Does the study involve the use of any ionising radiation?  Yes       No
b) Will you be taking new human tissue samples (or other human biological samples)?  Yes       No
c) Will you be using existing human tissue samples (or other human biological samples)?  Yes       No
3. In which countries of the UK will the research sites be located?(Tick all that apply)
 England
 Scotland
IRAS Form Reference:
17/LO/1684
IRAS Version 5.5.2
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 Wales
 Northern Ireland
3a. In which country of the UK will the lead NHS R&D office be located:
 England
 Scotland
 Wales
 Northern Ireland
 This study does not involve the NHS
4. Which applications do you require?
IMPORTANT: If your project is taking place in the NHS and is led from England select 'IRAS Form'. If your project is led
from Northern Ireland, Scotland or Wales select 'NHS/HSC Research and Development Offices' and/or relevant
Research Ethics Committee applications, as appropriate.
 IRAS Form
 Confidentiality Advisory Group (CAG)
 National Offender Management Service (NOMS) (Prisons & Probation)
For NHS/HSC R&D Offices in Northern Ireland, Scotland and Wales the CI must create NHS/HSC Site Specific
Information forms, for each site, in addition to the study wide forms, and transfer them to the PIs or local
collaborators. 
For participating NHS organisations in England different arrangements apply for the provision of site specific
information. Refer to IRAS Help for more information.
Most research projects require review by a REC within the UK Health Departments' Research Ethics Service. Is
your study exempt from REC review? 
 Yes       No
5. Will any research sites in this study be NHS organisations?
 Yes       No
5a. Are all the research costs and infrastructure costs (funding for the support and facilities needed to carry out
research e.g. NHS Support costs) for this study provided by a NIHR Biomedical Research Centre, NIHR Biomedical
Research Unit, NIHR Collaboration for Leadership in Health Research and Care (CLAHRC), NIHR Patient Safety
Translational Research Centre or a Diagnostic Evidence Co-operative in all study sites? 
Please see information button for further details.
 Yes       No
Please see information button for further details.
5b. Do you wish to make an application for the study to be considered for NIHR Clinical Research Network (CRN)
Support and inclusion in the NIHR Clinical Research Network Portfolio? 
Please see information button for further details.
 Yes       No
IRAS Form Reference:
17/LO/1684
IRAS Version 5.5.2
Date: 14/09/2017 228062/1128129/37/9832
The NIHR Clinical Research Network provides researchers with the practical support they need to make clinical studies
happen in the NHS e.g. by providing access to the people and facilities needed to carry out research “on the ground". 
If you select yes to this question, you must complete a NIHR Clinical Research Network (CRN) Portfolio Application Form
(PAF) immediately after completing this project filter question and before submitting other applications. Failing to complete
the PAF ahead of other applications e.g. HRA Approval, may mean that you will be unable to access NIHR CRN Support for
your study.
6. Do you plan to include any participants who are children?
 Yes       No
7. Do you plan at any stage of the project to undertake intrusive research involving adults lacking capacity to consent
for themselves?
 Yes       No
Answer Yes if you plan to recruit living participants aged 16 or over who lack capacity, or to retain them in the study following
loss of capacity. Intrusive research means any research with the living requiring consent in law. This includes use of
identifiable tissue samples or personal information, except where application is being made to the Confidentiality Advisory
Group to set aside the common law duty of confidentiality in England and Wales. Please consult the guidance notes for
further information on the legal frameworks for research involving adults lacking capacity in the UK.
8. Do you plan to include any participants who are prisoners or young offenders in the custody of HM Prison Service or
who are offenders supervised by the probation service in England or Wales?
 Yes       No
9. Is the study or any part of it being undertaken as an educational project? 
 Yes       No
Please describe briefly the involvement of the student(s): 
This study is being led by Alison Thomson as part of her professional role as Lecturer in Patient Public Involvement
and Public Engagement in Science at Queen Mary University of London (QMUL). The outcome measure being
developed through this study is a requirement Alison’s professional role.
Alison is also completing a PhD registered at Goldsmiths, University of London looking at how to improve the patient
experience for people with MS. Part of this study, specifically the exploration of patient experiential knowledge in this
PROM development process (i.e. how patients can discuss improvements for other patients based on their own
experiences), will be written about in the thesis. This discussion will only form a small part of the thesis.
9a. Is the project being undertaken in part fulfilment of a PhD or other doctorate?
 Yes       No
10. Will this research be financially supported by the United States Department of Health and Human Services or any of
its divisions, agencies or programs?
 Yes       No
11. Will identifiable patient data be accessed outside the care team without prior consent at any stage of the project
(including identification of potential participants)?
 Yes       No
IRAS Form Reference:
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Integrated Research Application System
Application Form for Research involving qualitative methods only
 IRAS Form (project information)
Please refer to the E-Submission and Checklist tabs for instructions on submitting this application.
The Chief Investigator should complete this form. Guidance on the questions is available wherever you see this
symbol displayed. We recommend reading the guidance first. The complete guidance and a glossary are available by
selecting Help. 
Please define any terms or acronyms that might not be familar to lay reviewers of the application.
Short title and version number: (maximum 70 characters - this will be inserted as header on all forms)   
Measurement on Our Terms (MOT)
Please complete these details after you have booked the REC application for review.
REC Name:
London Stanmore
REC Reference Number: 
17/LO/1684      
Submission date:   
14/09/2017
 PART A: Core study information
 1. ADMINISTRATIVE DETAILS
A1. Full title of the research:
Measurement on Our Terms: exploring the role of patients when developing an upper limb Patient Reported Outcome
Measurement for Multiple Sclerosis
A2-1. Educational projects
Name and contact details of student(s): 
Student 1
 
 Title   Forename/Initials  SurnameMiss Alison/A  Thomson
Address Centre for Neuroscience & Trauma Blizard
 Blizard Institute, QMUL
 4 Newark Street, Whitechapel
Post Code E1 2AT
E-mail a.thomson@qmul.ac.uk
Telephone 02078822367
Fax
Give details of the educational course or degree for which this research is being undertaken:
Name and level of course/ degree: 
IRAS Form Reference:
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PhD in Design
 
Name of educational establishment: 
Goldsmiths, University of London
 
 
Name and contact details of academic supervisor(s): 
Academic supervisor 1
 
 Title  Forename/Initials  SurnameDr  Alex  Wilkie
Address Department of Design
 Goldsmiths
 University of London, New Cross, London
Post Code SE14 6NW
E-mail a.wilkie@gold.ac.uk
Telephone
Fax
Academic supervisor 2
 
 Title   Forename/Initials  SurnameProfessor Bill  Gaver
Address Department of Design
 Goldsmiths
 University of London, New Cross, London
Post Code SE14 6NW
E-mail w.gaver@gold.ac.uk
Telephone
Fax
 
Please state which academic supervisor(s) has responsibility for which student(s): 
Please click "Save now" before completing this table. This will ensure that all of the student and academic supervisor
details are shown correctly. 
Student(s) Academic supervisor(s)
Student 1  Miss Alison/A Thomson  Dr Alex Wilkie
 Professor Bill Gaver
A copy of a current CV for the student and the academic supervisor (maximum 2 pages of A4) must be submitted with the
application.
A2-2. Who will act as Chief Investigator for this study?
 Student
 Academic supervisor
 Other
A3-1. Chief Investigator:
IRAS Form Reference:
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 Title   Forename/Initials  SurnameMiss Alison  Thomson
Post Lecturer in Public Engagement and Patient Public Involvement
Qualifications BSc Hons, MA RCA
ORCID ID    
Employer Queen Mary, University of London
Work Address Centre for Neuroscience & Trauma Blizard
 4 Newark Street, Blizard Institute, QMUL
 London
Post Code E1 2AT
Work E-mail a.thomson@qmul.ac.uk
* Personal E-mail a.thomson@qmul.ac.uk
Work Telephone 02078822367
* Personal Telephone/Mobile 07846598417
Fax
* This information is optional. It will not be placed in the public domain or disclosed to any other third party without prior
consent.
A copy of a current CV (maximum 2 pages of A4) for the Chief Investigator must be submitted with the application.
A4. Who is the contact on behalf of the sponsor for all correspondence relating to applications for this project?
This contact will receive copies of all correspondence from REC and HRA/R&D reviewers that is sent to the CI.
     
 Title  Forename/Initials  SurnameDr  Sally  Burtles
Address Joint Research Management Office (JRMO)
 Queen Mary Innovation Centre, Lower Ground Floor
 5 Walden Street , London
Post Code E1 2EF
E-mail sponsorsrep@bartshealth.nhs.uk
Telephone 020 7882 7265
Fax 020 7882 7276
A5-1. Research reference numbers. Please give any relevant references for your study:
Applicant's/organisation's own reference number, e.g. R & D (if
available):
Sponsor's/protocol number: 0.5
Protocol Version: 0.5
Protocol Date: 12/09/2017
Funder's reference number:
Project
website:
Additional reference number(s):
Ref.Number Description Reference Number
Registration of research studies is encouraged wherever possible. You may be able to register your study through
your NHS organisation or a register run by a medical research charity, or publish your protocol through an open
access publisher. If you have registered your study please give details in the "Additional reference number(s)"
IRAS Form Reference:
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section.  
A5-2. Is this application linked to a previous study or another current application?
 Yes       No
Please give brief details and reference numbers.
 2. OVERVIEW OF THE RESEARCH  
 
To provide all the information required by review bodies and research information systems, we ask a number of
specific questions. This section invites you to give an overview using language comprehensible to lay reviewers and
members of the public. Please read the guidance notes for advice on this section.
A6-1. Summary of the study.   Please provide a brief summary of the research (maximum 300 words) using language
easily understood by lay reviewers and members of the public. Where the research is reviewed by a REC within the UK
Health Departments’ Research Ethics Service, this summary will be published on the Health Research Authority (HRA)
website following the ethical review. Please refer to the question specific guidance for this question.
Patient Reported Outcome Measures (PROMs) are tools used in clinical practice to assess health, illness and
benefits of health care from the patient's perspective. However, the PROMs currently used to measure the impact of
Multiple Sclerosis (MS) on a persons upper limb function have been developed with little patient involvement resulting
in tools which are not condition specific nor up to date. In other health fields, such as mental health for example,
patients have been involved in the entire PROM development process therefore creating more effective measurement
tools. 
This research seeks to explore how people living with MS can contribute their experiences of living with the chronic
condition to the development of a new upper limb PROM.
Participants will be asked to attend three focus groups lasting an average of three hours over a three month period
and contribute their experience of how their MS has affected their ability to complete upper limb activities and tasks.
They will also be able to discuss their experience of completing PROMs and the role of measurement in their clinical
care. Explorative methods, such as focus groups, have been previously used to involve patients in service
development and improvement projects, but not in PROM development with people with MS.
The study is funded by the Horne Family Foundation and participants will be recruited from the Barts MS Service at the
Barts Health NHS Trust outpatient department. 
A6-2. Summary of main issues. Please summarise the main ethical, legal, or management issues arising from your study
and say how you have addressed them.
Not all studies raise significant issues. Some studies may have straightforward ethical or other issues that can be identified
and managed routinely. Others may present significant issues requiring further consideration by a REC, HRA, or other
review body (as appropriate to the issue). Studies that present a minimal risk to participants may raise complex
organisational or legal issues. You should try to consider all the types of issues that the different reviewers may need to
consider.
It is not the researchers' intent to cause undue worry or concern to any of the participants involved in this research
when discussing their health and experiences. Therefore in the design and planning of the study, the involvement of
people with MS within the Barts MS Patient Advisory Group was key to ensure that the research process and
discussion topics are appropriate for use by other people with MS. For example, considering factors such as the
impact of fatigue when attending the focus groups for people with MS has been carefully considered in the topic guide
and in the discussions themselves. Further, there is the possibility that the participants will share experiences of
increasing disability and describe activities that they no longer can take part in or complete due to their disability and
their MS. 
The study has addressed these issues by including activities to make participants feel supported to share their
experiences, including professional facilitation skills within the discussions and ensuring the relevant professional
roles can be accessed if necessary. 
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a lay person.
The secondary research objective is to develop a PROM to evaluate upper limb function in people with MS.
A further research objective is to explore how patients experiential knowledge can contribute to the development of a
PROM.
A12. What is the scientific justification for the research? Please put this in language comprehensible to a lay person.
The research will engage people with MS throughout the whole process of patient reported outcome measures
(PROM) development. There has been similar research which looked at developing outcome measures with patients
in mental health, but not specifically looking at upper limb function in MS. Within the field of MS, new PROMS to
measure upper limb function are being developed, but they are not interested in exploring the potential for patients to
be involved in this process, contributing their experiences of living with the chronic illness.
The research will discover how people with MS experience effects of MS on their day to day activities, how they feel
when they complete PROMs and take part in measurement activities. Discussions will explore and determine how
patients would like to receive PROMs from the health service and the role that measurement plays in their monitoring
of their own disease. This will give insights on how to improve PROM design and could lead to improved
measurement data. This qualitative study includes people with different experiences of living with MS from different
perspectives which will increase the chance of generating innovative ideas that have a good chance of working in
practice.The research will contribute to the literature on patient generated PROMs, exploring how the focus group
participants make sense of other patients experiences.
A13. Please summarise your design and methodology. It should be clear exactly what will happen to the research
participant, how many times and in what order. Please complete this section in language comprehensible to the lay person.
Do not simply reproduce or refer to the protocol. Further guidance is available in the guidance notes.
This is a mixed method study consisting of three qualitative focus groups and an online survey. Within the study, there
is a nested analysis of the impact of experiential knowledge on the development of a PROM. This study uses a focus
group method to involve patient participants in the PROM development process. The focus group sessions will enable
interactions between participants to help with the generation of new ideas and personal reflections based on their
experiences of living with MS. The three focus groups will take place over three months with an on-line survey posted
after the first focus group to identify topics for the subsequent focus groups. Participants will then discuss the results
of the survey and develop categories for a new PROM to measure upper limb function for PwMS. 
PwMS will be purposively sampled to ensure that a range of experiences of upper limb function, as described by their
expanded disability status score (EDSS) score, are captured and to ensure they are representative of the wider
population of people living with MS. For example, people living with MS and have an EDSS score of 4.0 will have very
different upper limb experiences to those with an EDSS score of 8.0. The MS Consultant and MS Nurse will be aware
of this sampling method and so will be selective in considering potential participants to speak to the researcher when
recruiting in The Royal London Hospital outpatient department.
Once the PI has spoken to patients, provided them with the printed study patient information and confirmed they would
like to be involved, she will make a note of the patient’s contact details (name, email, telephone number, address), the
date the patient information is given to the patient and a convenient time to contact them within 24-48 hours to enable
them to remember the conversation, or at another convenient time agreed with them. Each participant will be
telephoned or emailed as they prefer, to arrange dates, times and potentially transport for the three focus group
sessions. Once verbal consent has been gained, written informed consent will be gained from each participant on
attendance to the first focus group. To reduce patient burden and upper limb fatigue, written consent will be gained
once per participant.
Once participants has agreed to take part in the study they will be asked to complete a Web-based Expanded
Disability Status Scale survey (WebEDSS) and cardboard 9 Hole Peg Test (c9HPT). These will both be used to
describe the type of MS that each of the focus group participants have. The WebEDSS can be completed at home, on
their own computer, in their own time, taking approximately 10 minutes. The c9HPT will be posted to the participants
home and again, completed in their own time. Participants will be asked to share the results of both tests with the PI
either when they are communicating on email or the phone to organise the date of the focus group, or on arrival of the
first focus group. This also takes 10 minutes to complete.
Focus group overview:
Focus groups of between eight and ten people will be used to collect qualitative data via sound recordings that will
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provide detailed insights into individuals understanding and experiences of living with MS, how this affects their upper
limb function and also how this can be measured. Participants will work as a group to design a survey for other
patients, analyse these results then develop a new PROM.
Detailed description of focus group sessions:
The aim of the first focus group is to start the research process to identify upper limb activities important to people with
MS. The PF will introduce the participants to the study topic, the focus group process and to each other. The objective
of the focus group is to engage the participants to develop questions for an online survey, to gather activities of upper
limb function from another group of PwMS.   The focus group will be approx. 3 hours long. The PF will lead the group
through the three focus group sessions following the focus group topic guide. This topic guide was developed through
meetings with the research team and Barts MS Patient Advisory Group.
By the end of the first focus group, the group will have developed questions that could be used to develop an online
survey.   This will be used to gather information on the different upper limb activities that are affected by living with MS
with an EDSS of between 3.5 and 8.0. The survey will be created by the PI and posted on the Barts MS Research blog.
Social media (specifically blogs) have been used to collect evidence of content validity and concept identification in
new PROM development in the area of ALS. The benefit of using social media, over face-to-face interaction is that the
tool can be used to access a wide range of patients for the PROM development stage that would have not originally
been accessed as it reaches people who can not travel, and is also a cost effective way of including more patients. 
The survey aims to gather a minimum of 50 responses but we anticipate the survey gathering around 200 responses
through the Barts MS Research Blog. The survey will be closed after two weeks giving time for the data to be prepared
to be included in the second focus group. The response data will be anonymised of any identifiable information. If less
than 50 responses are gathered, the survey will be left open for three weeks, but the second focus group will not be
moved. 
The aim of the second focus group is to review and discuss the results from the online survey. Working in groups of 5,
each group has to work round tables reviewing the responses to identifying similarities, repetition and relevance. They
will then identify all the environmental factors which contribute to the different ways to complete each activity. 
The aim of the third focus group is to develop the format for the new PROM. The participants will discuss practical
aspects such as the name of the tool, the format of administration (digital, paper or group based), how it should be
distributed and discussing the need for instructions. 
The focus groups will be held in a community cafe meeting room in the Queen Elizabeth Olympic Park, East London,
lasting an average of three hours, led by the PF in conjunction with the PI. They will be held between two and three
weeks apart to ensure some memory of the previous discussion and to allow the study to keep up some momentum.
This space has been chosen by as it is not only has the capacity to hold a meeting with a number of wheelchair users
with a taxi drop off space at the entrance but it will provide a safe and respectful environment which is important for
focus groups to be held in a non-medical venue in the belief that this will encourage participants to speak more freely.
The Camden Society have provided a letter to confirm they are happy for the Unity Café to be used as a research site.
The study will end four months after the third focus group has been completed. Within this time, the data will have
been analysed, written up in a publication format and disseminated to both staff and patient groups. The study will last
eight months in total.
A14-1. In which aspects of the research process have you actively involved, or will you involve, patients, service users,
and/or their carers, or members of the public?
 Design of the research
 Management of the research
 Undertaking the research
 Analysis of results
 Dissemination of findings
 None of the above
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Give details of involvement, or if none please justify the absence of involvement.
The Barts MS Patient Advisory Group were consulted and their comments and suggested amendments were
incorporated and are reflected in the design of the research methodology, the focus group topic guide, patient
information and consent forms. They visited the space to evaluate it’s appropriateness for this research study and
agree that it will support the study's aims of providing a supportive, relaxed atmosphere that is appropriate for the
study. 
Focus group participants will be informed of the findings of the research when it has concluded. The participants will
receive via the postal system a written description of the conclusions of the focus group if they are interested, along
with any written publications.
 4. RISKS AND ETHICAL ISSUES
 RESEARCH PARTICIPANTS
A15. What is the sample group or cohort to be studied in this research?
Select all that apply: 
 Blood
 Cancer
 Cardiovascular
 Congenital Disorders
 Dementias and Neurodegenerative Diseases
 Diabetes
 Ear
 Eye
 Generic Health Relevance
 Infection
 Inflammatory and Immune System
 Injuries and Accidents
 Mental Health
 Metabolic and Endocrine
 Musculoskeletal
 Neurological
 Oral and Gastrointestinal
 Paediatrics
 Renal and Urogenital
 Reproductive Health and Childbirth
 Respiratory
 Skin
 Stroke
Gender:  Male and female participants
Lower age limit:  18  Years
Upper age limit:   No upper age limit
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The focus groups will be facilitated by a professional facilitator (PF) who is also living with MS. Although the PF is a
professional she is being involved in the study for both her professional facilitation skills and also her experience of
living with MS. Therefore, there is a responsibly of the study team to ensure that she is fully supported and comfortable
with her role. Care will be given to not overburden the PF and participants by expecting them to read large amounts of
technical text, meet for extended periods of time or engage in energy draining tasks. The PF will be verbally briefed
about how to deal with any distressed participants and will carry details and contact numbers for suitable support. 
Before starting each focus group session, in the opening address, the PF will reiterate the purpose of the focus group,
based on the written information previously provided. The groups will have the opportunity to introduce themselves at
the start of the sessions to help them feel at ease and that there will be regular breaks where refreshments will be
provided.   The PF will be aware and sensitive of any potential upsetting or concerning topics that are discussed.
Although the PF has worked on service development projects with the research team before, it is the PIs responsibility
to ensure facilitating these discussions and listening to others experiences does not over whelm or upset her.
During the focus group sessions a second researcher, who is experienced in qualitative research will be in the room
alongside the PI. This is to ensure the PI and PF are supported from the perspective of safety (lone worker) and to
ensure a coherent interpretation of the research themes identified during the focus groups.   Both are aware of Queen
Mary Universities lone working policy which can be accessed here: http://hsd.qmul.ac.uk/A-
Z/Lone%20Working/index.html. Each session will be followed by a verbal de-brief discussion between the PI, the
qualitative researcher (QR) and the PF to ensure that all questions have been answered and the PF feels supported.
The wider research team, consisting of the Professor of Neurology and an occupational therapist, will meet throughout
the study to support the PI and the analysis process. This will ensure an unbiased perspective is maintained
throughout the study.
The PI will be writing up part of this study for a PhD qualification and will be supported by two supervisors when doing
this once analysis is completed. The supervisors will not have access to any original data.
 3. PURPOSE AND DESIGN OF THE RESEARCH
A7. Select the appropriate methodology description for this research. Please tick all that apply:
 Case series/ case note review
 Case control
 Cohort observation
 Controlled trial without randomisation
 Cross-sectional study
 Database analysis
 Epidemiology
 Feasibility/ pilot study
 Laboratory study
 Metanalysis
 Qualitative research
 Questionnaire, interview or observation study
 Randomised controlled trial
 Other (please specify)
Focus groups and descriptive statistics
A10. What is the principal research question/objective? Please put this in language comprehensible to a lay person.
The principle research objective is to identify how patients with MS can contribute to PROM development. 
A11. What are the secondary research questions/objectives if applicable? Please put this in language comprehensible to
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A17-1. Please list the principal inclusion criteria (list the most important, max 5000 characters).
Participants will be invited to take part in the focus group sessions if they meet the inclusion criteria of being able to
give informed consent without assistance. 
Participants must be over the age of 18 and have been diagnosed with Multiple Sclerosis more than 6 months ago
and have an EDSS of between 3.5 and 8.0. 
Participants must be able to attend all three focus group sessions in East London.
Participants must have documented assessment attempts for Expanded Disability Status Scale (EDSS), via the
WebEDSS and cardboard 9-Hole Peg test (c9HPT) prior to the focus groups. 
Participants must also be able to understand and be able to communicate in English.
Participants who will be invited to complete the online survey that is generated from the first focus group will be
readers of the Barts MS Research Blog. This group of participants will not be recruited as patients so are subject of
local ethical approval only which is being requested. 
They will also be asked to complete the WebEDSS and c9HPT before completing the survey and must be over the age
of 18 and have been diagnosed with Multiple Sclerosis more than 6 months ago with an EDSS of between 3.5 and 8.0.
A17-2. Please list the principal exclusion criteria (list the most important, max 5000 characters).
Participants will be ineligible to participate if any inclusion criteria are not met. For example, if they do not want to
complete the c9HPT or WebEDSS score.
Due to the nature of study we will be unable to recruit non English speaking participants. This is due to not having the
resources to translate patient information or consent into different languages.
 RESEARCH PROCEDURES, RISKS AND BENEFITS  
A18. Give details of all non-clinical intervention(s) or procedure(s) that will be received by participants as part of the
research protocol. These include seeking consent, interviews, non-clinical observations and use of questionnaires.
Please complete the columns for each intervention/procedure as follows:
1. Total number of interventions/procedures to be received by each participant as part of the research protocol.
2. If this intervention/procedure would be routinely given to participants as part of their care outside the research,
how many of the total would be routine?
3. Average time taken per intervention/procedure (minutes, hours or days)
4. Details of who will conduct the intervention/procedure, and where it will take place.
Intervention or
procedure 1 2 3 4
Recruitment 1 10 mins The Principal Investigator will speak to patients in the outpatient department at
Barts Health NHS Trust and provide them with the printed study patient information.
If they confirm they would like to be involved, she will make a note of the patient’s
contact details (name, email, telephone number, address), the date the patient
information is given to the patient and a convenient time to contact them within 24-
48 hours to enable them to remember the conversation, or at another convenient
time agreed with them.
Phone call or
email to
patients to
arrange focus
group times
and dates
1 15
minutes
Each participant will be telephoned or emailed as they prefer, to arrange dates,
times and potentially transport for the three focus group sessions.
Written 1 10 mins The Principal Investigator will ask each participant to initial and sign the consent
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informed
consent
form at the start of the first focus group in the community cafe in the Queen Olympic
Park if they agree to their involvement in the study and sound recording of each
session.
WebEDSS 1 10
minutes
Patient will conduct on their own at home
Cardboard 9
Hole Peg Test
1 10
minutes
Patient will conduct on their own at home
Focus group 1 1 3 hours Principal Investigator, patient facilitator and the qualitative researcher.
Location to be a community cafe in the Queen Elizabeth Olympic Park.
Focus Group 2 1 3 hours Principal Investigator, patient facilitator and the qualitative researcher..
Location to be a community cafe in the Queen Elizabeth Olympic Park.
Focus Group 3 1 3 hours Principle Investigator, patient facilitator and the qualitative researcher.
Location to be a community cafe in the Queen Elizabeth Olympic Park.
Dissemination
of results
1 5
minutes
Principal Investigator - results to be emailed or posted to patients home address
A21. How long do you expect each participant to be in the study in total?
We expect participants to be in the study for three months.
A22. What are the potential risks and burdens for research participants and how will you minimise them?
For all studies, describe any potential adverse effects, pain, discomfort, distress, intrusion, inconvenience or changes
to lifestyle. Only describe risks or burdens that could occur as a result of participation in the research. Say what steps
would be taken to minimise risks and burdens as far as possible.
Talking about previous health care experiences may arouse feelings that need to be acknowledged and responded to
sensitively. The wellbeing of the participants in the group will take precedence over the session itself. During the
focus group, if necessary, the participants will be offered and encouraged to take short breaks throughout the
session. Sessions will only resume if all participants are in agreement and comfortable with the session resuming. If
not, the session may be terminated early and this will be recorded in the focus group session notes. The
researchers will provide appropriate contact names and telephone numbers for all participants to seek further
support if they wish. If there are any sensitive or disturbing issues discussed at the meetings for which the
researchers are unable to manage themselves then support services have been approached as follows. The Patient
Advisory Liaison service (PALS) have agreed to be contacted by individual patients in this instance, and so has
another consultant Neurologist who is not involved in the study, but who knows about it. Both of these contact details
are in the patient information. 
The PF and the PI will facilitate the discussions in a purposeful and open way, making sure everyone has the
opportunity to take part. The researcher will reiterate that participants can contact either the PI or Professor of
Neurology, part of the research team, if they have any issue they would like to discuss about the research activity.
A23. Will interviews/ questionnaires or group discussions include topics that might be sensitive, embarrassing or
upsetting, or is it possible that criminal or other disclosures requiring action could occur during the study?
 Yes       No
If Yes, please give details of procedures in place to deal with these issues:
The researcher and facilitator will encourage discussion, through a series of question prompts to the group, written
in the focus group topic guide, to encourage individuals to share their experiences and facilitate discussions in the
sessions. 
There is a possibility that the discussions may include topics of diagnosis, symptoms and experiences of increased
disability from patients. The researchers and PF will listen to the participants stories and provide sensitive
responses to any statements. The researchers will also be mindful that there are other patients involved in the
group and ensure that these stories do not cause upset or alarm. If this situation does arise, the researchers will
remind the group that the purpose of the research activity is to discuss feelings relating to completing activities. If
necessary, the researcher can suggest a refreshment break and move onto another topic after the break.
IRAS Form Reference:
17/LO/1684
IRAS Version 5.5.2
Date: 14/09/2017 228062/1128129/37/98314
If information is disclosed that requires followup action or notification, the researcher will immediately discuss this
with the more experienced researcher and then inform the Professor of Neurology. All topics of conversation and
interactions will be written up by the PI.
A24. What is the potential for benefit to research participants?
There are no immediate benefits for participants in taking part in this research. It is anticipated that in the future the
newly developed PROM will be used by patients and benefit anyone who uses it.
A26. What are the potential risks for the researchers themselves? (if any)
Potential risks to the researchers and the PF have been discussed with the research team and the PIs supervisors. If
there are any situations within the research activity where the PF or the PI feels uncomfortable by either approaching
participants or in the support of the PF of the focus groups, the PI will inform the Professor of Neurology and her
supervisors immediately. Both the PI and PF are aware of Queen Mary Universities lone working policy. Both are aware
of Queen Mary Universities lone working policy which can be accessed here: http://hsd.qmul.ac.uk/A-
Z/Lone%20Working/index.html. The PI will also keep a reflective diary throughout the research process to record her
feelings throughout the process. 
The Research team and the PI will meet monthly through out the duration of the research process. Within these
meetings any issues that have arisen that have concerned the PI will be discussed and any action that is needed will
be taken.
 RECRUITMENT AND INFORMED CONSENT
 In this section we ask you to describe the recruitment procedures for the study. Please give separate details fordifferent study groups where appropriate.
A27-1. How will potential participants, records or samples be identified? Who will carry this out and what resources
will be used?For example, identification may involve a disease register, computerised search of GP records, or review of
medical records. Indicate whether this will be done by the direct healthcare team or by researchers acting under
arrangements with the responsible care organisation(s).
The MS consultant and MS Nurse will identify potential patients of theirs who would be suitable to take part in the focus
groups within their outpatient clinic over a duration of one month. If a patient meets the inclusion criteria and is happy
to speak to the researcher, only then they will be approached. This will happen after their appointment while they are
still in the outpatient department. The researcher will not approach patients without direction from the MS consultant or
MS Nurse notifying them.   This way we avoid approaching patients who would like to take part but are ineligible. The
researcher will be aware of the vulnerability of patients when recruiting in the outpatient department. The researcher
has received GCP training and will answer any immediate questions or queries individuals may have.   
If patients would like to know more information about the study, they will be given verbal and written information in the
form of patient information and consent form.   The information will describe the purpose of the focus groups and
describe that they will be asked to participate in tasks of discussion, analysis, idea generation and reviewing as well
as contributing their experiences of living with MS. Informing the participants about the format of the research before
they participate, will ensure they are willing to provide information in the focus groups.   This information will also
include information about details of how confidentiality will be maintained throughout the research process, how data
will be recorded and their right to withdraw from the study or withdraw their consent at any point without having to
supply a reason.   Practical information such as details about building access, car parking and transport
arrangements. Study participants will either have travel expenses reimbursed or will have travel arranged for them by
the researcher.
The researcher will make a note of the patient’s contact details (name, email, telephone number, address), the date
the patient information is given to the patient and the researcher will confirm whether they are comfortable to be
contacted in 24-48 hours by a preferred method of phone or email. The researcher will only obtain the patients contact
details from the patient and will not share these. 
Once each of the patient has read the patient information and has confirmed they would like to be involved (by either
contacting the researcher, or at the follow up contact if they agreed to this), each participant will be telephoned or
emailed as they prefer to arrange dates, times and potentially transport for the three focus group sessions.
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Recruitment will approximately take 1 month.  
A27-2. Will the identification of potential participants involve reviewing or screening the identifiable personal
information of patients, service users or any other person?
 Yes       No
Please give details below:
A28. Will any participants be recruited by publicity through posters, leaflets, adverts or websites?
 Yes       No
A29. How and by whom will potential participants first be approached?
Patients will be first identified and approached by either the MS nurse or the MS consultant in charge of the patients
care when visiting the outpatient department for their Neurology appointment. They will be then referred to the
researcher and invited to participate in the research. Any immediate questions the participants may be answered by
the researcher.
The MS Nurse or MS Consultant will not share any patient details with the researcher. It is up to the patient to share
these with the researcher. 
If participants would like to discuss the study with another member of staff then details of how to contact them via
telephone or email are provided in the patient information.
A30-1. Will you obtain informed consent from or on behalf of research participants?
 Yes       No
If you will be obtaining consent from adult participants, please give details of who will take consent and how it will be
done, with details of any steps to provide information (a written information sheet, videos, or interactive material).
Arrangements for adults unable to consent for themselves should be described separately in Part B Section 6, and for
children in Part B Section 7.
If you plan to seek informed consent from vulnerable groups, say how you will ensure that consent is voluntary and
fully informed.
Informed consent will be obtained from each participant by the PI. Patient information and consent forms will be given
to all participants. When participants confirm they would like to take part in the study, they will be telephoned to
arrange dates and times for the three focus group sessions.
All participants will be asked to sign the consent form at the first focus group session in the presence of the PI, as
each participant will have received information prior to the focus group. The PI will later scan and post a copy of this
consent form to the participants and store the original
Recruitment will take approximately 1 month.
 
If you are not obtaining consent, please explain why not.
Please enclose a copy of the information sheet(s) and consent form(s).
A30-2. Will you record informed consent (or advice from consultees) in writing?
 Yes       No
A31. How long will you allow potential participants to decide whether or not to take part?
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 Title   Forename/Initials  SurnameMiss Alison  Thomson
Post Lecturer in PPI and PES
Qualifications
University of Dundee, Dundee BSc Hons 2008 Interactive Media Design
Royal College of Art, London MA RCA 2010 Design Interactions
Goldsmiths, Uni. of London PhD Exp. 2018 Design Research
Work Address 64 Turner Street
 Blizard Institute, QMUL
 London
Post Code E1 2AB
Work Email a.thomson@qmul.ac.uk
Work Telephone 02078822367
Fax
A43. How long will personal data be stored or accessed after the study has ended?
 Less than 3 months
 3 – 6 months
 6 – 12 months
 12 months – 3 years
 Over 3 years
A44. For how long will you store research data generated by the study?
Years: 20 
Months: 0 
A45. Please give details of the long term arrangements for storage of research data after the study has ended.Say
where data will be stored, who will have access and the arrangements to ensure security.
The original sound recordings will be stored by the PI on a Queen Mary University encrypted hard drive and stored in a
locked cabinet in the Blizard Institute in Queen Mary University of London building.   All documents related to the study
will be archived at Queen Mary University of London, including the listing of the identities of the participants involved in
the study which will be kept separate from other documents.   All documents relating to the study will be retained for at
least 20 years after the end of the study before being destroyed in line with the then existing secure Queen Mary
University of London practice. Patient identifying data will be securely destroyed within 12 months of the study
recruitment according to current Queen Mary University of London practice at the end of the study.  
 INCENTIVES AND PAYMENTS
A46. Will research participants receive any payments, reimbursement of expenses or any other benefits or incentives
for taking part in this research?
 Yes       No
If Yes, please give details. For monetary payments, indicate how much and on what basis this has been determined.
Travel expenses will be reimbursed for patient travel to and from the focus group sessions. Refreshments will be
provided for the participants in the break time in each focus group session. Participants will also be able to keep the
cardboard 9 Hole Peg Test that they were posted at the start of the study if they wish.
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A47. Will individual researchers receive any personal payment over and above normal salary, or any other benefits or
incentives, for taking part in this research?
 Yes       No
A48. Does the Chief Investigator or any other investigator/collaborator have any direct personal involvement (e.g.
financial, share holding, personal relationship etc.) in the organisations sponsoring or funding the research that may
give rise to a possible conflict of interest?
 Yes       No
 NOTIFICATION OF OTHER PROFESSIONALS
A49-1. Will you inform the participants’ General Practitioners (and/or any other health or care professional responsible
for their care) that they are taking part in the study?
 Yes       No
If Yes, please enclose a copy of the information sheet/letter for the GP/health professional with a version number and date.
 PUBLICATION AND DISSEMINATION
A50. Will the research be registered on a public database?
 Yes       No
Please give details, or justify if not registering the research.
The research will not be registered on a public database, as there seems to be none for this specific study area. If the
REC can recommend a relevant database, we have no objections to registering the research.
Registration of research studies is encouraged wherever possible.
You may be able to register your study through your NHS organisation or a register run by a medical research charity,
or publish your protocol through an open access publisher. If you are aware of a suitable register or other method of
publication, please give details. If not, you may indicate that no suitable register exists. Please ensure that you have
entered registry reference number(s) in question A5-1.
A51. How do you intend to report and disseminate the results of the study?Tick as appropriate:
 Peer reviewed scientific journals
 Internal report
 Conference presentation
 Publication on website
 Other publication
 Submission to regulatory authorities
 Access to raw data and right to publish freely by all investigators in study or by Independent Steering Committee
on behalf of all investigators
 No plans to report or disseminate the results
 Other (please specify)
A52. If you will be using identifiable personal data, how will you ensure that anonymity will be maintained when
publishing the results?
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Once the PI has spoken to patients, provided them with the printed study patient information and confirmed they would
like to be involved, she will make a note of the patient’s contact details (name, email, telephone number, address), the
date the patient information is given to the patient and a convenient time to contact them within 24-48 hours to enable
them to remember the conversation, or at another convenient time agreed with them.
A33-1. What arrangements have been made for persons who might not adequately understand verbal explanations or
written information given in English, or who have special communication needs?(e.g. translation, use of interpreters)
Due to the nature of study we will be unable to recruit non English speakers and we do not have the resources to
translate patient information or consents. Participants must be able to understand verbal and written English
information.
A35. What steps would you take if a participant, who has given informed consent, loses capacity to consent during the
study?  Tick one option only.
 The participant and all identifiable data or tissue collected would be withdrawn from the study. Data or tissue which
is not identifiable to the research team may be retained.
 The participant would be withdrawn from the study. Identifiable data or tissue already collected with consent would
be retained and used in the study. No further data or tissue would be collected or any other research procedures carried
out on or in relation to the participant.
 The participant would continue to be included in the study.
 Not applicable – informed consent will not be sought from any participants in this research.
 Not applicable – it is not practicable for the research team to monitor capacity and continued capacity will be
assumed.
 
Further details:
Participants may end their involvement at any time.   We will advise them that we plan to keep all data collected from them
before they end their involvement, unless they specify otherwise.   However, if they require it, we will destroy all their data,
which will be done securely. If data have been used in disseminations before withdrawal, we will advise participants that
this information cannot be withdrawn.
Participants must tell us by the end of the study if they wish to avoid their data being included in reports, presentations
and research materials. After this time, we can still remove data from our archives.   If a participant withdraws from the
study, they will not be replaced. 
 CONFIDENTIALITY  
 In this section, personal data means any data relating to a participant who could potentially be identified. It includespseudonymised data capable of being linked to a participant through a unique code number.
 Storage and use of personal data during the study
A36. Will you be undertaking any of the following activities at any stage (including in the identification of potential
participants)?(Tick as appropriate)
 Access to medical records by those outside the direct healthcare team
 Access to social care records by those outside the direct social care team
 Electronic transfer by magnetic or optical media, email or computer networks
 Sharing of personal data with other organisations
 Export of personal data outside the EEA
 Use of personal addresses, postcodes, faxes, emails or telephone numbers
 Publication of direct quotations from respondents
 Publication of data that might allow identification of individuals
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 Use of audio/visual recording devices
 Storage of personal data on any of the following:
   
 Manual files (includes paper or film)
 NHS computers
 Social Care Service computers
 Home or other personal computers
 University computers
 Private company computers
 Laptop computers
Further details:
Any data stored on a Queen Mary University computer of laptop will be anonymised. For monitoring and audit
purposes, the Sponsor and individuals from regulatory authorities may need to view data generated by the study
A37. Please describe the physical security arrangements for storage of personal data during the study?
The original sound recordings will be stored by the PI on a Queen Mary University encrypted hard drive in password
protected folders stored in a locked cabinet in the Blizard Institute building in Queen Mary University.   Only the PI will
listen to the sound recordings.   All documents related to the study will be archived at the study site, including the
listing of the identities of the participants involved in the study which will be kept separate from other documents.   
Any data stored on a Queen Mary University computer of laptop will be anonymised.
A38. How will you ensure the confidentiality of personal data?Please provide a general statement of the policy and
procedures for ensuring confidentiality, e.g. anonymisation or pseudonymisation of data.
When patients sign the consent form they will be given a “Participant Identification Number” which will be a randomly
generated number, generated from a simple Excel random function. This randomised number will ensure anonymity
of the patients throughout the research and analysis process. Participants will remain anonymous with regards to any
publications relating to the study unless they have requested to be named by either their name, pseudonym or initials
in the publication. 
The sound recorded data will remain on the recording device until back at the University building where it will be
transferred to the storage device where it will be stored in a password protected folder on an encrypted hard drive. The
sound recorders memory will be wiped. 
A40. Who will have access to participants' personal data during the study? Where access is by individuals outside the
direct care team, please justify and say whether consent will be sought.
The Professor of Neurology, Gavin Giovannoni, an authorized member of the research team, will access the Electronic
Health Records system to save a scanned copy of the Patient consent form to patient medical notes. Patient notes will
not be accessed again.
 Storage and use of data after the end of the study
A41. Where will the data generated by the study be analysed and by whom?
Only the PI will listen to the sound recordings when transcribing the data in a private Queen Mary University office. All
analysis activities within the research team will take place in this office.
A42. Who will have control of and act as the custodian for the data generated by the study?
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Identifiable personal data such as participants details (Names, addresses, email addresses and phone numbers)
will be collected at recruitment from patients but will not be shared.   When participants sign the consent form they will
be given a “Participant Identification Number” which will be a randomly generated number, generated from a simple
Excel random function.   This randomised number will ensure anonymity of the participants throughout the research
and analysis process.
When disseminating the results of the study, participants will have the option to have their names or a pseudonym
included in the study publications, crediting their involvement.
A53. Will you inform participants of the results?
 Yes       No
Please give details of how you will inform participants or justify if not doing so.
First and foremost, the researcher will return the key findings to the study participants along with a letter (sent via email
or post) of thanks. This will also include a one page hand out summarizing the key findings from each focus group,
and if they opted to be updated on the project development through the mailing list, they will also receive this.
 5. Scientific and Statistical Review
A54. How has the scientific quality of the research been assessed?Tick as appropriate:
 Independent external review
 Review within a company
 Review within a multi−centre research group
 Review within the Chief Investigator's institution or host organisation
 Review within the research team
 Review by educational supervisor
 Other
Justify and describe the review process and outcome. If the review has been undertaken but not seen by the
researcher, give details of the body which has undertaken the review:
The PI submitted the study protocol for peer review from two members of staff from Queen Mary University of London.
Dr Klaus Schmierer is a consultant Neurologist who is a specialist in the area of MS research and leads on activities
to improve the patient quality of life for people with upper limb issues. Dr Schmierer's comments regarded the
scientific background of the study and clarified the inclusion and exclusion criteria. Following this comments, the PI
included more relevant literature to this area.
Dr Karen Hoffman is an occupational Therapist based at Barts Health NHS Trust and has experience both treating
people with MS but also developing PROMs. Dr Hoffman's comments regarded the methodology of the study and the
qualitative analysis process. Following Dr Hoffman's comments, the PI re-arranged the layout of the protocol, clarified
the primary and secondary objectives and re-wrote the data analysis section of the protocol. 
For all studies except non-doctoral student research, please enclose a copy of any available scientific critique reports,
together with any related correspondence.
For non-doctoral student research, please enclose a copy of the assessment from your educational supervisor/ institution.
A59. What is the sample size for the research?  How many participants/samples/data records do you plan to study in
total? If there is more than one group, please give further details below.
Total UK sample size: 10 
Total international sample size (including UK): 10 
Total in European Economic Area: 10 
Further details:
Each focus group will comprise of, between eight and ten participants. Each participant will attend three focus group.
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This sample will be purposively sampled to ensure that a range of experiences are captured and conveying in the
group of participants that are involved in the study to ensure they are representative of the wider population of people
living with MS. The MS Consultant and MS Nurse will be aware of this sampling method when they refer potential
participants to speak to the research when recruiting in outpatients.
A60. How was the sample size decided upon?  If a formal sample size calculation was used, indicate how this was done,
giving sufficient information to justify and reproduce the calculation.
Each focus group will have between eight and ten participants. This number was decided upon based on previous
research experience with focus groups involving ten participants, and the Barts MS Advisory Group, involving ten. As
this is a qualitative study, the number of participants is small due to the role of their involvement in producing data.
A62. Please describe the methods of analysis (statistical or other appropriate methods, e.g. for qualitative research) by
which the data will be evaluated to meet the study objectives.
Descriptive statistics will be used to analyse quantitative information to describe the sample explaining the range of
EDSS and 9HPT scores of participants involved in both the focus groups and the online survey.
Qualitative data analysis will be used to determine how participants contributed to the PROM development and
interacted as a group in this process.   The process of Immersion/Crystallization   will be used to analyse the data
gathered from the focus group sessions. This method has been successfully used before by the researcher and in
similar research around analysing experiential knowledge and will enable the researcher to consider the unique role
that patients experiential knowledge plays in PROM development. 
Data analysis will occur before (recording the initial engagement with the topic and any prior biases), during and after
the data is collected to ensure it is high-quality. This will allow the researcher to consider the influence of their own
background on the final results and interpretation.   
The research team will then meet and establish key themes as a framework for initial analysis from the teams
previous knowledge and experience of PROM development activities and professional experience. Involving the
research team in the analysis process can ensure pitfalls such as drawing premature conclusions or inability to reach
closure, are avoided.
Discussion of the three focus groups will be transcribed verbatim by the researcher and subsequently coded along
with the researcher’s handwritten field notes recording group interactions and taking into consideration any
‘crystallizations’, insights or reflections noted during data collection in the field notes. This is key as a secondary aim
of the study, is to analyse the interactions amongst the participants within the focus group sessions.
The PI will immerse themselves in the data to create sub-themes can then be associated to key themes. The PI will
then aim to validate the established sub-themes by rereading the text, searching for alternative hypothesis and
interpretations.   The analysis will be presented back to the research team.   
After the three stages of focus groups have finished, the PI will feedback the conclusions reported to the participants.  
This will give the participants an opportunity to express any further reflections or points for discussion. After the
researcher has completed the analysis, a final account of the data will be created for dissemination.
 6. MANAGEMENT OF THE RESEARCH
A63. Other key investigators/collaborators. Please include all grant co−applicants, protocol co−authors and other key
members of the Chief Investigator’s team, including non-doctoral student researchers.
 
 Title  Forename/Initials  SurnameDr  Carol  Rivas
Post Senior Lecturer (Associate Professor)
Qualifications
PhD Medical Sociology, Queen Mary, London University (2012)
MSc Cognitive Neuropsychology (Distinction) (evening course), Birkbeck, London University (1991-
1993)
BSc (Hons) Zoology (Upper Second), Queen Mary College, London University (1978-1981):  
specialised in physiology and behaviour
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PGCAP (distinction) 2013
Employer University College London
Work Address SSRU, UCL
 18 Woburn Square
 
Post Code WC1H 0NR
Telephone 02076126923
Fax
Mobile
Work Email c.rivas@ucl.ac.uk
 
 Title   Forename/Initials  SurnameProfessor Gavin  Giovannoni
Post Professor of Neurology
Qualifications MBBCh, FCP, CCST, PhD
Employer Queen Mary University of London
Work Address Blizard Institute, Centre for Neuroscience and Trauma
 4 Newark Street
 
Post Code E1 2AT
Telephone 02078828954
Fax
Mobile
Work Email g.giovannoni@qmul.ac.uk
 A64. Details of research sponsor(s)
A64-1. Sponsor  
Lead Sponsor
Status:  NHS or HSC care organisation
 Academic
 Pharmaceutical industry
 Medical device industry
 Local Authority
 Other social care provider (including voluntary sector or private
organisation)
 Other
If Other, please specify:  
  Commercial status:   Non-
Commercial
Contact person
 
Name of organisation Queen Mary, University of London
Given name Sally
Family name Burtles
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Address Joint Research Management Office (JRMO), Queen Mary Innovation Centre, Lower GroundFloor, 5 Walde  
Town/city London
Post code E1 2EF
Country  UNITED KINGDOM
Telephone 02078827265
Fax 020 7882 7276
E-mail s.burtles@qmul.ac.uk
Is the sponsor based outside the UK?
 Yes       No
Under the Research Governance Framework for Health and Social Care, a sponsor outside the UK must appoint a
legal representative established in the UK. Please consult the guidance notes.
A65. Has external funding for the research been secured?
 Funding secured from one or more funders
 External funding application to one or more funders in progress
 No application for external funding will be made
What type of research project is this?
 Standalone project
 Project that is part of a programme grant
 Project that is part of a Centre grant
 Project that is part of a fellowship/ personal award/ research training award
 Other
Other – please state: 
Please give details of funding applications.
 
Organisation Horne Family Foundation
Address 1390 North McDowell Blvd., Suite G – #186,
 
 Petaluma
Post Code CA 94954
Telephone 707-775-2466
Fax
Mobile
Email info@hornefamilyfoundation.org
Funding Application Status:  Secured  In progress
Amount: 60,000.00 
 
Duration  
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Please enclose a copy of relevant documents.
A78. Could the research lead to the development of a new product/process or the generation of intellectual property?
 Yes  No  Not sure
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Years:
Months:
If applicable, please specify the programme/ funding stream:
What is the funding stream/ programme for this research project?
  
A66. Has responsibility for any specific research activities or procedures been delegated to a subcontractor (other
than a co-sponsor listed in A64-1) ?  Please give details of subcontractors if applicable.
 Yes       No
Name: Harriet Smith
 
Type of organisation:
 NHS  Academic  Commercial  Other
Please give further details of sub-contractor and main areas of delegated responsibility:   Professional facilitator
involved in leading the three focus groups
A67. Has this or a similar application been previously rejected by a Research Ethics Committee in the UK or another
country?
 Yes       No
Please provide a copy of the unfavourable opinion letter(s). You should explain in your answer to question A6-2 how the
reasons for the unfavourable opinion have been addressed in this application.
A68-1. Give details of the lead NHS R&D contact for this research:
     
 Title  Forename/Initials  Surname Pushpen  Joshi
Organisation Queen Mary, University of London
Address Joint Research Management Office (JRMO), Queen Mary Innovation Centre
 Lower Ground Floor, 5 Walden Street  
 London
Post Code E1 2EF
Work Email sponsorsrep@bartshealth.nhs.uk
Telephone 020 7882 6574
Fax 020 7882 6574
Mobile
Details can be obtained from the NHS R&D Forum website: http://www.rdforum.nhs.uk
A69-1. How long do you expect the study to last in the UK?
Planned start date: 01/10/2017
Planned end date: 31/05/2018
Total duration:  
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Years: 0 Months: 8 Days: 0 
A71-1. Is this study?
 Single centre
 Multicentre
A71-2. Where will the research take place? (Tick as appropriate)
 England
 Scotland
 Wales
 Northern Ireland
 Other countries in European Economic Area
Total UK sites in study
Does this trial involve countries outside the EU?
 Yes       No
A72. Which organisations in the UK will host the research?Please indicate the type of organisation by ticking the box and
give approximate numbers if known:
 NHS organisations in England 1 
 NHS organisations in Wales  
 NHS organisations in Scotland  
 HSC organisations in Northern Ireland  
 GP practices in England  
 GP practices in Wales  
 GP practices in Scotland  
 GP practices in Northern Ireland  
 Joint health and social care agencies (eg
community mental health teams)
 
 Local authorities  
 Phase 1 trial units  
 Prison establishments  
 Probation areas  
 Independent (private or voluntary sector)
organisations
 
 Educational establishments 1 
 Independent research units  
 Other (give details) 1 
Unity Kitchen Cafe
  
Total UK sites in study: 3
A73-1. Will potential participants be identified through any organisations other than the research sites listed above?
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 Yes       No
A74. What arrangements are in place for monitoring and auditing the conduct of the research?
The Principal Investigator will retain the right to audit any study, study site or central facility. In addition, any part of the
study may be inspected by the regulatory bodies and funders where applicable. Quality control checks of procedures
and documents will be undertaken should a need be identified. The sponsor delegates this responsibility to the
Principal Investigator. An internal audit may be conducted by the sponsor representative.
 A76. Insurance/ indemnity to meet potential legal liabilities  
 Note: in this question to NHS indemnity schemes include equivalent schemes provided by Health and Social Care(HSC) in Northern Ireland
A76-1. What arrangements will be made for insurance and/or indemnity to meet the potential legal liability of the
sponsor(s) for harm to participants arising from the management of the research?  Please tick box(es) as applicable.
Note: Where a NHS organisation has agreed to act as sponsor or co-sponsor, indemnity is provided through NHS schemes.
Indicate if this applies (there is no need to provide documentary evidence). For all other sponsors, please describe the
arrangements and provide evidence.
 NHS indemnity scheme will apply (NHS sponsors only)
 Other insurance or indemnity arrangements will apply (give details below)
Queen Mary University of London is the sponsor and has arranged suitable indemnity concerning negligent harm to
be in place for this study. 
Please enclose a copy of relevant documents.
A76-2. What arrangements will be made for insurance and/ or indemnity to meet the potential legal liability of the
sponsor(s) or employer(s) for harm to participants arising from the design of the research?  Please tick box(es) as
applicable.
Note: Where researchers with substantive NHS employment contracts have designed the research, indemnity is provided
through NHS schemes. Indicate if this applies (there is no need to provide documentary evidence). For other protocol
authors (e.g. company employees, university members), please describe the arrangements and provide evidence.
 NHS indemnity scheme will apply (protocol authors with NHS contracts only)
 Other insurance or indemnity arrangements will apply (give details below)
Please enclose a copy of relevant documents.
A76-3. What arrangements will be made for insurance and/ or indemnity to meet the potential legal liability of
investigators/collaborators arising from harm to participants in the conduct of the research? 
Note: Where the participants are NHS patients, indemnity is provided through the NHS schemes or through professional
indemnity. Indicate if this applies to the whole study (there is no need to provide documentary evidence). Where non-NHS
sites are to be included in the research, including private practices, please describe the arrangements which will be made at
these sites and provide evidence.
 NHS indemnity scheme or professional indemnity will apply (participants recruited at NHS sites only)
 Research includes non-NHS sites (give details of insurance/ indemnity arrangements for these sites below)
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 PART C: Overview of research sites  
Please enter details of the host organisations (Local Authority, NHS or other) in the UK that will be responsible for the
research sites.   For further information please refer to guidance.
Investigator
identifier Research site Investigator Name
IN1
 NHS site
 Non-NHS site
  
 
Institution name Queen Mary, University of London
Department name Neuroscience and Trauma, BlizardInstitute
Street address 4 Newark Street
Town/city London
Post Code E1 2AT
Country  UNITED KINGDOM
 
Forename Alison
Middle name
Family name Thomson
Email a.thomson@qmul.ac.uk
Qualification
(MD...)
Country  UNITED KINGDOM
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 PART D: Declarations
D1. Declaration by Chief Investigator
1. The information in this form is accurate to the best of my knowledge and belief and I take full responsibility for
it.   
2. I undertake to abide by the ethical principles underlying the Declaration of Helsinki and good practice
guidelines on the proper conduct of research.
3. If the research is approved I undertake to adhere to the study protocol, the terms of the full application as
approved and any conditions set out by review bodies in giving approval.
4. I undertake to notify review bodies of substantial amendments to the protocol or the terms of the approved
application, and to seek a favourable opinion from the main REC before implementing the amendment.
5. I undertake to submit annual progress reports setting out the progress of the research, as required by review
bodies.
6. I am aware of my responsibility to be up to date and comply with the requirements of the law and relevant
guidelines relating to security and confidentiality of patient or other personal data, including the need to register
when necessary with the appropriate Data Protection Officer. I understand that I am not permitted to disclose
identifiable data to third parties unless the disclosure has the consent of the data subject or, in the case of
patient data in England and Wales, the disclosure is covered by the terms of an approval under Section 251 of
the NHS Act 2006.
7. I understand that research records/data may be subject to inspection by review bodies for audit purposes if
required.
8. I understand that any personal data in this application will be held by review bodies and their operational
managers and that this will be managed according to the principles established in the Data Protection Act
1998.
9. I understand that the information contained in this application, any supporting documentation and all
correspondence with review bodies or their operational managers relating to the application:
Will be held by the REC (where applicable) until at least 3 years after the end of the study; and by NHS
R&D offices (where the research requires NHS management permission) in accordance with the NHS
Code of Practice on Records Management.
May be disclosed to the operational managers of review bodies, or the appointing authority for the REC
(where applicable), in order to check that the application has been processed correctly or to investigate
any complaint.
May be seen by auditors appointed to undertake accreditation of RECs (where applicable).
Will be subject to the provisions of the Freedom of Information Acts and may be disclosed in response
to requests made under the Acts except where statutory exemptions apply.
May be sent by email to REC members.
10. I understand that information relating to this research, including the contact details on this application, may be
held on national research information systems, and that this will be managed according to the principles
established in the Data Protection Act 1998.   
11. Where the research is reviewed by a REC within the UK Health Departments Research Ethics Service, I
understand that the summary of this study will be published on the website of the National Research Ethics
Service (NRES), together with the contact point for enquiries named below. Publication will take place no earlier
than 3 months after issue of the ethics committee’s final opinion or the withdrawal of the application.   
Contact point for publication(Not applicable for R&D Forms)
NRES would like to include a contact point with the published summary of the study for those wishing to seek further
information. We would be grateful if you would indicate one of the contact points below.
 Chief Investigator
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 Sponsor
 Study co-ordinator
 Student
 Other – please give details
 None
 
Access to application for training purposes (Not applicable for R&D Forms)
Optional – please tick as appropriate: 
 I would be content for members of other RECs to have access to the information in the application in confidence
for training purposes. All personal identifiers and references to sponsors, funders and research units would be
removed.   
This section was signed electronically by Miss Alison Thomson on 13/09/2017 10:48.
Job Title/Post: Lecturer in Public Engagement and Patient Public Involvement
Organisation: Queen Mary University of London
Email: a.thomson@qmul.ac.uk
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D2. Declaration by the sponsor's representative
If there is more than one sponsor, this declaration should be signed on behalf of the co−sponsors by a representative
of the lead sponsor named at A64-1.
I confirm that:
1. This research proposal has been discussed with the Chief Investigator and agreement in principle to
sponsor the research is in place.
2. An appropriate process of scientific critique has demonstrated that this research proposal is worthwhile and
of high scientific quality.
3. Any necessary indemnity or insurance arrangements, as described in question A76, will be in place before
this research starts. Insurance or indemnity policies will be renewed for the duration of the study where
necessary.
4. Arrangements will be in place before the study starts for the research team to access resources and support
to deliver the research as proposed.
5. Arrangements to allocate responsibilities for the management, monitoring and reporting of the research will
be in place before the research starts.
6. The duties of sponsors set out in the Research Governance Framework for Health and Social Care will be
undertaken in relation to this research.
Please note: The declarations below do not form part of the application for approval above. They will not be
considered by the Research Ethics Committee.   
7. Where the research is reviewed by a REC within the UK Health Departments Research Ethics Service, I
understand that the summary of this study will be published on the website of the National Research Ethics
Service (NRES), together with the contact point for enquiries named in this application. Publication will take
place no earlier than 3 months after issue of the ethics committee's final opinion or the withdrawal of the
application.   
8. Specifically, for submissions to the Research Ethics Committees (RECs) I declare that any and all clinical
trials approved by the HRA since 30th September 2013 (as defined on IRAS categories as clinical trials of
medicines, devices, combination of medicines and devices or other clinical trials) have been registered on a
publically accessible register in compliance with the HRA registration requirements for the UK, or that any
deferral granted by the HRA still applies. 
This section was signed electronically by Dr Sally Burtles on 13/09/2017 16:00.
Job Title/Post: Director of Research Services & Business Development
Organisation: Queen Mary, University of London
Email: sponsorsrep@bartshealth.nhs.uk
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D3. Declaration for student projects by academic supervisor(s)
1. I have read and approved both the research proposal and this application. I am satisfied that the scientific content
of the research is satisfactory for an educational qualification at this level.
 
2. I undertake to fulfil the responsibilities of the supervisor for this study as set out in the Research Governance
Framework for Health and Social Care.
 
3. I take responsibility for ensuring that this study is conducted in accordance with the ethical principles underlying
the Declaration of Helsinki and good practice guidelines on the proper conduct of research, in conjunction with
clinical supervisors as appropriate.
 
4. I take responsibility for ensuring that the applicant is up to date and complies with the requirements of the law and
relevant guidelines relating to security and confidentiality of patient and other personal data, in conjunction with
clinical supervisors as appropriate.
Academic supervisor 1 
This section was signed electronically by Professor William Gaver on 13/09/2017 11:58. 
Job Title/Post: Professor of Design
Organisation: Goldsmiths, University of London
Email: w.gaver@gold.ac.uk
Academic supervisor 2 
This section was signed electronically by Dr Alex Wilkie on 13/09/2017 11:46. 
Job Title/Post: Senior Lecturer
Organisation: Goldsmiths, University of London
Email: a.wilkie@gold.ac.uk
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Measurement 
on Our Terms
Patient study information
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Patient Information
Version 0.5
Date: 19th October 2017
Researcher: Alison Thomson
REC reference number: 17/LO/1684
IRAS project ID:  228062
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We would like to invite you to take part in our research study, 
Measurement on Our Terms. 
This research is being carried out by a researcher from the 
Barts Multiple Sclerosis (MS) Research Team at Queen Mary 
University of London (QMUL). 
Before you decide whether to take part you need to 
understand why the research is being carried out and what it 
would involve for you. 
Please take time to read this information about the study 
carefully.  Ask us if there is anything that is not clear or if you 
would like more information; our contact details are at the 
end of this booklet. 
Alison Thomson
Principal Investigator
Hello,
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4
What is the purpose of the study?
This study will explore how people with MS can contribute to 
the design of new ways to measure upper limb function. We 
plan to do this through three focus groups with people living 
with MS.
Why am I being invited to take part?
You have been invited to take part because you have 
been diagnosed with MS and you are a patient at The 
Royal London Hospital.  We are very interested to hear 
the experiences of people whose upper limb function is 
affected by their MS. We would like to ask you to share your 
experiences with us.
Do I have to take part?
No, it is up to you to decide whether or not to take part in this 
study.  A decision not to take part will not effect the standard 
of care or treatment you receive.
If you decide to take part you will be asked to sign a 
consent form allowing us to sound record the focus group 
discussions.  
You are free to leave the study at any time.  
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What would be involved?
You would take part in three focus groups that will be held 
over a period of three months.  The focus groups will involve 
other people with MS. If you decide you do not want to take 
part in every focus group then that is entirely your decision, 
but we hope to involve people who can commit to the three 
sessions.
The researcher and a professional patient facilitator will 
run the focus groups.  They will start by asking the group 
questions to prompt them to think about their experiences 
of completing upper limb activities at home.  The group will 
then create a survey that will gather these experiences from 
other patients online. At the next meeting, you will work as a 
group to discuss these results, then finally use them to create 
the new measure. 
Each focus group will last about three hours and will be 
sound recorded, transcribed into print and then analysed 
by the researcher.  You will receive a copy of the researchers’ 
analysis  and will be able to provide verbal and/or written 
comments on this.  You will also be provided with a copy of 
the final research report, if you wish to receive it.  
Where will the focus groups be held?
The focus groups will be held in a meeting room in the 
Unity Kitchen, within the Olympic Park in East London. The 
address is:
  Timber Lodge Cafe 
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  Queen Elizabeth Olympic Park
  E20 1DY
Stratford Underground, Overground and National Rail station 
is one mile away.
Transport to and from each focus group can be arranged 
for you free of charge, or your travel expenses will be 
reimbursed. The researcher can arrange this for you before 
each session. 
What do I have to do?
If you take part in the study it is important you attend all 
three focus groups on time. 
You will be asked to sign a consent form prior to the start 
of the first focus group session in the presence of the 
researcher. This form will be added to your patient notes by a 
member of your healthcare team.
You will also be asked to complete two MS outcome 
measures before you attend the first focus group and share 
your results with the researcher. The WebEDSS online survey 
and a 9 hole peg test, which will be posted to your home, 
both take around 10 minutes to complete. Your score is 
important to describe the different experiences of people 
involved in the focus group. 
Will I be identifiable in the transcriptions of the 
workshop discussion or in any other verbal or 
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Image 1: Location of focus group venue in East London
Image 2: Walking distance of focus group venue from 
Stratford station
252
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written report?
No.  You will not be personally identifiable in the typed 
transcriptions (you will be given a random participant 
identification number) or in any other verbal or written 
account.  The sound files will not be heard by anyone other 
than the researcher.  
For monitoring and audit purposes, the Sponsor and 
individuals from regulatory authorities may need to view 
data generated by the study.
All sound files will be stored securely in locked premises 
and electronic material will be password protected.  Sound 
files will be destroyed confidentially twenty years following 
completion of the study.  The draft analysis of each focus 
group will be given to everyone who takes part to read and 
provide written or verbal comments if they want to. Extracts 
may be published in articles and reports but no one would 
be able to identify you from these. 
Are there any benefits to taking part?
There are no direct benefits to you as an individual.  There 
will be benefits for other people with MS whose upper limb 
function is affected by their MS in the future. This study will 
provide insights to create information for people to record 
their activity. 
What are the possible disadvantages and risks of 
taking part?
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The study involves discussing your experiences of upper limb 
activities and how they are affected by MS.  It is possible that, 
depending on the issues discussed, this could be difficult 
or concern you.  Whilst other people in the discussion may 
provide you with support, you are free to leave if you want. 
If taking part in the study causes you concern, please discuss 
this with one of the members of our research team after the 
focus group.  
If you do not wish to discuss issues with the researcher, 
but wish to talk with someone who is independent of the 
research then the Patient Advice and Liaison service is 
available to you:
  Patient Advice and Liaison service 
Tel:  020 3594 2040
Email:   pals@bartshealth.nhs.uk
This is a free, confidential service for patients which helps to 
deal with issues, and concerns you may have.
What happens at the end of the study?
After the third focus group you will be sent a draft of the 
researchers’ final report.  You will have the opportunity to 
provide comments verbally and/or in writing and may do 
so anonymously if you want.  The final report will inform 
the design of future outcome measures. The report will 
be written up as a paper and submitted for publication in 
academic journals and presented at conferences.  
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At the end of the study, you have the option to join an email 
mailing list to receive updates about the results of the study.
Who is funding the study?
This is a non-commercial study which is being run by a 
researcher who will not receive any personal remuneration 
for taking part.  The Horne Family Foundation are funding 
the research.
If I want to discuss the study further with a 
member of the research team who do I contact?
Please contact: Alison Thomson
   Lecturer in Patient Public    
    Engagement     
Email:    a.thomson@qmul.ac.uk 
Tel:   020 7882 2367
If I want to discuss the study with someone who 
knows about it, but is not involved in it then who 
can I contact?
Please contact: Monica Marta
   Consultant Neurologist
Email:   m.marta@qmul.ac.uk  
Tel:   020 7882 2677
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Who has reviewed the research study?
The study has been reviewed and approved by the London-
Stanmore Research Ethics Committee.
What if something goes wrong? 
Queen Mary University of London has agreed that if you are 
harmed as a result of your participation in the study, you will 
be compensated, provided that, an injury was caused as a 
direct result of taking part in the study. 
These special compensation arrangements apply where an 
injury is caused to you that would not have occurred if you 
were not in the study. These arrangements do not affect your 
right to pursue a claim through legal action.
What do I do now?
Please contact Alison Thomson by either email or telephone 
to confirm that you would like to take part in this study. You 
will then be contacted with the prospective dates and times 
of the focus group sessions. You will be asked to sign the 
consent form prior to the start of the first focus group session 
in the presence of the researcher.
Thank you for taking the time to read this information.
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Version: 0.4    
Date:  19th October 2017 
Researcher: Alison Thomson 
REC reference number: 17/LO/1684 
IRAS project ID:  228062 
 
 
 
PATIENT CONSENT FORM 
 
Study Title: Measurement on Our Terms 
 
Participant Identification Number: 
 
 
Please initial box to indicate agreement: 
 
1 I confirm that I have read and understood the patient information dated 
19/10/2017 (Version 0.5) for the above study.  I have had the opportunity 
to consider the information, ask questions and have had these answered 
satisfactorily. 
 
2 I understand that my participation in the three focus groups, each lasting 
three hours is voluntary. I am free to withdraw at any time, without giving 
any reason, without my medical care or legal rights being affected. 
 
3 I understand that my participation will be sound recorded and I am aware 
of and consent to, use of these recordings for content analysis purposes.   
 
4 I understand that what I say in the focus groups will be transcribed, 
anonymised and used in publications (e.g. academic journals, conference 
presentations). I will be given a unique participant number. Confidentiality 
and anonymity will be maintained and it will not be possible to identify me 
from this quoted material.  
 
5 I understand that relevant sections of the data collected during the study, 
may be looked at by individuals from Queen Mary University of London, 
from regulatory authorities or from the NHS Trust, where it is relevant to 
my taking part in this research. I give permission for these individuals to 
have access to this data. For monitoring and audit purposes, the Sponsor 
and individuals from regulatory authorities may need to view data 
generated by the study 
 
6 I agree to take part in the above study.  
 
 
 
Name of Patient   Date  Signature 
 
 
 
Name of Researcher
  
 Date  Signature 
 
One copy of this form will be for the patient and one copy will be added to the patients notes by 
a member of their healthcare team. The original will be kept by the Researcher. 
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Topic Guide 
Version: 0.1   
Date:  15th August 2017 
Name of Researcher: Alison Thomson 
REC reference number  
IRAS project ID:   228062 
 
 
 
 
 
 
Focus Group 1 
 
1. Welcome and introduction 
The facilitator will start by introducing themselves and the other researchers in the room. She 
will give a brief overview of the research study and check that all participants are happy to 
continue, and to be audio recorded.  It will be made clear that if there are any questions, to 
either ask at any time, or mention to a researcher.  
 
Run through the timings of the focus group, mentioning breaks and refreshments.  
 
Safety information will be shared about the facilities and also ensuring confidentiality of any 
information that is shared within the focus group. 
 
As an ice-breaking activity, participants are to turn to person next to them and share an 
interesting fact. Then we share this with group.  
 
2. Background to the study 
a. Introduction to the study topic area of PROMS and their role in upper limb function for 
people with MS.   
b. Introduce the aim of this research  
i. Run three focus groups to find out: 
1. What are the relevant UL activities for PwMS? 
2. How do you complete these at home? 
3. If we created a PPROM, what would this be? 
c. Process for developing PROM (FDA) 
i. Focus group 1 – Design online survey  
ii. Run survey 
iii. Focus group 2 – Discuss survey results 
iv. Focus group 3 – Develop format for new PROM 
 
3. Group Discussion 
The facilitator will hold an open discussion with the participants around how their upper limb 
function, and the ability to complete everyday tasks has been affected by their MS.  
 
This will then lead onto a discussion about their experience of completing PROMS and the 
role and meaning of measurement in their lives. Is this something that they find important or 
useful? 
 
4. Break 
 
5. Design an online survey to collect a range of UL activities: 
This section will  
a. Design survey questions 
b. How should we collect the survey responses? E.g. text, written, video, image (non-identifiable) 
c. How will we discuss this information? 
d. Appropriate information for survey respondents - within the survey: consent, results. 
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6. Close and next steps 
Thank them for taking part in the focus group and describe what the next steps are.  
 
 
Focus group 2 
 
1. Welcome: 
Outline session timing reiterating important information about logistics and confidentiality.  
 
 
2. Discuss survey results 
Discuss the general response from survey including numbers of responses and any 
comments left relating to format of survey 
 
All of the participants will be given printed copies of the survey results and be asked to read 
through them all.  
• What are the common themes or categories of activities that come up? 
• Are there similar locations, formats or purpose of activities?  
 
3. Break 
 
4. Create terms of measurement 
What is a meaningful way to measure these activities? Is it success if completing it or doing it 
quickly? Are headings “impossible, difficult, easy” meaningful or useful? 
 
5. Close and next steps 
 
 
 
Focus Group 3: 
 
1. Welcome: 
Outline session timing reiterating important information about logistics and confidentiality.  
 
a. Re-write new instruction 
b. How and where does this PROM exist 
c. What does it do, and enable people to do 
 
2. Designing the PROM: 
a. Decide method of administration: self-administration, interview, group activity 
b. Format of administration: paper based/ digital 
c. Group to decide naming of the tool 
d. Develop instructions of use. 
e. What to do with results 
 
3. Break 
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4. Close and next steps for dissemination 
 
Thank them for taking part in the study and describe what the next steps are. Discuss 
logistics of compensation for travel expenses.  
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Respondent 
number
What hand and arm (upper 
limb) activities do you find 
difficult, due to your MS?
Are there any tips, hacks, 
devices or tools you use to 
help you complete any of 
these activities?
Are there any upper 
limb activities that you 
avoid doing?
Activity 1: Opening crisps 
3
Crisp packets or anything that 
requires the double grip and pull 
apart motion
9 Opening crisps
38 Opening packages eg. Crisps
Activity 2: Knife and fork
2 I can’t hold cutlery
9 Using a knife to cut
17 Cutlery use
19 Eating with cutlery
24
I can just about hold a knife, but 
can’t apply enough pressure to be of 
any use
29
If I concentrate on picking up 
something I can often do it, but 
for everyday things like picking up 
cutlery these usually end up flying 
across the room
38 Using a knife and fork
45
I eat with a small dessert fork - 
heavy weighted cutlery impossible 
as hand is also weak
48 Using a fork to stab food on my plate (weakness)
62 Using a fork
Use scissors a lot invaluable 
to open packets, cut up food, 
chop onions etc so I can eat 
using a fork in my right hand
64 Some of my fingers do not do what I want them to when holding cutlery
65
Gripping cutlery is more and more 
difficult, sometimes I cannot cut up 
my food by myself and things fall 
off my fork/spoon before they get to 
my mouth
Rubber band wrapped around 
cutlery handles is a great help
66 Cutting food and eating it as hands to weak
72 Using cutlery
74 Using a knife and fork
84 Using cutlery I eat mainly with just a fork
88 Use knife for difficult to cut food
Activity 3: Carrying liquids
3
I also have intention tremor so 
carrying liquids like drinks or food 
is quite unpredictable and often 
messy. I occasionally just drop 
things for no  apparent reason 
which I assume is muscle spasm in 
my hands
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20 Holding open containers of liquids
I ask people in cafes to carry 
coffee to my table for me. I take 
a mug with a sealing lid so I 
can carry a coffee at work
30
Carrying a mug of hot coffee - 
particularly difficult as i use a crutch 
in my good hand
Making a flask of coffee
34 Carrying hot drinks
37 Holding things such as glasses regardless full or empty
62
Use a tea trolley to get plates/
glasses from worksurface 
to table and to move things 
around the house
Activity 4: Dealing with coins
4 Picking up coins/small objects
Slide coins, small items to edge 
of table. Never use change 
from purse when paying
28
I started separating my coppers out 
of my purse prior to 2008 when I 
was diagnosed as I was finding them 
too fiddly
35 Pick up small objects (coins etc.) 
48 Picking the correct coin from my purse (fine motor skills)
69 Getting money out of purse
Activity 5: Pills out a blister pack
20 Handling tiny tablets .
38
Pill Cutter to help with 
medication as i cant snap 
medical pills in half
48 Picking up my daily tablet from the work surface (dexterity)
65
Have difficulty opening tablets and 
pills; not enough strength to open 
bottles especially child proof tops, 
awkward to push pills out of foil 
sheets and dropping them while 
putting them in my mouth
69 Sorting tablets into medidose container
77 Getting pills out of blister packs and not dropping them
82 Picking up pills out of pill container
Activity 6: Changing sheets
24
Changing bedclothes is 
pretty impossible and 
need help, but most other 
tasks are possible single 
handed
51 Changing beds
Activity 7: Tying shoe laces
9 Tying shoe laces Laces
11 Shoe Laces
24
Tasks I find difficult are dressing, 
including pulling up trousers and 
tying shoe laces
27 Shoe laces Tying shoe laces
29 Clothes with buttons or zips can be challenging so to are laces
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30 Fastening shoe laces
34 Tying shoes 
54 Doing up shoe laces
60 Shoes (laces)
62 Tying shoe laces
65 My husband ties my shoelaces 
69
Slip on, velcro or zip shoes. 
Luckily I can wear children’s 
sizes
Shoe laces
71 Tying shoelaces
Activity 8: Sewing
4 Sewing Sewing
8 Sewing
11 Using a needle and thread
13 Threading a needle
21 Threading a needle
22 While I can type and knit I cannot do it for any length of time
I no longer sew  and 
embroidery was one of my 
hobbies
33 Gripping knitting needle
34 Threading a needle Sewing
42 Fine motor activities, like sewing
48
Threading a needle, controlling 
fabric through a sewing machine, 
cutting accurately
Sewing
51 Sewing
52
When fatigued my fingers lose 
strength, ability to grip and do 
not react quickly - moving them 
becomes more concious I struggle 
to grip small things - keys, zip pulls, 
sewing needles etc and when I am 
fatigued my reynaud’s is often also 
worse so my fingers are more numb 
and have less sensation so I can’t 
feel very well
 
I can’t sew if I am tired 
becuase my fingers won’t 
grip the needle
65 Can no longer sew or mend clothes
69 Sewing
83 I try to avoid really fiddly jobs like sewing buttons
Activity 9: Using keys
7 Putting key in lock with left hand
29
I used drop my key when opening 
the door and then overbalance when 
picking it up. I now have my keys 
attached to my hand bag with a 
extendable ski pass holder
30 Turning the ignition key
42 Using a key in darkness
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46 Finding keys etc in bag/pocket without looking
52
When fatigued my fingers lose 
strength, ability to grip and do 
not react quickly - moving them 
becomes more concious I struggle to 
grip small things - keys
Activity 10: Playing piano / guitar / instrument
3 I can no longer play the violin or piano
8 Playing the recorder
11
Too much piano playing worsens 
the numb feeling in my fingertips 
and can become painful at times
Take breaks if playing the 
piano
21 Playing piano - the runs not the chords
I rarely play the piano 
these days 
50
Changed from an acoustic 
6 string guitar to a Bass (4 
strings) guitar
83
My arms tend to feel weak after 
playing the piano and the slight 
numbness in my fingertips makes 
prolonged playing sometimes 
uncomfortable, almost painful
Activity 11: Lifting heavy pots while cooking
33 Lifting and tipping saucepans to get out contents
Serving from full 
saucepans
34 Lifting pots while cooking Anything need to hold especially hot pans
41 Heavy cooking pans
46 Lifting a pan of pasta/potatoes for a family of 4 . Lifting anything heavy
48
Draining water from a pan of 
cooked vegetables, tipping cooked 
food from a pan (eg beans)
49 Carrying pots 
51 Lifting saucepans
54
Anything that needs lifted 
with 2 hands is avoided 
such as pots, casserole 
dishes
60 Transferring food from saucepan
84 Lifting heavy pans Lifting pans
Activity 12: Hair; washing, drying, brushing, straightning
4 Doing hair (arm tires easily)
9 Washing hair
18 Doing my hair - tricky to keep my hands/arms above shoulder height
19 Unable wash back legs hair
25 Washing my hair
I haven’t found another 
way of washing my hair 
other than someone else 
doing it for me
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29
If I concentrate on picking up 
something I can often do it, but 
for everyday things like picking up 
hairbrush
Sometimes I’m not able to 
dry my hair with dryer due 
to tremors and wealness
30 Fasten my hair back
37 Washing my hair
45 Tremor in right arm means it is impossible to blow-dry hair
48 Washing my hair
54
Straightening hair is 
impossible with just one 
arm/hand so I’ve gone 
curly
60 Washing Hair
65
Difficulty using hair dryer and 
brushing/combing hair, some days 
I cannot lift my arms high enough 
and find the hair dryer to heavy to 
hold steady
72 Washing hair in shower
76
Have noticed that my hair, partner’s 
hair and the dog’s coat feel much 
coarser now so I think i have lost 
some fine touch but it does not 
affect day to day tasks
82 Holding blow dryer above my head to dry hair
84 Brushing hair
Activity 13: Typing
1 Typing on computer 1-, 2-finger typing
3 All keyboard activities and touchscreen to a lesser extent
14 Typing on a Computer
18  Typing after a while
19 Typing ipad or computer 
21 I type slower with more mistakes
22 While I can type and knit I cannot do it for any length of time
27 Typing on a computer
30 I now only use my left hand for typing and operating the mouse
36 Typing after a long period of time
39 Typing on a keyboard
40
Typing is usually ok but have slowed 
mouse cursor down so it’s less 
sensitive
43 Typing, especially on a smart phone
51 Typing on computer
54 Typing
58 Typing to fill this in is making my right hand burn
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62 Typing
67 With prolonged typing
72 Typing
74 Typing
76
Typing can be difficult at times, 
especially if the keys are quite raised 
(like the ones at work)
Activity 14: Touchscreen tech 
2 Using touchscreen tech - texting
3 All keyboard activities and touchscreen to a lesser extent
19 ipad Typing ipad or computer 
20
Problems with tremor, pins and 
needles in fingertips, security of 
grip, judgement of grip, strength and 
repeated actions; eg writing, using 
touchscreens
29
Tremor in arms and hand cause me 
to double click when using keyboard 
on laptop/phone/tablet
34 Touch screens (correct pressure)
43 Typing, especially on a smart phone 
82
Any repetitive activities, holding cell 
phone in one hand, texting, using 
my finger to delete e- mails, pressing 
iPad control buttons, when scrolling 
with finger down iPad accidentally 
activate other sights due to finger 
jumping
Activity 15: Handwritting
3
Handwriting longer than a sentence 
or two becomes both illegible and 
painful
4 Writing Writing unless I really have too
8 Handwriting Cursive handwriting
9 Writing Writing 
11 Lots of writing
Not really at the moment 
though I don’t spend too long 
writing in one go
14 Writing
16 Writing by hand
17 Writing
18 Handwriting
20 Writing Writing more than a line
22
Writing is difficult as I cannot feel 
properly or control my fingers to 
hold a pen
23 Writing
26 Writing
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30 Sometimes I’m unable to write
34 Handwritten forms on bad day
35 The left hand has become dominant, but not able to handwrite
36 Writing with a pen
39 Holding a pen and controlling it to write
40
Only thing I can’t do with left hand 
is write & writings v difficult for me 
now & sometimes impossible. So 
I often avoid writing or ask others 
to do. This has all happened in the 
past year. I work full time in an 
office job
Weighted fat pen. Helps a bit Writing 
42 Hand writing up to a certain extent
45 Tremor in r hand/fingers makes it impossible handwrite Hand-writing
46 Writing legibly is tricky unless i concentrate
65
My handwriting is unrecognisable 
and my signature could be anyone! 
due to not being able to grip the pen 
firmly and my hand not moving 
smoothly across the page
66  Writing
68
I steady my hand with my 
other hand, and use my left 
arm for a lot of tasks (except for 
writing.)
71 Writing is becoming more difficult Have to write more slowly
72 Writing with affected dominant hand
I use a very fat pen for writing 
which makes the task easier 
and my penmanship more 
legible
Writing
73 Writing I try to avoid writing
74 Writing
79 Writing for any length of time With writing I generally hope for the best
82 Handwriting gets worse as my hand tries holding pen
83 Finding handwriting more difficult these days - seem a little shaky
84 Writing-gripping the pen properly
89
Sometimes if i am doing extensive 
writing my letters start to smush 
together
Activity 16: Putting on Jewellery 
4 Putting on earrings and necklace
9 Jewelry necklace
29 I can no longer put on jewellery on my own like bracelets and necklaces
30 Fastening a necklace Wearing necklaces which go over my head
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37 Putting on earings
39 Jewellery fastenings eg necklaces, earrings
46 Can’t do up necklaces Rarely wear jewellery
51 Fastening jewellery
54 Putting on jewellery
61 Difficulty with putting earring in right ear
65
Can push earrings through my 
pierced ears but cannot do up the 
back
81 Eg putting jewellery on
88 Cannot put on earrings or necklaces that need to open and close
Activity 17: Make up
4 Putting on makeup
48
Applying makeup (weakness to keep 
my hand up at face height, fine 
motor movement to apply eyeliner/
mascara/lipstick)
58
Lifting right arm e.G. Putting on 
mascara causes a burning sensation 
all along
73 Putting on make-up
84 Putting on makeup
Activity 18: Putting on a bra
9 Bra on
20 Doing up a bra My husband helps me do my bra
45 Cannot wear a bra so use a light sports bra with no hooks
Cannot wear a bra so use a 
light-weight sports bra with no 
hooks
48 Fastening / unfastening my bra
63 Bra the hardest thing
65 My husband ties my shoelaces and does up my bra for me
79 Doing up the back of my bra
I put my bra on with the clips 
on the front, do them up, twist 
it to the back and slip the arm 
straps up. Almost anyone who 
wears a bra can show what I’m 
talking about. I usually buy 
sports bras now
Activity 19: Opening a jar
2 Opening jars
13 Jar openers
29 Weakness in hands means I’m unable to undo jar lids
33 Opening jars
43 Grippers for jars
51 Gadget to open jars
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53 Opening jars
67 Opening jars
78 Opening jars
79 Opening tight jar lids or small bottles
84 Opening jars
Activity 20: Chopping vegetables
21 Chopping vegetables or fruit with a knife quickly
23 Chopping food
46 Chopping tricky veg eg butternut squash, sweet potatoes, celeriac
48 Chopping vegetables, peeling vegetables
52
I don’t use sharp knives eg 
chop vegetables etc if I am 
fatigued because of the 
risk of cutting myself
60 Cutting food Chopping board with spikes to hold food
62 Chop onions etc
67 I also have difficulty chopping vegetables
72 Chopping vegetables
81
I am not as fast at preparing food 
(cutting/cooking) and have to look at 
what I am doing all the time
84 Chopping vegetables
Activity 21: Getting dressed
9 Putting on socks, putting on knickers and trousers
24
Tasks I find difficult are dressing, 
including pulling up trousers and 
tying shoe laces
Most activities can be achieved 
one handed and selecting 
easier to wear clothing is 
essential. Elastic waist track 
bottoms and avoiding buttons 
are a couple of examples
32 Putting on socks 
34 Dressing
36 Putting on socks on myself or on my 7 year old son
44 Tucking tops into trousers
48
Putting my arm into a shirt, 
gripping clothing to be able to pull 
it on (pants, socks, trousers etc), 
fastening buttons, pitting the zipper 
in the zip, gripping the zip on jeans 
to pull the zip up
50 Putting socks on
51 Getting dressed
60
Dressing: buttons, zips, pulling up 
trousers, putting on / off tight fitting 
tops, socks
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62
Left arm/hand weakness. So 
difficult activities are getting 
dressed/undressed, doing buttons 
or zips
Wear trousers that when done 
up go over my hips, use a belt 
to keep up. 
Activity 23: Buttons
2 Sometimes buttoning shirts & blouses
3 As all small buttons   Buttons
4 Small buttons
9 Doing up buttons. Buttons
11 Doing up buttons 
13 Intricate things like fastening buttons
14 Closing buttons
16 Buttoning shirts Don’t buy clothes with buttons Buttoning shirts
17 Buttons
21
 
Using buttons on clothing, 
especially small ones
26 I find doing up buttons of a shirt difficult
29 Clothes with buttons 
35 Or open the buttons
42 Buttoning my shirts 
45 Difficult to do up buttons
46 Fastening a button
48 Fastening buttons
50 Avoid wearing buttoned shirts
53 Doing up shirt buttons sometimes
54 Buttons
56 Doing up buttons 
60 Buttons
62 Doing buttons
63 Buttons Keeping buttons on blouses done up all the time
65 I can no longer do up buttons and zips are becoming more difficult
66 Buttons
71 Doing up buttons
72 Buttons
73 Doing up small buttons
74 Buttons Buttons
77 Doing up cuff buttons
78 Doing buttons up behind my back as numb fingers seem to need sight
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Respondent number
What external factors affect how you complete 
upper limb activities?
External Factor 1: Time of day
3
If I am exhausted from doing too much physically generally hand 
function also declines. I am better doing anything physical in the 
morning, late afternoon my nadir and evening I am improved again like 
the morning
4 Amount of time spent, as day goes on gets harder
13
Time of day (it’s worse in the evenings) and after activity (if I am tired or 
have done a lot that day it is worse)
18 Time of day
20 Everything is worse in late evening
22 My hand gets worse throughout the day. It is best early morning
24
I manage better in the morning before fatigue sets in and makes things 
much harder
29
My legs and arms tend to kick out more in the evening or at night in 
bed.  But sometimes if i have overdone it the day before i can get it 
earlier in the day
32 Morning - 10:30 
33 Evenings, after a couple of hours of knitting
36 First thing in the morning or anytime if feeling especially fatigued
37 Easier for me in the morning
41 The evening is worse, when I’m tied
43 Worse as day goes on. Much better first thing in the am
49 Any time of day on my own
50 Symptoms deteriorate as the day progresses and with fatigue
51 Time of day, how tired I am, whether I have exercised at all that day
53 Time of day (much more capable in the mornings)
54
Left side does not function when tired so need help afternoons and 
evenings
55
I get more fatigued as the day goes on so I try to do any jobs I need to do 
in the morning
60 Time of day
62
What time of day it is and wnen I’ve taken my muscle relaxant tablets 
that maybe allows me to do a few activities
63 Time of day
66 Afternoons and evenings are worst
67 Worse later in the day
68 Seems to be more of a problem in the afternoon
71
In morning dressing is very slow, particularly buttons. In evening wrists 
are weaker and manual dexterity fades
72 Time of day
77
I’m better in the morning, before fatigue sets in, unless I’ve had a 
shower in which case i need time to recover before doing anything
79 I generally function better in the morning
80 Time od the day-night
82 Later in the day more fatigued
84
If i get out of bed late, eg. An hour later than normal at weekend, i feel 
much weaker doing tasks than on weekdays. If the day before has been 
busy, again, i am weaker the day after
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86 Late in evening
External Factor 2: Duration of activity
2 Overuse affect spasticity / spasm
3
As with all activities i am much better at doing anything for the first 
couple of minutes muscle fatigue in fingers hands wrists arms shoulders 
kicks in very quickly. 
4 Amount of time spent, as day goes on gets harder
18 length of the activity
30
How long I’ve been doing the activity for, i.e. I can write for a short 
while. 
34 repetition &/or prolonged lift of heavy pots
67 Worse with repetition
76
Obviously worse when I am tired and if I get stressed at work about how 
long it is taking me to type
83
Playing the piano can be exhausting, especially at the end of a long day 
or if I have to play for a long time such as during a church service
External Factor 3: Temperature
2 Cold temperatures
3
I am very sensitive to cold and become quite rigid and tremor ridden 
when cold, hot weather improves my function.  As above i need to use 
a walking stick, so in very cold weather when my hands get cold it’s 
greatly limits my ability to use the stick and so to walk 
4 If too warm or too cold I am either wobbly or stiff
7 Cold weather
14 Also when it is warm
16 Heat
29 Temperature
34 Needle threading length worse when tired or hot
55 If it is hot weather I feel very fatigued
58 Worse if cold. If my hands get cold they feel numb and get cold burn
65
If I am hot I find it more difficult to do anything as my arms/hands just 
stop working
66 Heat makes them worse 
69 I suppose a bit worse when tired or too hot or hands cold
70 I think my hands are worse if they are cold
73 Gripping is difficult in cold weather.
74 Body temperature (weather or fever)
77 When it’s very hot I find everything more difficult
79 I generally function better if it is cooler
81
Being tired and heat very much affects me. I work inside so that usually 
helps, but being in australia if it is summer and hot out then when i 
first start sometimes it takes a while to cool off and then I can be extra 
clumsy when I start
82 Heat
86 Weather; too hot and too cold
External Factor 4: Visibility
42 If I cannot see what I’m doing, darkness
63
They work better when I can see what I am doing with them.  Doing up 
my bra is sometimes impossible.  
External Factor 5: Emotion
2 High emotion
28 Nothing particular maybe feeling flustered 
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29
Stress (particularly when I was at work as I was not supported at all and 
so fatigue set in and I was unable to move my upper body, I would also 
shake a bit like the nodding dog!!
37 Other people yelling, unexpected activity, emotional situation
39 How I’m feeling, whether I’m feeling rushed
40
Generally unaffected by external factors. But stress does make tremor 
worse
53
How confident I feel because of fatigue and how well my balance is at 
the time
76
Obviously worse when I am tired and if I get stressed at work about how 
long it is taking me to type
79 I generally function better if I’m feeling cheerful
External Factor 6: Being watched
11
Probably fumble a bit more if other people are around waiting for me/
watching
20
Also if I’m in unfamiliar surroundings, situation or with unfamiliar 
people, everything is harder and worse
39 How I’m feeling, whether I’m feeling rushed
53 I do not attempt the activities unless a family member is present
60 Being watched
65 I find that I become more clumsy if someone is watching me
76 Others waiting for me etc. (Shared hospital ward computers)
83
If I am surrounded by people and they’re watching me then my 
handwriting tends to be worse and i’m more shaky. I do struggle with 
my nerves playing in front of other people
External Factor 7: The activity before
5 After exercising, or after work (I do eight hour shifts at a care home)
9 If I am tired, rushing, in a different environment
11 Writing is harder if hand has been used previously on other tasks
13 After activity (if I am tired or have done a lot that day it is worse)
18 What I did before
20 What I’ve been doing before
63 What I have been doing before
68 Also relates to how hard I’ve been working
72 How well I slept, how exerted I am
77
If I’ve had a shower in which case I need time to recover before doing 
anything
89
Fatigue is always worse at the end of a workday and the end of a 
workweek. These make my grip strength and weakness worse
External Factor 8: Other
15 Ongoing infection worsens it
17
Only really can dress myself in my ofwn home where everything is the 
exact height, in the correct place etc
21 Level of fatigue, how I am feeling (weak or not)
23 At home mum and partner prepare food & make & carry drinks
73
Worse in the few days before my tysabri infusion, gripping is difficult in 
cold weather
78
The higher the fatigue the more difficult, tending to drop things more if  
am talking or multitasking 
81
Being tired and heat very much affects me. I work inside so that usually 
helps, but being in australia if it is summer and hot out then when i 
first start sometimes it takes a while to cool off and then i can be extra 
clumsy when I start. The level of neuropathic pain I get in my arms/
hands is also a factor
88
Husband helps with earrings and jewellery , do not wear clothes with 
buttons, cooking virtually impossible at any time of day. I hate not being 
able to function independently 
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Participant number Are there any tips, hacks, devices or tools you use to help you complete activities?
Tech  solution
2
I have haptic feedback on my mobile phone and can unlock the phone with a 
fingerprint sensor
3
Voice input for anything electronic, I recommend Dragon nuance version 10 
and above for serious paperwork on both PC and Mac
26
I use Dragon dictation software because of difficulty writing or using a computer 
key board
27 Voice operation facilities some help
62 Use voice to dictate texts
67 I use audio recording for some computer work 
74 Voice to speech
Change type of object
4
Wear dangly earrings with hook rather than butterfly, wear other jewellery with 
magnetic clasps
8 Using a large threaded needle
15 Tried weighted silverware and push buttons. Can be hard to push
18 thin narrow keyboard
19 Light weight cutlery
21 Use a pen with a rubber gripper
27 Elastic shoe laces, dish washer, slicing tools, electric nail cutter/filer
30
Wearing necklaces which go over my head; use an electric tin opener; make 
more use of the dish washer
34 Use scissors instead of knives to cut herbs, fish etc.
41 I use the smallest and lightest weight kettle for the kitchen, made out of plastic
43 Use scissors to open bags
45
Cannot wear a bra so use a light-weight sports bra with no hooks, get my 
eyelashes and eyebrows tinted at beauticians, similarly nails manicured.  Vanity, 
I know!
46 Magnetic fastenings for necklaces. I’m thoughtful about what pans I buy
49 A bottle opener  some times work or ask neighbor 
54
Electric tin opener is great, use dyson stick vacuum as cannot pull plugs out of 
sockets anymore, sketchers with no laces are amazing. Bought an automatic car 
as moving gears stick was impossible
56 Food processor would help probably
62
Wear trousers that when done up go over my hips, use a belt to keep up. Use 
stylfile clippers with rubber band, for grip, on to cut finger nails -clippers with 
scissor action so easier to use. Use scissors a lot invaluable to open packets, cut 
up food, chop onions etc so I can eat using a fork in my right hand. Use clothes 
pegs to close packets instead of fiddly metal ties. Magnetic necklace clasps
65
Rubber band wrapped around cutlery handles is a great help, velcro fastenings 
are good for shoes, using cups and mugs with big handles, wearing clothes that 
slip on with no buttons or fiddly fastenings
69 Slip on, velcro or zip shoes. Luckily I can wear children’s sizes
72
I use a very fat pen for writing which makes the task easier and my penmanship 
more legible
79 I usually buy sports bras now
85
Holding things: opt for plastic instead of glass/ceramic, try to pay close attention 
to my “gripping”
Introduction of a secialist device / tool
3 I have perch stools and grab rails everywhere at home
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13 I use kitchen devices such as jar openers and grips
18 Special mouse
20 Using a stylus for my mobile. I use a mouse with the laptop
20 I take a mug with a sealing lid so I can carry a coffee at work
23 Weighted wrist bands but they make my arms tired
29
Ski pass holder. I use a hot water machine at home where I place my cup under 
the nozzle and push a button which dispenses the correct amount of water for 
my whatever size cup I am using. I use a walker whichapart from helping me 
balance also holds myhandbag do that  I do not having to carry it
30 Have a steering knob fitted on my car
38 Pill Cutter to help with medication as i cant snap medical pills in half
40 Weighted fat pen. Helps a bit
43 Needle threaders, grippers for jars, proper pen
51
Electric can opener, gadget to open jars,not storing foodstuffs in high or very 
low shelves, unless I can pick them up with a grabber. A low trolley so that 
things can be dragged or pushed rather than lifted
53 Aid to open jars; use of a perching stool; rail to help me pull myself out of bed
55 I use a grab stick to help me pick up things
58
Have a vertical mouse at work. A ambidextrous, cordless vertical mouse has 
been ordered for work and will hopefully help
60
Sharp knives with special handles. Fat handled peelers (oxo). helping hand 
grabbers, chopping board with spikes to hold food
76
Have taken far too much work home because of the typing issue but also use a 
dictaphone a lot more than others (have secretarial support thankfully)
79
I have some plastic grippy material and a battery operated jar opener. I also have 
an aid to help open ring pull cans
84 Wrist weight helps with writing
Change in technique
7 Use right hand
9 Bra on. Back to front. Use teeth and hand to open packets
20
My husband helps me do my bra and does all cooking and refills the kettle with 
only a small amount of water. I ask people in cafes to carry coffee to my table for 
me
24
Most activities can be achieved one handed and selecting easier to wear clothing 
is essential. Elastic waist track bottoms and avoiding buttons are a couple of 
examples. I believe targeted exercise helps maintain some strength and sure 
that using a seated row machine at the gym has improved my ability to pull up 
trousers. A stress ball has helped keep a small amount of grip strength
28 Licking fingers
30
Using the handle of a wooden spoon to open ring pulls on tins; I’ve learnt to do 
many things with my non dominant hand as that is not affected; put some items 
on to a lower shelf so I can reach them; making a flask of coffee
32 Kneel on floor next to bed or similar support
34
Sit while cooking so balance isn’t an issue, use a dryer indoors for washing (both 
hanging rack and tumble drier), batch prepare meals so can just microwave 
when ready, sit to dress and especially socks/shoes
41
I fill the water to the minimal level for boiling. I use plastic plates for camping 
and outdoor eating as they are light weight to carry
46
My non-dominant hand is getting better at doing buttons etc as that side is less 
damaged by the MS
53 Make sure I am sitting down to complete the activities
59 Some aspects of driving are easier when I am wearing gloves
61
I use my left hand more.  I am left handed but over time used my right more and 
more but have now returned to being more of a lefty
62
Use a tea trolley to get plates/glasses from worksurface to table and to move 
things around the house. Use a wheely bag to transport shopping from shop to 
car then car to house.
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63 Keeping buttons on blouses done up all the time
64 My husband 
68
I steady my hand with my other hand, and use my left arm for a lot of tasks 
(except for writing.)
71 Have to write more slowly
77 My family :-)
78 Stabbing the milk top!
79
I put my bra on with the clips on the front, do them up, twist it to the back and 
slip the arm straps up. Almost anyone who wears a bra can show what I’m 
talking about. I usually buy sports bras now
81
Using air con to maximum (esspecially in car, when I am en route somewhere).  
Buying food that is prepared as much as possible (stuff that is already cut up). 
I live alone, and with fatigue and food prep being a problem if it is not easy it 
will not happen (and I refuse to live off microwave meals). Managing fatigue is 
important for me (it increases neuropathic pain, decreases ability to use hands, 
and I keep the meds to a minimum as the effect my cognition and increase 
fatigue and ability to work)
84
I eat mainly with just a fork, use thumb to press aerosols, use teeth to open tight 
tubes and lids (I know! idiot!) microwave veg instead of heavy pans of water
85
Opening containers: rubber gaskets/hot water/wet cloth/husband. Boots: dont’ 
wear them 
Rest / take breaks
11 Take breaks if playing the piano
14 Resting, asking my Family for help, eating ice-cream
18 Breaks
52
Rest until possible even if that means just going to bed and trying again 
tomorrow
83 Not at the moment but I try not to write or play the piano too much in one go
86 Try to relax, if evening put things away and usually go to bed
